

Welcome to STN International! Enter x:x

LOGINID:sssptaul29pxo

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

09/830,559

(Please enter
into case)

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 FEB 28 PATDPAFULL - New display fields provide for legal status
data from INPADOC
NEWS 4 FEB 28 BABS - Current-awareness alerts (SDIs) available
NEWS 5 MAR 02 GBFULL: New full-text patent database on STN
NEWS 6 MAR 03 REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS 7 MAR 03 MEDLINE file segment of TOXCENTER reloaded
NEWS 8 MAR 22 KOREAPAT now updated monthly; patent information enhanced
NEWS 9 MAR 22 Original IDE display format returns to REGISTRY/ZREGISTRY
NEWS 10 MAR 22 PATDPASPC - New patent database available
NEWS 11 MAR 22 REGISTRY/ZREGISTRY enhanced with experimental property tags
NEWS 12 APR 04 EPFULL enhanced with additional patent information and new
fields
NEWS 13 APR 04 EMBASE - Database reloaded and enhanced
NEWS 14 APR 18 New CAS Information Use Policies available online
NEWS 15 APR 25 Patent searching, including current-awareness alerts (SDIs),
based on application date in CA/CAPLUS and USPATFULL/USPAT2
applications.
NEWS 16 APR 28 Improved searching of U.S. Patent Classifications for
U.S. patent records in CA/CAPLUS
NEWS 17 MAY 23 GBFULL enhanced with patent drawing images
NEWS 18 MAY 23 REGISTRY has been enhanced with source information from
CHEMCATS
NEWS 19 JUN 06 STN Patent Forums to be held in June 2005
NEWS 20 JUN 06 The Analysis Edition of STN Express with Discover!
(Version 8.0 for Windows) now available
NEWS 21 JUN 13 RUSSIAPAT: New full-text patent database on STN
NEWS 22 JUN 13 FRFULL enhanced with patent drawing images
NEWS 23 JUN 20 MEDICONF to be removed from STN

NEWS EXPRESS JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer

agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 21:59:10 ON 26 JUN 2005

=> file reg	SINCE FILE	TOTAL
COST IN U.S. DOLLARS	ENTRY	SESSION
FULL ESTIMATED COST	1.68	1.68

FILE 'REGISTRY' ENTERED AT 22:04:04 ON 26 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 24 JUN 2005 HIGHEST RN 852980-90-6
DICTIONARY FILE UPDATES: 24 JUN 2005 HIGHEST RN 852980-90-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*


Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>
Uploading C:\Program Files\Stnexp\Queries\599.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 [@1], [@2]

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 22:04:24 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 4 TO ITERATE

100.0% PROCESSED 4 ITERATIONS 0 ANSWERS
 SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
 PROJECTED ITERATIONS: 4 TO 200
 PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> search l1


ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:.
 ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:full
 FULL SEARCH INITIATED 22:04:35 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 134 TO ITERATE

100.0% PROCESSED 134 ITERATIONS 1 ANSWERS
 SEARCH TIME: 00.00.01

L3 1 SEA SSS FUL L1

=> d l3

L3 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 124037-52-1 REGISTRY
 ED Entered STN: 01 Dec 1989
 CN Benzeneacetamide, 3-[[3-[(7-chloro-2-quinolinyl)methoxy]phenyl][3-(dimethylamino)-3-oxopropyl]thio]methyl]-N-(phenylsulfonyl)- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C36 H34 Cl N3 O5 S2
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=>

Uploading C:\Program Files\Stnexp\Queries\559b.str

L4 STRUCTURE UPLOADED

=> s l4

SAMPLE SEARCH INITIATED 22:18:00 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 198 TO ITERATE

100.0% PROCESSED 198 ITERATIONS
 SEARCH TIME: 00.00.01

28 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**

PROJECTED ITERATIONS: 3116 TO 4804
 PROJECTED ANSWERS: 243 TO 877

L5 28 SEA SSS SAM L4

=> search l4

ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:.
 ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:full
 FULL SEARCH INITIATED 22:18:07 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 4097 TO ITERATE

100.0% PROCESSED 4097 ITERATIONS
 SEARCH TIME: 00.00.01

525 ANSWERS

L6 525 SEA SSS FUL L4

=> file caplus
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
333.96	335.64

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 22:18:14 ON 26 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 Jun 2005 VOL 143 ISS 1
FILE LAST UPDATED: 24 Jun 2005 (20050624/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 16
L7 130 L6

=> d 17 fbib ab hitstr 1-130

L7 ANSWER 1 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2005:283517 CAPLUS
DN 142:341820
TI Drug conjugates with an affinity for plasma proteins and showing increased plasma half-lives
IN Doerwald, Florencio Zaragoza; Peschke, Bernd
PA Novo Nordisk A/S, Den.
SO PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005028516	A2	20050331	WO 2004-DK625	20040917
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

DK 2003-1366	A 20030919
US 2003-505501P	P 20030924
DK 2003-1788	A 20031204
US 2003-526864P	P 20031204

OS MARPAT 142:341820

AB Drug conjugates that can bind plasma proteins with an increase in the intravascular half-life of the drug are described. The drugs are conjugated, via a spacer, to an ester of a compound with an affinity for a plasma protein. The plasma protein-binding compound may be a peptide, such as glucagon-like peptide 1, with modifications to improve resistance to proteinases. The preparation of ketoprofen derivs. for conjugation to glucagon-like peptides is described.


IT **792955-14-7P 792955-16-9P 848432-27-9P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reactions of; peptide carriers for drug conjugates with increased plasma half-lives)


RN 792955-14-7 CAPLUS

CN Butanoic acid, 4-[[[2-(3-benzoylphenyl)-1-oxopropyl]amino]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 792955-16-9 CAPLUS

CN Butanoic acid, 4-[[[2-(3-benzoylphenyl)-1-oxopropyl]amino]sulfonyl]- (9CI) (CA INDEX NAME)



RN 848432-27-9 CAPLUS

CN Hexanoic acid, 6-[[[2-(3-benzoylphenyl)-1-oxopropyl]amino]sulfonyl]-, ethyl ester (9CI) (CA INDEX NAME)



IT **848432-28-0P**


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and therapeutic use; peptide carriers for drug conjugates with

increased plasma half-lives)

RN 848432-28-0 CAPLUS

CN Hexanoic acid, 6-[[[2-(3-benzoylphenyl)-1-oxopropyl]amino]sulfonyl]- (9CI)
(CA INDEX NAME)



L7 ANSWER 2 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:996215 CAPLUS

DN 141:411227

TI Preparation of peptides for use in treating obesity

IN Sensfuss, Ulrich; Conde Frieboes, Kilian Waldemar; Christensen, Leif;
Petterson, Ingrid Vivika; Hansen, Thomas Kruse; Ankersen, Michael; Madsen,
Kjeld

PA Novo Nordisk A/S, Den.

SO PCT Int. Appl., 211 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2004099246	A2	20041118	WO 2004-DK308	20040505
	WO 2004099246	A3	20050519		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				DK 2003-706	A 20030509
				US 2003-470639P	P 20030515
				DK 2004-172	A 20040205
				US 2004-543962P	P 20040212

OS MARPAT 141:411227

AB Novel cyclic and linear peptides R1-X-X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-
R2 [R1, which is bonded to an N-terminal NH2 group, is absent, alkanoyl or
a protracting group R4 optionally attached to X via a linker S; X is a
bond, an amino acid, a di- or tripeptide residue; X1 is a bond or an amino
acid residue with a functional group in the side chain to which a
protracting group R4 may be attached, optionally via a linker S; X2 is a
bond, an amino acid, di-, tri- or tetrapeptide residue; X3 is a bond or an
amino acid residue optionally capable of making a bridge to X10; X4, X9,
X11 are a bond or an amino acid or dipeptide residue; X5 is an amino acid
residue of defined structure; X6 is D-Phe in which the Ph moiety is
optionally substituted with halogen, hydroxy, alkoxy, nitro, Me,
trifluoromethyl or cyano; X7 is Arg; X8 is Trp or 2-naphthylalanine; X10

is a bond or an amino acid residue optionally capable of making a bridge to X3; R2 is OH or NRR', where R and R' independently represent H, alkyl, alkenyl or alkynyl; the peptide is optionally cyclized from X3 to X10 via a lactam or a disulfide bridge (provisos; one protracting group and at least 7 amino acid residues)] or their pharmaceutically-acceptable salts were prepared for use in the treatment of obesity. Thus, octanoyl-Nle-cyclo[Glu-His-D-Phe-Arg-Trp-Lys]-NH2 was prepared by solid-phase peptide coupling, followed by acylation, deprotection, cyclization, and resin cleavage steps.

IT 792954-14-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of peptides for treating obesity)


RN 792954-14-4 CAPLUS


CN L-Lysinamide, N-[4-[[[2-(3-benzoylphenyl)-1-oxopropyl]amino]sulfonyl]-1-oxobutyl]glycyl-L-seryl-L-glutaminy-L-histidyl-L-seryl-L-norleucyl-L- α -glutamyl-(4R)-4-hydroxy-L-prolyl-D-phenylalanyl-L-arginyl-L-tryptophyl-, (7 \rightarrow 12)-lactam (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B






IT 792955-14-7P 792955-16-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of peptides for treating obesity)


RN 792955-14-7 CAPLUS

CN Butanoic acid, 4-[[[2-(3-benzoylphenyl)-1-oxopropyl]amino]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 792955-16-9 CAPLUS

CN Butanoic acid, 4-[[[2-(3-benzoylphenyl)-1-oxopropyl]amino]sulfonyl]- (9CI)
(CA INDEX NAME)



L7 ANSWER 3 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:927179 CAPLUS

DN 141:395430

TI Preparation of isoquinoline-5-sulfonic acid amides as inhibitors of Akt (Protein kinase B) for treating neoplasms and viral infections

IN Al Awar, Rima Salim; Barda, David Anthony; Henry, Kenneth James, Jr.; Joseph, Sajjan; Lin, Ho-Shen; Lopez, Jose Eduardo; Richett, Michael Enrico; Somoza, Carmen

PA Eli Lilly and Company, USA; Dee, Albert Gerard

SO PCT Int. Appl., 115 pp.

CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004094386	A1	20041104	WO 2004-US6093	20040325
	WO 2004094386	C1	20050217		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

US 2003-458988P P 20030328


OS MARPAT 141:395430

AB Title compds. I [wherein R1 = H, halo, NH₂, OH; R2 = H, alkenyl, (un)substituted alkyl; R3 = H, alkyl; R4 = H, halo, alkyl, alkoxy; R5 = H, halo, alkyl, alkoxy, CF₃, NO₂; or R4CCR5 = benzo-fused ring; R6 = H, halo, alkoxy, CF₃, NO₂, CN, cycloalkyl, OPh, phenethyl, isoxazolyl, furyl, methylsulfonyl, (un)substituted alkyl, Ph, thienyl, benzyl, benzoyl; Y = (CH₂)_n; n = 2-3; X = O, S(O)_p, NH and derivs.; p = 0-2] were prepared as inhibitors of AKT activity. For example, DIBAL-H reduction of [4-bromo-2-(isoxazol-5-yl)phenoxy]acetic acid Me ester (preparation given) and reductive amination with isoquinoline-5-sulfonic acid (2-aminoethyl)amide gave amine II. I had IC₅₀ values ≤ 2 μM in an Akt1 phosphorylation assay. Thus, I are useful for the treatment of susceptible neoplasms and viral infections.

IT **787575-58-0P**, [(3-Benzylphenyl)oxy]acetic acid methyl ester
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of isoquinoline-5-sulfonic acid amides as Protein kinase B inhibitors for treating neoplasms and viral infections)

RN 787575-58-0 CAPLUS

CN Acetic acid, [3-(phenylmethyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:698117 CAPLUS

DN 141:202277


TI Dialkylbenzene hydroxylamide histone deacetylase inhibitors for use in therapeutics

IN Urano, Yasuharu; Hosaka, Mitsuru; Kamijo, Kazunori


PA Fujisawa Pharmaceutical Co., Ltd., Japan
 SO PCT Int. Appl., 75 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004071401	A2	20040826	WO 2004-JP1437	20040210
	WO 2004071401	A3	20041014		
	W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				AU 2003-900587	A 20030211


OS MARPAT 141:202277
 AB Compds. R1R2CH-C6H4-L-COR3 (R1 = lower alkyl optionally substituted with one or more suitable substituent(s), aryl optionally substituted with one or more suitable substituent(s), fused ring; R2 = acylamino, optionally protected OH; L = lower alkenylene; R3 = hydroxyamino), or salts thereof, are disclosed. The compds. are useful as inhibitors of histone deacetylase and may be used to treat a variety of diseases, e.g., inflammatory disorders, diabetes, cirrhosis, acute promyelocytic leukemia, protozoal infections, etc. Thus, over 100 compds. were synthesized and 4 were shown to inhibit histone deacetylase and to inhibit T cell growth.
 IT 741707-85-7P 741707-86-8P 741707-90-4P
 741707-91-5P 741707-98-2P 741707-99-3P
 741708-03-2P 741708-04-3P 741708-08-7P
 741708-09-8P 741708-16-7P 741708-17-8P
 741708-20-3P 741708-21-4P 741708-29-2P
 741708-30-5P 741708-46-3P 741708-47-4P
 741708-51-0P 741708-52-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (dialkylbenzene hydroxylamide histone deacetylase inhibitors for use in therapeutics)
 RN 741707-85-7 CAPLUS
 CN 2-Propenoic acid, 3-[3-[(acetylamino)[1,1'-biphenyl]-4-ylmethyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 741707-86-8 CAPLUS
 CN 2-Propenoic acid, 3-[3-[(acetylamino)[1,1'-biphenyl]-4-ylmethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 741707-90-4 CAPLUS
 CN 2-Propenoic acid, 3-[3-[[1,1'-biphenyl]-4-yl]-(methylsulfonyl)amino]methyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 741707-91-5 CAPLUS
 CN 2-Propenoic acid, 3-[3-[[1,1'-biphenyl]-4-yl]-(methylsulfonyl)amino]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 741707-98-2 CAPLUS
 CN 2-Propenoic acid, 3-[3-[(benzoylamino)(4-chlorophenyl)methyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 741707-99-3 CAPLUS
 CN 2-Propenoic acid, 3-[3-[(benzoylamino)(4-chlorophenyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 741708-03-2 CAPLUS

CN 2-Propenoic acid, 3-[3-[(acetylamino)(4-chlorophenyl)methyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 741708-04-3 CAPLUS

CN 2-Propenoic acid, 3-[3-[(acetylamino)(4-chlorophenyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 741708-08-7 CAPLUS

CN 2-Propenoic acid, 3-[3-[(benzoylamino)(4-ethoxyphenyl)methyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 741708-09-8 CAPLUS


CN 2-Propenoic acid, 3-[3-[(benzoylamino)(4-ethoxyphenyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 741708-16-7 CAPLUS
 CN 2-Propenoic acid, 3-[3-[(acetylamino)(4-ethoxyphenyl)methyl]phenyl]-,
 ethyl ester (9CI) (CA INDEX NAME)




RN 741708-17-8 CAPLUS
 CN 2-Propenoic acid, 3-[3-[(acetylamino)(4-ethoxyphenyl)methyl]phenyl]- (9CI)
 (CA INDEX NAME)




RN 741708-20-3 CAPLUS
 CN 2-Propenoic acid, 3-[3-[1,3-benzodioxol-5-yl(benzoylamino)methyl]phenyl]-,
 ethyl ester (9CI) (CA INDEX NAME)




RN 741708-21-4 CAPLUS
 CN 2-Propenoic acid, 3-[3-[1,3-benzodioxol-5-yl(benzoylamino)methyl]phenyl]-
 (9CI) (CA INDEX NAME)




RN 741708-29-2 CAPLUS
 CN 2-Propenoic acid, 3-[3-[(acetylamino)-1,3-benzodioxol-5-ylmethyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 741708-30-5 CAPLUS
 CN 2-Propenoic acid, 3-[3-[(acetylamino)-1,3-benzodioxol-5-ylmethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 741708-46-3 CAPLUS
 CN 2-Propenoic acid, 3-[3-[(benzoylamino)[4-(dimethylamino)phenyl]methyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 741708-47-4 CAPLUS
 CN 2-Propenoic acid, 3-[3-[(benzoylamino)[4-(dimethylamino)phenyl]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 741708-51-0 CAPLUS
 CN 2-Propenoic acid, 3-[3-[(acetylamino)[4-(dimethylamino)phenyl]methyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 741708-52-1 CAPLUS
 CN 2-Propenoic acid, 3-[3-[(acetylamino)[4-(dimethylamino)phenyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




L7 ANSWER 5 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2004:498556 CAPLUS
 DN 141:218298
 TI Synthesis and pharmacological evaluation of amide conjugates of NSAIDs with L-cysteine ethyl ester, combining potent antiinflammatory and antioxidant properties with significantly reduced gastrointestinal toxicity
 AU Galanakis, Dimitrios; Kourounakis, Angeliki P.; Tsiakitzis, Karyophyllis C.; Doulgkeris, Christos; Rekka, Eleni A.; Gavalas, Antonios; Kravaritou, Constantina; Charitos, Christos; Kourounakis, Panos N.
 CS Department of Pharmaceutical Chemistry, School of Pharmacy, Aristotelian University of Thessaloniki, Thessaloniki, 541 24, Greece
 SO Bioorganic & Medicinal Chemistry Letters (2004), 14(14), 3639-3643
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier Science B.V.
 DT Journal
 LA English
 OS CASREACT 141:218298
 AB The synthesis and pharmacol. evaluation of a series of amide derivs. of NSAIDs with L-cysteine Et ester is described. The novel derivs. are potent antiinflammatory, antioxidant and hypocholesterolemic-hypolipidemic agents, while they demonstrate considerably reduced gastrointestinal toxicity. This mol. modification may offer a general route to safer antiinflammatory agents, potentially suitable for chronic use in conditions such as neurodegenerative disorders.
 IT **745825-48-3P**
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (synthesis and antiinflammatory and antioxidant activities of amide conjugates of NSAIDs with L-cysteine Et ester with reduced gastrointestinal toxicity)
 RN 745825-48-3 CAPLUS
 CN L-Cysteine, N-[2-(3-benzoylphenyl)-1-oxopropyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:394366 CAPLUS
DN 141:99077
TI Efficient 3D database screening for novel HIV-1 IN inhibitors
AU Barreca, Maria Letizia; Rao, Angela; De Luca, Laura; Zappala, Maria; Gurnari, Cristina; Monforte, Pietro; De Clercq, Erik; Van Maele, Benedicte; Debyser, Zeger; Witvrouw, Myriam; Briggs, James M.; Chimirri, Alba
CS Dipartimento Farmaco-Chimico, Universita di Messina, Messina, 98168, Italy
SO Journal of Chemical Information and Computer Sciences (2004), 44(4), 1450-1455
CODEN: JCISD8; ISSN: 0095-2338
PB American Chemical Society
DT Journal
LA English
AB We describe the use of pharmacophore modeling as an efficient tool in the discovery of novel HIV-1 integrase (IN) inhibitors. A three-dimensional hypothetical model for the binding of diketo acid analogs to the enzyme was built by means of the Catalyst program. Using these models as a query for virtual screening, we found several compds. that contain the specified 3D patterns of chemical functions. Biol. testing shows that our strategy was successful in searching for new structural leads as HIV-1 IN inhibitors.
IT 717862-47-0
RL: BSU (Biological study, unclassified); BIOL (Biological study) (efficient 3D database screening for novel HIV-1 integrase inhibitors)
RN 717862-47-0 CAPLUS
CN 2-Butenoic acid, 2-hydroxy-4-[2-(1-methylethoxy)-5-(phenylmethyl)phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RE.CNT 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 7 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:300905 CAPLUS
DN 141:23256
TI Rational Design and Synthesis of Novel Dimeric Diketoacid-Containing Inhibitors of HIV-1 Integrase: Implication for Binding to Two Metal Ions

on the Active Site of Integrase

AU Long, Ya-Qiu; Jiang, Xiao-Hua; Dayam, Raveendra; Sanchez, Tino; Shoemaker, Robert; Sei, Shizuko; Neamati, Nouri

CS State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, CAS, Shanghai, 201203, Peop. Rep. China

SO Journal of Medicinal Chemistry (2004), 47(10), 2561-2573
CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal

LA English


OS CASREACT 141:23256

AB Discovery of diketo acid-containing compds. as HIV-1 integrase (IN) inhibitors played a major role in validating this enzyme as an important target for the development of therapeutics against HIV infection. In fact, S-1360, the first clin. used IN inhibitor containing a triazole ring as a bioisostere of a carboxylic acid moiety belongs to this class of compds. To understand the role of divalent metal-chelating in the inhibition of IN (J. Med. Chemical 2002, 45, 5661-5670), a series of novel dimeric diketo-containing compds. were prepared with the notion that such dimeric compds. may simultaneously bind to two divalent metal ions on the active site of IN. Thus, the two diketo subunits separated by uniquely designed linkers can potentially chelate two metal ions that are either provided from one IN active site or two active sites juxtaposed together in a higher order tetramer. All the new compds. are highly potent against purified IN with varied selectivity for strand transfer, and some of the analogs exert potent inhibition of the cytopathic effect of HIV-1 in infected CEM cells. This study represents the first attempt to rationally target two divalent metal ions on the active site of IN and may have potential implications for the design of second generation diketo acid-containing class of inhibitors.

IT **698983-28-7P**
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of dimeric aryldioxobutyric acids as inhibitors of HIV-1 integrase)

RN 698983-28-7 CAPLUS

CN 2-Butenoic acid, 4,4'-[[[(2-fluorophenyl)methylene]di-3,1-phenylene]bis[2-hydroxy-4-oxo- (9CI) (CA INDEX NAME)



RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 8 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:153582 CAPLUS

DN 140:357012

TI Design and synthesis of photoactivatable aryl diketo acid-containing HIV-1 integrase inhibitors as potential affinity probes

AU Zhang, Xuechun; Marchand, Christophe; Pommier, Yves; Burke, Terrence R.

CS Center for Cancer Research, Laboratory of Medicinal Chemistry,
NCI-Frederick, Frederick, MD, 21702-1201, USA

SO Bioorganic & Medicinal Chemistry Letters (2004), 14(5), 1205-1207
CODEN: BMCLE8; ISSN: 0960-894X

PB Elsevier Science B.V.

DT Journal


LA English

AB Aryl diketo acids (ADKs) represent an important new class of HIV-1 integrase (IN) inhibitors. In order to facilitate examination of the structural basis underlying IN-ADK interaction, biphenyl ketone and Ph azide photophores were incorporated into ADK structures. Of particular note is the novel dual utilization of azide and Ph ketone moieties for both enzyme recognition and for crosslinking. The resulting analogs, 3-RC₆H₄COCH₂COC(=O)R [R = PhCO, 4-PhCOC₆H₄CH₂O, N₃], maintained low micromolar inhibitory potency against IN in recombinant in vitro assays. These potential HIV-1 integrase photoaffinity labels may provide useful tools for studying enzyme interactions of the ADK inhibitor class.

IT **682360-14-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of aryldioxobutanoic acids as HIV-1 integrase inhibitors and potential affinity probes)

RN 682360-14-1 CAPLUS

CN 2-Butenoic acid, 4-(3-benzoylphenyl)-2-hydroxy-4-oxo-, ethyl ester (9CI)
(CA INDEX NAME)



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 9 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:912953 CAPLUS

DN 139:391370

TI Compositions and methods for combating lower urinary tract dysfunctions with delta opioid receptor agonists

IN Chang, Kwen-Jen; Gengo, J. Peter; Biciunas, Kestutis P.; Ma, Xin; Pendergast, William; Jan, Shyi-Tai

PA Ardent Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 73 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003094853	A2	20031120	WO 2003-US14730	20030509
	WO 2003094853	A3	20040819		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,

TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2002-379186P P 20020509
 US 2003-434004 A 20030508
 US 2004002503 A1 20040101 US 2003-434004 20030508
 US 2002-379186P P 20020509
 EP 1501513 A2 20050202 EP 2003-726769 20030509
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 US 2002-379186P P 20020509
 US 2003-434004 A 20030508
 WO 2003-US14730 W 20030509

OS MARPAT 139:391370

AB Compns. and methods for treatment of a urinary tract dysfunction by administering to a subject in need of such treatment a pharmaceutical composition including a delta opioid receptor agonist in an amount effective to reduce the effects of the urinary tract dysfunction. The compns. may further include an addnl. active agent that is used to treat urinary tract dysfunctions, e.g., alpha-adrenergic agonists, anticholinergics, alpha-adrenergic antagonists and tricyclic antidepressants.


IT **561068-34-6P**, 3-[(α R)- α -((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-4-(diethylaminocarbonyl)benzyl]phenoxyacetic acid
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(compns. and methods for combating lower urinary tract dysfunctions with delta opioid receptor agonists combined with other agents)

RN 561068-34-6 CAPLUS

CN Acetic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][(2S,5R)-2,5-dimethyl-4-(2-propenyl)-1-piperazinyl]methyl]phenoxy]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT **561068-35-7P**, Methyl 3-[(α R)- α -((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-4-(diethylaminocarbonyl)benzyl]phenoxyacetate
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (compns. and methods for combating lower urinary tract dysfunctions)

with delta opioid receptor agonists combined with other agents)
 RN 561068-35-7 CAPLUS
 CN Acetic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][(2S,5R)-2,5-dimethyl-4-(2-propenyl)-1-piperazinyl]methyl]phenoxy]-, methyl ester (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 10 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2003:868115 CAPLUS
 DN 139:388570
 TI Succinic and/or glutaric anhydrides for polyamic acids, polyimides, and polyamideimides as alignment films for liquid crystal displays
 IN Tamura, Noriaki
 PA Chisso Corp., Japan; Chisso Petrochemical Corporation
 SO Jpn. Kokai Tokkyo Koho, 25 pp.
 CODEN: JKXXAF

DT Patent
 LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2003313180	A2	20031106	JP 2002-370522	20021220
				JP 2002-44900	A 20020221

OS MARPAT 139:388570

AB The anhydrides are B1A1B2 [A1 = bivalent organic group; B1, B2 = P, Q; R11, R12 = H, (alkoxy or fluoro)alkyl; R31, R32 = H, monovalent organic group; when A1 is arom ring-containing group and B1 is same as B2, neither R11 nor R12 is H; when A1 is noncyclic group and B1 is same as B2, neither R11 nor R12 is H or propyl]. The alignment films provide appropriate pretilt angles and residual voltage to liquid crystal displays, and the displays show no ghosting of previous images.

IT 622851-29-0P


RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)

(succinic and/or glutaric anhydrides for polyamic acids, polyimides, and polyamideimides as alignment films for liquid crystal displays)

RN 622851-29-0 CAPLUS

CN 1,3-Benzenediacetic acid, α,α' -bis(2-ethoxy-1-methyl-2-oxoethylidene)-5-[[4-(trans-4-propylcyclohexyl)phenyl]methyl]-, diethyl ester, ($\alpha Z,\alpha'Z$)- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



L7 ANSWER 11 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:551384 CAPLUS
DN 139:117440
TI Preparation of novel piperazinylbenzyl derivatives and method of treating
premature ejaculation with these and known delta opioid receptor agonists
IN Chank, Kwen-jen; King, Klim; Biciunas, Kestutis P.; McNutt, Robert W.;
Pendergast, William; Jan, Shyi-tai
PA Ardent Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 138 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003057223	A1	20030717	WO 2003-US87	20030102
	WO 2003057223	C2	20040429		
	WO 2003057223	C1	20040729		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
				US 2002-345216P	P 20020102
	US 2003186872	A1	20031002	US 2003-335764	20030102
				US 2002-345216P	P 20020102
	EP 1469850	A1	20041027	EP 2003-710631	20030102
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
				US 2002-345216P	P 20020102
				WO 2003-US87	W 20030102
OS	MARPAT 139:117440				
AB	Compsn. and methods for treatment of sexual dysfunctions (particularly premature ejaculation) by administering to a subject a pharmaceutical				

composition comprising a delta opioid receptor agonist (known compds. such as deltorphin I as well as new piperazinybenzyl compds. shown as I; variables defined below; e.g. 4-[(α S)- α -(2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl]benzyl]-N,N-diethylbenzamide (shown as II)) in an amount effective to delay the onset of ejaculation in the subject during sexual stimulation are claimed. Blocking the delta opioid receptor by the selective antagonist naltrindole eliminated the effect of the known delta opioid receptor agonist SNC-80 on ejaculation, indicating that activation of the receptor reduced the electroejaculation in male mice. Binding affinity to delta opioid receptors and EDs and % ejaculation inhibition in mice for some examples of I are tabulated. Although the methods of preparation are not claimed, .apprx.40 example preps. of I are included. For I: Ar1 is a 5- or 6-member carbocyclic or heterocyclic aromatic ring with atoms C, N, O and S and may include thiophenyl, thiazolyl, furanyl, pyrrolyl, Ph, or pyridyl, and having on a 1st C atom thereof a substituent Y (e.g. H, halo, C1-6 acyl) and on a 2nd ring C thereof a substituent R1 (e.g. H, halo, C1-4 alkyl). Z = H, hydroxy and carboxy and esters thereof; alkoxy, carboxyalkoxy, alkoxy-carboxylic acid, hydroxymethyl, and esters thereof; and amino, carboxamides and sulfonamides thereof; G is C or N; R2 is H, halogen, or C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl; R3, R4 and R5 = H and Me, and wherein at least one of R3, R4 or R5 is not H, subject to the proviso that the total number of Me groups does not exceed two, or any two of R3, R4 and R5 together may form a bridge = 1-3 C atoms; R6 = H, C1-6 alkyl, C2-6 alkenyl, etc.; R7 = H, F; addnl. details are given in the claims; although general structures other than I are claimed, all of the examples appear to fit the I structure.

IT 561068-34-6P, 3-[(α R)- α -(2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl]-4-(diethylaminocarbonyl)benzyl]phenoxyacetic acid
 561068-36-8P, 3-[(α R)- α -(2S,5R)-4-Benzyl-2,5-dimethyl-1-piperazinyl]-4-(diethylaminocarbonyl)benzyl]phenoxyacetic acid
 561068-37-9P, 3-[(α R)-4-(Diethylaminocarbonyl)- α -(2S,5R)-2,5-dimethyl-4-(4-fluorobenzyl)-1-piperazinyl]benzyl]phenoxyacetic acid
 561068-76-6P, [3-[(R)-(3-Diethylcarbamoylphenyl)](2S,5R)-4-(3-hydroxybenzyl)-2,5-dimethylpiperazin-1-yl]methyl]phenoxy]acetic acid
 561068-77-7P, [3-[(R)-(3-Diethylcarbamoylphenyl)](2S,5R)-4-(3-methoxybenzyl)-2,5-dimethylpiperazin-1-yl]methyl]phenoxy]acetic acid
 561068-78-8P, [3-[(2R,5S)-4-[(R)-[3-(Carboxymethoxy)phenyl](3-diethylcarbamoylphenyl)methyl]-2,5-dimethylpiperazin-1-yl]methyl]phenoxy]acetic acid


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of novel piperazinybenzyl derivs. and method of treating premature ejaculation with these and known delta opioid receptor agonists)

RN 561068-34-6 CAPLUS

CN Acetic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl]](2S,5R)-2,5-dimethyl-4-(2-propenyl)-1-piperazinyl]methyl]phenoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 561068-36-8 CAPLUS

CN Acetic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl] [(2S,5R)-2,5-dimethyl-4-(phenylmethyl)-1-piperazinyl]methyl]phenoxy] - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 561068-37-9 CAPLUS

CN Acetic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl] [(2S,5R)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]methyl]phenoxy] - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 561068-76-6 CAPLUS

CN Acetic acid, [3-[(R)-[3-[(diethylamino)carbonyl]phenyl][(2S,5R)-4-[(3-hydroxyphenyl)methyl]-2,5-dimethyl-1-piperazinyl]methyl]phenoxy] - (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 561068-77-7 CAPLUS

CN Acetic acid, [3-[(R)-[3-[(diethylamino)carbonyl]phenyl][(2S,5R)-4-[(3-methoxyphenyl)methyl]-2,5-dimethyl-1-piperazinyl]methyl]phenoxy] - (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 561068-78-8 CAPLUS


CN Acetic acid, [3-[[[(2R,5S)-4-[(R)-[3-(carboxymethoxy)phenyl][3-[(diethylamino)carbonyl]phenyl]methyl]-2,5-dimethyl-1-piperazinyl]methyl]phenoxy] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 561068-35-7P, Methyl 3-[(αR)-α-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-4-(diethylaminocarbonyl)benzyl]phenoxyacetate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of novel piperazinylbenzyl derivs. and method of treating premature ejaculation with these and known delta opioid receptor agonists)
RN 561068-35-7 CAPLUS
CN Acetic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][(2S,5R)-2,5-dimethyl-4-(2-propenyl)-1-piperazinyl]methyl]phenoxy]-, methyl ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 12 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:472352 CAPLUS
DN 139:36342
TI Aroyl(hydroxy)propenoic acids as HIV integrase inhibitors
IN Burke, Terrence R.; Zhang, Xuechun; Pais, Godwin C. G.; Svarovskaia, Evguenia; Pathak, Vinay K.; Marchand, Christophe; Pommier, Yves
PA The Government of the United States of America as Represented by the Secretary, Department of Health and Human Services, USA
SO PCT Int. Appl., 83 pp.

CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003049695	A2	20030619	WO 2002-US39254	20021206
	WO 2003049695	A3	20040429		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
				US 2001-339137P	P 20011207
EP 1463741		A2	20041006	EP 2002-795784	20021206
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
				US 2001-339137P	P 20011207
				WO 2002-US39254	W 20021206

OS MARPAT 139:36342

AB RCOCH:C(OH)CO2R1 [R = (un)substituted aryl, heteroaryl; R1 = H, alkyl, alkenyl, alkynyl] were prepared for use as inhibitors of the retroviral integrase enzyme that are useful in the treatment of HIV infection, AIDS, and other similar diseases characterized by integration of a retroviral genome into a host chromosome. Thus, 3-MeC6H4COMe was brominated, treated with NaN3, followed by EtO2CCO2Et and ester hydrolysis to give 3-N3CH2C6H4COCH:C(OH)CO2H which had an IC50 for inhibition of HIV-1 integrase of 1.53±0.27 µM.


IT 544467-17-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aroyl(hydroxy)propenoic acids as HIV integrase inhibitors)

RN 544467-17-6 CAPLUS

CN 2-Butenoic acid, 4-(3-benzoylphenyl)-2-hydroxy-4-oxo- (9CI) (CA INDEX NAME)



L7 ANSWER 13 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:394816 CAPLUS

DN 138:406916

TI Water-soluble non-effervescent pharmaceutical compositions comprising nonsteroidal anti-inflammatory drugs

IN Reiner, Alberto; Reiner, Giorgio

PA APR Applied Pharma Research S.A., Switz.

SO Eur. Pat. Appl., 10 pp.

CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1312355	A1	20030521	EP 2001-204432	20011120
	EP 1312355	B1	20030611		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
	AT 242626	E	20030615	AT 2001-204432	20011120
				EP 2001-204432	A 20011120
	PT 1312355	T	20031031	PT 2001-204432	20011120
				EP 2001-204432	A 20011120
	ES 2199916	T3	20040301	ES 2001-1204432	20011120
				EP 2001-204432	A 20011120
	WO 2003043600	A1	20030530	WO 2002-EP12983	20021119
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				EP 2001-204432	A 20011120
	BR 2002006371	A	20031223	BR 2002-6371	20021119
				EP 2001-204432	A 20011120
				WO 2002-EP12983	W 20021119

AB Water-soluble non-effervescent pharmaceutical compns. comprising a water-soluble salt of a NSAID having an arylpropionic or arylacetic structure and a mixture of at least 2 completely salified di- or tricarboxylic organic acids to mask the taste of the NSAID salt in aqueous solution are described. The compns.,

even without flavors, provide perfectly drinkable aqueous solns. that, after ingestion, do not elicit the unpleasant irritating feeling typical of known formulation. Thus, granules contained sodium diclofenac 50, disodium tartrate hydrate 50, tripotassium citrate 250, saccharin 10, aspartame 100, and mannitol 440 mg.


IT 527688-21-7

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (water-soluble non-effervescent pharmaceutical compns. comprising nonsteroidal anti-inflammatory drugs)

RN 527688-21-7 CAPLUS

CN L-Lysine, N2-[2-(3-benzoylphenyl)-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 14 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:315967 CAPLUS

DN 138:287410

TI Preparation of 3-phenylacrylamides and analogs as inhibitors of
cyclooxygenase II

IN Mauleon Casellas, David; Garcia Perez, Luisa; Palomer Benet, Albert;
Pascual Avellana, Jaime

PA Laboratorios Menarini, S.A., Spain

SO Span., 27 pp.

CODEN: SPXXAD

DT Patent

LA Spanish

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	ES 2164564	A1	20020216	ES 1999-2287	19991018
	ES 2164564	B1	20030216		
				ES 1999-2287	19991018

OS MARPAT 138:287410

AB Carboxylic acids, amides and esters I [D = (alkyl)eth(en)ylene or ethynylene; A = CO, O, S, NH; X = NH or alkylimino; E = halo, alk(en)(yn)yl, cycloalkyl, cycloalkylalkyl, arylalkyl, haloalkyl, acyl, etc.; Z = (un)substituted Ph, pyridyl, furyl or thienyl; R1 = H, alkyl or phenylalkyl] or their pharmaceutically-acceptable salts were prepared as inhibitors of cyclooxygenase II for treatment of inflammation, pain, fever, colorectal cancer, and Alzheimer's disease. Thus, 3-(3-benzoyl-5-ethyl)acrylamide was prepared by a multistep sequence starting from Me 5-aminoisophthalate and involving reaction of 3-bromo-5-ethylbenzophenone with acrylamide in the final step.

IT 505076-37-9P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of phenylacrylamides and analogs as inhibitors of cyclooxygenase II)

RN 505076-37-9 CAPLUS

CN 2-Propenoic acid, 3-(3-benzoyl-5-ethylphenyl)-, ethyl ester, (2E)- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.



IT 505076-38-0P 505076-66-4P 505076-68-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of phenylacrylamides and analogs as inhibitors of
cyclooxygenase II)

RN 505076-38-0 CAPLUS

CN 2-Propenoic acid, 3-(3-benzoyl-5-ethylphenyl)-, (2E)- (9CI) (CA INDEX
NAME)


Double bond geometry as shown.



RN 505076-66-4 CAPLUS

CN 2-Propenoic acid, 3-(3-benzoyl-5-propylphenyl)-, ethyl ester, (2E)- (9CI)
(CA INDEX NAME)


Double bond geometry as shown.



RN 505076-68-6 CAPLUS

CN 2-Propenoic acid, 3-(3-benzoyl-5-propylphenyl)-, (2E)- (9CI) (CA INDEX
NAME)

Double bond geometry as shown.



L7 ANSWER 15 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2002:905927 CAPLUS

DN 138:305

TI Preventive or recurrence-suppressive agents for liver cancer

IN Ohnota, Hideki; Hayashi, Morimichi; Kuroda, Junji; Komatsu, Yoshimitsu;
Nishimura, Toshihiro

PA Kissei Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 142 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002094319	A1	20021128	WO 2002-JP4601	20020513
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
				JP 2001-149775	A 20010518

OS MARPAT 138:305


AB Preventive or recurrence-suppressive agents for liver cancer containing as the active ingredient thyroid hormone receptor agonists having an effect of inhibiting the expression of liver estrogen sulfotransferase; and usage of the agents. The thyroid hormone receptor agonists are preferably compds. represented by the general formula I (R1 and R2 = alkyl, halogeno, or the like; R3 = hydrogen, alkyl, halogeno, or the like; X = hydroxyl or the like; W = O, S, CH2, or the like; Y = alkyl, -Q-T (wherein Q = O, CH2, CH(OH), or the like; and T = optionally substituted aryl or the like), or the like; Z = hydrogen, alkoxy, or the like; and A = -NHCO-Y1-CO2R8, -CH2CH(R9)NR10R11, or the like) or pharmaceutically acceptable salts thereof.

IT 373642-79-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preventive or recurrence-suppressive agents for liver cancer containing thyroid hormone receptor agonists)

RN 373642-79-6 CAPLUS

CN 2-Propenoic acid, 3-[3-[[5-(2,6-dimethyl-4-nitrophenoxy)-2-hydroxyphenyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 16 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2002:814896 CAPLUS

DN 137:325228

TI Preparation of substituted aminobenzene derivatives as glucocorticoid receptor modulators

IN Link, James T.; Sorensen, Bryan K.; Patel, Jyoti R.; Arendsen, David L.; Li, Gaoquan

PA USA

SO U.S. Pat. Appl. Publ., 121 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002156311	A1	20021024	US 2002-72548	20020208
	US 6583180	B2	20030624		
	CA 2438480	AA	20020822	US 2001-268787P	P 20010214
				CA 2002-2438480	20020212
				US 2001-783636	A 20010214
				US 2002-72548	A 20020208
				WO 2002-US4501	W 20020212
EP 1363876	A1	20031126	EP 2002-714910		20020212
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR					
			US 2001-783636	A	20010214
			US 2002-72548	A	20020208
			WO 2002-US4501	W	20020212
JP 2005510450	T2	20050421	JP 2002-564483		20020212
			US 2001-783636	A	20010214
			US 2002-72548	A	20020208
			WO 2002-US4501	W	20020212

PATENT FAMILY INFORMATION:

FAN 2002:637641

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002064550	A1	20020822	WO 2002-US4501	20020212
	WO 2002064550	C1	20021114		
W: CA, JP, MX					
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR					
CA 2438480	AA	20020822	US 2001-783636	A	20010214
			CA 2002-2438480		20020212
			US 2001-783636	A	20010214
			US 2002-72548	A	20020208
			WO 2002-US4501	W	20020212
EP 1363876	A1	20031126	EP 2002-714910		20020212
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR					
			US 2001-783636	A	20010214
			US 2002-72548	A	20020208
			WO 2002-US4501	W	20020212
JP 2005510450	T2	20050421	JP 2002-564483		20020212
			US 2001-783636	A	20010214
			US 2002-72548	A	20020208
			WO 2002-US4501	W	20020212

OS MARPAT 137:325228

AB Title compds. I [LD, La = bond, divalent alkyl; A, D = aryl, cycloalkyl, heterocycle; R7-8 = absent, H, alkenyl, alkenylthio, alkoxy, etc.; R1-3 = H, alkoxy, carbonyl, alkoxy, alkyl, carbonyl, etc.; R4 = H, alkenyl, alkoxy, alkoxyalkenyl, etc.; R5 = H, alkyl; R6 = H, alkoxy, carbonyl, alkoxy, sulfonyl, aryl, alkoxy, carbonyl] were prepared For instance, N-(2-methyl-3-nitrophenyl)methanesulfonamide (preparation given) was reduced to the corresponding aniline (EtOAc, Pd/C, H₂, 24 h) and alkylated with 2-bromobenzaldehyde (CH₂Cl₂, HOAc, NaHB(OAc)₃) to afford N-[3-[bis[(2-bromophenyl)methyl]amino]-2-methylphenyl]methanesulfonamide (II) in 7% yield. II at 1.7 μM resulted in 88% inhibition of glucocorticoid receptor binding and had IC₅₀ = 600 nM for the progesterone


receptor. I are useful for treatment of symptoms related to type II diabetes and for treatment of diseases associated with an excess or deficiency of glucocorticoids, e.g., obesity, Syndrome X, Cushing's Syndrome, Addison's disease, inflammatory diseases, etc.

IT **448953-81-9P**, Acetic acid, [3-[4-[[[2-methyl-3-[(methylsulfonyl)amino]phenyl](phenylmethyl)amino]methyl]benzoyl]phenoxy]-
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 1,3-diaminobenzene derivs. as glucocorticoid receptor modulators)

RN 448953-81-9 CAPLUS

CN Acetic acid, [3-[4-[[[2-methyl-3-[(methylsulfonyl)amino]phenyl](phenylmethyl)amino]methyl]benzoyl]phenoxy]- (9CI) (CA INDEX NAME)




IT **448956-87-4P**, Acetic acid, [3-[4-[[[3-[bis(methylsulfonyl)amino]-2-methylphenyl](phenylmethyl)amino]methyl]benzoyl]phenoxy]-, ethyl ester
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 1,3-diaminobenzene derivs. as glucocorticoid receptor modulators)

RN 448956-87-4 CAPLUS

CN Acetic acid, [3-[4-[[[3-[bis(methylsulfonyl)amino]-2-methylphenyl](phenylmethyl)amino]methyl]benzoyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



L7 ANSWER 17 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2002:637641 CAPLUS

DN 137:169309

TI Preparation of substituted aminobenzene derivatives as glucocorticoid receptor modulators

IN Link, James T.; Sorensen, Bryan K.; Patel, Jyoti R.; Arendsen, David L.; Li, Gaoquan

PA Abbott Laboratories, USA

SO PCT Int. Appl., 272 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002064550	A1	20020822	WO 2002-US4501	20020212
	WO 2002064550	C1	20021114		
	W: CA, JP, MX				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
	CA 2438480	AA	20020822	US 2001-783636	A 20010214
				CA 2002-2438480	20020212
				US 2001-783636	A 20010214
				US 2002-72548	A 20020208
				WO 2002-US4501	W 20020212
EP 1363876	A1	20031126	EP 2002-714910		20020212
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
				US 2001-783636	A 20010214
				US 2002-72548	A 20020208
				WO 2002-US4501	W 20020212
JP 2005510450	T2	20050421	JP 2002-564483		20020212
			US 2001-783636	A 20010214	
			US 2002-72548	A 20020208	
			WO 2002-US4501	W 20020212	

PATENT FAMILY INFORMATION:

FAN 2002:814896

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002156311	A1	20021024	US 2002-72548	20020208
	US 6583180	B2	20030624		
	CA 2438480	AA	20020822	US 2001-268787P	P 20010214
				CA 2002-2438480	20020212
				US 2001-783636	A 20010214
				US 2002-72548	A 20020208
				WO 2002-US4501	W 20020212
EP 1363876	A1	20031126	EP 2002-714910		20020212
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
				US 2001-783636	A 20010214
				US 2002-72548	A 20020208
				WO 2002-US4501	W 20020212
JP 2005510450	T2	20050421	JP 2002-564483		20020212
			US 2001-783636	A 20010214	
			US 2002-72548	A 20020208	
			WO 2002-US4501	W 20020212	

OS MARPAT 137:169309

AB Gen, hydroxyalkyl, substituted amine; R4 is substituted aminobenzenes I were prepared and are novel glucocorticoid receptor modulators and are useful for treating type II diabetes in a mammal, wherein R1-R3 are each independently hydrogen, alkoxycarbonyl, alkoxy, alkoxyalkyl, alkyl, alkylcarbonyl, carboxy, halogen, hydroxyalkyl, substituted amine; R4 is hydrogen, alkenyl, alkoxy, alkoxyalkenyl, alkoxyalkoxy, alkoxyalkyl, alkoxyalkynyl, alkoxycarbonyl, alkoxycarbonylalkoxy, alkoxycarbonylalkenyl, alkoxycarbonylalkyl, alkoxycarbonylalkynyl, alkyl, alkylcarbonyl, alkylcarbonylalkenyl, alkylcarbonylalkoxy, alkylcarbonylalkyl, alkylcarbonylalkynyl, alkynyl, carboxy, carboxyalkenyl, carboxyalkyl, carboxyalkynyl, haloalkoxy, haloalkyl, haloalkenyl, haloalkynyl, halogen, hydroxyalkyl, substituted amine; R5 is

hydrogen, alkyl; R6 is hydrogen, alkoxycarbonyl, alkoxysulfonyl, alkyl, alkylcarbonyl, alkylsulfonyl, arylalkoxycarbonyl, arylalkylcarbonyl, arylalkylsulfonyl, arylcarbonyl, arylsulfonyl, cycloalkylcarbonyl, cycloalkylalkylcarbonyl, cycloalkylsulfonyl, cycloalkylalkylsulfonyl, heterocyclecarbonyl, heterocyclealkylcarbonyl, heterocyclesulfonyl, heterocyclealkylsulfonyl, amide, aminosulfonyl; X and Y are independently heteroatom-containing hydrocarbon. Thus, N-[3-(dibenzylamino)-2-methylphenyl]ethanesulfonamide was prepared as glucocorticoid receptor modulator. A method of treating symptoms related to type II diabetes wherein said symptoms are selected from the group consisting of hyperglycemia, hyperinsulinemia, inadequate, glucose clearance, obesity, hypertension and high glucocorticoid levels in a mammal comprising administering a therapeutically effective amount of a compound of title compds. A method of treating diseases associated with an excess or deficiency of glucocorticoids, said diseases selected from the group consisting of diabetes, obesity, Syndrome X, Cushing's Syndrome, Addison's disease, inflammatory diseases such as asthma, rhinitis and arthritis, allergy, autoimmune disease, immunodeficiency, anorexia, cachexia, bone loss or bone frailty, and wound healing comprising administering a therapeutically effective amount of a compound of title compds.


IT **448953-81-9P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted aminobenzene derivs. as glucocorticoid receptor modulators)

RN 448953-81-9 CAPLUS

CN Acetic acid, [3-[4-[[[2-methyl-3-[(methylsulfonyl)amino]phenyl] (phenylmethyl)amino]methyl]benzoyl]phenoxy]- (9CI) (CA INDEX NAME)




IT **448956-87-4P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of substituted aminobenzene derivs. as glucocorticoid receptor modulators)

RN 448956-87-4 CAPLUS

CN Acetic acid, [3-[4-[[[3-[bis(methylsulfonyl)amino]-2-methylphenyl] (phenylmethyl)amino]methyl]benzoyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 18 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:428637 CAPLUS
DN 137:20220
TI Preparation of 4-phenoxyphenylacetic acids active at the glucocorticoid
receptor II
IN Pelcman, Benjamin; Gustafsson, Annika; Kym, Philip R.
PA Karo Bio AB, Swed.; Abbott Laboratories
SO PCT Int. Appl., 41 pp.
CODEN: PIXXD2

DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002043648	A2	20020606	WO 2001-IB2302	20011128
	WO 2002043648	C1	20020906		
	WO 2002043648	A3	20041229		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				GB 2000-29102	A 20001129
CA 2430311	AA	20020606	CA 2001-2430311		20011128
			GB 2000-29102	A	20001129
			WO 2001-IB2302	W	20011128
AU 2002023105	A5	20020611	AU 2002-23105		20011128
			GB 2000-29102	A	20001129
			WO 2001-IB2302	W	20011128
TR 200300763	T2	20040921	TR 2003-200300763		20011128
			GB 2000-29102	A	20001129
JP 2004536025	T2	20041202	JP 2002-545627		20011128
			GB 2000-29102	A	20001129
			WO 2001-IB2302	W	20011128
BR 2001015750	A	20041207	BR 2001-15750		20011128
			WO 2001-IB2302	A	20011128
EP 1509188	A2	20050302	EP 2001-998301		20011128
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR				
			GB 2000-29102	A	20001129

NO 2003002415	A	20030527	WO 2001-IB2302	W	20011128
			NO 2003-2415		20030527
			GB 2000-29102	A	20001129
BG 107871	A	20040227	WO 2001-IB2302	W	20011128
			BG 2003-107871		20030602
			GB 2000-29102	A	20001129
			WO 2001-IB2302	W	20011128
US 2004063781	A1	20040401	US 2003-433015		20031014
			GB 2000-29102	A	20001129
			WO 2001-IB2302	W	20011128

OS MARPAT 137:20220

AB The title compds. [I; X = CH₂, CHYR7, CHYCOR7, CO, CS, C:NOR8; Y = O, S, NR8; R1 = CO₂H, heteroaryl; R2, R3 = H, halo, alkyl, provided that one of R2 or R3 is other than hydrogen; R4 = alkyl, alkenyl, alkynyl, halo, etc.; R5 = alkyl which is substituted by A (provided that A is not halo), alkyl, alkenyl, etc.; R6 = alkyl, cycloalkyl, heterocycloalkyl, etc.; R7 = H; R8 = H, alkyl, cycloalkyl, etc.; A = halo, cycloalkyl, alkenyl, etc.] that are liver selective glucocorticoid receptor antagonists, useful in therapy and in the regulation of metabolism, especially lowering blood glucose levels, were

prepared E.g., a multi-step synthesis of I [R1 = CO₂H; R2, R3 = Br; R4 = iso-Pr; R5 = (CH₂)₂C(:CH₂)Me; X = CO; R6 = 3-MeC₆H₄] was given. The compds. I exhibit an affinity for the glucocorticoid receptor in the range between 0.1 and 5000 nM.


IT 434327-14-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 4-phenoxyphenylacetic acids active at the glucocorticoid receptor II)

RN 434327-14-7 CAPLUS

CN Benzeneacetic acid, 4-[2-benzoyl-4-(carboxymethoxy)-5-(1-methylethyl)phenoxy]-3,5-dibromo- (9CI) (CA INDEX NAME)



L7 ANSWER 19 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2002:294153 CAPLUS

DN 136:316938

TI Positive resist composition and process for forming resist pattern using photosensitive laminate

IN Okubo, Waki; Sato, Kazufumi; Nitta, Kazuyuki; Ogata, Toshiyuki

PA Tokyo Ohka Kogyo Co., Ltd., Japan

SO U.S. Pat. Appl. Publ., 16 pp., Cont.-in-part of U.S. Ser. No. 651,099.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002045123	A1	20020418	US 2001-799549	20010307
	US 6638684	B2	20031028		
				JP 1999-245684	A 19990831
				US 2000-651099	A2 20000830
				JP 2000-263211	A 20000831
	JP 2001142217	A2	20010525	JP 2000-263211	20000831
				JP 1999-245684	A 19990831

PATENT FAMILY INFORMATION:

FAN 2001:379722

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2001142217	A2	20010525	JP 2000-263211	20000831
				JP 1999-245684	A 19990831
	US 2002045123	A1	20020418	US 2001-799549	20010307
	US 6638684	B2	20031028		
				JP 1999-245684	A 19990831
				US 2000-651099	A2 20000830
				JP 2000-263211	A 20000831

OS MARPAT 136:316938


AB The present invention relates to a photosensitive laminate including a substrate and a 500-5800 angstroms thick photoresist layer formed on the substrate. A composition for the resist layer includes (A) a compound which generates an acid upon irradiation with radioactive ray; (B) an alkali-soluble novolak resin; and (C) a compound having at least one acid-decomposable dissoln.-inhibiting group, and the dissoln.-inhibiting group is decomposable by action of an acid generated from the ingredient (A) to yield an organic carboxylic acid. This photosensitive laminate is sequentially subjected to selective exposure to KrF excimer laser light or to light having a short wavelength equal to or less than that of F2 laser, post-exposure baking, and developing with an alkali to yield a resist pattern.

IT 340755-42-2

RL: TEM (Technical or engineered material use); USES (Uses)
(pos. resist composition and process for forming resist pattern using photosensitive laminate containing)

RN 340755-42-2 CAPLUS

CN Acetic acid, 2,2'-[methylenebis[[6-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-2,5-dimethyl-3,1-phenylene]methylene(2,5-dimethyl-3,1-phenylene)oxy]]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




L7 ANSWER 20 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:131262 CAPLUS
DN 136:207677


FAN.CNT 1

CN Acetic acid, 2,2'-[methylenebis[[6-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-2,5-dimethyl-3,1-phenylene]methylene(2,5-dimethyl-3,1-phenylene)oxy]]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

L7 ANSWER 21 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2002:116942 CAPLUS
 DN 137:134460
 TI Structure-Based Design of Cyclooxygenase-2 Selectivity into Ketoprofen
 AU Palomer, Albert; Pascual, Jaume; Cabre, Marta; Borrás, Liset; Gonzalez, Gracia; Aparici, Monica; Carabaza, Assumpta; Cabre, Francesc; Garcia, M. Luisa; Mauleon, David
 CS R&D Department, Laboratorios Menarini S.A., Alfonso XII 587, Badalona, 08918, Spain
 SO Bioorganic & Medicinal Chemistry Letters (2002), 12(4), 533-537
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier Science Ltd.
 DT Journal
 LA English
 OS CASREACT 137:134460
 AB We have recently described how to achieve COX-2 selectivity from the non-selective inhibitor indomethacin using a combination of a pharmacophore and computer 3-D models based on the known x-ray crystal structures of cyclooxygenases. In the present study we have focused on the design of COX-2 selective analogs of the NSAID ketoprofen. The design is similarly based on the combined use of the previous pharmacophore together with traditional medicinal chemical techniques motivated by the comparative modeling of the 3-D structures of 2 docked into the COX active sites. The anal. includes use of the program GRID to detect isoenzyme differences near the active site region and is aimed at suggesting modifications of the basic benzophenone frame of the lead compound 2. The resulting series of compds. bearing this central framework is exemplified by the potent and selective COX-2 inhibitor 17 (LM-1669).
 IT **444992-75-0P 444992-76-1P**
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (structure-based design of cyclooxygenase-2 selectivity into ketoprofen)
 RN 444992-75-0 CAPLUS
 CN 2-Propenoic acid, 3-(3-benzoyl-5-ethylphenyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 444992-76-1 CAPLUS
 CN 2-Propenoic acid, 3-(3-benzoyl-5-ethylphenyl)- (9CI) (CA INDEX NAME)



RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 22 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:900125 CAPLUS
DN 136:19952
TI Preparation of carbamimidoylphenylurea derivatives and thio analogs as
factor VIIa inhibitors
IN Klingler, Otmar; Schudok, Manfred; Nestler, Hans-Peter; Matter, Hans;
Schreuder, Herman
PA Aventis Pharma Deutschland G.m.b.H., Germany
SO Eur. Pat. Appl., 28 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1162194	A1	20011212	EP 2000-112116	20000606
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CA 2410862	AA	20011213	CA 2001-2410862	20010526
			EP 2000-112116	A 20000606
			WO 2001-EP6029	W 20010526
WO 2001094301	A2	20011213	WO 2001-EP6029	20010526
WO 2001094301	A3	20020404		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1299354	A2	20030409	EP 2000-112116	A 20000606
			EP 2001-955291	20010526
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
			EP 2000-112116	A 20000606
			WO 2001-EP6029	W 20010526
BR 2001011264	A	20030617	BR 2001-11264	20010526
			EP 2000-112116	A 20000606
			WO 2001-EP6029	W 20010526
JP 2003535844	T2	20031202	JP 2002-501818	20010526
			EP 2000-112116	A 20000606
			WO 2001-EP6029	W 20010526
EE 200200617	A	20040415	EE 2002-617	20010526
			EP 2000-112116	A 20000606
			WO 2001-EP6029	W 20010526

NZ 522960	A	20040528	NZ 2001-522960	20010526
			EP 2000-112116	A 20000606
			WO 2001-EP6029	W 20010526
US 2002052417	A1	20020502	US 2001-874318	20010606
US 6743790	B2	20040601		
			EP 2000-112116	A 20000606
ZA 2002009018	A	20031008	ZA 2002-9018	20021106
			EP 2000-112116	A 20000606
NO 2002005810	A	20021203	NO 2002-5810	20021203
			EP 2000-112116	A 20000606
			WO 2001-EP6029	W 20010526

OS MARPAT 136:19952

AB Carbamimidoylphenyl urea derivs. I (X = O; R1 = H, OH, alkoxy, carbonyl, (un)substituted arylalkoxy, carbonyl and aryloxy, carbonyl; R2 = H, alkyl, aryl, arylalkyl, (un)substituted arylalkyl and alkylaryl; R3 = H, CN, OH, alkyl; R4 = (un)substituted alkyl, aryl, arylalkyl, heterocycle and heterocyclealkyl; R5 = H, (un)substituted alkyl, aryl, arylalkyl, heterocycle, heterocyclealkyl, arylalkylaminocarbonyl, heterocyclealkylaminocarbonyl; R4 and R5 may together with the carbon atom to which they are attached form a (un)substituted 3-8 membered ring which is carbocyclic or heterocyclic; R6 = H, OH, alkoxy, arylalkoxy; A = halogen; m = 0-4; n = 0-3) and their thiourea analogs I (X = S) are prepared and their use as factor VIIa inhibitors is disclosed. Thus, compound II was prepared by amidation of L-alanine Et ester with 4-aminobenzonitrile with subsequent hydrolysis, amidation, addition of hydrogen sulfide, methylation and reaction with ammonia. I exhibited strong antithrombotic effects and are suitable, for example, for the therapy and prophylaxis of thromboembolic diseases and restenoses. Inhibition consts. of I towards factor VIIa/tissue factor ranged from 0.13-20.2 uM. I are reversible inhibitors of the blood clotting enzyme factor VIIa and can in general be applied in conditions in which an undesired activity of factor VIIa is present or for the cure or prevention of which an inhibition of factor VIIa is intended.


IT 379259-88-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compound; preparation of carbamimidoylphenylurea derivs. and thio analogs as factor VIIa inhibitors useful in the treatment of cardiovascular disorders, thromboembolic diseases or restenoses)

RN 379259-88-8 CAPLUS

CN Acetic acid, [3-[[[[[4-(aminoiminomethyl)phenyl]amino]carbonyl]amino]acetyl]amino]phenylmethyl]phenoxy]- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 23 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2001:850646 CAPLUS

DN 135:371527

TI Preparation of bisacylguanidine with cardioprotective activity

IN Gericke, Rolf; Beier, Norbert
 PA Merck Patent G.m.b.H., Germany
 SO Ger. Offen., 12 pp.
 CODEN: GWXXBX
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 10024319	A1	20011122	DE 2000-10024319	20000517
	WO 2001087829	A1	20011122	WO 2001-EP4425	20010419
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	DE 2000-10024319				A 20000517

OS CASREACT 135:371527; MARPAT 135:371527


AB Bisacylguanidines I [one of R1, R2, R3, R4 or R5 = CON:C(NH2)2, CH:CMcON:C(NH2)2 and one of R6, R7, R8, R9 or R10 = CON:C(NH2)2, CH:CMcON:C(NH2)2; the other R1 - R10 = H, A, CH, F, Cl, Br, I, SA, OA, SO2A, OH, NH2, NHA, NA2, COA, (un)substituted Ph, CH2Ph, OPh, N-, S-, O-containing heterocycle; X = S, SO2, (CH2)n, CO, O, OCH2; A = C1-8-alkyl; n = 1 - 3] and their physiol. harmless salts and/or solvates, with cardioprotective characteristics and works as inhibitors of the cellular Na+/H+ antiporters of the Subtyp 1 are described. Thus, N-{3-[2-(3-guanidinocarbonylphenyl)ethyl]benzoyl}guanidine dihydrochloride (II·HCl), was prepared from 3-[2-(3-carboxyphenyl)ethyl]benzoic acid and Boc-guanidine in 1-methyl-2-pyrrolidone containing 2-chloro-1-methylpyridinium iodide and Et2NCHMe2, followed by hydrolysis with aqueous HCl. Formulations for use in injections, suppositories, solns., tablets, capsules and ampules are given.

IT 374681-89-7

RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of cardioprotective bisacylguanidines that work as inhibitors of the cellular Na+/H+ antiporters)

RN 374681-89-7 CAPLUS

CN 2-Propenoic acid, 3-[3-[[4-(2-carboxy-1-propenyl)phenyl]methyl]phenyl]-2-methyl- (9CI) (CA INDEX NAME)



L7 ANSWER 24 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2001:833261 CAPLUS

DN 135:371762

TI Preparation of malonanilic acid derivatives as preventives or remedies for circulatory disease

IN Shiohara, Hiroaki; Nakamura, Tetsuya; Kikuchi, Norihiko; Ohnota, Hideki;
Koizumi, Takashi; Kitazawa, Makio
PA Kissei Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 118 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001085670	A1	20011115	WO 2001-JP3499	20010424
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG JP 2000-140743 A 20000512				

OS MARPAT 135:371762

AB Compds. represented by the general formula (I) or pharmacol. acceptable salts thereof [wherein W represents oxygen, sulfur, methylene, CO, SO, or SO₂; R represents hydrogen, C1-6 alkyl or aryl-C1-6 alkyl; R1 and R2 represent each C1-3 alkyl, CF₃, or halogeno; R3 represents hydrogen, C1-3 alkyl, halogeno, or CF₃; Y represents C1-6 alkyl, CF₃, 6-oxo-1,6-dihydropyridazin-3-ylmethyl, or -Q-T (wherein Q represents oxygen, methylene, hydroxymethylene, or CO; and T represents optionally substituted aryl or arylmethyl or cycloalkylmethyl optionally containing O in the ring); and Z represents hydrogen or C1-3 alkoxy or Y and Z are linked together to form tetramethylene] are prepared. These compds. I have excellent effects of lowering neutral fat level and non-HDL cholesterol level in the blood, inhibiting or suppressing the accumulation of neutral fat in the liver and protecting or ameliorating the liver function and, therefore, are useful as preventives or remedies for circulatory diseases such as hyperlipemia, arteriosclerosis, fatty liver, and hepatitis. Thus, 4-[3-(4-fluorobenzoyl)-4-hydroxyphenoxy]-3,5-dimethylmalonanilic acid Et ester was reduced by NaBH₄ in THF at room temperature for 13 h to give 4-[3-[(4-fluorophenyl)hydroxymethyl]-4-hydroxyphenoxy]-3,5-dimethylmalonanilic acid Et ester which was converted into 4-[3-[(4-fluorophenyl)hydroxymethyl]-4-hydroxyphenoxy]-3,5-dimethylmalonanilic acid potassium salt (II). II at 30 nmol/kg twice a day for 2 wk lowered the triglyceride level in liver of male KK-Ay mice from 16.1 (control) to 2.8 mg/1 g liver.


IT 373642-79-6P 373642-81-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of malonanilic acid derivs. lowering neutral fat level and non-HDL cholesterol level in blood as preventives or remedies for circulatory diseases)


RN 373642-79-6 CAPLUS

CN 2-Propenoic acid; 3-[3-[[5-(2,6-dimethyl-4-nitrophenoxy)-2-hydroxyphenyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 373642-81-0 CAPLUS

CN 2-Propenoic acid, 3-[3-[[5-(4-amino-2,6-dimethylphenoxy)-2-hydroxyphenyl]methyl]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 25 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2001:774952 CAPLUS

DN 136:189476

TI Mechanism of chiral recognition in the enantioseparation of
2-aryloxypropionic acids on new brush-type chiral stationary phases

AU Vinkovic, Vladimir; Kontrec, Darko; Sunjic, Vitomir; Navarini, Luciano;
Zanetti, Flavio; Azzolina, Ornella

CS Ruder Boskovic Institute, Zagreb, Croatia

SO Chirality (2001), 13(9), 581-587

CODEN: CHRLEP; ISSN: 0899-0042

PB Wiley-Liss, Inc.

DT Journal

LA English

AB New brush-type chiral stationary phases (CSP I-IV) comprising
N-3,5,6-trichloro-2,4-dicyanophenyl-L- α -amino acids (1-4) were
prepared by binding of chiral selectors 1-4 to γ -aminopropyl silica
gel. To check the role of excess free aminopropyl groups, CSP V was
prepared by binding N-3,5,6-trichloro-2,4-dicyanophenyl-L-alanyl-(3-
triethoxysilyl)propylamide to unmodified silica gel. The best separation of
racemic 2-aryloxypropionic acids (TR-1-13) was obtained with CSP I; the
-(-)-S enantiomer were regularly eluted first, as determined by a CD detector.
The mechanism of chiral recognition implies a synergistic interaction of
carboxylic acid analyte with the chiral selector and achiral free
 γ -aminopropyl units on silica. In fact, CSP V, which is lacking an
achiral aminopropyl spacer, shows a lower separation ability for
2-aryloxypropionic acids, but a similar enantioselective discrimination of
esters TR-19-20, in comparison with CSP I. CSP I-IV retain unaltered
separation ability after a few months of continuous work using a large number
of various mobile phases.


IT 74168-02-8 117852-24-1 117852-26-3

RL: ANT (Analyte); ANST (Analytical study)

(resolution of 2-arylpropionic acids by HPLC using silica gel and
Nucleosil 100-5 brush-type chiral stationary phases)


RN 74168-02-8 CAPLUS

CN Propanoic acid, 2-(3-benzoylphenoxy)- (9CI) (CA INDEX NAME)




RN 117852-24-1 CAPLUS
 CN Propanoic acid, 2-(3-benzoylphenoxy)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 117852-26-3 CAPLUS
 CN Propanoic acid, 2-(3-benzoylphenoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 26 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2001:597941 CAPLUS
 DN 135:180625
 TI Preparation of the R enantiomers of N-(2-arylpropionyl)amides for the inhibition of IL-8 induced chemotaxis of neutrophils
 IN Allegretti, Marcello; Bertini, Riccardo; Cinzia, Bizzarri; Sabbatini, Vilma; Caselli, Gianfranco; Cesta, Maria Candida; Gandolfi, Carmelo; Colotta, Francesco
 PA Dompe S.p.A., Italy
 SO PCT Int. Appl., 55 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001058852	A2	20010816	WO 2001-EP1285	20010206
	WO 2001058852	A3	20020314		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				

CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

			IT 2000-MI227	A	20000211
IT 1317826	B1	20030715	IT 2000-MI227		20000211
CA 2396937	AA	20010816	CA 2001-2396937		20010206
			IT 2000-MI227	A	20000211
			WO 2001-EP1285	W	20010206
AU 2001044125	A5	20010820	AU 2001-44125		20010206
			IT 2000-MI227	A	20000211
			WO 2001-EP1285	W	20010206
EP 1255726	A2	20021113	EP 2001-916976		20010206
R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR		
			IT 2000-MI227	A	20000211
			WO 2001-EP1285	W	20010206
BR 2001008152	A	20030325	BR 2001-8152		20010206
			IT 2000-MI227	A	20000211
			WO 2001-EP1285	W	20010206
JP 2003522750	T2	20030729	JP 2001-558404		20010206
			IT 2000-MI227	A	20000211
			WO 2001-EP1285	W	20010206
EE 200200441	A	20031215	EE 2002-441		20010206
			IT 2000-MI227	A	20000211
			WO 2001-EP1285	W	20010206
NZ 519925	A	20041224	NZ 2001-519925		20010206
			IT 2000-MI227	A	20000211
			WO 2001-EP1285	A	20010206
NO 2002003817	A	20020812	NO 2002-3817		20020812
			IT 2000-MI227	A	20000211
			WO 2001-EP1285	W	20010206
US 2004181073	A1	20040916	US 2003-203463		20031027
			IT 2000-MI227	A	20000211
			WO 2001-EP1285	W	20010206

OS MARPAT 135:180625

AB (R)-N-(2-arylpropionyl)amides I (aryl = an (un)substituted aryl group; R = H, C1-C4-alkyl, allyl, propargyl, CH₂CO₂H, (CH₂)₂CO₂H; R₁ = amino acid residue of straight or branched C1-C6-alkyl, alkenyl, cycloalkyl, phenylalkyl substituted with one or more CO₂H and/or with an O or S heteroatom; a residue of (CH₂)₂X(CH₂CH₂O)nR (R already defined) and n = 0-5 and X = O, S; a residue of (R)- or (S)-CH(Me)CH₂O(CH₂)₂OH; a residue of OR (R already defined); a residue of -CH₂CH₂Z where Z = 2-(1-methylpyrrolidyl), 2- or 4-pyridyl, 1- or 4-imidazolyl, 1-Me-4-(or -5-)imidazolyl or a N-Y-containing 3-7 membered heterocyclic ring where Y = CH₂, O, S, N-R_c and R_c = H, C1-C6 alkyl or hydroxyalkyl or alkylaryl group) and their pharmaceutically acceptable salts were prepared for use as agents inhibiting the chemotaxis of neutrophils induced by interleukin 8. Thus II was prepared in a multistep synthesis from (R)-(-)-ibuprofen and L-alanine Me ester HCl and was found to inhibit, in a dose-dependent way, the chemotaxis induced by IL 8 (10 ng/mL) in the concentration range from 10⁻⁸

to

10⁻¹⁰ M. The R enantiomers of N-(2-arylpropionyl)amides are useful in the prevention and treatment of tissue damage due to the exacerbate recruitment of polymorphonuclear neutrophils (leukocytes PMN) at the inflammatory sites and also in the treatment of psoriasis, ulcerative

colitis, glomerular nephritis, acute respiratory insufficiency, idiopathic fibrosis, and rheumatoid arthritis.

IT 354901-27-2P 354904-86-2P 354904-89-5P

354904-94-2P 354906-70-0P 354907-08-7P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of the R enantiomers of N-(2-arylpropionyl)amides for the inhibition of IL-8 induced chemotaxis of neutrophils)

RN 354901-27-2 CAPLUS

CN Glycine, N-[(2R)-2-(3-benzoylphenyl)-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 354904-86-2 CAPLUS

CN Glycine, N-[(2R)-1-oxo-2-[3-(1-phenylethyl)phenyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 354904-89-5 CAPLUS

CN Glycine, N-[(2R)-2-[3-(hydroxyphenylmethyl)phenyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 354904-94-2 CAPLUS


CN Glycine, N-[(2R)-2-[3-(1-hydroxy-1-phenylethyl)phenyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 354906-70-0 CAPLUS
 CN Glycine, N-[(2R)-2-(5-benzoyl-2-hydroxyphenyl)-1-oxopropyl]- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 354907-08-7 CAPLUS
 CN Glycine, N-[(2R)-1-oxo-2-[3-[(1R)-1-phenylethyl]phenyl]propyl]- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry. Rotation (-).



L7 ANSWER 27 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2001:416889 CAPLUS
 DN 135:33373
 TI Synthesis of novel tri-substituted phenyl derivatives (e.g. alkoxy
 substituted 3-aryl propionyl derivatives) for use in conditions associated
 with insulin resistance
 IN Boije, Maria; Faegerhag, Jonas; Lindstedt Alstermark, Eva-Lotte; Ohlsson,
 Bengt
 PA Astrazeneca AB, Swed.
 SO PCT Int. Appl., 49 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001040172	A1	20010607	WO 2000-SE2385	20001129

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG


			SE 1999-4421	A	19991203
TW 224590	B1	20041201	TW 2000-89124657		20001121
			SE 1999-4421	A	19991203
CA 2392039	AA	20010607	CA 2000-2392039		20001129
			SE 1999-4421	A	19991203
			WO 2000-SE2385	W	20001129
BR 2000016130	A	20020820	BR 2000-16130		20001129
			SE 1999-4421	A	19991203
			WO 2000-SE2385	W	20001129
EP 1237856	A1	20020911	EP 2000-983619		20001129
EP 1237856	B1	20040512			
			R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR		
			SE 1999-4421	A	19991203
			WO 2000-SE2385	W	20001129
JP 2003515583	T2	20030507	JP 2001-541859		20001129
			SE 1999-4421	A	19991203
			WO 2000-SE2385	W	20001129
AU 766533	B2	20031016	AU 2001-20351		20001129
AU 2001020351	A5	20010612			
			SE 1999-4421	A	19991203
			WO 2000-SE2385	W	20001129
AT 266633	E	20040515	AT 2000-983619		20001129
			SE 1999-4421	A	19991203
			WO 2000-SE2385	W	20001129
PT 1237856	T	20040831	PT 2000-983619		20001129
			SE 1999-4421	A	19991203
ES 2219425	T3	20041201	ES 2000-983619		20001129
			SE 1999-4421	A	19991203
ZA 2002003798	A	20030813	ZA 2002-3798		20020513
			SE 1999-4421	A	19991203
NO 2002002590	A	20020729	NO 2002-2590		20020531
			SE 1999-4421	A	19991203
			WO 2000-SE2385	W	20001129
US 2003149104	A1	20030807	US 2002-148850		20021113
US 6750252	B2	20040615			
			SE 1999-4421	A	19991203
			WO 2000-SE2385	W	20001129

OS MARPAT 135:33373

AB Compds. I and their pharmaceutical formulations are claimed [wherein; A = CR3R4-CR1R2-X or CR3:CR1-X [where X = CHO, ester or amide; R1 = alk(en/yn)yl, aryl, CN, alkoxy, etc.; R2 = H, halo, alkyl, or (alkyl)aryl; R3, R4 = H, alkyl, (alkyl)aryl or halo]; m = 0-1; n = 1-6; D = oxysulfonyl, oxyamido, aminoacyl, amino, sulfonyl, sulfonamido, etc.; D' = H, alkyl, acyl, (alkyl)aryl, halo, CN, etc.; D'' = alkyl, acyl, (alkyl)aryl, halo, CN, etc.; p = 1-2]. Nineteen synthetic examples are given. For instance, II was prepared from Et 3-(3-benzyl-4-hydroxyphenyl)-2-ethoxypropanoate and 2-[4-[(tert-butoxycarbonyl)amino]phenyl]ethyl 4-methylbenzenesulfonate (1.5 mol equivalent) in 2-butanone (with PEG-400 added) and K2CO3 at reflux for 8 h. Compds. of the invention are for use in clin. conditions associated with insulin resistance (no data).

IT 343870-58-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (synthesis of tri-substituted Ph derivs. for use in conditions associated
 with insulin resistance)
 RN 343870-58-6 CAPLUS
 CN 2-Propenoic acid, 2-ethoxy-3-[4-(phenylmethoxy)-3-(phenylmethyl)phenyl]-,
 ethyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 28 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2001:379722 CAPLUS
 DN 134:374053
 TI Photosensitive substrate, formation of resist pattern, and
 positive-working resist composition
 IN Okubo, Kazuyoshi; Sato, Kazushi; Nitta, Kazuyuki; Ogata, Toshiyuki
 PA Tokyo Ohka Kogyo Co., Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 21 pp.
 CODEN: JKXXAF

DT Patent
 LA Japanese
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2001142217	A2	20010525	JP 2000-263211	20000831
				JP 1999-245684	A 19990831
	US 2002045123	A1	20020418	US 2001-799549	20010307
	US 6638684	B2	20031028		
				JP 1999-245684	A 19990831
				US 2000-651099	A2 20000830
				JP 2000-263211	A 20000831

PATENT FAMILY INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002045123	A1	20020418	US 2001-799549	20010307
	US 6638684	B2	20031028		
				JP 1999-245684	A 19990831
				US 2000-651099	A2 20000830
				JP 2000-263211	A 20000831
	JP 2001142217	A2	20010525	JP 2000-263211	20000831
				JP 1999-245684	A 19990831

AB The photosensitive substrate has a 500-5,800 Å-thick resist layer on a support, wherein resist composition comprises (A) a photoacid, (B) an alkaline soluble novolak resin, and (C) a compound which contains ≥1 acid-decomposable solubility-suppressing group and releases an organic carboxylic acid upon reaction with an acid generated from the photoacid. The photosensitive substrate


is exposed by a KrF excimer laser, a F2 laser, or a laser having a lower wavelength. This photosensitive substrate showed excellent dry etching resistance and high sensitivity.

IT **340755-42-2**

RL: TEM (Technical or engineered material use); USES (Uses)
(pos.-working photoresist composition from)

RN 340755-42-2 CAPLUS

CN Acetic acid, 2,2'-[methylenebis[[6-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-2,5-dimethyl-3,1-phenylene]methylene(2,5-dimethyl-3,1-phenylene)oxy]]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



L7 ANSWER 29 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2000:605271 CAPLUS

DN 134:12809

TI A model system using modulation of lanthanide luminescence to signal Zn²⁺ in competitive aqueous media

AU Reany, Ofer; Gunnlaugsson, Thorfinnur; Parker, David

CS Department of Chemistry, University of Durham, Durham, DH1 3LE, UK

SO Perkin 2 (2000), (9), 1819-1831

CODEN: PRKTFO

PB Royal Society of Chemistry

DT Journal

LA English

AB Two pentadentate tribasic ligand systems containing aniline or benzylamine nitrogens covalently linked to a proximate kinetically stable Eu or Tb complex are described. The affinity of these complexes and their nonconjugated analogs for Zn²⁺, Ca²⁺ and Mg²⁺ ions was measured at ambient pH in a high salt background. Apparent binding consts. for the parent ligands (L1: Zn²⁺ log β_{ML} 5.04, Ca²⁺ 3.91, Mg²⁺ 2.1, L3: Zn²⁺ 5.93, Ca²⁺ 5.00, Mg²⁺ 3.60) were slightly lowered in the aniline-based terbium conjugate [TbL4], and were the same for the benzylamine-based conjugate [LnL2], except for zinc binding for which a slightly enhanced affinity was observed. Changes as ligand absorption and emission spectra and in the intensity of delayed lanthanide luminescence characterized metal ion binding. With [LnL2], a 42 and 26% increase in emission at 700 nm (Eu) and 545 nm (Tb) accompanied zinc binding in a simulated extracellular background, with an apparent dissociation constant of 0.6 μM (295 K).


IT **156462-42-9**

RL: ARU (Analytical role, unclassified); PRP (Properties); ANST
(Analytical study)

(model system using modulation of lanthanide luminescence to signal Zn²⁺ in competitive aqueous media)

RN 156462-42-9 CAPLUS

CN Glycine, N-[4-(9-anthracenylmethyl)-2-(carboxymethoxy)phenyl]-N-(carboxymethyl)- (9CI) (CA INDEX NAME)




RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 30 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2000:600530 CAPLUS
DN 133:200808
TI Silver halide color photographic material with improved light-resistant
magenta image
IN Ishii, Fumio
PA Konica Co., Japan
SO Jpn. Kokai Tokkyo Koho, 35 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2000235246	A2	20000829	JP 1999-35812	19990215
				JP 1999-35812	19990215

OS MARPAT 133:200808
AB The title photog. material contains an image stabilizer represented by the
general formula I (R1, R2 = substituent; n1 = 1-4) and a magenta coupler
represented by the general formula II (R = H, substituent; X = H, group
capable of cleaving upon reaction with developing agent oxide; Z = atoms
for forming N-containing heterocycle ring) in a photog. layer.
IT **289623-44-5**
RL: DEV (Device component use); USES (Uses)
(stabilizer in Ag halide color photog. material with improved
light-resistant magenta image)
RN 289623-44-5 CAPLUS
CN 2-Propenoic acid, 3,3'-[ethylidenebis(2-hydroxy-5-methyl-3,1-
phenylene)]bis-, dimethyl ester (9CI) (CA INDEX NAME)



L7 ANSWER 31 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2000:518905 CAPLUS
 DN 133:112648
 TI (E)-2-Methyl-5-(1-naphthylmethyl)cinnamic acid
 AU Gerkin, Roger E.
 CS Department of Chemistry, The Ohio State University, Columbus, OH, 43210, USA
 SO Acta Crystallographica, Section C: Crystal Structure Communications (2000), C56(6), 674-676
 CODEN: ACSCEE; ISSN: 0108-2701
 PB Munksgaard International Publishers Ltd.
 DT Journal
 LA English
 AB The title compound, C₂₁H₁₈O₂, crystallized in the centrosym. space group P2₁/n with Z = 1. Crystallog. data are given. There is a single H bond, with an Odonor...Oacceptor distance of 2.624(2) Å, which forms a cyclic dimer about a center of symmetry. The carboxyl group O atoms are ordered, while the carboxyl-H atom is disordered. A single leading intermol. C-H...O interaction has an H...O distance of 2.68 Å and a C-H...O angle of 178°; this interaction forms chains. Taken together with the H bond, it generates chains and rings. Structural comparisons are made with trans-cinnamic acid and with 4-methyl-trans-cinnamic acid.
 IT **282550-17-8**
 RL: PRP (Properties)
 (crystal structure of)
 RN 282550-17-8 CAPLUS
 CN 2-Propenoic acid, 3-[2-methyl-5-(1-naphthalenylmethyl)phenyl]-, (2E)-(9CI) (CA INDEX NAME)


Double bond geometry as shown.




RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 32 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2000:441578 CAPLUS
DN 133:53700
TI Combination therapy for the treatment of sepsis with activated protein C
and a secretory phospholipase A2 (sPLA2) inhibitor
IN Maciak, Ronald Steven
PA Eli Lilly and Company, USA
SO PCT Int. Appl., 279 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000037022	A2	20000629	WO 1999-US30433	19991220
	WO 2000037022	A3	20020613		
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
				US 1998-113124P	P 19981221
	CA 2358492	AA	20000629	CA 1999-2358492	19991220
				US 1998-113124P	P 19981221
				WO 1999-US30433	W 19991220
	AU 2000019408	A1	20000712	AU 2000-19408	19991220
				US 1998-113124P	P 19981221
				WO 1999-US30433	W 19991220
	EP 1214041	A2	20020619	EP 1999-963109	19991220
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY			
				US 1998-113124P	P 19981221
				WO 1999-US30433	W 19991220
	JP 2002542148	T2	20021210	JP 2000-589136	19991220
				US 1998-113124P	P 19981221
				WO 1999-US30433	W 19991220
OS	MARPAT 133:53700				
AB	The invention provides a method of prevention and treatment for sepsis for mammals. The treatment is a combination therapy of activated protein C and an sPLA2 inhibitor.				
IT	278171-82-7 278171-82-7D, prodrug derivs. RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (activated protein C-secretory phospholipase A2 inhibitor combination for sepsis treatment)				
RN	278171-82-7 CAPLUS				
CN	Acetic acid, [[5-(aminocarbonyl)-2-[(3-fluorophenyl)methyl]-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (9CI) (CA INDEX NAME)				



RN 278171-82-7 CAPLUS
 CN Acetic acid, [[5-(aminocarbonyl)-2-[(3-fluorophenyl)methyl]-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



L7 ANSWER 33 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2000:335363 CAPLUS
 DN 132:347371
 TI Preparation of novel compounds and medicinal use thereof
 IN Chaki, Hisaaki; Takakura, Tadakazu; Tsuchida, Keiichi; Yokotani, Junichi;
 Kotsubo, Hironori; Aikawa, Yukihiko; Hirono, Shuichi; Shiozawa, Shunichi
 PA Toyama Chemical Co., Ltd., Japan
 SO PCT Int. Appl., 260 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000027792	A1	20000518	WO 1999-JP6166	19991105
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2348763	AA	20000518	JP 1998-328792	A 19981105
			JP 1999-80693	A 19990325
			CA 1999-2348763	19991105
			JP 1998-328792	A 19981105
			JP 1999-80693	A 19990325
			WO 1999-JP6166	W 19991105

JP 2000336063	A2	20001205	JP 1999-315210	19991105
			JP 1998-328792	A 19981105
			JP 1999-80693	A 19990325
EP 1127869	A1	20010829	EP 1999-954398	19991105
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
			JP 1998-328792	A 19981105
			JP 1999-80693	A 19990325
			WO 1999-JP6166	W 19991105
BR 9915090	A	20011030	BR 1999-15090	19991105
			JP 1998-328792	A 19981105
			JP 1999-80693	A 19990325
			WO 1999-JP6166	W 19991105
NZ 511489	A	20030829	NZ 1999-511489	19991105
			JP 1998-328792	A 19981105
			JP 1999-80693	A 19990325
			WO 1999-JP6166	W 19991105
AU 769778	B2	20040205	AU 2000-10778	19991105
			JP 1998-328792	A 19981105
			JP 1999-80693	A 19990325
			WO 1999-JP6166	W 19991105

OS MARPAT 132:347371


AB Title compds. I [wherein N1 represents an atom to which a donor hydrogen atom in a hydrogen bond donor group is bonded or a hydrogen bond acceptor atom in a hydrogen bond acceptor group; N3 represents a hydrogen bond acceptor atom in a hydrogen bond acceptor group; and N2, N4 and N5 represent each an arbitrary carbon atom constituting a hydrophobic group; having an atom corresponding to N3 and atoms corresponding to at least two atoms selected from N1, N2, N4 and N5 among the five atoms constituting a pharmacophore specified by the interat. distances among N1, N2, N3, N4 and N5; and, in the optimized stereochem. structure thereof, the interat. distances between the atom corresponding to N3 and atoms corresponding to at least two atoms selected from N1, N2, N4 and N5 fall within the scope of the pharmacophore interat. distance], stereoisomers, or salts thereof are prepared Because of having an effect of inhibiting the activity of a transcription factor AP-1, these compds. are useful as preventives/remedies for diseases in which the excessive expression of AP-1 participates and as AP-1 inhibitors. The title compds. II, III, IV, and V were prepared

IT 268564-23-4P 268564-25-6P 268564-26-7P
 268564-56-3P 268564-57-4P 268564-59-6P
 268564-60-9P 268564-61-0P 268564-62-1P
 268564-65-4P 269081-85-8P 269081-86-9P
 269082-74-8P 269082-75-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of medicinal useful compds. as AP-1 inhibitors in prevention and treatment of diseases)


RN 268564-23-4 CAPLUS

CN 2-Propenoic acid, 3-[5-[2,4-bis(2-methylpropoxy)benzoyl]-2-(2-methylpropoxy)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 268564-25-6 CAPLUS

CN 2-Propenoic acid, 3-[5-[2,4-bis(2-methylpropoxy)benzoyl]-2-(2-methylpropoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 268564-26-7 CAPLUS

CN 2-Propenoic acid, 3-[5-[[2,4-bis(2-methylpropoxy)phenyl]hydroxymethyl]-2-(2-methylpropoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 268564-56-3 CAPLUS

CN Acetic acid, [5-[2,4-bis(2-methylpropoxy)benzoyl]-2-(3-methylbutoxy)phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 268564-57-4 CAPLUS

CN Acetic acid, [5-[2,4-bis(3-methylbutoxy)benzoyl]-2-(3-methylbutoxy)phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 268564-59-6 CAPLUS

CN Acetic acid, [5-[2,4-bis(2-methylpropoxy)benzoyl]-2-(2-methylpropoxy)phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 268564-60-9 CAPLUS

CN Acetic acid, [5-[2,4-bis(2-methylpropoxy)benzoyl]-2-(2-methylpropoxy)phenoxy]- (9CI) (CA INDEX NAME)




RN 268564-61-0 CAPLUS

CN Acetic acid, [5-[2,4-bis(2-methylpropoxy)benzoyl]-2-(3-methylbutoxy)phenoxy]- (9CI) (CA INDEX NAME)




RN 268564-62-1 CAPLUS

CN Acetic acid, [5-[2,4-bis(3-methylbutoxy)benzoyl]-2-(3-methylbutoxy)phenoxy]-(9CI) (CA INDEX NAME)




RN 268564-65-4 CAPLUS

CN Benzenepropanamide, 5-[2,4-bis(2-methylpropoxy)benzoyl]-2-(2-methylpropoxy)-N-(methylsulfonyl)-(9CI) (CA INDEX NAME)




RN 269081-85-8 CAPLUS

CN 2-Butenoic acid, 4-[5-[2,4-bis(2-methylpropoxy)benzoyl]-2-(2-methylpropoxy)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 269081-86-9 CAPLUS

CN 2-Butenoic acid, 4-[5-[2,4-bis(2-methylpropoxy)benzoyl]-2-(3-methylbutoxy)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 269082-74-8 CAPLUS

CN 2-Butenoic acid, 4-[5-[2,4-bis(2-methylpropoxy)benzoyl]-2-(2-methylpropoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 269082-75-9 CAPLUS

CN 2-Butenoic acid, 4-[5-[2,4-bis(2-methylpropoxy)benzoyl]-2-(3-methylbutoxy)phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 34 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2000:290989 CAPLUS

DN 132:321722

TI Preparation of N-(2-arylpropionyl)sulfonamides as inhibitors of neutrophil chemotaxis and degranulation induced by interleukin 8.

IN Bertini, Riccardo; Bizzarri, Cinzia; Sabbatini, Vilma; Porzio, Stefano; Caselli, Gianfranco; Allegretti, Marcello; Cesta, Maria Candida; Gandolfi, Carmelo A.; Mantovanini, Marco; Colotta, Francesco

PA Dompe' S.P.A., Italy; et al.

SO PCT Int. Appl., 41 pp.

CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000024710	A1	20000504	WO 1999-EP7740	19991014
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	IT 1303249	B1	20001106	IT 1998-MI2280	A 19981023
	CA 2347752	AA	20000504	IT 1998-MI2280	19981023
				CA 1999-2347752	19991014
				IT 1998-MI2280	A 19981023
				WO 1999-EP7740	W 19991014
	BR 9914741	A	20010703	BR 1999-14741	19991014
				IT 1998-MI2280	A 19981023
				WO 1999-EP7740	W 19991014
	EP 1123276	A1	20010816	EP 1999-953824	19991014
	EP 1123276	B1	20030108		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
				IT 1998-MI2280	A 19981023
				WO 1999-EP7740	W 19991014
	TR 200101124	T2	20011022	TR 2001-200101124	19991014
				IT 1998-MI2280	A 19981023
	EE 200100233	A	20020815	EE 2001-233	19991014
				IT 1998-MI2280	A 19981023
				WO 1999-EP7740	W 19991014
	JP 2002528434	T2	20020903	JP 2000-578281	19991014
				IT 1998-MI2280	A 19981023
				WO 1999-EP7740	W 19991014
	AT 230723	E	20030115	AT 1999-953824	19991014
				IT 1998-MI2280	A 19981023
				WO 1999-EP7740	W 19991014
	PT 1123276	T	20030430	PT 1999-953824	19991014
				IT 1998-MI2280	A 19981023
	ES 2190264	T3	20030716	ES 1999-953824	19991014
				IT 1998-MI2280	A 19981023
	NZ 511077	A	20030829	NZ 1999-511077	19991014
				IT 1998-MI2280	A 19981023
				WO 1999-EP7740	W 19991014
	AU 769850	B2	20040205	AU 2000-10375	19991014
				IT 1998-MI2280	A 19981023
				WO 1999-EP7740	W 19991014
	NO 2001002000	A	20010620	NO 2001-2000	20010423
				IT 1998-MI2280	A 19981023
				WO 1999-EP7740	W 19991014
	US 6887903	B1	20050503	US 2001-830075	20011121
				IT 1998-MI2280	A 19981023
				WO 1999-EP7740	W 20011121
	NZ 525084	A	20040827	NZ 2003-525084	20030401
				IT 1998-MI2280	A 19981023
	US 2003216392	A1	20031120	US 2003-460203	20030613
	US 6881755	B2	20050419		

IT 1998-MI2280	A 19981023
WO 1999-EP7740	W 19991014
US 2001-830075	A3 20011121

OS MARPAT 132:321722

AB R2CHMeCONR1SO2R (R2 = aryl; R = alkyl, CF3, cyclohexyl, o-tolyl, 3-pyridyl, 2-pyridylethyl, p-cyanophenylmethyl, p-aminophenylmethyl, 3-cyano-1-Pr, 4-aminobutyl, etc.; R1 = H, alkyl), were prepared. Thus, (R)-2-(4-isobutylphenyl)propionyl chloride in MeCN was added to NH3 in H2O at 0-5° to give (R)-2-(4-isobutylphenyl)propionamide. Title compds. inhibited chemotaxis of PMN human leukocytes with IC50 = 10-7 to 10-9M.

IT 266359-85-7P 266359-86-8P 266359-90-4P

266359-91-5P 266359-92-6P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-(2-arylpropionyl)sulfonamides as inhibitors of neutrophil chemotaxis and degranulation induced by interleukin 8)

RN 266359-85-7 CAPLUS

CN Benzeneacetamide, 3-benzoyl- α -methyl-N-(methylsulfonyl)-, (α R) - (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 266359-86-8 CAPLUS

CN Benzeneacetamide, 3-benzoyl- α -methyl-N-(methylsulfonyl)-, (α S) - (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 266359-90-4 CAPLUS

CN Benzeneacetamide, 3-(hydroxyphenylmethyl)- α -methyl-N-(methylsulfonyl)-, (α R) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 266359-91-5 CAPLUS


CN Benzeneacetamide, α-methyl-N-(methylsulfonyl)-3-(phenylmethyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 266359-92-6 CAPLUS

CN Benzeneacetamide, 2-(acetyloxy)-5-benzoyl-α-methyl-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 35 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2000:130260 CAPLUS

DN 132:264938

TI Synthesis and antimicrobial activity of 1,1,1-trichloro-2-(4'-carboxymethoxyphenyl)-2-(carboxyaryl/carboxymethoxyaryl)ethanes

AU Purohit, D. M.; Shah, V. H.

CS Chemistry Department, Saurashtra University, Rajkot, 360 005, India

SO Journal of the Institution of Chemists (India) (1999), 71(2), 58-59

CODEN: JOICA7; ISSN: 0020-3254

PB Institution of Chemists (India)

DT Journal

LA English

AB Title compds. such as I were prepared from phenoxyacetic acid and chloral hydrate via 4-Cl₃CCH(OH)C₆H₄OCH₂CO₂H. Most of the products showed moderate to significant antibacterial and antifungal activity.


IT 263139-25-9P 263139-26-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and antimicrobial activity of)


RN 263139-25-9 CAPLUS

CN Acetic acid, [4-[1-[5-(carboxymethoxy)-2-chlorophenyl]-2,2,2-trichloroethyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 263139-26-0 CAPLUS

CN Acetic acid, [4-[1-[3-(carboxymethoxy)-4-nitrophenyl]-2,2,2-trichloroethyl]phenoxy]- (9CI) (CA INDEX NAME)



L7 ANSWER 36 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2000:130258 CAPLUS

DN 132:264937

TI Synthesis and antimicrobial screening of 1,1,1-trichloro-2-(4'-carboxymethoxy-3'-methylphenyl)-2-(carboxyaryl/carboxymethoxyaryl)ethanes

AU Purohit, D. M.; Shah, V. H.

CS Department of Chemistry, Saurashtra University, Rajkot, 360 005, India

SO Journal of the Institution of Chemists (India) (1999), 71(2), 56-57

CODEN: JOICA7; ISSN: 0020-3254

PB Institution of Chemists (India)

DT Journal

LA English

AB Title compds. such as I were prepared from 2-MeC6H4OCH2CO2H and chloral hydrate via II. The products showed moderate to good antimicrobial activity as compared to known standard drugs, ampicillin, chloramphenicol, norfloxacin and griseofulvin.


IT **263141-80-6P 263141-81-7P 263141-82-8P 263141-83-9P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)


(preparation and antimicrobial activity of)

RN 263141-80-6 CAPLUS


CN Acetic acid, [4-[1-[3-(carboxymethoxy)-4-chlorophenyl]-2,2,2-trichloroethyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 263141-81-7 CAPLUS
 CN Acetic acid, [4-[1-[5-(carboxymethoxy)-2-chlorophenyl]-2,2,2-trichloroethyl]-2-methylphenoxy] - (9CI) (CA INDEX NAME)



RN 263141-82-8 CAPLUS
 CN Acetic acid, [5-[1-[4-(carboxymethoxy)-3-methylphenyl]-2,2,2-trichloroethyl]-2-nitrophenoxy] - (9CI) (CA INDEX NAME)



RN 263141-83-9 CAPLUS
 CN Acetic acid, [3-[1-[4-(carboxymethoxy)-3-methylphenyl]-2,2,2-trichloroethyl]-4-nitrophenoxy] - (9CI) (CA INDEX NAME)



L7 ANSWER 37 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1999:783939 CAPLUS

DN 132:22755
 TI Preparation of aromatic and heteroaromatic 4-aryl-2,4-dioxobutyric acid derivatives useful as HIV integrase inhibitors
 IN Young, Steven D.; Egbertson, Melissa; Payne, Linda S.; Wai, John S.; Fisher, Thorsten E.; Guare, James P., Jr.; Embrey, Mark W.; Tran, Lee; Zhuang, Linghang; Vacca, Joseph P.; Langford, Marie; Melamed, Jeffrey; Clark, David L.; Medina, Julio C.; Jaen, Juan
 PA Merck and Co., Inc., USA
 SO PCT Int. Appl., 319 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9962520	A1	19991209	WO 1999-US12093	19990601
	W: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			US 1998-87820P GB 1998-15175 CA 1999-2333707 US 1998-87820P GB 1998-15175 WO 1999-US12093 AU 1999-42254 US 1998-87820P GB 1998-15175 WO 1999-US12093 EP 1999-926094 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO US 1998-87820P GB 1998-15175 WO 1999-US12093 US 1999-323417 US 1998-87820P JP 2000-551776 US 1998-87820P WO 1999-US12093	P 19980603 A 19980713 19990601 P 19980603 A 19980713 W 19990601 19990601 P 19980603 A 19980713 W 19990601 19990601 19990601 19990601 P 19980603 A 19980713 W 19990601 P 19980603 19990601 P 19980603 W 19990601
	CA 2333707	AA	19991209		
	AU 9942254	A1	19991220		
	EP 1082121	A1	20010314		
	US 6380249	B1	20020430		
	JP 2002516863	T2	20020611		

OS MARPAT 132:22755
 AB Certain six-membered aromatic and heteroarom. 2,4-dioxobutyric acid derivs. are described, specifically compds. ArCOCH₂COCO₂R [I; Ar = certain (un)substituted (hetero)aromatic groups; R = H, C1-6 alkyl]. I are inhibitors of HIV integrase, and are useful as inhibitors of HIV replication. The compds. are thus useful in the prevention or treatment of infection by HIV and the treatment of AIDS, either as compds., pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals [e.g., the HIV protease inhibitor indinavir], immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described. Over 200 specific compds. were prepared and/or claimed. For instance, title compound II was prepared as follows: (1) lithiation of 1,3-dibromobenzene and reaction with 5-methylthiophene-2-carboxaldehyde; (2) reduction of the resultant alc. with Et₃SiH to give 2-(3-bromobenzyl)-5-methylthiophene; (3) lithiation of the latter bromide

and acetylation with AcN(Me)OMe; (4) condensation of the resultant Me ketone with di-Et oxalate; and (5) alkaline hydrolysis of the obtained Et ester. Representative compds. I inhibited HIV replication in T-lymphoid cells with IC95 values < 10 μ M, and had IC50 values of < 1 μ M in reference integrase and preintegration complex assays (no addnl. data).


IT 251964-65-5P, 4-(7-Benzylbenzo[1,3]dioxol-5-yl)-2-hydroxy-4-oxobut-2-enoic acid

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compound; preparation of aromatic and heteroarom. aryldioxobutyric acid
derivs. as HIV integrase inhibitors)

RN 251964-65-5 CAPLUS

CN 2-Butenoic acid, 2-hydroxy-4-oxo-4-[7-(phenylmethyl)-1,3-benzodioxol-5-yl]-
(9CI) (CA INDEX NAME)



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 38 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1999:780157 CAPLUS

DN 132:122347

TI Synthesis and antimicrobial screening of 1,1,1-trichloro-2-[3-(carboxymethoxy)-4-chlorophenyl]-2-(carboxyaryl/carboxymethoxyaryl)ethanes

AU Purohit, D. M.; Shah, V. H.

CS Chemistry Department, Saurashtra University, Rajkot, 360005, India

SO Journal of the Institution of Chemists (India) (1999), 71(1), 37-39

CODEN: JOICA7; ISSN: 0020-3254

PB Institution of Chemists (India)

DT Journal

LA English

AB Title compds. such as I were prepared from benzyl alc. derivative II and substituted benzenes in the presence of concentrated sulfuric acid. The products were active against Gram pos. and neg. bacteria and fungi.

IT 256379-76-7P 256379-77-8P 256379-78-9P

256379-79-0P 256379-80-3P 256379-81-4P

256379-82-5P 256379-83-6P 256379-84-7P

256379-85-8P 256379-86-9P 256379-87-0P

256379-88-1P 256379-89-2P 256379-90-5P


256379-91-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and antimicrobial activity of)


RN 256379-76-7 CAPLUS

CN Benzoic acid, 5-[1-[3-(carboxymethoxy)-4-chlorophenyl]-2,2,2-trichloroethyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 256379-77-8 CAPLUS

CN Benzoic acid, 3-[1-[3-(carboxymethoxy)-4-chlorophenyl]-2,2,2-trichloroethyl]- (9CI) (CA INDEX NAME)




RN 256379-78-9 CAPLUS

CN Benzeneacetic acid, 4-[1-[3-(carboxymethoxy)-4-chlorophenyl]-2,2,2-trichloroethyl]-alpha-(phenylmethylene)- (9CI) (CA INDEX NAME)




RN 256379-79-0 CAPLUS

CN Benzeneacetic acid, 4-[1-[3-(carboxymethoxy)-4-chlorophenyl]-2,2,2-trichloroethyl]- (9CI) (CA INDEX NAME)




RN 256379-80-3 CAPLUS


CN Benzoic acid, 5-[1-[3-(carboxymethoxy)-4-chlorophenyl]-2,2,2-trichloroethyl]-2-hydroxy- (9CI) (CA INDEX NAME)




RN 256379-81-4 CAPLUS
 CN 1,2-Benzenedicarboxylic acid, 4-[1-[3-(carboxymethoxy)-4-chlorophenyl]-2,2,2-trichloroethyl]- (9CI) (CA INDEX NAME)




RN 256379-82-5 CAPLUS
 CN 1,4-Benzenedicarboxylic acid, 2-[1-[3-(carboxymethoxy)-4-chlorophenyl]-2,2,2-trichloroethyl]- (9CI) (CA INDEX NAME)




RN 256379-83-6 CAPLUS
 CN Benzoic acid, 5-[1-[3-(carboxymethoxy)-4-chlorophenyl]-2,2,2-trichloroethyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 256379-84-7 CAPLUS
 CN Benzoic acid, 3-[1-[3-(carboxymethoxy)-4-chlorophenyl]-2,2,2-trichloroethyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 256379-85-8 CAPLUS
 CN Benzoic acid, 5-[1-[3-(carboxymethoxy)-4-chlorophenyl]-2,2,2-trichloroethyl]-2-chloro- (9CI) (CA INDEX NAME)




RN 256379-86-9 CAPLUS

CN Benzoic acid, 3-[1-[3-(carboxymethoxy)-4-chlorophenyl]-2,2,2-trichloroethyl]-4-chloro- (9CI) (CA INDEX NAME)




RN 256379-87-0 CAPLUS

CN Benzoic acid, 3-[1-[3-(carboxymethoxy)-4-chlorophenyl]-2,2,2-trichloroethyl]-5-methoxy- (9CI) (CA INDEX NAME)




RN 256379-88-1 CAPLUS

CN Acetic acid, [3-[1-[3-(carboxymethoxy)-4-chlorophenyl]-2,2,2-trichloroethyl]-4-chlorophenoxy]- (9CI) (CA INDEX NAME)




RN 256379-89-2 CAPLUS

CN Acetic acid, [5-[1-[3-(carboxymethoxy)-4-chlorophenyl]-2,2,2-trichloroethyl]-2-nitrophenoxy]- (9CI) (CA INDEX NAME)




RN 256379-90-5 CAPLUS

CN Acetic acid, [4-[1-[3-(carboxymethoxy)-4-chlorophenyl]-2,2,2-trichloroethyl]-3-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 256379-91-6 CAPLUS

CN Acetic acid, [3-[1-[3-(carboxymethoxy)-4-chlorophenyl]-2,2,2-trichloroethyl]-4-methylphenoxy]- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 39 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1999:626040 CAPLUS

DN 131:257570

TI Preparation of phenylmethylbenzoquinones as NF-κB inhibitors

IN Nunokawa, Yoichi; Suzuki, Kenji; Saitoh, Masayuki

PA Suntory Limited, Japan

SO PCT Int. Appl., 159 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 9948491	A1	19990930	WO 1999-JP1422	19990319

W: AU, CA, CN, HU, JP, KR, US
 RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
 PT, SE

CA 2290630	AA	19990930	JP 1998-92431	A	19980320
			CA 1999-2290630		19990319
			JP 1998-92431	A	19980320
			WO 1999-JP1422	W	19990319
AU 9928543	A1	19991018	AU 1999-28543		19990319
			JP 1998-92431	A	19980320
			WO 1999-JP1422	W	19990319
EP 1008346	A1	20000614	EP 1999-909284		19990319
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
			JP 1998-92431	A	19980320
			WO 1999-JP1422	W	19990319
US 2004030129	A1	20040212	US 2002-243737		20020916
			JP 1998-92431	A	19980320
			WO 1999-JP1422	W	19990319
			US 1999-424059	A1	19991118

OS MARPAT 131:257570


AB The title compds. I [R1, R2 and R3 independently represent each H, C1-5 alkyl or C1-5 alkoxy; R4 represents H, hydroxymethyl, alkyl, etc.; Z is phenylene, etc.; and n is 0 to 6] are prepared The title compound II showed IC50 of 21 μ M against TNF- α production in RAW 264.7 cells stimulated by lipopolysaccharide. (Stimulation of cells by lipopolysaccharide causes the activation NF- κ B, followed by production of TNF- α).

IT 245088-54-4

RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of phenylmethylbenzoquinones as NF- κ B inhibitors)

RN 245088-54-4 CAPLUS

CN 2-Propenoic acid, 3-[3-[(2,3,4,5-tetramethoxy-6-methylphenyl)methyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 40 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1999:533606 CAPLUS

DN 131:286234

TI Synthesis of 1,1,1-trichloro-2,2-bis(carboxymethoxyaryl)ethanes as potential antimicrobial and insecticidal agents

AU Purohit, D. M.; Shah, V. H.

CS Department of Chemistry, Saurashtra University, Rajkot, 360 005, India

SO Indian Journal of Chemistry, Section B: Organic Chemistry Including

Medicinal Chemistry (1999), 38B(5), 618-622

CODEN: IJSBDB; ISSN: 0376-4699

PB National Institute of Science Communication, CSIR

DT Journal

LA English

AB Some new 1,1,1-trichloro-2,2-bis(carboxymethoxyaryl)ethanes have been synthesized by treating aryloxyacetic acids (2 mol) with chloral hydrate (1 mol) in the presence of a catalytic amount of concentrated sulfuric acid.

The aryloxyacetic acids are prepared by reaction of phenols with chloroacetic acid in the presence of aqueous sodium hydroxide. The antimicrobial activities of these compds. have been assayed against Gram pos. and Gram neg. bacteria and fungi; insecticidal activities have been examined against the rice leaf hopper.


IT 246149-78-0P 246149-79-1P 246149-81-5P
246149-84-8P 246149-85-9P 246149-86-0P
246149-87-1P 246149-88-2P 246149-89-3P
246149-90-6P 246149-92-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and antimicrobial and insecticidal activity of)


RN 246149-78-0 CAPLUS

CN Acetic acid, 2,2'-[(2,2,2-trichloroethylidene)bis[(5,6-dichloro-3,1-phenylene)oxy]]bis- (9CI) (CA INDEX NAME)




RN 246149-79-1 CAPLUS

CN Acetic acid, 2,2'-[(2,2,2-trichloroethylidene)bis[(4,6-dichloro-3,1-phenylene)oxy]]bis- (9CI) (CA INDEX NAME)




RN 246149-81-5 CAPLUS

CN Acetic acid, 2,2'-[(2,2,2-trichloroethylidene)bis[(2,4,6-trichloro-3,1-phenylene)oxy]]bis- (9CI) (CA INDEX NAME)




RN 246149-84-8 CAPLUS

CN Acetic acid, 2,2'-[(2,2,2-trichloroethylidene)bis[(4-methyl-3,1-phenylene)oxy]]bis- (9CI) (CA INDEX NAME)




RN 246149-85-9 CAPLUS

CN Acetic acid, 2,2'-[(2,2,2-trichloroethylidene)bis[(4,6-dimethyl-3,1-phenylene)oxy]]bis- (9CI) (CA INDEX NAME)




RN 246149-86-0 CAPLUS

CN Acetic acid, 2,2'-[(2,2,2-trichloroethylidene)bis[(2,5-dimethyl-3,1-phenylene)oxy]]bis- (9CI) (CA INDEX NAME)




RN 246149-87-1 CAPLUS

CN Acetic acid, 2,2'-[(2,2,2-trichloroethylidene)bis[(2-nitro-3,1-phenylene)oxy]]bis- (9CI) (CA INDEX NAME)




RN 246149-88-2 CAPLUS

CN Acetic acid, 2,2'-[(2,2,2-trichloroethylidene)bis[(5-nitro-3,1-phenylene)oxy]]bis- (9CI) (CA INDEX NAME)




RN 246149-89-3 CAPLUS

CN Acetic acid, 2,2'-[(2,2,2-trichloroethylidene)bis[(4-nitro-3,1-phenylene)oxy]]bis- (9CI) (CA INDEX NAME)




RN 246149-90-6 CAPLUS

CN Acetic acid, 2,2',2'',2'''-[(2,2,2-trichloroethylidene)bis[4,1,2-benzenetriylbis(oxy)]]tetrakis- (9CI) (CA INDEX NAME)



RN 246149-92-8 CAPLUS

CN Acetic acid, 2,2',2'',2'''-[(2,2,2-trichloroethylidene)bis[2,1,4-benzenetriylbis(oxy)]]tetrakis- (9CI) (CA INDEX NAME)




RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 41 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1999:453001 CAPLUS
DN 131:266542
TI Carboxylic Acid Analogues of Tamoxifen: (Z)-2-[p-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine. Estrogen Receptor Affinity and Estrogen Antagonist Effects in MCF-7 Cells
AU Kraft, Kelly S.; Ruenitz, Peter C.; Bartlett, Michael G.
CS College of Pharmacy, University of Georgia, Athens, GA, 30602-2352, USA
SO Journal of Medicinal Chemistry (1999), 42(16), 3126-3133
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
AB The triarylethylene estrogen mimetic (E,Z)-4-[1-(p-hydroxyphenyl)-2-phenyl-1-butenyl]phenoxyacetic acid (I) represents a novel class of estrogen receptor (ER) ligands which, like tamoxifen (II), can elicit estrogen agonist and antagonist effects, in turn, in nonreproductive and reproductive tissues. Analogs of I, incorporating structural features shown previously in triarylethylenes to improve ER affinity and estrogen antagonist properties, were prepared with the ultimate aim of identifying substances with improved estrogenicity exclusive of reproductive tissues. Thus, the side chain of I was elongated to give oxybutyric acid derivative (III), which was further altered by (a) repositioning of its p-hydroxyl to the neighboring m-position (IV) and (b) ethylenic bond reduction (V). Also, the p-hydroxyl group and oxyacetic acid groups of I were, in turn, shifted to the neighboring m-positions, affording 8 and 9. III had about 2 times the affinity for human ER α as I, and its antiproliferative effect in MCF-7 cells was greater than II. V, which was conformationally similar to cis-III, had very low ER affinity and antiestrogenicity, and IV also had reduced ER affinity and potency, but its MCF-7 cell antiproliferative efficacy was retained. Modest ER affinity and antiproliferative potency were seen in which phenolic and Ph rings were trans to one another, but 9 in which these rings were cis, was inactive. Therefore, 2-carbon side-chain elongation and/or m-positioning of the hydroxyl group in I affords analogs with dominant estrogen antagonist effects in MCF-7 cells.
IT **245556-89-2P 245556-90-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(carboxylic acid analogs of tamoxifen, (Z)-2-[p-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine, estrogen receptor affinity and estrogen antagonist effects in MCF-7 cells)
RN 245556-89-2 CAPLUS
CN Acetic acid, [3-[(1E)-2-phenyl-1-[4-(phenylmethoxy)phenyl]-1-


butenyl]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 245556-90-5 CAPLUS

CN Acetic acid, [3-[2-phenyl-1-[4-(phenylmethoxy)phenyl]butyl]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)




IT 203917-15-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(carboxylic acid analogs of tamoxifen, (Z)-2-[p-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine, estrogen receptor affinity and estrogen antagonist effects in MCF-7 cells)

RN 203917-15-1 CAPLUS

CN Acetic acid, [3-[(1E)-1-(4-hydroxyphenyl)-2-phenyl-1-butenyl]phenoxy]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 42 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1999:285722 CAPLUS
 DN 131:102065
 TI Synthesis of 1,1,1-trichloro-2-(2',4'-dichloro-5'-carboxymethoxyphenyl)-2-(carboxyaryl/carboxymethoxyaryl)ethanes as possible antimicrobial agents
 AU Purohit, D. M.; Shah, V. H.
 CS Department of Chemistry, Saurashtra University, Rajkot, 360 005, India
 SO Indian Journal of Heterocyclic Chemistry (1999), 8(3), 209-212
 CODEN: IJCHEI; ISSN: 0971-1627
 PB Prof. R. S. Varma
 DT Journal
 LA English
 AB The title compds. I (R = HO₂C, HO₂CCH₂:CH, HO₂CCH₂, HO₂CCH₂O; R₁ = H, HO₂C, Me, Cl, MeO, NO₂, HO₂CCH₂O) were prepared by reaction of 2,4-Cl₂C₆H₃OCH₂CO₂H with chloral hydrate in the presence of concentrated H₂SO₄ to afford the (trichloroethyl)phenoxyacetic acid II. II reacted with RR₁C₆H₄ in the presence of a catalytic amount of concentrated H₂SO₄ to give I. All products were screened for antimicrobial activity. The mol. structures of the products were supported by IR, PMR, and mass spectroscopy and elemental anal.
 IT 231628-58-3P 231628-59-4P 231628-60-7P
 231628-61-8P 231628-62-9P 231628-63-0P
 231628-64-1P 231628-65-2P 231628-66-3P
 231628-67-4P 231628-68-5P 231628-69-6P
 231628-70-9P 231628-71-0P 231628-72-1P
 231628-73-2P 231628-74-3P 231628-75-4P
 231628-76-5P 231628-77-6P 231628-78-7P
 231628-79-8P 231628-80-1P 231628-81-2P
 231628-82-3P 231628-83-4P 231628-84-5P
 231628-85-6P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and bactericidal/fungicidal activities of [(carboxymethoxy)dichlorophenyl]trichloroethanes)
 RN 231628-58-3 CAPLUS
 CN Benzoic acid, 3-[1-[5-(carboxymethoxy)-2,4-dichlorophenyl]-2,2,2-trichloroethyl]- (9CI) (CA INDEX NAME)




RN 231628-59-4 CAPLUS
 CN 2-Propenoic acid, 3-[4-[1-[5-(carboxymethoxy)-2,4-dichlorophenyl]-2,2,2-trichloroethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 231628-60-7 CAPLUS

CN Benzeneacetic acid, 4-[1-[5-(carboxymethoxy)-2,4-dichlorophenyl]-2,2,2-trichloroethyl]- (9CI) (CA INDEX NAME)




RN 231628-61-8 CAPLUS

CN 1,2-Benzenedicarboxylic acid, 4-[1-[5-(carboxymethoxy)-2,4-dichlorophenyl]-2,2,2-trichloroethyl]- (9CI) (CA INDEX NAME)




RN 231628-62-9 CAPLUS

CN 1,3-Benzenedicarboxylic acid, 5-[1-[5-(carboxymethoxy)-2,4-dichlorophenyl]-2,2,2-trichloroethyl]- (9CI) (CA INDEX NAME)




RN 231628-63-0 CAPLUS

CN 1,4-Benzenedicarboxylic acid, 2-[1-[5-(carboxymethoxy)-2,4-dichlorophenyl]-2,2,2-trichloroethyl]- (9CI) (CA INDEX NAME)




RN 269082-37-3 CAPLUS

CN Benzenepropanoic acid, 2-(3-methylbutoxy)-5-[4-(3-methylbutoxy)-2-(2-methylpropoxy)benzoyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 269082-39-5 CAPLUS

CN Benzenepropanoic acid, 5-[2-methoxy-4-(2-methylpropoxy)benzoyl]-2-(2-methylpropoxy)-, methyl ester (9CI) (CA INDEX NAME)




RN 269082-41-9 CAPLUS

CN Benzenepropanoic acid, 5-[2-(4-ethoxy-4-oxobutoxy)-4-(2-methylpropoxy)benzoyl]-2-(2-methylpropoxy)-, methyl ester (9CI) (CA INDEX NAME)




2




RN 231628-64-1 CAPLUS

CN Benzoic acid, 5-[1-[5-(carboxymethoxy)-2,4-dichlorophenyl]-2,2,2-trichloroethyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 231628-65-2 CAPLUS

CN Benzoic acid, 3-[1-[5-(carboxymethoxy)-2,4-dichlorophenyl]-2,2,2-trichloroethyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 231628-66-3 CAPLUS

CN Benzoic acid, 3-[1-[5-(carboxymethoxy)-2,4-dichlorophenyl]-2,2,2-trichloroethyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 231628-67-4 CAPLUS


CN Benzoic acid, 5-[1-[5-(carboxymethoxy)-2,4-dichlorophenyl]-2,2,2-trichloroethyl]-2-chloro- (9CI) (CA INDEX NAME)




RN 231628-68-5 CAPLUS
 CN Benzoic acid, 3-[1-[5-(carboxymethoxy)-2,4-dichlorophenyl]-2,2,2-trichloroethyl]-5-chloro- (9CI) (CA INDEX NAME)




RN 231628-69-6 CAPLUS
 CN Benzoic acid, 3-[1-[5-(carboxymethoxy)-2,4-dichlorophenyl]-2,2,2-trichloroethyl]-4-chloro- (9CI) (CA INDEX NAME)



RN 231628-70-9 CAPLUS
 CN Benzoic acid, 5-[1-[5-(carboxymethoxy)-2,4-dichlorophenyl]-2,2,2-trichloroethyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 231628-71-0 CAPLUS
 CN Benzoic acid, 3-[1-[5-(carboxymethoxy)-2,4-dichlorophenyl]-2,2,2-trichloroethyl]-5-methoxy- (9CI) (CA INDEX NAME)




RN 231628-72-1 CAPLUS

CN Benzoic acid, 3-[1-[5-(carboxymethoxy)-2,4-dichlorophenyl]-2,2,2-trichloroethyl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 231628-73-2 CAPLUS

CN Benzoic acid, 2-(carboxymethoxy)-5-[1-[5-(carboxymethoxy)-2,4-dichlorophenyl]-2,2,2-trichloroethyl]- (9CI) (CA INDEX NAME)




RN 231628-74-3 CAPLUS

CN Acetic acid, [5-[1-[3-(carboxymethoxy)-4-chlorophenyl]-2,2,2-trichloroethyl]-2,4-dichlorophenoxy]- (9CI) (CA INDEX NAME)




RN 231628-75-4 CAPLUS


CN Acetic acid, [5-[1-[4-(carboxymethoxy)-2-chlorophenyl]-2,2,2-trichloroethyl]-2,4-dichlorophenoxy]- (9CI) (CA INDEX NAME)




RN 231628-76-5 CAPLUS
 CN Acetic acid, [5-[1-[5-(carboxymethoxy)-2-chlorophenyl]-2,2,2-trichloroethyl]-2,4-dichlorophenoxy]- (9CI) (CA INDEX NAME)




RN 231628-77-6 CAPLUS
 CN Acetic acid, [5-[1-[5-(carboxymethoxy)-2,4-dichlorophenyl]-2,2,2-trichloroethyl]-2-nitrophenoxy]- (9CI) (CA INDEX NAME)




RN 231628-78-7 CAPLUS
 CN Acetic acid, [4-[1-[5-(carboxymethoxy)-2,4-dichlorophenyl]-2,2,2-trichloroethyl]-3-nitrophenoxy]- (9CI) (CA INDEX NAME)




RN 231628-79-8 CAPLUS
 CN Acetic acid, [3-[1-[5-(carboxymethoxy)-2,4-dichlorophenyl]-2,2,2-trichloroethyl]-4-nitrophenoxy]- (9CI) (CA INDEX NAME)




RN 231628-80-1 CAPLUS
 CN Acetic acid, [5-[1-[5-(carboxymethoxy)-2,4-dichlorophenyl]-2,2,2-trichloroethyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 231628-81-2 CAPLUS
 CN Acetic acid, [4-[1-[5-(carboxymethoxy)-2,4-dichlorophenyl]-2,2,2-trichloroethyl]-3-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 231628-82-3 CAPLUS
 CN Acetic acid, [3-[1-[5-(carboxymethoxy)-2,4-dichlorophenyl]-2,2,2-trichloroethyl]-4-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 231628-83-4 CAPLUS
 CN Acetic acid, 2,2'-[[4-[1-[5-(carboxymethoxy)-2,4-dichlorophenyl]-2,2,2-trichloroethyl]-1,2-phenylene]bis(oxy)]bis- (9CI) (CA INDEX NAME)



RN 231628-84-5 CAPLUS
 CN Acetic acid, 2,2'-[[2-[1-[5-(carboxymethoxy)-2,4-dichlorophenyl]-2,2,2-trichloroethyl]-1,4-phenylene]bis(oxy)]bis- (9CI) (CA INDEX NAME)



RN 231628-85-6 CAPLUS
 CN Acetic acid, 2,2'-[[5-[1-[5-(carboxymethoxy)-2,4-dichlorophenyl]-2,2,2-trichloroethyl]-1,3-phenylene]bis(oxy)]bis- (9CI) (CA INDEX NAME)



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 43 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1999:231505 CAPLUS
 DN 130:272005
 TI Compositions and methods for treating respiratory disorders using naproxen and cetirizine
 IN Mitra, Sekhar
 PA The Procter & Gamble Company, USA
 SO PCT Int. Appl., 19 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9915173	A1	19990401	WO 1998-IB1339	19980828
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2304005	AA	19990401	US 1997-934033	A 19970919
			CA 1998-2304005	19980828
			US 1997-934033	A 19970919
			WO 1998-IB1339	W 19980828
AU 9887443	A1	19990412	AU 1998-87443	19980828
			US 1997-934033	A 19970919
			WO 1998-IB1339	W 19980828
EP 1014983	A1	20000705	EP 1998-938852	19980828
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				

			US 1997-934033	A	19970919
			WO 1998-IB1339	W	19980828
BR 9812660	A	20000822	BR 1998-12660		19980828
			US 1997-934033	A	19970919
			WO 1998-IB1339	W	19980828
JP 2001517626	T2	20011009	JP 2000-512542		19980828
			US 1997-934033	A	19970919
			WO 1998-IB1339	W	19980828

AB The present invention relates to compns. and methods for providing improved treatment, management or mitigation of cold, cold-like, allergy, sinus and/or flu symptoms by administering a safe and effective amount of a composition comprising naproxen along with cetirizine. E.g., a hard compressed tablet composition was prepared by combining naproxen sodium 220-440,

cetirizine

5, microcryst. cellulose 110, povidone 10, talc 12, Mg stearate 2 and Opadry clear/Colorcon (containing HPMC) 5.0 mg, resp. Oral administration of tablets every 12 h to human in need of treatment provides improved relief from cough, cold-like, flu, flu-like and allergic rhinitis symptoms.


IT **221887-12-3**

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. and methods for treating respiratory disorders using naproxen and cetirizine)

RN 221887-12-3 CAPLUS

CN L-Lysine, N2-[(2S)-2-(3-benzoylphenyl)-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 44 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1998:606867 CAPLUS

DN 129:302428

TI Thromboxane modulating agents. 4. Design and synthesis of 3-[2-[[[(4-chlorophenyl)sulfonyl]amino]ethyl]benzenepropanoic acid derivatives as potent thromboxane receptor antagonists

AU Dack, Kevin N.; Dickinson, Roger P.; Long, Clive J.; Steele, John
CS Department of Discovery Chemistry, Pfizer Central Research, Kent, CT13 9NJ, UK

SO Bioorganic & Medicinal Chemistry Letters (1998), 8(16), 2061-2066
CODEN: BMCLE8; ISSN: 0960-894X

PB Elsevier Science Ltd.

DT Journal

LA English

AB The design of a series of thromboxane receptor antagonists based on the title acid (I) is described. Addition of an arylmethyl group at the 5-position of I gave exceptionally potent agents in vitro and in vivo, with II (UK-147,535) giving complete blockade of the TxA2 receptor for >12 h in dogs, following an oral dose of 0.1 mg/kg.

IT **214406-52-7P 214406-53-8P 214406-54-9P**

214406-55-0P 214406-60-7P 214406-61-8P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(3-[2-[[[4-chlorophenyl)sulfonyl]amino]ethyl]benzenepropanoic acid
derivs. as thromboxane receptor antagonists)

RN 214406-52-7 CAPLUS

CN 2-Propenoic acid, 3,3'-[5-[(4-fluorophenyl)hydroxymethyl]-1,3-phenylene]bis-, diethyl ester, (2E,2'E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 214406-53-8 CAPLUS

CN 2-Propenoic acid, 3,3'-[5-[hydroxy(2-methoxyphenyl)methyl]-1,3-phenylene]bis-, diethyl ester, (2E,2'E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 214406-54-9 CAPLUS

CN 2-Propenoic acid, 3,3'-[5-(hydroxyphenylmethyl)-1,3-phenylene]bis-, diethyl ester, (2E,2'E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 214406-55-0 CAPLUS

CN 2-Propenoic acid, 3,3'-[5-[(3-fluorophenyl)hydroxymethyl]-1,3-phenylene]bis-, diethyl ester, (2E,2'E)-(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 214406-60-7 CAPLUS

CN 2-Propenoic acid, 3-[3-bromo-5-[1-(4-fluorophenyl)-1-hydroxyethyl]phenyl]-, ethyl ester, (2E)-(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 214406-61-8 CAPLUS

CN 2-Propenoic acid, 3-[3-[(1E)-3-amino-3-oxo-1-propenyl]-5-[1-(4-fluorophenyl)ethenyl]phenyl]-, ethyl ester, (2E)-(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 45 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1998:591169 CAPLUS
DN 129:289960
TI Minor coumarins from *Calophyllum teysmannii* var. *inophylloide* and synthesis of cytotoxic calanone derivatives
AU Cao, Shu-Geng; Wu, Xiao-Hua; Sim, Keng-Yeow; Tan, Benny H. K.; Vittal, Jagadese J.; Pereira, Joan T.; Goh, Swee-Hock
CS Department Chemistry, National University Singapore, Singapore, 119260, Singapore
SO Helvetica Chimica Acta (1998), 81(8), 1404-1416
CODEN: HCACAV; ISSN: 0018-019X
PB Verlag Helvetica Chimica Acta AG
DT Journal
LA English
OS CASREACT 129:289960
AB A chemotaxonomic survey for biol. active compds. from Malaysian *Calophyllum* species led to the finding of new benzoylcoumarins, including an unusual prenylated 6-benzoylcoumarin, compds. I and II, and 2 uncommon coumarins with a pyran-4-one moiety fused at C(6) and C(7), all isolated from the bark of *C. teysmannii* var. *inophylloide*. Their structures were determined by spectroscopic anal. and chemical transformations. X-ray crystal-structure determination of I provided information on the conformational preferences of substituents in this class of coumarins. Addnl., the syntheses of the cytotoxic calanone II and of some related coumarins starting from 1,3,5-(HO)3C6H3 and PhCOCH2CO2Et are described.
IT **213834-98-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 213834-98-1 CAPLUS
CN 2-Propenoic acid, 3-(6-benzoyl-5,7-dimethoxy-2,2-dimethyl-2H-1-benzopyran-8-yl)-3-phenyl-, methyl ester, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L7 ANSWER 46 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1998:430728 CAPLUS
 DN 129:148826
 TI Preparation of hydroxamic acids and their use as antitumor agents
 IN Suzuki, Tsuneji; Tsuchiya, Katsutoshi; Saito, Akiko; Yamashita, Satoshi
 PA Mitsui Petrochemical Industries, Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 20 pp.
 CODEN: JKXXAF

DT Patent
 LA Japanese
 FAN. CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 10182583	A2	19980707	JP 1996-345797	19961225
				JP 1996-345797	19961225

OS MARPAT 129:148826
 AB Hydroxamic acids I [A = CH₂CH₂, CH:CH, C.tplbond.C; R₁, R₂ = H, NH₂, NO₂, OH, halo, C1-4 alkyl, C1-4 alkoxy, C1-4 (di)alkylamino, C1-4 alkylthio; Z = bond, CO, NHCO, CH₂; the bond A is at meta or para position against the terminal benzene ring] and their pharmacol. acceptable salts are prepared
 Amidation of 3-[4-(N,N-dimethyl)amino]benzoylcinnamic acid with H₂NOH.HCl gave the corresponding hydroxamic acid with 14% yield, which at 1 μM induced differentiation of A2780 cell.

IT **96251-93-3P 210705-48-9P 210705-49-0P**
210705-50-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of hydroxamic acids as antitumor agents)


RN 96251-93-3 CAPLUS
 CN 2-Propenoic acid, 3-(3-benzoylphenyl)-, ethyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 210705-48-9 CAPLUS
CN 2-Propenoic acid, 3-[3-[4-(dimethylamino)benzoyl]phenyl]-, ethyl ester,
(2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 210705-49-0 CAPLUS
CN 2-Propenoic acid, 3-[3-[4-(dimethylamino)benzoyl]phenyl]-, (2E)- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.



RN 210705-50-3 CAPLUS
CN 2-Propenoic acid, 3-(3-benzoylphenyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L7 ANSWER 47 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1998:430109 CAPLUS
DN 129:108898
TI Preparation of fungicidal benzophenones
IN Curtze, Jorgen; Rudolph, Christine Helene Gertrud; Schroder, Ludwig;
Albert, Guido; Rehnig, Annerose Edith Elise; Sieverding, Ewald Gerhard
PA American Cyanamid Co., USA
SO U.S., 22 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 5773663	A	19980630	US 1996-641592	19960501

US 5866722	A	19990202	US 1997-846345	19970430
			EP 1995-100792	A 19950120
			US 1996-641592	A3 19960501
US 5922919	A	19990713	US 1998-67096	19980427
			US 1996-641592	A3 19960501

PATENT FAMILY INFORMATION:

FAN 1996:718140

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CA 2167550	AA	19960721	CA 1996-2167550	19960118
				EP 1995-100792	A 19950120
				US 1995-479502	A 19950607
	US 5679866	A	19971021	US 1995-479502	19950607
				EP 1995-100792	A 19950120
	CZ 294096	B6	20041013	CZ 1996-89	19960111
				EP 1995-100792	A 19950120
				US 1995-479502	A 19950607
	EP 727141	A2	19960821	EP 1996-300285	19960115
	EP 727141	A3	19980128		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
				EP 1995-100792	A 19950120
				US 1995-479502	A 19950607
	ZA 9600304	A	19970715	ZA 1996-304	19960115
				EP 1995-100792	A 19950120
	AU 9642091	A1	19960801	AU 1996-42091	19960119
				EP 1995-100792	A 19950120
				US 1995-479502	A 19950607
	JP 08277243	A2	19961022	JP 1996-26047	19960119
				EP 1995-100792	A 19950120
				US 1995-479502	A 19950607
	BR 9600165	A	19980106	BR 1996-165	19960119
				EP 1995-100792	A 19950120
				US 1995-479502	A 19950607
	RU 2129788	C1	19990510	RU 1996-100845	19960119
				EP 1995-100792	A 19950120
	IN 183968	A	20000527	IN 1996-CA91	19960119
				US 1995-479502	A 19950607
	RO 117827	B1	20020830	RO 1996-100	19960119
				EP 1995-100792	A 19950120
				US 1995-479502	A 19950607
	CN 1134929	A	19961106	CN 1996-101014	19960122
				EP 1995-100792	A 19950120
				US 1995-479502	A 19950607
	TW 391957	B	20000601	TW 1996-85102973	19960312
				EP 1995-100792	A 19950120
				US 1995-479502	A 19950607
	AU 744632	B2	20020228	AU 1999-59535	19991118
	AU 9959535	A1	20000224		
				EP 1995-100792	A 19950120
	IN 186700	A	20011027	IN 2000-CA168	20000321
				US 1995-479502	A 19950607
				IN 1996-CA91	A 19960119

OS MARPAT 129:108898

AB The title compds. [I; R1 = alkyl; m = 1, 2, 4; R2 = halo, alkyl, alkoxy; R3 = alkyl, alkenyl; R4 = alkyl; R5 = alkoxy, alkenyloxy, alkynyloxy, etc.; n = 1-2; R6 = (un)substituted alkoxy; X, Y = O], useful for the control of phytopathogenic fungi and disease caused thereby, were prepared. Thus, reaction of 4-methylveratrol with 2,6-dichlorobenzoyl chloride in the presence of FeCl₃ afforded 91.4% I [R1 = Cl; R2 = 6-Cl; R3 = Me; R4 = Me; R5 = MeO; X = Y = O; m = 1; n = 0] which showed 100% control against


Erysiphe graminis f.sp. hordei and Erysiphe graminis f.sp. tritici at 100 ppm. There are further provided benzophenone compds. I which are useful as fungicidal agents and compns. useful for the protection of plants from the damaging effects of phytopathogenic fungi and fungal disease.

IT 183724-70-1P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of fungicidal benzophenones)

RN 183724-70-1 CAPLUS

CN Acetic acid, [5-(2,6-dichlorobenzoyl)-2-methoxy-4-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 48 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1998:352804 CAPLUS

DN 129:40990

TI Bi-aromatic compounds with RXR receptor activity, pharmaceutical and cosmetic compositions containing them, and their uses

IN Bernardon, Jean-Michel; Diaz, Philippe

PA Centre International de Recherches Dermatologiques Galderma (C.I.R.D. Galder, Fr.; Bernardon, Jean-Michel; Diaz, Philippe

SO PCT Int. Appl., 71 pp.

CODEN: PIXXD2

DT Patent

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9822423	A1	19980528	WO 1997-FR2063	19971117
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	FR 2755965	A1	19980522	FR 1996-14098	A 19961119
	FR 2755965	B1	19981218	FR 1996-14098	19961119
	CA 2243404	AA	19980528	CA 1997-2243404	19971117
	CA 2243404	C	20040120		
	AU 9852254	A1	19980610	FR 1996-14098	A 19961119
	AU 719468	B2	20000511	AU 1998-52254	19971117
				FR 1996-14098	A 19961119
				WO 1997-FR2063	W 19971117
	JP 11503472	T2	19990326	JP 1998-523275	19971117

JP 3232484	B2	20011126	FR 1996-14098	A	19961119
			WO 1997-FR2063	W	19971117
BR 9707153	A	19990406	BR 1997-7153		19971117
			FR 1996-14098	A	19961119
			WO 1997-FR2063	W	19971117
EP 915823	A1	19990519	EP 1997-947075		19971117
EP 915823	B1	20010418			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
			FR 1996-14098	A	19961119
			WO 1997-FR2063	W	19971117
AT 200661	E	20010515	AT 1997-947075		19971117
			FR 1996-14098	A	19961119
			WO 1997-FR2063	W	19971117
US 6258775	B1	20010710	US 1997-101622		19971117
			FR 1996-14098	A	19961119
			WO 1997-FR2063	W	19971117
JP 2001233821	A2	20010828	JP 2000-399456		19971117
			FR 1996-14098	A	19961119
			JP 1998-523275	A3	19971117
PT 915823	T	20010830	PT 1997-947075		19971117
			FR 1996-14098	A	19961119
ES 2158597	T3	20010901	ES 1997-947075		19971117
			FR 1996-14098	A	19961119
GR 3035762	T3	20010731	GR 2001-400605		20010419
			FR 1996-14098	A	19961119
			WO 1997-FR2063	W	19971117

OS MARPAT 129:40990

AB The invention concerns novel bi-aromatic compds. I [R1 = Me, CH2OR5, OR5, COR6; Y = (un)substituted CH:CH or C.tplbond.C; A = (un)substituted divalent (ortho or meta) benzene, furan, thiophene, or pyridine nucleus; X = O, S, SO, SO2, CO, C(:CH2), C(:CMe2), CH2, etc.; R2, R3 = H, alkyl, OR5, SR5, polyether; or R2R3 may form ring optionally substituted by Me or interrupted by O or S; R4 = H, halo, alkyl, OR5, polyether; R5 = H, alkyl, acyl; R6 = H, alkyl, (un)substituted NH2 or OH]. The compds. are agonists or antagonists of RXR receptors (no data), and can be used in pharmaceutical compns. for human or veterinary medicine (in particular for treating dermatol., rheumatic, respiratory, cardiovascular, and ophthalmol. disorders), as well as cosmetic compns. For instance, Friedel-Crafts acylation of 5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene with 3-iodobenzoyl chloride (54.6%), followed by Pd-catalyzed vinylation of the iodide with Me acrylate (77%), and hydrolysis of the resultant ester with aqueous NaOH in THF (86%), gave title compound II.


IT **208186-12-3P 208186-14-5P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of biarom. compds. with RXR receptor activity as pharmaceuticals and cosmetics)


RN 208186-12-3 CAPLUS

CN 2-Propenoic acid, 3-[3-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbonyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 208186-14-5 CAPLUS

CN 2-Propenoic acid, 3-[3-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)carbonyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)




IT 208185-39-1P 208185-43-7P 208185-45-9P
208185-51-7P 208185-57-3P 208185-58-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of biarom. compds. with RXR receptor activity as pharmaceuticals and cosmetics)


RN 208185-39-1 CAPLUS

CN 2-Propenoic acid, 3-[3-[1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 208185-43-7 CAPLUS

CN 2-Propenoic acid, 3-[3-[1-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)ethenyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 208185-45-9 CAPLUS

CN 2-Propenoic acid, 3-[3-[1-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)ethyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 208185-51-7 CAPLUS

CN 2-Propenoic acid, 3-[3-[1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 208185-57-3 CAPLUS

CN 2-Propenoic acid, 3-[3-[(hydroxyimino)(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 208185-58-4 CAPLUS

CN 2-Propenoic acid, 3-[3-[(hydroxyimino)(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)methyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



IT 208185-33-5P 208185-34-6P 208185-40-4P
208185-44-8P 208185-46-0P 208185-52-8P
208185-59-5P 208185-60-8P 208185-63-1P


208185-64-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of biarom. compds. with RXR receptor activity as pharmaceuticals and cosmetics)


RN 208185-33-5 CAPLUS

CN 2-Propenoic acid, 3-[3-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 208185-34-6 CAPLUS

CN 2-Propenoic acid, 3-[3-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 208185-40-4 CAPLUS

CN 2-Propenoic acid, 3-[3-[1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl]phenyl]- (9CI) (CA INDEX NAME)




RN 208185-44-8 CAPLUS

CN 2-Propenoic acid, 3-[3-[1-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)ethenyl]phenyl]- (9CI) (CA INDEX NAME)




RN 208185-46-0 CAPLUS

CN 2-Propenoic acid, 3-[3-[1-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 208185-52-8 CAPLUS

CN 2-Propenoic acid, 3-[3-[1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 208185-59-5 CAPLUS

CN 2-Propenoic acid, 3-[3-[(hydroxyimino)(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 208185-60-8 CAPLUS

CN 2-Propenoic acid, 3-[3-[(hydroxyimino)(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 208185-63-1 CAPLUS

CN 2-Propenoic acid, 3-[3-[(hydroxyamino)(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 208185-64-2 CAPLUS

CN 2-Propenoic acid, 3-[3-[(hydroxyamino)(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)methyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 49 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1998:178891 CAPLUS

DN 128:180197

TI A Scalable Synthesis of the Thromboxane Receptor Antagonist
3-[3-[2-(4-Chlorobenzenesulfonamido)ethyl]-5-(4-fluorobenzyl)phenyl]propionic Acid via a Regioselective Heck
Cross-Coupling Strategy

AU Waite, D. C.; Mason, C. P.

CS Department of Process Research and Development, Pfizer Central Research,
Sandwich/Kent, CT13 9NJ, UK

SO Organic Process Research & Development (1998), 2(2), 116-120
CODEN: OPRDFK; ISSN: 1083-6160

PB American Chemical Society

DT Journal

LA English

AB A regioselective Heck cross-coupling strategy is presented for the
large-scale preparation of the title compound (I). Com. available
3-bromo-5-iodobenzoic acid was first converted to the corresponding acid
chloride, and this was then condensed with 4-fluorobenzene via a

Friedel-Crafts acylation reaction to give 3-bromo-5-iodophenyl 4-fluorophenyl ketone. Regioselective cross-coupling with Et acrylate and then N-vinylphthalimide, each under phosphine-free Heck conditions, led to formation of Et 3-[3-(4-fluorobenzoyl)-5-(2-phthalimidovinyl)phenyl]propionate. Reduction of the benzophenone moiety and saturation of the olefin double bonds, followed by phthalimide ring cleavage, then gave Et 3-[3-(2-aminoethyl)-5-(4-fluorobenzoyl)phenyl]propionate monocation salt. This was converted to I via a two-step, one-pot procedure in which sulfonamide formation was achieved via condensation with 4-chlorobenzenesulfonyl chloride, followed by Et ester saponification. The

route

described avoids hazards identified with the original medicinal chemical based synthesis and allows bulk quantities of drug substance to be produced for toxicol. and clin. trials.


IT 203243-53-2P 203243-54-3P 203243-55-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of thromboxane receptor antagonist 3-[3-[2-(4-chlorobenzenesulfonamido)ethyl]-5-(4-fluorobenzoyl)phenyl]propionic acid)


RN 203243-53-2 CAPLUS

CN 2-Propenoic acid, 3-[3-bromo-5-(4-fluorobenzoyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 203243-54-3 CAPLUS

CN 2-Propenoic acid, 3-[3-[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethenyl]-5-(4-fluorobenzoyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 203243-55-4 CAPLUS


CN 2-Propenoic acid, 3-[3-[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethenyl]-5-[(4-fluorophenyl)methyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L7 ANSWER 50 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1998:152156 CAPLUS
DN 128:230533
TI Synthesis of novel heterocyclic 3-aryl-2-butenic acid retinoids
AU Gale, Jonathan B.; Calvo Vega, Mario
CS Centro de Investigaciones en Productos Naturales (CIPRONA), Escuela de
Quimica, Programa de Estudios de Posgrado, Universidad de Costa Rica, San
Jose, 2060, Costa Rica
SO Ingenieria y Ciencia Quimica (1997), 17(2), 58-60
CODEN: ICQUD9; ISSN: 0250-8303
PB Colegio Federado de Quimicos y de Ingenieros Quimicos de Costa Rica
DT Journal
LA English
AB Several heterocyclic benzophenone-like retinoids e.g. I (R = R1 = H; R =
H, R1 = Me; R = Me, R1 = H; X = O, CH2) containing a terminal methylcinnamic
acid moiety were prepared. The compds. were designed to mimic either
all-trans retinoic acid or 9-cis retinoic acid, depending on the Me
substitution pattern of the aromatic ring closest to the terminal carboxyl
group. The syntheses consist of three or four steps starting from a known
core benzothienyl system via a Heck-type aryl-vinyl coupling reaction.
IT 204638-02-8P 204638-03-9P 204638-06-2P
204638-09-5P 204638-42-6P 204638-43-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of novel benzothienyl 3-aryl-2-butenic acid retinoids)
RN 204638-02-8 CAPLUS
CN 2-Butenoic acid, 3-[3-[(2,3-dihydro-3,3-dimethylbenzo[b]thien-5-
yl)carbonyl]phenyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 204638-03-9 CAPLUS
CN 2-Butenoic acid, 3-[3-[1-(2,3-dihydro-3,3-dimethylbenzo[b]thien-5-
yl)ethenyl]phenyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 204638-06-2 CAPLUS

CN 2-Butenoic acid, 3-[3-[(2,3-dihydro-3,3-dimethylbenzo[b]thien-5-yl)carbonyl]phenyl]-, phenyl ester, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 204638-09-5 CAPLUS

CN 2-Butenoic acid, 3-[3-[(2,3-dihydro-3,3-dimethylbenzo[b]thien-5-yl)carbonyl]-4-methylphenyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 204638-42-6 CAPLUS

CN 2-Butenoic acid, 3-[3-[(2,3-dihydro-3,3-dimethylbenzo[b]thien-5-yl)carbonyl]-4-methylphenyl]-, phenyl ester, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 204638-43-7 CAPLUS

CN 2-Butenoic acid, 3-[3-[(2,3-dihydro-3,3-dimethylbenzo[b]thien-5-yl)carbonyl]-2-methylphenyl]-, phenyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




IT 204638-10-8P 204638-11-9P 204638-12-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of novel benzothienyl 3-aryl-2-butenic acid retinoids)

RN 204638-10-8 CAPLUS

CN 2-Butenoic acid, 3-[3-[(2,3-dihydro-3,3-dimethylbenzo[b]thien-5-yl)carbonyl]-2-methylphenyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 204638-11-9 CAPLUS

CN 2-Butenoic acid, 3-[3-[1-(2,3-dihydro-3,3-dimethylbenzo[b]thien-5-yl)ethenyl]-4-methylphenyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 204638-12-0 CAPLUS

CN 2-Butenoic acid, 3-[3-[1-(2,3-dihydro-3,3-dimethylbenzo[b]thien-5-yl)ethenyl]-2-methylphenyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 51 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1998:112555 CAPLUS

DN 128:181082

TI Light stabilizers based on benzophenone derivatives of hindered amines

IN Gaa, Karl; Zaeh, Matthias; Mehrer, Mathias; Pfahler, Gerhard; Staehrfeldt, Thomas

PA Clariant G.m.b.H., Germany

SO Ger. Offen., 18 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19631244	A1	19980212	DE 1996-19631244	19960802
EP 822221	A2	19980204	EP 1997-112675	19970724
EP 822221	A3	19981118		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
AU 9732364	A1	19980212	DE 1996-19631244	A 19960802
			AU 1997-32364	19970729
			DE 1996-19631244	A 19960802
CN 1173493	A	19980218	CN 1997-115494	19970730
			DE 1996-19631244	A 19960802
US 5919933	A	19990706	US 1997-903017	19970731
			DE 1996-19631244	A 19960802
CA 2212261	AA	19980202	CA 1997-2212261	19970801
			DE 1996-19631244	A 19960802

NO 9703555	A	19980203	NO 1997-3555	19970801
			DE 1996-19631244	A 19960802
JP 10158243	A2	19980616	JP 1997-208007	19970801
			DE 1996-19631244	A 19960802
ZA 9706879	A	19980804	ZA 1997-6879	19970801
			DE 1996-19631244	A 19960802
BR 9706713	A	19990518	BR 1997-6713	19970801
			DE 1996-19631244	A 19960802
SG 50030	A1	20000620	SG 1997-2770	19970802
			DE 1996-19631244	A 19960802

OS MARPAT 128:181082

AB Benzophenone derivs. of specified structure bearing hindered amine groups are light stabilizers with decreased rates of migration into and leaching out of organic materials. The reaction of benzophenone-2-carbonyl chloride with 2,2,6,6-tetramethyl-4-piperidinol in the presence of Et₃N gave 63% 2,2,6,6-tetramethyl-4-piperidinyl benzophenone-2-carboxylate (I). When polypropylene containing 0.1% I was exposed as a film to UV for 200 h, 67% of the I could not be extracted by CH₂Cl₂; vs. 28% with bis(tetramethylpiperidinyl) sebacate in place of I.

IT **203060-43-9P 203060-44-0P**


RL: IMF (Industrial manufacture); MOA (Modifier or additive use); PREP (Preparation); USES (Uses)

(light stabilizers based on benzophenone derivs. of hindered amines)


RN 203060-43-9 CAPLUS

CN Acetic acid, 2,2'-[[4-(4-nitrobenzoyl)-1,2-phenylene]bis(oxy)]bis-, bis(2,2,6,6-tetramethyl-4-piperidinyl) ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 203060-44-0 CAPLUS
CN Acetic acid, 2,2'-[[4-(3-nitrobenzoyl)-1,2-phenylene]bis(oxy)]bis-,
bis(2,2,6,6-tetramethyl-4-piperidiny) ester (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A



IT 203060-32-6P 203060-33-7P
RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and reaction with tetramethylpiperidines)
RN 203060-32-6 CAPLUS
CN Acetic acid, 2,2'-[[4-(4-nitrobenzoyl)-1,2-phenylene]bis(oxy)]bis-,
dimethyl ester (9CI) (CA INDEX NAME)



RN 203060-33-7 CAPLUS
 CN Acetic acid, 2,2'-[[4-(3-nitrobenzoyl)-1,2-phenylene]bis(oxy)]bis-,
 dimethyl ester (9CI) (CA INDEX NAME)



L7 ANSWER 52 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1998:67392 CAPLUS
 DN 128:201102
 TI Estrogenic tamoxifen derivatives: categorization of intrinsic
 estrogenicity in MCF-7 cells
 AU Ruenitz, Peter C.; Moore, Susan A.; Kraft, Kelly S.; Bourne, Caryl S.
 CS College of Pharmacy, University of Georgia, Athens, GA, 30602-2352, USA
 SO Journal of Steroid Biochemistry and Molecular Biology (1997), 63(4-6),
 203-209
 CODEN: JSBBEZ; ISSN: 0960-0760
 PB Elsevier Science Ltd.
 DT Journal
 LA English
 AB Triarylethylenes bearing acetic acid side chains, exemplified by
 4-[1-(p-hydroxyphenyl)-2-phenyl-1-butenyl]phenoxyacetic acid (4HTA), a
 derivative of tamoxifen (TAM), are of current interest as estrogen mimics
 lacking reproductive tract effects. Affinities for estrogen receptors
 (ER) and effects on cell growth kinetics of a diverse series of such
 compds. were compared with 4HTA, TAM, and with standard estrogens
 17 β -estradiol (E2) and chlorotrianisene (CTA) in MCF-7 cells. These
 compds. exhibited concentration dependent cell growth stimulation comparable to
 that of CTA but less than that of E2. Growth stimulation of the more
 potent compds. was antagonized by TAM, signifying that effects were
 mediated via interaction with ER. At concns. of 1 μ M or higher,
 compds. with efficacies less than that of E2 were weak antagonists of
 estradiol-stimulated growth. Both intracellular ER affinities and growth
 rate stimulation potencies of the triarylethylene acetic acids and the
 standard ER ligands varied over a range of nearly three orders of magnitude.
 Anal. of growth stimulatory potency as a function of ER affinity revealed
 dual parallel correlations: the potency/ER affinity ratios of 4HTA and
 four of its analogs was about 100-fold less than those of the
 hydroxytriarylethane and bisphenolic analogs and the three standard ER
 ligands. These results suggested that ER liganded with the latter
 substances is more 'effective' at nuclear effector sites than is ER

liganded with 4HTA and the other acidic triarylethylenes.

IT 203917-15-1


RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)

(estrogenic tamoxifen derivs. and categorization of intrinsic estrogenicity in MCF-7 cells)

RN 203917-15-1 CAPLUS

CN Acetic acid, [3-[(1E)-1-(4-hydroxyphenyl)-2-phenyl-1-butenyl]phenoxy]-(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 53 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1997:723427 CAPLUS

DN 128:22689

TI 1,1,1-Trichloro-2-[2,4,6-trichloro-5-(carboxymethoxy)phenyl]-2-(carboxymethoxy)ethanes

AU Purohit, D. M.; Shah, V. H.

CS Chemistry Department, Shri M and N Virani Science College, Rajkot, 5, India

SO Journal of the Institution of Chemists (India) (1997), 69(4), 120-122
CODEN: JOICA7; ISSN: 0020-3254

PB Institution of Chemists (India)

DT Journal

LA English

AB The preparation of the title compds., i.e., [[(carboxymethoxy)trichlorophenyl]trichlorohydroxyethyl]benzoic acid derivs., and their evaluation as antimicrobial agents (bactericides, fungicides) was reported.


IT 199337-62-7P 199337-65-0P 199337-68-3P
199337-69-4P 199337-71-8P 199337-72-9P
199337-74-1P 199337-75-2P 199337-77-4P
199337-87-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)


(preparation of [[(carboxymethoxy)trichlorophenyl]alkyl]benzoic acid derivs. as antimicrobial agents)

RN 199337-62-7 CAPLUS


CN Benzoic acid, 5-[1-[3-(carboxymethoxy)-2,4,6-trichlorophenyl]-2,2,2-trichloro-1-hydroxyethyl]-2-hydroxy- (9CI) (CA INDEX NAME)




RN 199337-65-0 CAPLUS
 CN 1,4-Benzenedicarboxylic acid, 2-[1-[3-(carboxymethoxy)-2,4,6-trichlorophenyl]-2,2,2-trichloro-1-hydroxyethyl]- (9CI) (CA INDEX NAME)




RN 199337-68-3 CAPLUS
 CN Benzoic acid, 3-[1-[3-(carboxymethoxy)-2,4,6-trichlorophenyl]-2,2,2-trichloro-1-hydroxyethyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 199337-69-4 CAPLUS
 CN Benzoic acid, 3-[1-[3-(carboxymethoxy)-2,4,6-trichlorophenyl]-2,2,2-trichloro-1-hydroxyethyl]-2-chloro- (9CI) (CA INDEX NAME)




RN 199337-71-8 CAPLUS
 CN Benzoic acid, 3-[1-[3-(carboxymethoxy)-2,4,6-trichlorophenyl]-2,2,2-trichloro-1-hydroxyethyl]-4-chloro- (9CI) (CA INDEX NAME)




RN 199337-72-9 CAPLUS
 CN Benzoic acid, 5-[1-[3-(carboxymethoxy)-2,4,6-trichlorophenyl]-2,2,2-trichloro-1-hydroxyethyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 199337-74-1 CAPLUS
 CN Benzoic acid, 3-[1-[3-(carboxymethoxy)-2,4,6-trichlorophenyl]-2,2,2-trichloro-1-hydroxyethyl]-4-methoxy- (9CI) (CA INDEX NAME)



RN 199337-75-2 CAPLUS
 CN Acetic acid, [3-[1-[4-(carboxymethoxy)-3-chlorophenyl]-2,2,2-trichloro-1-hydroxyethyl]-2,4,6-trichlorophenoxy]- (9CI) (CA INDEX NAME)




RN 199337-77-4 CAPLUS
 CN Acetic acid, [3-[1-[5-(carboxymethoxy)-2-chlorophenyl]-2,2,2-trichloro-1-hydroxyethyl]-2,4,6-trichlorophenoxy]- (9CI) (CA INDEX NAME)



RN 199337-87-6 CAPLUS

CN Acetic acid, [3-[1-[5-(carboxymethoxy)-2,4-dichlorophenyl]-2,2,2-trichloro-1-hydroxyethyl]-2,4,6-trichlorophenoxy]- (9CI) (CA INDEX NAME)




IT 199337-59-2P 199337-60-5P 199337-61-6P
 199337-63-8P 199337-64-9P 199337-66-1P
 199337-67-2P 199337-70-7P 199337-73-0P
 199337-76-3P 199337-78-5P 199337-79-6P
 199337-80-9P 199337-81-0P 199337-82-1P
 199337-83-2P 199337-84-3P 199337-85-4P
 199337-86-5P


RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of [[(carboxymethoxy)trichlorophenyl]alkyl]benzoic acid derivs.
 as antimicrobial agents)

RN 199337-59-2 CAPLUS


CN Benzoic acid, 3-[1-[3-(carboxymethoxy)-2,4,6-trichlorophenyl]-2,2,2-trichloro-1-hydroxyethyl]- (9CI) (CA INDEX NAME)




RN 199337-60-5 CAPLUS
 CN Benzeneacetic acid, 4-[1-[3-(carboxymethoxy)-2,4,6-trichlorophenyl]-2,2,2-trichloro-1-hydroxyethyl]- α -methylene- (9CI) (CA INDEX NAME)




RN 199337-61-6 CAPLUS
 CN Benzeneacetic acid, 4-[1-[3-(carboxymethoxy)-2,4,6-trichlorophenyl]-2,2,2-trichloro-1-hydroxyethyl]- (9CI) (CA INDEX NAME)




RN 199337-63-8 CAPLUS
 CN 1,2-Benzenedicarboxylic acid, 4-[1-[3-(carboxymethoxy)-2,4,6-trichlorophenyl]-2,2,2-trichloro-1-hydroxyethyl]- (9CI) (CA INDEX NAME)




RN 199337-64-9 CAPLUS
 CN 1,3-Benzenedicarboxylic acid, 5-[1-[3-(carboxymethoxy)-2,4,6-trichlorophenyl]-2,2,2-trichloro-1-hydroxyethyl]- (9CI) (CA INDEX NAME)




RN 199337-66-1 CAPLUS
 CN Benzoic acid, 5-[1-[3-(carboxymethoxy)-2,4,6-trichlorophenyl]-2,2,2-trichloro-1-hydroxyethyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 199337-67-2 CAPLUS
 CN Benzoic acid, 3-[1-[3-(carboxymethoxy)-2,4,6-trichlorophenyl]-2,2,2-trichloro-1-hydroxyethyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 199337-70-7 CAPLUS
 CN Benzoic acid, 3-[1-[3-(carboxymethoxy)-2,4,6-trichlorophenyl]-2,2,2-trichloro-1-hydroxyethyl]-5-chloro- (9CI) (CA INDEX NAME)




RN 199337-73-0 CAPLUS
 CN Benzoic acid, 3-[1-[3-(carboxymethoxy)-2,4,6-trichlorophenyl]-2,2,2-trichloro-1-hydroxyethyl]-5-methoxy- (9CI) (CA INDEX NAME)




RN 199337-76-3 CAPLUS
 CN Acetic acid, [3-[1-[4-(carboxymethoxy)-2-chlorophenyl]-2,2,2-trichloro-1-hydroxyethyl]-2,4,6-trichlorophenoxy]-(9CI) (CA INDEX NAME)



RN 199337-78-5 CAPLUS
 CN Acetic acid, [3-[1-[3-(carboxymethoxy)-4-nitrophenyl]-2,2,2-trichloro-1-hydroxyethyl]-2,4,6-trichlorophenoxy]-(9CI) (CA INDEX NAME)




RN 199337-79-6 CAPLUS
 CN Acetic acid, [3-[1-[4-(carboxymethoxy)-2-nitrophenyl]-2,2,2-trichloro-1-hydroxyethyl]-2,4,6-trichlorophenoxy]-(9CI) (CA INDEX NAME)




RN 199337-80-9 CAPLUS

CN Acetic acid, [3-[1-[5-(carboxymethoxy)-2-nitrophenyl]-2,2,2-trichloro-1-hydroxyethyl]-2,4,6-trichlorophenoxy]-(9CI) (CA INDEX NAME)




RN 199337-81-0 CAPLUS

CN Benzoic acid, 2-(carboxymethoxy)-5-[1-[3-(carboxymethoxy)-2,4,6-trichlorophenyl]-2,2,2-trichloro-1-hydroxyethyl]-(9CI) (CA INDEX NAME)





RN 199337-82-1 CAPLUS


CN Acetic acid, 2,2'-[[4-[1-[3-(carboxymethoxy)-2,4,6-trichlorophenyl]-2,2,2-trichloro-1-hydroxyethyl]-1,2-phenylene]bis(oxy)]bis-(9CI) (CA INDEX NAME)




RN 199337-83-2 CAPLUS
 CN Acetic acid, 2,2'-[[2-[1-[3-(carboxymethoxy)-2,4,6-trichlorophenyl]-2,2,2-trichloro-1-hydroxyethyl]-1,4-phenylene]bis(oxy)]bis- (9CI) (CA INDEX NAME)



RN 199337-84-3 CAPLUS
 CN Acetic acid, [3-[1-[4-(carboxymethoxy)-3-methylphenyl]-2,2,2-trichloro-1-hydroxyethyl]-2,4,6-trichlorophenoxy]- (9CI) (CA INDEX NAME)




RN 199337-85-4 CAPLUS
 CN Acetic acid, [3-[1-[4-(carboxymethoxy)-2-methylphenyl]-2,2,2-trichloro-1-hydroxyethyl]-2,4,6-trichlorophenoxy]- (9CI) (CA INDEX NAME)



RN 199337-86-5 CAPLUS

CN Acetic acid, [3-[1-[5-(carboxymethoxy)-2-methylphenyl]-2,2,2-trichloro-1-hydroxyethyl]-2,4,6-trichlorophenoxy]-(9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 54 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1997:698526 CAPLUS

DN 128:43408

TI Chiral resolution, configurational study and pharmacological profile of 2-phenoxypropionic acids

AU Azzolina, Ornella; Collina, Simona; Vercesi, Dina; Ghislandi, Victor; Bonabello, Angelo; Galmozzi, Maria Rosa

CS Dipartimento di Chimica Farmaceutica, Universita di Pavia, Pavia, 27100, Italy

SO Farmaco (1997), 52(6-7), 449-456

CODEN: FRMCE8; ISSN: 0014-827X

PB Societa Chimica Italiana

DT Journal

LA English

AB The racemates and several enantiomers of 2-phenoxypropionic acids, bearing alkyl, acetyl, benzyl, benzoyl, Ph, difluorophenyl, Cl, NO₂ groups on the aromatic moiety, were investigated as potential analgesic-antiinflammatory drugs. The enantiomers, whose absolute configuration has been previously determined by us, were prepared by chiral resolution of the diastereoisomeric salts

of the racemates with cynchonidine. The enantiomeric excess was determined by chiral chromatog. The chiroptical properties of the dextroisomers were investigated by CD. The pharmacol. properties of the racemates and the enantiomers were monitored by analgesic-antiinflammatory activity tests as well as by gastrotolerability and acute toxicity tests. Some compds. were shown to be superior to ASA and ketoprofen because they have higher or similar analgesic properties, with less gastroulcerogenetic activity. Furthermore low acute toxicity was found for the compds. with high values of ED₅₀. Correlations between the configuration of the enantiomers and their activity are not evident. For the most active compds., the activity of one of the enantiomers is superior to that of the racemates. This is particularly true for (S)-3, (R)-15 and (S)-18.


IT 74168-02-8

RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or

effector, except adverse); BSU (Biological study, unclassified); PRP
 (Properties); BIOL (Biological study)
 (chiral resolution, configuration and analgesic-antiinflammatory activity
 of 2-phenoxypropionic acids)

RN 74168-02-8 CAPLUS

CN Propanoic acid, 2-(3-benzoylphenoxy)- (9CI) (CA INDEX NAME)



IT 117852-25-2 117852-27-4

RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or
 effector, except adverse); BSU (Biological study, unclassified); PRP
 (Properties); BIOL (Biological study)
 (configuration and analgesic-antiinflammatory activity of
 2-phenoxypropionic acids)

RN 117852-25-2 CAPLUS


CN Cinchonan-9-ol, (8 α ,9R)-, mono[(R)-2-(3-benzoylphenoxy)propanoate]
 (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 117852-24-1

CMF C16 H14 O4

Absolute stereochemistry. Rotation (+).




CM 2

CRN 485-71-2

CMF C19 H22 N2 O

Absolute stereochemistry.




RN 117852-27-4 CAPLUS
CN Cinchonan-9-ol, (8 α ,9R)-, mono[(S)-2-(3-benzoylphenoxy)propanoate]
(salt) (9CI) (CA INDEX NAME)

CM 1

CRN 117852-26-3
CMF C16 H14 O4


Absolute stereochemistry. Rotation (-).



CM 2

CRN 485-71-2
CMF C19 H22 N2 O

Absolute stereochemistry.




RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 55 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1997:631661 CAPLUS
DN 127:242815
TI Anionic- and Lipophilic-Mediated Surface Binding Inhibitors of Human
Leukocyte Elastase
AU Regan, John; McGarry, Daniel; Bruno, Joseph; Green, Daniel; Newman, Jack;
Hsu, Chin-Yi; Kline, Jane; Barton, Jeffrey; Travis, Jeffrey; Choi, Yong
Mi; Volz, Francis; Pauls, Henry; Harrison, Richard; Zilberstein, Asher;
Ben-Sasson, Shmuel A.; Chang, Michael
CS Departments of Medicinal Chemistry and Inflammation Biology, Rhone-Poulenc
Rorer, Collegeville, PA, 19426, USA
SO Journal of Medicinal Chemistry (1997), 40(21), 3408-3422
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
AB We report the synthesis of a series of diphenylmethane-based oligomers
containing anionic and lipophilic functionalities that are potent inhibitors




IT 147067-39-8P 147067-41-2P 195601-58-2P
 195601-59-3P 195601-60-6P 195601-61-7P
 195601-62-8P 195601-63-9P 195601-64-0P

(synthesis of diphenylmethane-based oligomers as selective inhibitors of human leukocyte elastase)

CN Acetic acid, [2-[[5-(carboxymethoxy)-4-[[[5-(carboxymethoxy)-4-[[[5-(carboxymethoxy)-4-(hydroxymethyl)-2-(phenylmethoxy)phenyl]methyl]-2-(phenylmethoxy)phenyl]methyl]-2-(phenylmethoxy)phenyl]methyl]-4-hydroxyphenoxy]- (9CI) (CA INDEX NAME)





CN	Acetic acid, [2-[[5-(carboxymethoxy)-4-[[5-(carboxymethoxy)-4-[[5-(carboxymethoxy)-4-[[5-(carboxymethoxy)-4-[[5-(carboxymethoxy)-4-[[5-(carboxymethoxy)-4-(hydroxymethyl)-2-(phenylmethoxy)phenyl]methyl]-2-(phenylmethoxy)phenyl]methyl]-2-(phenylmethoxy)phenyl]methyl]-2-(phenylmethoxy)phenyl]methyl]-2-(phenylmethoxy)phenyl]methyl]-4-hydroxyphenoxy]- (9CI) (CA INDEX NAME)
----	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



RN 195601-58-2 CAPLUS



CN Acetic acid, [2-[[5-(carboxymethoxy)-4-[[5-(carboxymethoxy)-4-[[5-(carboxymethoxy)-4-[[5-(carboxymethoxy)-4-(hydroxymethyl)-2-(phenylmethoxy)phenyl]methyl]-2-(phenylmethoxy)phenyl]methyl]-2-(phenylmethoxy)phenyl]methyl]-2-(phenylmethoxy)phenyl]methyl]-4-hydroxyphenoxy] - (9CI) (CA INDEX NAME)





RN 195601-59-3 CAPLUS


CN Acetic acid, [2-[[4-[[5-(carboxymethoxy)-4-[[4-[[5-(carboxymethoxy)-4-[(5-hydroxy-2-methoxy-4-methylphenyl)methyl]-2-methoxyphenyl)methyl]-5-hydroxy-2-methoxyphenyl)methyl]-2-methoxyphenyl)methyl]-5-hydroxy-2-methoxyphenyl)methyl]-4-methoxyphenoxy] - (9CI) (CA INDEX NAME)




RN 195601-60-6 CAPLUS

CN Acetic acid, [2-[[4-[[5-(carboxymethoxy)-4-[[4-[[5-(carboxymethoxy)-2-methoxy-4-[[2-methoxy-5-[(2-methoxyethoxy)methoxy]-4-methylphenyl)methyl]phenyl)methyl]-2-methoxy-5-[(2-methoxyethoxy)methoxy]phenyl)methyl]-2-methoxyphenyl)methyl]-2-methoxy-5-[(2-methoxyethoxy)methoxy]phenyl)methyl]-4-methoxyphenoxy] - (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 195601-61-7 CAPLUS

CN Acetic acid, [2-[[4-[[5-(carboxymethoxy)-4-[[4-[[5-(carboxymethoxy)-4-[[4-(hydroxymethyl)-2-methoxy-5-(phenylmethoxy)phenyl]methyl]-2-methoxyphenyl]methyl]-2-methoxy-5-(phenylmethoxy)phenyl]methyl]-2-methoxyphenyl]methyl]-2-methoxy-5-(phenylmethoxy)phenyl]methyl]-4-hydroxyphenoxy] - (9CI) (CA INDEX NAME)



PAGE 1-A





RN 195601-62-8 CAPLUS


CN Acetic acid, [2-[[4-[[5-(carboxymethoxy)-4-[[4-[[5-(carboxymethoxy)-2-methoxy-4-[[2-methoxy-4-methyl-5-(3-phenylpropoxy)phenyl]methyl]phenyl]methyl]-2-methoxy-5-(3-phenylpropoxy)phenyl]methyl]-2-methoxyphenyl]methyl]-2-methoxy-5-(3-phenylpropoxy)phenyl]methyl]-4-methoxyphenoxy] - (9CI) (CA INDEX NAME)




RN 195601-63-9 CAPLUS

CN Acetic acid, [2-[[4-[[5-(carboxymethoxy)-4-[[4-[[5-(carboxymethoxy)-4-[[5-(hexyloxy)-2-methoxy-4-methylphenyl]methyl]-2-methoxyphenyl]methyl]-5-(hexyloxy)-2-methoxyphenyl]methyl]-2-methoxyphenyl]methyl]-5-(hexyloxy)-2-methoxyphenyl]methyl]-4-methoxyphenoxy] - (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 195601-64-0 CAPLUS

CN Acetic acid, [2-[[4-[[5-(carboxymethoxy)-4-[[4-[[5-(carboxymethoxy)-4-[[5-(cyclohexylmethoxy)-2-methoxy-4-methylphenyl]methyl]-2-methoxyphenyl]methyl]-5-(cyclohexylmethoxy)-2-methoxyphenyl]methyl]-2-methoxyphenyl]methyl]-5-(cyclohexylmethoxy)-2-methoxyphenyl]methyl]-4-methoxyphenoxy] - (9CI) (CA INDEX NAME)

PAGE 1-A





RE.CNT 70 THERE ARE 70 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 56 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1997:480922 CAPLUS
DN 127:121546
TI Synthesis of Functionalized Aromatic Oligomers from a Versatile Diphenylmethane Template
AU Bruno, J. G.; Chang, M. N.; Choi-Sledeski, Y. M.; Green, D. M.; McGarry, D. G.; Regan, J. R.; Volz, F. A.
CS Department of Medicinal Chemistry, Rhone-Poulenc Rorer, Collegeville, PA, 19426-0995, USA
SO Journal of Organic Chemistry (1997), 62(15), 5174-5190
CODEN: JOCEAH; ISSN: 0022-3263
PB American Chemical Society
DT Journal
LA English
AB An efficient synthesis of the functionalized diphenylmethane system I [R = H, R1 = CH2OCH2CH2OMe, R2 = OSi(CMe3)Ph2] is described. Selective unmasking of the latent phenol groups allowed the introduction of various appendages onto the diphenylmethane scaffold via simple alkylation, Mitsunobu etherification, and transition-metal-mediated C-C bond formation. Conversion to iodide I [R = I, R1 = Me, R2 = OSi(CMe3)Ph2] and benzylic zinc reagent I (R = H, R1 = CH2OCH2CH2OMe, R2 = ZnBr), followed by palladium(0)-mediated coupling of these derivs., provided homolog II. Repetitive application of this homologation protocol was used to prepare oligomers of chain length up to 16. Several examples of functional group manipulations on these higher order oligomers are presented. I [R = H, R1 = CH2OCH2CH2OMe, R2 = OSi(CMe3)Ph2] was also employed as a key building block in the synthesis of the elastase inhibitor III. The potential application of extended aromatic oligomers to the field of drug discovery is discussed.
IT 192698-68-3P 192698-69-4P 192698-70-7P
192698-83-2P 192698-84-3P 192698-85-4P
192698-86-5P 192698-87-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(functionalized aromatic oligomers from versatile diphenylmethane template)



RN

CN

CC(C)(C)[Si](c1ccccc1)(c2ccccc2)OCc3cc(OC)c(Cc4cc(OC)c(OC)c(Cc5cc(OC)c(Cc6cc(OC)c(COC(=O)C(C)(C)C)O6)c5)c4)c3Cc7cc(OC)c(COC(=O)C(C)(C)C)O7[illegible]


RN

CN




RN 192698-70-7 CAPLUS

CN Acetic acid, [3-[[3-[[5-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-3-[[3-[[5-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-3-[[3-[[5-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-3-[[3-formyl-2-methoxy-5-(phenylmethoxy)phenyl]methyl]-2-methoxyphenyl]methyl]-2-methoxy-5-(phenylmethoxy)phenyl]methyl]-2-methoxyphenyl]methyl]-2-methoxy-5-(phenylmethoxy)phenyl]methyl]-4-[(2-methoxyethoxy)methoxy]phenoxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




PAGE 1-B



RN 192698-83-2 CAPLUS

CN Benzoic acid, 5-[[2-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-4-[[3-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]-2-methoxy-5-(phenylmethoxy)phenyl]methyl]-5-(phenylmethoxy)phenyl]ethynyl]-2-[(2-methoxyethoxy)methoxy]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—CH₂—OMe

RN 192698-84-3 CAPLUS


CN Benzoic acid, 5-[2-[2-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-4-[[3-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]-2-methoxy-5-(phenylmethoxy)phenyl]methyl]-5-(phenylmethoxy)phenyl]ethyl]-2-[(2-methoxyethoxy)methoxy]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B


—CH₂—Ph



RN 192698-85-4 CAPLUS

CN Benzoic acid, 5-[2-[2-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-4-[[3-(hydroxymethyl)-2-methoxy-5-(phenylmethoxy)phenyl]methyl]-5-(phenylmethoxy)phenyl]ethyl]-2-[(2-methoxyethoxy)methoxy]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—CH₂—Ph

RN 192698-86-5 CAPLUS

CN Benzoic acid, 5-[2-[4-[[3-(bromomethyl)-2-methoxy-5-(phenylmethoxy)phenyl]methyl]-2-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-5-(phenylmethoxy)phenyl]ethyl]-2-[(2-methoxyethoxy)methoxy]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 1-B

—CH₂—Ph

RN 192698-87-6 CAPLUS
CN Benzoic acid, 3,3'-[1,2-ethanediylbis[[2-methoxy-5-(phenylmethoxy)-3,1-phenylene]methylene[2-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-5-(phenylmethoxy)-4,1-phenylene]-2,1-ethanediyl]]bis[6-[(2-methoxyethoxy)methoxy]-, dimethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A






—CH₂—OMe


IT 192698-71-8P 192698-73-0P 192698-88-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
(functionalized aromatic oligomers from versatile diphenylmethane template)

RN 192698-71-8 CAPLUS



CN Benzoic acid, 3-[[5-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-3-[[3-[[5-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-3-[[3-[[5-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-3-[[3-[[5-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-2-[(2-methoxyethoxy)methoxy]phenyl]methyl]-2-methoxy-5-(phenylmethoxy)phenyl]methyl]-2-methoxyphenyl]methyl]-2-methoxy-5-(phenylmethoxy)phenyl]methyl]-2-methoxyphenyl]methyl]-2-methoxy-5-(phenylmethoxy)phenyl]methyl]-2-methoxyphenyl]methyl]-2-methoxy-5-(phenylmethoxy)- (9CI) (CA INDEX NAME)





RN 192698-73-0 CAPLUS


CN Acetic acid, [3-[[5-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-3-[[5-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-3-[[5-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-3-[[5-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-3-[[5-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-2-[(2-methoxyethoxy)methoxy]phenyl]methyl]-2-methoxyphenyl]methyl]-2-methoxyphenyl]methyl]-2-methoxyphenyl]methyl]-2-methoxyphenyl]methyl]-4-methoxy-5-methylphenoxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




—CH₂—OMe

RN 192698-88-7 CAPLUS
 CN Benzoic acid, 3,3'-[1,2-ethanediylbis[[2-methoxy-5-(phenylmethoxy)-3,1-phenylene]methylene[2-(carboxymethoxy)-5-(phenylmethoxy)-4,1-phenylene]-2,1-ethanediyl]]bis[6-hydroxy- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RE.CNT 71 THERE ARE 71 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 57 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1997:271236 CAPLUS
 DN 127:4973
 TI 2-Arylmethyl-1,4-benzoquinones. II. Novel inhibitors of platelet aggregation: synthesis and pharmacological evaluation
 AU Suzuki, Kenji; Tatsuoka, Toshio; Ishihara, Takafumi; Ogino, Ryoko;

Miyazaki, Tomoko; Satoh, Fumio; Miyano, Seiji; Sumoto, Kunihiro
 CS Suntory Inst. Biomedical Res., Osaka, 618, Japan
 SO Chemical & Pharmaceutical Bulletin (1997), 45(4), 668-674
 CODEN: CPBTAL; ISSN: 0009-2363
 PB Pharmaceutical Society of Japan
 DT Journal
 LA English
 AB Two new series of 2-arylmethyl-1,4-benzoquinones I (R = Me, X = OCH₂CO₂H, OCH₂CO₂Et, OCH₂COR₁, Y = H, OCH₂CO₂H, OCH₂CO₂Et, OCH₂COR₁, R₁ = morpholino; R = OMe, X = OCH₂CO₂H, OCH₂CO₂Et, H, Y = H, OCH₂CO₂H, OCH₂CO₂Et, R₁ = morpholino), II (Y = CO₂Et, CONMe₂, COR₁, R₁ = morpholino, thiazino), and III (Y = CO₂Et, COR₁, R₁ = morpholino) were synthesized for evaluation of their pharmacol. activities. These compds. showed significant inhibition of platelet aggregation and some of them possessed a protective effect against endothelial cell injury. Structure-activity relationship studies indicated that I (R = Me, X = OCH₂CO₂Et, Y = H; R = Me, X = H, Y = OCH₂CO₂H) and II (Y = COR₁, R₁ = morpholino) (IV) are potent inhibitors of platelet aggregation induced by arachidonic acid (AA) with an IC₅₀ in the range of 1-10 µg/mL. Among them, IV showed a significant inhibitory activity against endothelial cell injury caused by hydrogen peroxide (H₂O₂) at 1 µM.
 IT **146476-33-7P**
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and platelet aggregation inhibitory activity of (arylmethyl)benzoquinones)
 RN 146476-33-7 CAPLUS
 CN Acetic acid, [3-[(2-hydroxy-3,4-dimethoxy-6-methylphenyl)methyl]phenoxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 58 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1997:97157 CAPLUS
 DN 126:157280
 TI Preparation of aromatic alkanolic acid and alkanol derivatives as antithrombotics
 IN Hashizume, Hiroichi; Hagiwara, Masaki; Myamae, Tetsuhisa; Ogawa, Masaji; Ppongo, Tomoko; Morikawa, Tadanori
 PA Fuji Yakuhin Kogyo Kk, Japan
 SO Jpn. Kokai Tokkyo Koho, 17 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

PI JP 08333287 A2 19961217 JP 1995-158813 19950602
 JP 1995-158813 19950602
 OS MARPAT 126:157280
 AB The title compds. I [A = (un)substituted benzene, etc.; X, Y = (O- or N-containing) alkylene; Z = amino, OH, carboxyl, aminocarbonyl, etc.] are prepared The title compds. in vitro showed IC50 values of 0.068 to 15.3 μ M against thrombin-induced platelet aggregation.
 IT **185995-33-9P**
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of aromatic alkanolic acid and alkanol derivs. as antithrombotics)
 RN 185995-33-9 CAPLUS
 CN Acetic acid, [3-([1,1':2',1''-terphenyl]-4'-ylmethyl)phenoxy]- (9CI) (CA INDEX NAME)



L7 ANSWER 59 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1997:13364 CAPLUS
 DN 126:89592
 TI Application of the Heck reaction in the synthesis of truncated naphthoic acid retinoids
 AU Yu, Kuo-Long; Chen, Simin; Ostrowski, Jacek; Tramposch, Kenneth M.; Reczek, Peter R.; Mansuri, Muzammil M.; Starrett, John E., Jr.
 CS Pharm. Res. Inst., Bristol-Myers Squibb Co., Wallingford, CT, 06492, USA
 SO Bioorganic & Medicinal Chemistry Letters (1996), 6(23), 2859-2864
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier
 DT Journal
 LA English
 OS CASREACT 126:89592
 AB A series of truncated naphthoic acid retinoids have been prepared using the Heck reaction These retinoids were evaluated in the RAR transactivation assay in vitro and in the utriculi reduction assay in vivo. It has been found that the naphthalene ring of the retinoids is crucial for their retinoid activity and receptor selectivity.
 IT **185685-39-6P**
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
 (synthesis of truncated naphthoic acid retinoids via Heck reaction)
 RN 185685-39-6 CAPLUS
 CN 2-Propenoic acid, 3-[3-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbonyl]phenyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 185685-41-0P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(synthesis of truncated naphthoic acid retinoids via Heck reaction)

RN 185685-41-0 CAPLUS

CN 2-Propenoic acid, 3-[3-[hydroxy(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)methyl]phenyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 185685-59-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(synthesis of truncated naphthoic acid retinoids via Heck reaction)

RN 185685-59-0 CAPLUS

CN 2-Propenoic acid, 3-[3-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbonyl]phenyl]-, methyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 60 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1996:718140 CAPLUS

DN 126:7819

TI Preparation of benzophenone derivatives as agrochemical fungicides

IN Curtz, Juergen; Rudolph, Christine Helene Gertrud; Schroeder, Ludwig; Albert, Guido; Rehnig, Annerose Edith Elise; Sieverding, Ewald Gerhard

PA American Cyanamid Company, USA
 SO Can. Pat. Appl., 100 pp.
 CODEN: CPXXEB
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CA 2167550	AA	19960721	CA 1996-2167550	19960118
				EP 1995-100792	A 19950120
				US 1995-479502	A 19950607
	US 5679866	A	19971021	US 1995-479502	19950607
				EP 1995-100792	A 19950120
	CZ 294096	B6	20041013	CZ 1996-89	19960111
				EP 1995-100792	A 19950120
				US 1995-479502	A 19950607
	EP 727141	A2	19960821	EP 1996-300285	19960115
	EP 727141	A3	19980128		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
				EP 1995-100792	A 19950120
				US 1995-479502	A 19950607
	ZA 9600304	A	19970715	ZA 1996-304	19960115
				EP 1995-100792	A 19950120
	AU 9642091	A1	19960801	AU 1996-42091	19960119
				EP 1995-100792	A 19950120
				US 1995-479502	A 19950607
	JP 08277243	A2	19961022	JP 1996-26047	19960119
				EP 1995-100792	A 19950120
				US 1995-479502	A 19950607
	BR 9600165	A	19980106	BR 1996-165	19960119
				EP 1995-100792	A 19950120
				US 1995-479502	A 19950607
	RU 2129788	C1	19990510	RU 1996-100845	19960119
				EP 1995-100792	A 19950120
	IN 183968	A	20000527	IN 1996-CA91	19960119
				US 1995-479502	A 19950607
	RO 117827	B1	20020830	RO 1996-100	19960119
				EP 1995-100792	A 19950120
				US 1995-479502	A 19950607
	CN 1134929	A	19961106	CN 1996-101014	19960122
				EP 1995-100792	A 19950120
				US 1995-479502	A 19950607
	TW 391957	B	20000601	TW 1996-85102973	19960312
				EP 1995-100792	A 19950120
				US 1995-479502	A 19950607
	AU 744632	B2	20020228	AU 1999-59535	19991118
	AU 9959535	A1	20000224		
				EP 1995-100792	A 19950120
	IN 186700	A	20011027	IN 2000-CA168	20000321
				US 1995-479502	A 19950607
				IN 1996-CA91	A 19960119

PATENT FAMILY INFORMATION:

FAN 1998:430109

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5773663	A	19980630	US 1996-641592	19960501
	US 5866722	A	19990202	US 1997-846345	19970430
				EP 1995-100792	A 19950120
				US 1996-641592	A3 19960501
	US 5922919	A	19990713	US 1998-67096	19980427

OS MARPAT 126:7819


AB The title compds. [I; R1 = halo, (un)substituted alkyl or alkoxy, cyano, NO₂; R2 = halo, (un)substituted alkyl or alkoxy, NO₂; or adjacent R1 and R2 combine together to form an (un)substituted CH:CHCH:CH, alkylene, oxyalkyleneoxy; R3 = H, halo, cyano, CO₂H, OH, NO₂, etc.; R4 = H, (un)substituted alkyl or acyl; R5 = H, halo, NO₂, aryloxy, etc.; R6 = halo, (un)substituted alkyl, alkenyl, alkynyl, etc.; X = O, S, NOR; R = H, (un)substituted alkyl, aralkyl, aryl, or acyl; Y = O, S, etc.; m = 0-4; n = 0-2] are prepared I are useful for controlling phytopathogenic fungi and fungi disease. Thus, 4-methylveratrol was reacted with 2,6-dichlorobenzoyl chloride in the presence of FeCl₃ to give 91.4% I (R1 = Cl, R2 = 6-Cl, R3 = R4 = Me, R5 = OMe, X = Y = O, m = 1, n = 0) (II). II at 100 ppm controlled 100% barley and wheat Erysiphe graminis.

IT 183724-70-1P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of benzophenone derivs. as agrochem. fungicides)

RN 183724-70-1 CAPLUS

CN Acetic acid, [5-(2,6-dichlorobenzoyl)-2-methoxy-4-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



L7 ANSWER 61 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1996:428170 CAPLUS

DN 125:100171

TI Positive-working resist composition with improved antihalation properties

IN Ozawa, Kakuei; Hayashi, Hiroshi; Ishihara, Misaki; Sone, Atsushi; Togo, Masami

PA Nippon Zeon Co, Japan

SO Jpn. Kokai Tokkyo Koho, 8 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN. CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 08087109	A2	19960402	JP 1994-248474	19940916
				JP 1994-248474	19940916

OS MARPAT 125:100171


AB The title resist composition contains an alkali-soluble phenolic resin, a quinonediazidesulfonate-type photosensitive agent, and a bisphenol compound I [R1, R2 = H, halo, OH, (substituted) alkyl, (substituted) alkoxy, OCOR₅, X, Y = CN, CO₂R₆, CO₂H, NO₂; R₅, R₆ = (substituted) alkyl]. A resist prepared by adding II to ZIR 9300 (pos.-working photoresist) showed high photosensitivity, high resolution, and improved focus depth and antihalation properties.

IT 178562-48-6P

RL: MOA (Modifier or additive use); PNU (Preparation, unclassified); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)


(pos.-working resist composition containing bisphenol compound)

RN 178562-48-6 CAPLUS
CN 2-Propenoic acid, 3,3'-[methylenebis(4,6-dihydroxy-3,1-phenylene)]bis[2-cyano-, diethyl ester (9CI) (CA INDEX NAME)




L7 ANSWER 62 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1996:420255 CAPLUS
DN 125:114415
TI The behavior of 4-triphenylmethyl-1,2-benzoquinone towards alkoxy-carbonylmethylene(triphenyl)phosphoranes and triphenylphosphine in acetic anhydride
AU Osman, Fayez H.; El-Samahy, Fatma A.
CS Dep. Pesticide Chem., Natl. Res. Cent., Cairo, 12622, Egypt
SO Phosphorus, Sulfur and Silicon and the Related Elements (1996), 108(1-4), 21-30
CODEN: PSSLEC; ISSN: 1042-6507
PB Gordon & Breach
DT Journal
LA English
AB The reaction of alkoxy-carbonylmethylenetriphenylphosphoranes with 4-(triphenylmethyl)-1,2-benzoquinone (I) in acetic anhydride at room temperature for 7 h led to the formation of alkyl (6-acetoxy- α,α,α -triphenyl-m-tolyl)fumarates, alkyl (6-acetoxy- α,α,α -triphenyl-m-tolyl)maleates, benzofuran derivs., 3,4-diacetoxytetraphenylmethane and triphenylphosphine and triphenylphosphine oxide. The reactions of I with triphenylphosphine were also studied. Possible reaction mechanisms were considered.
IT 179125-07-6P 179125-11-2P 179125-12-3P
179125-16-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(reaction of (triphenylmethyl)benzoquinone with (phosphoranylidene)acetates or triphenylphosphine)
RN 179125-07-6 CAPLUS
CN 2-Butenedioic acid, 2-[2-(acetyloxy)-5-(triphenylmethyl)phenyl]-, dimethyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 179125-11-2 CAPLUS
CN 2-Butenedioic acid, 2-[2-hydroxy-5-(triphenylmethyl)phenyl]-, dimethyl ester, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 179125-12-3 CAPLUS
CN 2-Butenedioic acid, 2-[2-hydroxy-5-(triphenylmethyl)phenyl]-, diethyl ester, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 179125-16-7 CAPLUS
CN 2-Butenedioic acid, 2-[2-(acetyloxy)-5-(triphenylmethyl)phenyl]-, dimethyl ester, (Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



IT 179125-09-8P 179125-10-1P 179125-13-4P
179125-18-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(reaction of (triphenylmethyl)benzoquinone with
(phosphoranylidene)acetates or triphenylphosphine)
RN 179125-09-8 CAPLUS

CN 2-Butenedioic acid, 2-[2-(acetyloxy)-5-(triphenylmethyl)phenyl]-, diethyl ester, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 179125-10-1 CAPLUS

CN 2-Butenedioic acid, 2-[2-(acetyloxy)-5-(triphenylmethyl)phenyl]-, diethyl ester, (Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 179125-13-4 CAPLUS

CN 2-Butenedioic acid, 2-[2-methoxy-5-(triphenylmethyl)phenyl]-, diethyl ester, (Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 179125-18-9 CAPLUS


CN 2-Butenedioic acid, 2-[2-methoxy-5-(triphenylmethyl)phenyl]-, dimethyl ester, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




L7 ANSWER 63 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1996:80389 CAPLUS
 DN 124:231983
 TI 2-Arylmethyl-1,4-benzoquinones. I. Novel inhibitors of platelet aggregation: synthesis and pharmacological evaluation
 AU Suzuki, Kenji; Tatsuoka, Toshio; Murakami, Tomiko; Ishihara, Takafumi; Aisaka, Kazuo; Inoue, Teruyoshi; Ogino, Ryoko; Kuroki, Manami; Miyazaki, Tomoko; et al.
 CS Suntory Inst. for Biomedical Research, Osaka, 618, Japan
 SO Chemical & Pharmaceutical Bulletin (1996), 44(1), 139-44
 CODEN: CPBTAL; ISSN: 0009-2363
 PB Pharmaceutical Society of Japan
 DT Journal
 LA English
 AB A new series of 2-arylmethyl-1,4-benzoquinones was synthesized for evaluation of their pharmacol. activities. These compds. showed significant inhibition of platelet aggregation induced by arachidonic acid (AA) and some of them possessed a protective effect against endothelial cell injury caused by hydrogen peroxide.
 IT **174868-70-3P 174868-71-4P 174868-75-8P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of arylmethylbenzoquinone platelet aggregation inhibitors)
 RN 174868-70-3 CAPLUS
 CN 2-Propenoic acid, 3-[3-[(acetyloxy) (2,5-dimethoxy-3,4,6-trimethylphenyl)methyl]phenyl]-, ethyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 174868-71-4 CAPLUS
 CN 2-Propenoic acid, 3-[3-[(2,5-dimethoxy-3,4,6-trimethylphenyl)methyl]phenyl]-, ethyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 174868-75-8 CAPLUS
 CN 2-Propenoic acid, 3-[3-[(acetyloxy)[2-(acetyloxy)-3,4-dimethoxy-6-methylphenyl]methyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



L7 ANSWER 64 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1995:960190 CAPLUS
 DN 124:8796
 TI Preparation of 4,5-diaryloxazole derivatives as PGI2 agonists
 IN Taniguchi, Kiyoshi; Nagano, Masanobu; Hattori, Kouji; Tsubaki, Kazunori;
 Okitsu, Osamu; Tabuchi, Seiichiro
 PA Fujisawa Pharmaceutical Co., Ltd., Japan
 SO PCT Int. Appl., 115 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9517393	A1	19950629	WO 1994-JP2116	19941216
	W: AU, CA, CN, HU, JP, KR, RU, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
				GB 1993-25962	A 19931220
				GB 1994-22404	A 19941107
	CA 2179399	AA	19950629	CA 1994-2179399	19941216
				GB 1993-25962	A 19931220
				GB 1994-22404	A 19941107
	AU 9512006	A1	19950710	AU 1995-12006	19941216
	AU 686286	B2	19980205		
				GB 1993-25962	A 19931220
				GB 1994-22404	A 19941107
				WO 1994-JP2116	W 19941216
	EP 736018	A1	19961009	EP 1995-902969	19941216
	EP 736018	B1	20000705		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
				GB 1993-25962	A 19931220
				GB 1994-22404	A 19941107
				WO 1994-JP2116	W 19941216
	CN 1138328	A	19961218	CN 1994-194557	19941216
	CN 1046714	B	19991124		

			GB 1993-25962	A	19931220
			GB 1994-22404	A	19941107
JP 09506894	T2	19970708	JP 1994-517312		19941216
			GB 1993-25962	A	19931220
			GB 1994-22404	A	19941107
			WO 1994-JP2116	W	19941216
HU 76341	A2	19970828	HU 1996-1685		19941216
			GB 1993-25962	A	19931220
			GB 1994-22404	A	19941107
AT 194335	E	20000715	AT 1995-902969		19941216
			GB 1993-25962	A	19931220
			GB 1994-22404	A	19941107
			WO 1994-JP2116	W	19941216
ES 2147836	T3	20001001	ES 1995-902969		19941216
			GB 1993-25962	A	19931220
			GB 1994-22404	A	19941107
PT 736018	T	20001031	PT 1995-902969		19941216
			GB 1993-25962	A	19931220
			GB 1994-22404	A	19941107
RU 2176640	C2	20011210	RU 1996-115170		19941216
			GB 1993-25962	A	19931220
			GB 1994-22404	A	19941107
			WO 1994-JP2116	W	19941216
US 6025375	A	20000215	US 1998-92027		19980605
			GB 1993-25962	A	19931220
			GB 1994-22404	A	19941107
CN 1229795	A	19990929	CN 1998-116704		19980725
CN 1090184	B	20020904			
			GB 1993-25962	A	19931220
			GB 1994-22404	A	19941107
GR 3034542	T3	20010131	GR 2000-402232		20001004
			GB 1993-25962	A	19931220
			GB 1994-22404	A	19941107
			WO 1994-JP2116	W	19941216
OS	MARPAT 124:8796				
AB	Title compds. [I; R = R1A1OZA2Z1; A1 = alkylene; A2 = bond, alkylene; R1 = (protected)CO2H; R2,R3 = (un)substituted aryl; Z = phenylene; Z1 = phenylene, cycloalk(en)ylene(methylene)] were prepared Thus, Et 5(R)-acetoxy-1-cyclopentenecarboxylate was alkylated by the Grignard reagent from 3-(MeO)C6H4CH2Cl and the saponified product esterified by benzoin to give, after cyclization with NH4OAc and 3 addnl. steps, title compound (S)-II (III; n = 0). III (N = 1) gave 31.3% decrease in blood pressure in rats at 3.2mg/kg orally.				
IT	171045-88-8P 171046-23-4P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of 4,5-diaryloxazole derivs. as PGI2 agonists)				
RN	171045-88-8 CAPLUS				
CN	Acetic acid, [3-[[2-(4,5-diphenyl-2-oxazolyl)phenyl]methyl]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)				



RN 171046-23-4 CAPLUS

CN Acetic acid, [3-[[2-(4,5-diphenyl-2-oxazolyl)phenyl]methyl]phenoxy]-, sodium salt (9CI) (CA INDEX NAME)



● Na

L7 ANSWER 65 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1995:846535 CAPLUS

DN 123:256774

TI Preparation of benzodiazepine derivatives as ulcer inhibitors

IN Hagishita, Yamaji; Seno, Kaoru; Myakoshi, Masanori; Tsushima, Tadahiko; Ishihara, Yasunobu

PA Shionogi Seiyaku Kk, Japan

SO Jpn. Kokai Tokkyo Koho, 42 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 07097371	A2	19950411	JP 1993-242712	19930929
	JP 3257731	B2	20020218		
				JP 1993-242712	19930929

OS MARPAT 123:256774

AB The title compds. I [R1, R3 = H, halo, etc.; R2 = H, alkyl; R4 = single bond, CO; R5 = NH, etc.; R6 = alkylene; R7 = Q1, etc.] are prepared In an in vitro test for gastrin antagonism, the title compound II [n = 1]

(preparation


given) showed IC50 of 12 nM. In the above test, II [n = 2] showed IC50 of 25 nM.

IT 168762-78-5P 168762-79-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of benzodiazepine derivs. as ulcer inhibitors)


RN 168762-78-5 CAPLUS

CN Acetic acid, [3-[hydroxy[2-(methylamino)phenyl]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 168762-79-6 CAPLUS

CN Acetic acid, [3-[2-[(chloroacetyl)methylamino]benzoyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



L7 ANSWER 66 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1995:758633 CAPLUS

DN 123:169337

TI Preparation of aryloethanolamine derivatives useful for the treatment of gastrointestinal disorders

IN Shiokawa, Youichi; Taniguchi, Kiyoshi; Nagano, Masanobu; Take, Kazuhiko; Kato, Takeshi; Tsubaki, Kazunori; Tabuchi, Seiichiro

PA Japan

SO PCT Int. Appl., 85 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9425427	A1	19941110	WO 1994-JP671	19940422
	W: AU, CA, CN, HU, JP, KR, RU, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
				GB 1993-8618	A 19930426
				GB 1993-22238	A 19931028
	AU 9465812	A1	19941121	AU 1994-65812	19940422
				GB 1993-8618	A 19930426
				GB 1993-22238	A 19931028
				WO 1994-JP671	W 19940422
	HU 69285	A2	19950928	HU 1994-2835	19940422

			GB 1993-8618	A 19930426
			GB 1993-22238	A 19931028
JP 08509491	T2	19961008	JP 1994-524095	19940422
			GB 1993-8618	A 19930426
			GB 1993-22238	A 19931028
			WO 1994-JP671	W 19940422

OS MARPAT 123:169337

AB Title compds. I (R1 = aryl, (aryloxy)alkyl, heterocyclyl, each of which may be substituted; R2 = H, N-protective group; R3, R4 = acylalkoxy; A = alkylene), and pharmaceutically acceptable salts thereof, are prepared (-)-(1R)-N-benzyl-1-(3-chlorophenyl)-2-[[[(2S or 2R)-4,4-bis(4-ethoxycarbonylmethoxyphenyl)-2-butyl]amino]ethanol-HCl (preparation given), Pd/C involving water in PhCl and EtOH were stirred for 2 h to give after workup the title compound (-)-(1R)-1-(3-chlorophenyl)-2-[[[(2S or 2R)-4,4-bis(4-ethoxycarbonylmethoxyphenyl)-2-butyl]amino]ethanol-HCl. The usefulness of I was demonstrated. I are claimed for therapeutic treatment or prevention of dysuria, spasm, hyperanakinesia, ulcer, pancreatitis, obesity, diabetes, glaucoma and melancholia (no data).

IT 166960-96-9P 166961-07-5P 166961-08-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation or aryethanolamine derivs. useful for the treatment of gastrointestinal disorders)

RN 166960-96-9 CAPLUS


CN Acetic acid, 2,2'-[[[3-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propylidene]bis(3,1-phenyleneoxy)]bis-, diethyl ester, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 166960-95-8

CMF C31 H36 Cl N O7

Absolute stereochemistry.




CM 2

CRN 110-17-8


CMF C4 H4 O4

Double bond geometry as shown.



RN 166961-07-5 CAPLUS
 CN Acetic acid, 2,2'-[[3-[[2-(3-chlorophenyl)-2-hydroxyethyl](phenylmethyl)amino]propylidene]bis(3,1-phenyleneoxy)]bis-, diethyl ester, hydrochloride, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 166961-08-6 CAPLUS
 CN Acetic acid, 2,2'-[[4-[[2-(3-chlorophenyl)-2-hydroxyethyl](phenylmethyl)amino]butylidene]bis(3,1-phenyleneoxy)]bis-, diethyl ester, hydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT **166960-53-8P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation or aryethanolamine derivs. useful for the treatment of gastrointestinal disorders)
 RN 166960-53-8 CAPLUS
 CN Acetic acid, 2,2'-[[3-[(phenylmethyl)amino]propylidene]bis(3,1-phenyleneoxy)]bis-, diethyl ester (9CI) (CA INDEX NAME)



OS MARPAT 123:44372

AB The title composition comprises (1) 40-90% polymer compound in which 5-50 mol% of groups providing alkaline solubility is substituted with protective groups decomposable by an acid, (2) 10-55% compound which becomes alkaline soluble upon decomposition by an acid, and (3) 0.03-15% compound forming an acid upon irradiation of light. This composition provides a large solubility ratio of exposed and nonexposed regions of the resist film with a developer.


IT **163915-97-7**
RL: POF (Polymer in formulation); TEM (Technical or engineered material use); USES (Uses)
 (pos.-working resist composition and patterning using same)

RN 163915-97-7 CAPLUS

CN Acetic acid, 2,2'-[[5-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-2-methyl-1,3-phenylene]bis[methylene(4-methyl-3,1-phenylene)oxy]]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




L7 ANSWER 68 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1995:606099 CAPLUS
 DN 123:313491
 TI Chiral resolution of methyl 2-aryloxypropionates by biocatalytic stereospecific hydrolysis
 AU Azzolina, Ornella; Vercesi, Dina; Collina, Simona; Ghislandi, Victor
 CS Dip. Chim. Farmaceutica, Univ. Pavia, Pavia, 27100, Italy
 SO Farmaco (1995), 50(4), 221-6
 CODEN: FRMCE8
 PB Societa Chimica Italiana
 DT Journal
 LA English
 AB The hydrolysis of 2-aryloxypropionyl Me esters by α -chymotrypsin, lipase P and carboxylesterase NP was carried out to perform chiral resolution of their racemates. The biocatalytic activity of carboxylesterase NP was undoubtedly higher than that of the other enzymes: in fact the reaction rate was greater and the enantioselectivity values were better even though less amount of enzyme was employed. This enzyme was thus the most suitable to catalyze the stereoselective hydrolysis of the tested compds. in aqueous media. The reaction was also attempted in organic solvents. The evaluation of the produced acid and the unreacted ester was accomplished by chiral HPLC on Chiralcel OD, OD-H and Chiralpak AD columns. In general the configuration of the preferentially hydrolyzed enantiomer was S, but for all the compds. having an alkyl substituent (Me or ethyl) on the 2 position of the aromatic ring the enantioselectivity of the enzymic conversion was reverse. When compared, there did not appear to be any particular relationship between conversion, enantioselectivity data and chemical features (size or position of the substituents on the aromatic ring).
 IT **153472-82-3**, Propanoic acid, 2-(3-benzoylphenoxy), methyl ester, (\pm)
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (resolution of Me 2-(aryloxy)propanoates via enzymic hydrolysis)
 RN 153472-82-3 CAPLUS
 CN Propanoic acid, 2-(3-benzoylphenoxy)-, methyl ester (9CI) (CA INDEX NAME)




IT **117852-24-1P**, Propanoic acid, 2-(3-benzoylphenoxy), (R)-
117852-26-3P, Propanoic acid, 2-(3-benzoylphenoxy), (S)-
153545-77-8P, Propanoic acid, 2-(3-benzoylphenoxy), methyl ester, (S)
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (resolution of Me 2-(aryloxy)propanoates via enzymic hydrolysis)
 RN 117852-24-1 CAPLUS
 CN Propanoic acid, 2-(3-benzoylphenoxy)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 117852-26-3 CAPLUS
 CN Propanoic acid, 2-(3-benzoylphenoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 153545-77-8 CAPLUS
 CN Propanoic acid, 2-(3-benzoylphenoxy)-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 69 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1995:592280 CAPLUS
 DN 123:285008
 TI Synthesis of C-Alkyl Calix[4]arenes. 3. Acid-Catalyzed Rearrangement of 2,6-Dimethoxycinnamate Prior to Tetramerization to Calix[4]arenes
 AU Botta, Bruno; Delle Monache, Giuliano; De Rosa, Maria C.; Carbonetti, Angela; Bacs-Baitz, Eszter; Botta, Maurizio; Corelli, Federico; Misiti, Domenico
 CS Dipartimento di Studi di Chimica e Tecnologia, Universita La Sapienza, Rome, 00185, Italy
 SO Journal of Organic Chemistry (1995), 60(12), 3657-62
 CODEN: JOCEAH; ISSN: 0022-3263
 PB American Chemical Society
 DT Journal
 LA English
 AB A study concerning the versatility of the acid-catalyzed conversion of

cinnamates to calix[4]resorcinarenes was carried out; it was demonstrated that Et 2,6-dimethoxycinnamate underwent a rearrangement to afford the same calix[4]resorcinarenes as those obtained from Et 2,4-dimethoxycinnamate. The exptl. results were substantiated by mol. mechanics calcns.


IT 169394-62-1P 169394-63-2P 169394-64-3P
169394-65-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
(rearrangement of dimethoxycinnamate and tetramerization to
alkylcalix[4]arenes)

RN 169394-62-1 CAPLUS

CN Benzenepropanoic acid, β -(2,6-dimethoxyphenyl)-3-(3-ethoxy-3-oxo-1-propenyl)-2,4-dimethoxy-, ethyl ester, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 169394-63-2 CAPLUS

CN Benzenepropanoic acid, β -(2,6-dimethoxyphenyl)-3-(3-ethoxy-3-oxo-1-propenyl)-2,4-dimethoxy-, ethyl ester, (Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 169394-64-3 CAPLUS

CN Benzenepropanoic acid, β -(2,4-dimethoxyphenyl)-3-(3-ethoxy-3-oxo-1-propenyl)-2,4-dimethoxy-, ethyl ester, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 169394-65-4 CAPLUS
 CN Pentanedioic acid, 3-(2,6-dimethoxyphenyl)-2-[(2,6-dimethoxyphenyl)[3-(3-ethoxy-3-oxo-1-propenyl)-2,4-dimethoxyphenyl]methyl]-, diethyl ester (9CI)
 (CA INDEX NAME)



L7 ANSWER 70 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1995:541359 CAPLUS
 DN 122:278056
 TI Toner for development of electrostatic image
 IN Matsuura, Yuji; Mukudai, Osamu; Anzai, Mitsutoshi; Watanabe, Kayoko
 PA Hodogaya Chemical Co., Ltd., Japan
 SO Ger. Offen., 20 pp.
 CODEN: GWXXBX

DT Patent
 LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4417797	A1	19941201	DE 1994-4417797	19940520
				JP 1993-142553	A 19930524
	JP 06332264	A2	19941202	JP 1993-142553	19930524
	GB 2278453	A1	19941130	GB 1994-9050	19940506
	GB 2278453	B2	19960508		
				JP 1993-142553	A 19930524
	US 5413892	A	19950509	US 1994-245542	19940518
				JP 1993-142553	A 19930524

OS MARPAT 122:278056

AB The title toner contains a compound of the formula X-OCH(Y)CO2H [X = I, II,

II; the point of attachment is at 4 position with respect to D in I and II and p'-position in III; D = H, electron donating group; R1, R2 = H, alkyl, cycloalkyl, alkoxy, aryl, aralkyl, OH, amino, dialkylamino, diarylamino, diaralkylamino, halogen, CN, formyl, carboxyl, carbamoyl, acyloxy, , acyl, etc.; R1 and R2 can not be both H at the same time; R1 and R2 together may form a ring; Y = H, alkyl, aryl]. The material produces high quality images and provide improved triboelec. charge controlling properties and have good stability and dispersibility.


IT **162922-14-7**

RL: MOA (Modifier or additive use); USES (Uses)

(electrophotog. charge controlling agent with good stability and dispersibility)

RN 162922-14-7 CAPLUS

CN Benzeneacetic acid, 2-chloro- α -[4-methyl-3-(phenylmethyl)phenoxy]-(9CI) (CA INDEX NAME)



L7 ANSWER 71 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1995:522641 CAPLUS

DN 122:278146

TI Positive-working photoresist composition with durability, high sensitivity, and high resolution

IN Aoso, Toshiaki; Yamanaka, Tsukasa; Kokubo, Tadayoshi

PA Fuji Photo Film Co Ltd, Japan

SO Jpn. Kokai Tokkyo Koho

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 06266109	A2	19940922	JP 1993-54121	19930315
				JP 1993-54121	19930315

AB The title composition comprises a solvent with b.p. 130-155° and a dissoln. inhibitor having ≥ 2 groups capable of dissoln. upon reaction with an acid.


IT **153698-51-2**

RL: DEV (Device component use); USES (Uses)

(pos.-working photoresist composition with durability, high sensitivity, and high resolution)

RN 153698-51-2 CAPLUS

CN Acetic acid, 2,2'-[[4-[bis[4-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-3,5-dimethylphenyl)methyl]-1,2-phenylene]bis(oxy)]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



L7 ANSWER 72 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1995:444021 CAPLUS

DN 122:213749

TI Preparation of benzenealkanoic acids for treatment of cardiovascular diseases

IN Dickinson, Roger Peter; Dack, Kevin Neil; Steele, John

PA Pfizer Ltd., UK; Pfizer Inc.; Pfizer Research and Development Co., N.V./S.A.

SO PCT Int. Appl., 66 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9406761	A1	19940331	WO 1993-EP2488	19930914
	W: AU, BR, CA, CZ, FI, HU, JP, KR, NO, NZ, PL, RU, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
				GB 1992-20137	A 19920923
	IL 106993	A1	19970610	IL 1993-106993	19930913
				GB 1992-20137	A 19920923
	EP 662950	A1	19950719	EP 1993-919328	19930914
	EP 662950	B1	19980114		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
				GB 1992-20137	A 19920923
				WO 1993-EP2488	W 19930914
	HU 70512	A2	19951030	HU 1995-838	19930914
				GB 1992-20137	A 19920923
	AU 666976	B2	19960229	AU 1993-49600	19930914
	AU 9349600	A1	19940412		
				GB 1992-20137	A 19920923
				WO 1993-EP2488	W 19930914
	JP 08502046	T2	19960305	JP 1994-507788	19930914
				GB 1992-20137	A 19920923
				WO 1993-EP2488	W 19930914
	AT 162184	E	19980115	AT 1993-919328	19930914
				GB 1992-20137	A 19920923
	ES 2111176	T3	19980301	ES 1993-919328	19930914
				GB 1992-20137	A 19920923
	RU 2110512	C1	19980510	RU 1995-108547	19930914
				GB 1992-20137	A 19920923
				WO 1993-EP2488	W 19930914
	PL 174431	B1	19980731	PL 1993-308144	19930914

			GB 1992-20137	A	19920923
			WO 1993-EP2488	W	19930914
BR 9307091	A	19990330	BR 1993-7091		19930914
			GB 1992-20137	A	19920923
			WO 1993-EP2488	W	19930914
CA 2145296	C	20020129	CA 1993-2145296		19930914
			GB 1992-20137	A	19920923
			WO 1993-EP2488	W	19930914
ZA 9306961	A	19950322	ZA 1993-6961		19930921
			GB 1992-20137	A	19920923
CN 1087080	A	19940525	CN 1993-117896		19930923
CN 1037176	B	19980128			
			GB 1992-20137	A	19920923
US 5618941	A	19970408	US 1995-397063		19950315
			GB 1992-20137	A	19920923
			WO 1993-EP2488	W	19930914
NO 9501080	A	19950321	NO 1995-1080		19950321
NO 302698	B1	19980414			
			GB 1992-20137	A	19920923
			WO 1993-EP2488	A	19930914
FI 9501341	A	19950322	FI 1995-1341		19950322
FI 114862	B1	20050114			
			GB 1992-20137	A	19920923
			WO 1993-EP2488	W	19930914

OS MARPAT 122:213749

AB Title compds. I (R1, R2, R3, and R4 = H, C1-4 alkyl; R5 = R6O2SNH(CH2)m, R6CONH(CH2)m wherein R6 = C1-6 alkyl, C3-6 cycloalkyl optionally substituted by aryl, aryl or heteroaryl; R7 = H, C1-4 alkyl, C1-4 alkoxy, halo, F3C, F3CO, NC, H2NCO, C1-4 alkyl-S(O)n; X = H2C, MeCH, CH(OH), MeC(OH), H2C:C, CO, O; m = 0,1; n = 0-2), and their pharmaceutically acceptable salts and biolabile esters, antagonists of thromboxane A2 and for prevention of reocclusion after percutaneous transluminal angioplasty (no data), are prepared 4-ClC6H4SO2Cl was added to Et 3-(2-aminoethyl)-5-[(4-fluorophenyl)methyl]benzenepropanoate (preparation given) to give the sulfonylamino derivative which was treated with NaOH/MeOH and acidified with HCl to give I (R1 = R2 = R3 = R4 = H, R5 = 4-ClC6H4SO2NHCH2, R7 = F, X = CH2). A capsule formulation comprising I are given.


IT 161778-07-0P 161778-08-1P 161778-09-2P
 161778-10-5P 161778-11-6P 161778-12-7P
 161778-13-8P 161778-14-9P 161778-15-0P
 161778-16-1P 161778-17-2P 161778-19-4P
 161778-20-7P 161778-21-8P 161778-22-9P
 161778-23-0P 161778-24-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of benzenealkanoic acids as cardiovascular agents)

RN 161778-07-0 CAPLUS


CN 2-Propenoic acid, 3-[3-bromo-5-[(4-fluorophenyl)hydroxymethyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 161778-08-1 CAPLUS
 CN 2-Propenoic acid, 3-[3-bromo-5-(hydroxyphenylmethyl)phenyl]-, ethyl ester
 (9CI) (CA INDEX NAME)




RN 161778-09-2 CAPLUS
 CN 2-Propenoic acid, 3-[3-bromo-5-[(3-fluorophenyl)hydroxymethyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 161778-10-5 CAPLUS
 CN 2-Propenoic acid, 3-[3-bromo-5-[1-(4-fluorophenyl)-1-hydroxyethyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 161778-11-6 CAPLUS
 CN 2-Propenoic acid, 3-[3-(3-amino-3-oxo-1-propenyl)-5-[(4-fluorophenyl)hydroxymethyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 161778-12-7 CAPLUS
 CN 2-Propenoic acid, 3-[3-(3-amino-3-oxo-1-propenyl)-5-

(hydroxyphenylmethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 161778-13-8 CAPLUS

CN 2-Propenoic acid, 3-[3-(3-amino-3-oxo-1-propenyl)-5-[(3-fluorophenyl)hydroxymethyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 161778-14-9 CAPLUS

CN 2-Propenoic acid, 3-[3-(3-amino-3-oxo-1-propenyl)-5-[1-(4-fluorophenyl)ethenyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 161778-15-0 CAPLUS


CN 2-Propenoic acid, 3,3'-[5-[(4-fluorophenyl)hydroxymethyl]-1,3-phenylene]bis-, diethyl ester (9CI) (CA INDEX NAME)



RN 161778-16-1 CAPLUS


CN 2-Propenoic acid, 3,3'-[5-[(2-fluorophenyl)hydroxymethyl]-1,3-phenylene]bis-, diethyl ester (9CI) (CA INDEX NAME)

phenylene]bis-, diethyl ester (9CI) (CA INDEX NAME)




RN 161778-17-2 CAPLUS

CN 2-Propenoic acid, 3,3'-[5-[hydroxy(3-methoxyphenyl)methyl]-1,3-phenylene]bis-, diethyl ester (9CI) (CA INDEX NAME)




RN 161778-19-4 CAPLUS

CN 2-Propenoic acid, 3,3'-[5-[(acetyloxy)(4-fluorophenyl)methyl]-1,3-phenylene]bis-, diethyl ester (9CI) (CA INDEX NAME)



RN 161778-20-7 CAPLUS


CN 2-Propenoic acid, 3,3'-[5-[(acetyloxy)(2-fluorophenyl)methyl]-1,3-phenylene]bis-, diethyl ester (9CI) (CA INDEX NAME)



RN 161778-21-8 CAPLUS


CN 2-Propenoic acid, 3,3'-[5-[(acetyloxy)(2-methoxyphenyl)methyl]-1,3-phenylene]bis-, diethyl ester (9CI) (CA INDEX NAME)

phenylene]bis-, diethyl ester (9CI) (CA INDEX NAME)




RN 161778-22-9 CAPLUS

CN 2-Propenoic acid, 3-[3-[(acetyloxy)phenylmethyl]-5-(3-amino-3-oxo-1-propenyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 161778-23-0 CAPLUS

CN 2-Propenoic acid, 3-[3-[(acetyloxy)(4-fluorophenyl)methyl]-5-(3-amino-3-oxo-1-propenyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 161778-24-1 CAPLUS

CN 2-Propenoic acid, 3-[3-[(acetyloxy)(3-fluorophenyl)methyl]-5-(3-amino-3-oxo-1-propenyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




L7 ANSWER 73 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN


AN 1995:338655 CAPLUS
 DN 122:170350
 TI Chiral recognition of alkyl 2-aryloxypropionates by HPLC
 AU Azzolina, O.; Collina, S.
 CS Dip. Chim. Farm., Univ. Pavia, Pavia, 27100, Italy
 SO Journal of Liquid Chromatography (1995), 18(1), 81-92
 CODEN: JLCHD8; ISSN: 0148-3919
 PB Dekker
 DT Journal
 LA English
 AB Chiral resolution of a series of antiphlogistic Me and Et
 2-aryloxypropionates on R-DNBPG and S-DNBL chiral stationary phases (CSPs)
 was attempted. Most of the resolved enantiomers were eluted in a very
 short time on both CSPs and the α and K' values of the chromatog.
 sepns. performed by R-DNBPG phase were generally better than those using
 S-DNBL. The elution order of the compds. was detd: the S isomer of all
 esters was eluted last from the R-DNBPG and vice versa from the S-DNBL
 column. The role of the substituents on the chiral resolution was also
 elucidated. It was more influenced by the electronic features than by
 their steric hindrance. Finally, the chiral recognition mechanism which
 permitted resolution of the enantiomers was individuated.
 IT 74167-91-2 74167-96-7 153472-82-3
 153472-83-4
 RL: ANT (Analyte); ANST (Analytical study)
 (chiral resolution of 2-aryloxypropionate esters by HPLC)
 RN 74167-91-2 CAPLUS
 CN Propanoic acid, 2-(3-benzoylphenoxy)-, ethyl ester (9CI) (CA INDEX NAME)




RN 74167-96-7 CAPLUS
 CN Propanoic acid, 2-[3-(4-chlorobenzoyl)-2-methylphenoxy]-, ethyl ester
 (9CI) (CA INDEX NAME)




RN 153472-82-3 CAPLUS
 CN Propanoic acid, 2-(3-benzoylphenoxy)-, methyl ester (9CI) (CA INDEX NAME)



RN 153472-83-4 CAPLUS
 CN Propanoic acid, 2-[3-(4-chlorobenzoyl)-2-methylphenoxy]-, methyl ester
 (9CI) (CA INDEX NAME)




L7 ANSWER 74 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1995:32842 CAPLUS
 DN 122:10553
 TI Use of a new sonically cleavable and acido-labile handle for solid-phase peptide amide synthesis
 AU Calmes, Monique; Daunis, Jacques; David, Dominique; Jacquier, Robert
 CS Aminoacids Peptides laboratory, Montpellier University II, Montpellier, Fr.
 SO International Journal of Peptide & Protein Research (1994), 44(1), 58-60
 CODEN: IJPPC3; ISSN: 0367-8377
 DT Journal
 LA English
 OS CASREACT 122:10553
 AB A new handle (I; Fmoc = 9-fluorenylmethoxycarbonyl), usable for solid-phase peptide amide synthesis was designed. New releasing conditions of the peptide using sonication allowed much shorter reaction times at lower CF₃CO₂H (TFA) concns.
 IT **159415-21-1P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and fluorenylmethoxycarbonylation of)
 RN 159415-21-1 CAPLUS
 CN Acetic acid, [3-[amino(2-methoxyphenyl)methyl]-4-methoxyphenoxy]- (9CI)
 (CA INDEX NAME)



IT **159415-19-7P 159415-20-0P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and reduction of, with zinc, benzhydrylamine from)
 RN 159415-19-7 CAPLUS
 CN Acetic acid, [3-[(hydroxyimino)(2-methoxyphenyl)methyl]-4-methoxyphenoxy]-, (Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 159415-20-0 CAPLUS

CN Acetic acid, [3-[(hydroxyimino) (2-methoxyphenyl)methyl] -4-methoxyphenoxy] - , (E)-. (9CI) (CA INDEX NAME)

Double bond geometry as shown.




IT 159415-14-2P

RL: SPN (Synthetic preparation); PREP (Preparation)


(preparation of, as acid-labile linker for solid-phase preparation of peptide amides)

RN 159415-14-2 CAPLUS


CN Acetic acid, [3-[[[(9H-fluoren-9-ylmethoxy)carbonyl]amino] (2-methoxyphenyl)methyl] -4-methoxyphenoxy] - (9CI) (CA INDEX NAME)



IT **159415-17-5P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation, separation from regioisomer, and oximation of)
 RN 159415-17-5 CAPLUS
 CN Acetic acid, [4-methoxy-3-(2-methoxybenzoyl)phenoxy]- (9CI) (CA INDEX NAME)



IT **159415-15-3P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation, separation from regioisomer, and saponification of)
 RN 159415-15-3 CAPLUS
 CN Acetic acid, [4-methoxy-3-(2-methoxybenzoyl)phenoxy]-, methyl ester (9CI)
 (CA INDEX NAME)




L7 ANSWER 75 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1994:645517 CAPLUS
 DN 121:245517
 TI Synthesis and biological evaluation of ketoprofen glycinate methyl ester:
 a prodrug concept - part I
 AU Dhaneshwar, Suneela S.; Chaturvedi, S. C.
 CS Department Pharmacy, S.G.S.I.T.S., Indore, 452 003, India
 SO Indian Drugs (1994), 31(8), 374-7
 CODEN: INDRBA; ISSN: 0019-462X
 DT Journal
 LA English
 AB Ketoprofen glycinate Me ester was synthesized from ketoprofen acid
 chloride and Glycine Me ester by modified Schotten-Baumann Reaction.
 Formation of compound was confirmed by physicochem. characterization and IR
 spectrum. In vitro hydrolysis study has indicated rapid hydrolysis in
 simulated intestinal fluid. The compound has shown better anti-inflammatory
 and analgesic activity than ketoprofen at 15 mg/kg dose.
 IT **129612-72-2P**
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological
 process); BSU (Biological study, unclassified); SPN (Synthetic
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); PROC (Process); USES (Uses)

(preparation and biol. evaluation of ketoprofen glycinate Me ester as prodrug)

RN 129612-72-2 CAPLUS

CN Glycine, N-[2-(3-benzoylphenyl)-1-oxopropyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 76 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1994:477612 CAPLUS

DN 121:77612

TI 'Off-on' fluorescent sensors for physiological levels of magnesium ions based on photoinduced electron transfer (PET), which also behave as photoionic OR logic gates

AU Prasanna de silva, A.; Gunaratne, H. Q. Nimal; Maguire, Glenn E. M.

CS Sch. Chem., Queen's Univ., Belfast, BT9 5AG, UK

SO Journal of the Chemical Society, Chemical Communications (1994), (10), 1213-14

CODEN: JCCCCAT; ISSN: 0022-4936

DT Journal

LA English

AB The fluorescence of mols. I, II, and III is enhanced by factors of up to 67 in the presence of magnesium and calcium ions in neutral water which allows the selective monitoring of magnesium ions under simulated physiol. conditions and permits the construction of truth tables with OR logic when these mols. are viewed as ion input-photon output mol. devices.


IT 156462-42-9

RL: ANST (Analytical study)

(off-on fluorescent sensor, for magnesium determination)

RN 156462-42-9 CAPLUS

CN Glycine, N-[4-(9-anthracenylmethyl)-2-(carboxymethoxy)phenyl]-N-(carboxymethyl)- (9CI) (CA INDEX NAME)




L7 ANSWER 77 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1994:422448 CAPLUS
 DN 121:22448
 TI Electrophotographic toner
 IN Anzai, Mitsutoshi; Matsuura, Yuji; Mukudai, Osamu; Kanno, Miki; Watanabe, Kayoko
 PA Hodogaya Chemical Co., Ltd., Japan
 SO Eur. Pat. Appl., 21 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	EP 566835	A1	19931027	EP 1993-102253	19930212
	EP 566835	B1	19970514		
	R: DE, FR, GB				
				JP 1992-127953	A 19920422
				JP 1992-257661	A 19920902
	JP 05297638	A2	19931112	JP 1992-127953	19920422
	JP 06083111	A2	19940325	JP 1992-257661	19920902
	US 5378573	A	19950103	US 1993-10574	19930128
				JP 1992-127953	A 19920422
				JP 1992-257661	A 19920902


OS MARPAT 121:22448
 AB The title material contains a compd XC(Y):C(Z)CO₂H [X, Y = H, phenyl group optionally substituted with 1 electron donating group at 2 or 4 positions or 2 electron donating groups at 2 and 5 positions and 0-2 R (R = H, halogen, alkyl, cycloalkyl, aralkyl, aryl, acyl, nitro, CN, R₂SO₂ (R₂ = OH, amino, alkyl-substituted alkyl, cycloalkyl, aralkyl, aryl, alkoxy)); naphthyl group substituted with an electron donating group at 2 or 4 position and 0-2 R; or a biphenyl group substituted with an electron donating group at 4' position and optionally one R group in each benzene ring (R = same as above except R₂SO₂)]. The compds. are useful as charge control agents.
 IT **155904-33-9**
 RL: USES (Uses)
 (as charge control agent in electrophotog. toner)
 RN 155904-33-9 CAPLUS
 CN 2-Propenoic acid, 3-[2-hydroxy-5-(phenylmethyl)phenyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 78 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1994:216878 CAPLUS
 DN 120:216878
 TI A Novel Route to Calix[4]arenes. 2. Solution- and Solid-State Structural Analyses and Molecular Modeling Studies
 AU Botta, Bruno; Di Giovanni, Maria Cristina; Delle Monache, Giuliano; De Rosa, Maria Cristina; Gacs-Baitz, Eszter; Botta, Maurizio; Corelli,

Federico; Tafi, Andrea; Santini, Antonello; et al.
 CS Dipartimento Studi Chimica Tecnologia Sostanze Biologicamente Attive,
 Universita La Sapienza, 00185, Italy
 SO Journal of Organic Chemistry (1994), 59(6), 1532-41
 CODEN: JOCEAH; ISSN: 0022-3263
 DT Journal
 LA English
 OS CASREACT 120:216878
 AB A versatile route to a series of C-alkylcalix[4]resorcinarenes, e.g. I, has been developed, using 2,4-dimethoxycinnamates as starting materials under carefully controlled reaction conditions employing BF₃ as a Lewis acid catalyst. Depending on the reaction conditions and the nature of the ester side chain in the cinnamates, the calixarenes can adopt 1,2-alternate, 1,3-alternate, or flattened-cone conformational states. An extensive study, relating to the influence of the Lewis acid, temperature, and reaction time, has provided information on the relative ratios of the different conformations and their interconversion. Structural assignments are based on detailed spectroscopic analyses including X-ray analyses. The latter provide evidence of their mol. structure and shape in the solid state. A detailed mol. modeling study has been completed and is described. From the data obtained, good agreement with NMR data, X-ray analyses and exptl. results is observed
 IT **140111-49-5P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 140111-49-5 CAPLUS
 CN Benzenepropanoic acid, β -(2,4-dimethoxyphenyl)-2,4-dimethoxy-5-(3-methoxy-3-oxo-1-propenyl)-, methyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




L7 ANSWER 79 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1994:207779 CAPLUS
 DN 120:207779
 TI Optical resolution of aryloxypropionic acids and their esters by HPLC on cellulose tris(3,5-dimethyltriphenylcarbamate) derivative
 AU Azzolina, Ornella; Collina, Simona; Ghislandi, Victor
 CS Dip. Chim. Farm., Univ. Pavia, Pavia, 27100, Italy
 SO Farmaco (1993), 48(10), 1401-16
 CODEN: FRMCE8; ISSN: 0014-827X
 DT Journal


LA English
 AB Chiral chromatog. resolution of a series of anti-inflammatory 2-aryloxypropionic acids and their Me and Et esters was performed using a Chiralcel OD column. The chiral stationary phase (CSP) selected resolved most of the acids and esters efficiently, the enantiomers being well separated without requiring time consuming anal. Chromatog. separation of R enriched samples was performed to determine the correct elution order. Using eluting systems such as hexane and 2-propanol, or hexane, 2-propanol and formic acid, the S enantiomer of all acids and esters was always found to elute first. The authors also considered the role of electron-donating or electron-withdrawing substituents (at the aryloxylic moiety) on the chiral resolution. It was shown that the electronic features of the substituents have more influence on the chiral interactions between the solutes and the CSP than their steric hindrance. Finally the authors determined, by mol. models, the interaction between CSP and solutes. In this way the authors were able to determine all the potential sites for interactions, which are comparable with the conformations of the compds. and the structure of the stationary phase, and point out those interactions which enable chiral resolution

IT 74167-91-2 74167-96-7 74168-02-8
 74168-08-4 153472-82-3 153472-83-4
 RL: PROC (Process)
 (resolution of, by HPLC on cellulose tris(dimethyltriphenylcarbamate) derivative)


RN 74167-91-2 CAPLUS
 CN Propanoic acid, 2-(3-benzoylphenoxy)-, ethyl ester (9CI) (CA INDEX NAME)




RN 74167-96-7 CAPLUS
 CN Propanoic acid, 2-[3-(4-chlorobenzoyl)-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 74168-02-8 CAPLUS
 CN Propanoic acid, 2-(3-benzoylphenoxy)- (9CI) (CA INDEX NAME)




RN 74168-08-4 CAPLUS
 CN Propanoic acid, 2-[3-(4-chlorobenzoyl)-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 153472-82-3 CAPLUS
 CN Propanoic acid, 2-(3-benzoylphenoxy)-, methyl ester (9CI) (CA INDEX NAME)



RN 153472-83-4 CAPLUS
 CN Propanoic acid, 2-[3-(4-chlorobenzoyl)-2-methylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)




IT 117819-26-8 117819-30-4 117819-32-6
 117819-33-7 117819-34-8 117819-35-9
 117852-24-1 117852-26-3 153545-77-8
 153545-78-9 153546-10-2 153546-11-3

RL: PROC (Process)
 (separation of, by HPLC on cellulose tris(dimethyltriphenylcarbamate) derivative)

RN 117819-26-8 CAPLUS
 CN Propanoic acid, 2-[3-(4-chlorobenzoyl)-2-methylphenoxy]-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 117819-30-4 CAPLUS

CN Propanoic acid, 2-[3-(4-chlorobenzoyl)-2-methylphenoxy]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 117819-32-6 CAPLUS

CN Propanoic acid, 2-(3-benzoylphenoxy)-, ethyl ester, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 117819-33-7 CAPLUS

CN Propanoic acid, 2-(3-benzoylphenoxy)-, ethyl ester, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 117819-34-8 CAPLUS

CN Propanoic acid, 2-[3-(4-chlorobenzoyl)-2-methylphenoxy]-, ethyl ester, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 117819-35-9 CAPLUS

CN Propanoic acid, 2-[3-(4-chlorobenzoyl)-2-methylphenoxy]-, ethyl ester, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 117852-24-1 CAPLUS

CN Propanoic acid, 2-(3-benzoylphenoxy)-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 117852-26-3 CAPLUS

CN Propanoic acid, 2-(3-benzoylphenoxy)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 153545-77-8 CAPLUS

CN Propanoic acid, 2-(3-benzoylphenoxy)-, methyl ester, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 153545-78-9 CAPLUS

CN Propanoic acid, 2-[3-(4-chlorobenzoyl)-2-methylphenoxy]-, methyl ester, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 153546-10-2 CAPLUS

CN Propanoic acid, 2-(3-benzoylphenoxy)-, methyl ester, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 153546-11-3 CAPLUS

CN Propanoic acid, 2-[3-(4-chlorobenzoyl)-2-methylphenoxy]-, methyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 80 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1994:204700 CAPLUS

DN 120:204700

TI Positive-type light-sensitive composition

IN Yamanaka, Tsukasa; Aoai, Toshiaki; Uenichi, Kazuya; Kondo, Shunichi;

Kokubo, Tadayoshi
 PA Fuji Photo Film Co., Ltd., Japan
 SO Eur. Pat. Appl., 81 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	EP 541112	A1	19930512	EP 1992-119043	19921106
	EP 541112	B1	20010905		
	R: BE, DE, FR, GB				
				JP 1991-319600	A 19911108
				JP 1992-47705	A 19920205
				JP 1992-47782	A 19920205
				JP 1992-166685	A 19920603
				JP 1992-299093	A 19921013
	JP 06051519	A2	19940225	JP 1992-299093	19921013
				JP 1991-319600	A1 19911108
				JP 1992-47705	A1 19920205
				JP 1992-47782	A1 19920205
				JP 1992-166685	A1 19920603

OS MARPAT 120:204700

AB A pos.-type light-sensitive composition useful in manufacture of a lithog. plate or

a semiconductor device and having less layer shrinkage by baking after exposing, less layer decrease in developing, a good profile, and a high resolution comprises (a) a resin which is insol. in water and soluble in an alkaline aqueous solution, (b) a compound which generates an acid by irradiation with active rays or radial rays, and (c) an acid-decomposable dissoln. inhibitor, having a mol. weight of not more than 3000 and having groups decomposable by the action of the generated acid to increase the solubility of said inhibitor in an alkaline developing solution, wherein said inhibitor (c) is at least one compound selected from the group consisting of (i) compds. having two of said acid decomposable groups which are separated by 10 or more bonded atoms excluding the atoms constituting the acid decomposable groups and (ii) compds. having at least three of said acid decomposable groups and two of said groups which are at the farthest positions are separated by 9 or more bonded atoms excluding the atoms constituting the acid decomposable groups.


IT 153698-51-2

RL: USES (Uses)

(pos. photoresist compns. containing alkali-soluble resins, photosensitive acid generators and, for lithog. plate and semiconductor device manufacture)

RN 153698-51-2 CAPLUS

CN Acetic acid, 2,2'-[[4-[bis[4-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-3,5-dimethylphenyl]methyl]-1,2-phenylene]bis(oxy)]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



L7 ANSWER 81 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1993:459724 CAPLUS

DN 119:59724

TI Resist for forming patterns

IN Hayase, Rumiko; Onishi, Yasunobu; Niki, Hirokazu; Oyasato, Naohiko; Kobayashi, Yoshihito; Hayase, Shuzi

PA Toshiba Corp., Japan

SO Ger. Offen., 41 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	DE 4214363	A1	19921105	DE 1992-4214363	19920430
	DE 4214363	C2	19980129		
				JP 1991-128737	A 19910430
				JP 1991-276188	A 19910930
	JP 05181279	A2	19930723	JP 1992-100310	19920327
	JP 3238465	B2	20011217		
				JP 1991-128737	A1 19910430
				JP 1991-276188	A1 19910930
	US 5403695	A	19950404	US 1992-876457	19920430
				JP 1991-128737	A 19910430
				JP 1991-276188	A 19910930
	US 5580702	A	19961203	US 1994-357179	19941213
				JP 1991-128737	A 19910430
				JP 1991-276188	A 19910930
				US 1992-876457	A3 19920430
	JP 2001264970	A2	20010928	JP 2001-35977	20010213
	JP 3238146	B2	20011210		
				JP 1991-128737	A 19910430
				JP 1991-276188	A 19910930
				JP 1992-100310	A3 19920327

AB A resist composition is described comprising a compound producing an acid on irradiation and an acid substitute, e.g. having the formula $(\text{CH}_2\text{CH}(\text{p-C}_6\text{H}_4\text{OH}))_m(\text{CH}_2\text{CH}(\text{p-C}_6\text{H}_4\text{OCH}_2\text{CO}_2\text{R}_1))_n$ [R1 = organic group; m = 0 or pos. integer; n = pos. integer] several other acid substitutes are used. The resist is sensitive to UV as well as ionizing radiation, has high sensitivity, and can be used to form semiconductor devices or electronic circuits.


IT 146969-16-6

RL: USES (Uses)

(resist compns. containing)

RN 146969-16-6 CAPLUS

CN Acetic acid, 2,2',2''-[[4-[3,4-bis[2-(1,1-dimethylethoxy)-2-oxoethoxy]benzoyl]-1,2,3-benzenetriyl]tris(oxy)]tris-, tris(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



L7 ANSWER 82 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1993:191343 CAPLUS

DN 118:191343

TI Preparation of aromatic oligomeric compounds useful as mimics of bioactive macromolecules

IN Regan, John R.; McGarry, Daniel G.; Chang, Michael N.; Barton, Jeffrey N.; Newman, Jack; Ben-Sasson, Schmuel

PA Rhone-Poulenc Rorer International (Holdings) Inc., USA

SO PCT Int. Appl., 99 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9220350	A1	19921126	WO 1992-US4274	19920520
	W: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, PL, RO, RU, SD, SE, US				
	RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GN, GR, IT, LU, MC, ML, MR, NL, SE, SN, TD, TG				
				US 1991-703061	A2 19910520
	AU 9220107	A1	19921230	AU 1992-20107	19920520
				US 1991-703061	A 19910520
				WO 1992-US4274	A 19920520
	EP 585371	A1	19940309	EP 1992-912715	19920520
	EP 585371	B1	20020417		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL				
				US 1991-703061	A 19910520
				WO 1992-US4274	W 19920520
	AT 216247	E	20020515	AT 1992-912715	19920520
				US 1991-703061	A 19910520
				WO 1992-US4274	W 19920520
	ES 2174834	T3	20021116	ES 1992-912715	19920520
				US 1991-703061	A 19910520
	US 5571506	A	19961105	US 1993-119456	19930910
				US 1989-393873	B2 19890814
				US 1989-440584	B2 19891122
				US 1989-440586	B2 19891122
				US 1991-703061	B1 19910520

PATENT FAMILY INFORMATION:

FAN	1991:550384				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9103226	A2	19910321	WO 1990-US4580	19900814
	WO 9103226	A3	19910530		
	W: AU, CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE				
				US 1989-393873	A 19890814
	IL 95353	A1	19950124	IL 1990-95353	19900813
				US 1989-393873	A 19890814
	CA 2064575	AA	19910215	CA 1990-2064575	19900814
				US 1989-393873	A 19890814
	AU 9063375	A1	19910408	AU 1990-63375	19900814
	AU 649963	B2	19940609		
				US 1989-393873	A 19890814
				WO 1990-US4580	A 19900814
	EP 489102	A1	19920610	EP 1990-913407	19900814
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
				US 1989-393873	A 19890814
				WO 1990-US4580	W 19900814
	JP 05503506	T2	19930610	JP 1990-512506	19900814
				US 1989-393873	A 19890814
				WO 1990-US4580	W 19900814
	US 5571506	A	19961105	US 1993-119456	19930910
				US 1989-393873	B2 19890814
				US 1989-440584	B2 19891122
				US 1989-440586	B2 19891122
				US 1991-703061	B1 19910520
FAN	1992:46289				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9107183	A1	19910530	WO 1990-US6847	19901121
	W: AU, CA, JP, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
				US 1989-440584	A2 19891122
				US 1989-440586	A 19891122
	AU 9169191	A1	19910613	AU 1991-69191	19901121
	AU 658133	B2	19950406		
				US 1989-440584	A 19891122
				US 1989-440586	A 19891122
				WO 1990-US6847	A 19901121
	EP 502117	A1	19920909	EP 1991-901098	19901121
	EP 502117	B1	19990623		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
				US 1989-440584	A 19891122
				US 1989-440586	A 19891122
				WO 1990-US6847	W 19901121
	JP 05508665	T2	19931202	JP 1991-501518	19901121
				US 1989-440584	A 19891122
				US 1989-440586	A 19891122
				WO 1990-US6847	W 19901121
	AT 181506	E	19990715	AT 1991-901098	19901121
				US 1989-440584	A 19891122
				US 1989-440586	A 19891122
	IL 96441	A1	19950124	IL 1990-96441	19901122
				US 1989-440584	A 19891122
				US 1989-440586	A 19891122
	US 5571506	A	19961105	US 1993-119456	19930910
				US 1989-393873	B2 19890814
				US 1989-440584	B2 19891122

US 1989-440586 B2 19891122
US 1991-703061 B1 19910520

FAN 1997:684140

PATENT NO.

KIND

DATE

APPLICATION NO.

DATE

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5674482	A	19971007	US 1991-742794	19910809
			US 1989-393873	B2 19890814
			US 1989-440584	B2 19891122
			US 1989-440586	B2 19891122
US 5571506	A	19961105	US 1993-119456	19930910
			US 1989-393873	B2 19890814
			US 1989-440584	B2 19891122
			US 1989-440586	B2 19891122
			US 1991-703061	B1 19910520

OS MARPAT 118:191343

AB Title compds. M(M1)mM2 (m = 2-50; M, M1, M2 = substituted aromatic carbocyclyl or aromatic heteterocyclyl), useful as mimics of bioactive macromols. (glycosaminoglycans), are prepared 4-HOC6H4(CH2)2CO2Me (preparation given) in MeOH at 0° was treated with H2SO4 followed by HCOH to give bis[5-(2-methoxycarbonylethyl)-3-[5-(2-methoxycarbonylethyl)-2-hydroxybenzyl]-2-hydroxyphenyl]methane which was stirred with NaOH, quenched with HCl, and then treated with NH4OH to give title compound (I) as the ammonium salt. In the APTT anticoagulation assay, the concentration

required

to double clotting time for the title compds. was 35-700 µg/mL.



IT 147067-39-8 147067-40-1 147067-41-2

147067-42-3 147067-44-5 147067-45-6

RL: RCT (Reactant); RACT (Reactant or reagent)
(glycosaminoglycan mimetic)




RN 147067-39-8 CAPLUS

CN Acetic acid, [2-[[5-(carboxymethoxy)-4-[[5-(carboxymethoxy)-4-[[5-(carboxymethoxy)-4-(hydroxymethyl)-2-(phenylmethoxy)phenyl]methyl]-2-(phenylmethoxy)phenyl]methyl]-2-(phenylmethoxy)phenyl]methyl]-4-hydroxyphenoxy]- (9CI) (CA INDEX NAME)




RN 147067-40-1 CAPLUS

CN Acetic acid, 2,2'-[1,2-ethanediylbis[[5-(carboxymethoxy)-2-hydroxy-4,1-phenylene]methylene(4-hydroxy-2,1-phenylene)oxy]]bis- (9CI) (CA INDEX NAME)

O=C(O)CCOC1=CC=C(C=C1)COC2=CC=C(C=C2)COC3=CC=C(C=C3)COC4=CC=C(C=C4)COC5=CC=C(C=C5)COC6=CC=C(C=C6)COC7=CC=C(C=C7)COC8=CC=C(C=C8)COC9=CC=C(C=C9)COC10=CC=C(C=C10)COC11=CC=C(C=C11)COC12=CC=C(C=C12)COC13=CC=C(C=C13)COC14=CC=C(C=C14)COC15=CC=C(C=C15)COC16=CC=C(C=C16)COC17=CC=C(C=C17)COC18=CC=C(C=C18)COC19=CC=C(C=C19)COC20=CC=C(C=C20)COC21=CC=C(C=C21)COC22=CC=C(C=C22)COC23=CC=C(C=C23)COC24=CC=C(C=C24)COC25=CC=C(C=C25)COC26=CC=C(C=C26)COC27=CC=C(C=C27)COC28=CC=C(C=C28)COC29=CC=C(C=C29)COC30=CC=C(C=C30)COC31=CC=C(C=C31)COC32=CC=C(C=C32)COC33=CC=C(C=C33)COC34=CC=C(C=C34)COC35=CC=C(C=C35)COC36=CC=C(C=C36)COC37=CC=C(C=C37)COC38=CC=C(C=C38)COC39=CC=C(C=C39)COC40=CC=C(C=C40)COC41=CC=C(C=C41)COC42=CC=C(C=C42)COC43=CC=C(C=C43)COC44=CC=C(C=C44)COC45=CC=C(C=C45)COC46=CC=C(C=C46)COC47=CC=C(C=C47)COC48=CC=C(C=C48)COC49=CC=C(C=C49)COC50=CC=C(C=C50)COC51=CC=C(C=C51)COC52=CC=C(C=C52)COC53=CC=C(C=C53)COC54=CC=C(C=C54)COC55=CC=C(C=C55)COC56=CC=C(C=C56)COC57=CC=C(C=C57)COC58=CC=C(C=C58)COC59=CC=C(C=C59)COC60=CC=C(C=C60)COC61=CC=C(C=C61)COC62=CC=C(C=C62)COC63=CC=C(C=C63)COC64=CC=C(C=C64)COC65=CC=C(C=C65)COC66=CC=C(C=C66)COC67=CC=C(C=C67)COC68=CC=C(C=C68)COC69=CC=C(C=C69)COC70=CC=C(C=C70)COC71=CC=C(C=C71)COC72=CC=C(C=C72)COC73=CC=C(C=C73)COC74=CC=C(C=C74)COC75=CC=C(C=C75)COC76=CC=C(C=C76)COC77=CC=C(C=C77)COC78=CC=C(C=C78)COC79=CC=C(C=C79)COC80=CC=C(C=C80)COC81=CC=C(C=C81)COC82=CC=C(C=C82)COC83=CC=C(C=C83)COC84=CC=C(C=C84)COC85=CC=C(C=C85)COC86=CC=C(C=C86)COC87=CC=C(C=C87)COC88=CC=C(C=C88)COC89=CC=C(C=C89)COC90=CC=C(C=C90)COC91=CC=C(C=C91)COC92=CC=C(C=C92)COC93=CC=C(C=C93)COC94=CC=C(C=C94)COC95=CC=C(C=C95)COC96=CC=C(C=C96)COC97=CC=C(C=C97)COC98=CC=C(C=C98)COC99=CC=C(C=C99)COC100=CC=C(C=C100)COC101=CC=C(C=C101)COC102=CC=C(C=C102)COC103=CC=C(C=C103)COC104=CC=C(C=C104)COC105=CC=C(C=C105)COC106=CC=C(C=C106)COC107=CC=C(C=C107)COC108=CC=C(C=C108)COC109=CC=C(C=C109)COC110=CC=C(C=C110)COC111=CC=C(C=C111)COC112=CC=C(C=C112)COC113=CC=C(C=C113)COC114=CC=C(C=C114)COC115=CC=C(C=C115)COC116=CC=C(C=C116)COC117=CC=C(C=C117)COC118=CC=C(C=C118)COC119=CC=C(C=C119)COC120=CC=C(C=C120)COC121=CC=C(C=C121)COC122=CC=C(C=C122)COC123=CC=C(C=C123)COC124=CC=C(C=C124)COC125=CC=C(C=C125)COC126=CC=C(C=C126)COC127=CC=C(C=C127)COC128=CC=C(C=C128)COC129=CC=C(C=C129)COC130=CC=C(C=C130)COC131=CC=C(C=C131)COC132=CC=C(C=C132)COC133=CC=C(C=C133)COC134=CC=C(C=C134)COC135=CC=C(C=C135)COC136=CC=C(C=C136)COC137=CC=C(C=C137)COC138=CC=C(C=C138)COC139=CC=C(C=C139)COC140=CC=C(C=C140)COC141=CC=C(C=C141)COC142=CC=C(C=C142)COC143=CC=C(C=C143)COC144=CC=C(C=C144)COC145=CC=C(C=C145)COC146=CC=C(C=C146)COC147=CC=C(C=C147)COC148=CC=C(C=C148)COC149=CC=C(C=C149)COC150=CC=C(C=C150)COC151=CC=C(C=C151)COC152=CC=C(C=C152)COC153=CC=C(C=C153)COC154=CC=C(C=C154)COC155=CC=C(C=C155)COC156=CC=C(C=C156)COC157=CC=C(C=C157)COC158=CC=C(C=C158)COC159=CC=C(C=C159)COC160=CC=C(C=C160)COC161=CC=C(C=C161)COC162=CC=C(C=C162)COC163=CC=C(C=C163)COC164=CC=C(C=C164)COC165=CC=C(C=C165)COC166=CC=C(C=C166)COC167=CC=C(C=C167)COC168=CC=C(C=C168)COC169=CC=C(C=C169)COC170=CC=C(C=C170)COC171=CC=C(C=C171)COC172=CC=C(C=C172)COC173=CC=C(C=C173)COC174=CC=C(C=C174)COC175=CC=C(C=C175)COC176=CC=C(C=C176)COC177=CC=C(C=C177)COC178=CC=C(C=C178)COC179=CC=C(C=C179)COC180=CC=C(C=C180)COC181=CC=C(C=C181)COC182=CC=C(C=C182)COC183=CC=C(C=C183)COC184=CC=C(C=C184)COC185=CC=C(C=C185)COC186=CC=C(C=C186)COC187=CC=C(C=C187)COC188=CC=C(C=C188)COC189=CC=C(C=C189)COC190=CC=C(C=C190)COC191=CC=C(C=C191)COC192=CC=C(C=C192)COC193=CC=C(C=C193)COC194=CC=C(C=C194)COC195=CC=C(C=C195)COC196=CC=C(C=C196)COC197=CC=C(C=C197)COC198=CC=C(C=C198)COC199=CC=C(C=C199)COC200=CC=C(C=C200)COC201=CC=C(C=C201)COC202=CC=C(C=C202)COC203=CC=C(C=C203)COC204=CC=C(C=C204)COC205=CC=C(C=C205)COC206=CC=C(C=C206)COC207=CC=C(C=C207)COC208=CC=C(C=C208)COC209=CC=C(C=C209)COC210=CC=C(C=C210)COC211=CC=C(C=C211)COC212=CC=C(C=C212)COC213=CC=C(C=C213)COC214=CC=C(C=C214)COC215=CC=C(C=C215)COC216=CC=C(C=C216)COC217=CC=C(C=C217)COC218=CC=C(C=C218)COC219=CC=C(C=C219)COC220=CC=C(C=C220)COC221=CC=C(C=C221)COC222=CC=C(C=C222)COC223=CC=C(C=C223)COC224=CC=C(C=C224)COC225=CC=C(C=C225)COC226=CC=C(C=C226)COC227=CC=C(C=C227)COC228=CC=C(C=C228)COC229=CC=C(C=C229)COC230=CC=C(C=C230)COC231=CC=C(C=C231)COC232=CC=C(C=C232)COC233=CC=C(C=C233)COC234=CC=C(C=C234)COC235=CC=C(C=C235)COC236=CC=C(C=C236)COC237=CC=C(C=C237)COC238=CC=C(C=C238)COC239=CC=C(C=C239)COC240=CC=C(C=C240)COC241=CC=C(C=C241)COC242=CC=C(C=C242)COC243=CC=C(C=C243)COC244=CC=C(C=C244)COC245=CC=C(C=C245)COC246=CC=C(C=C246)COC247=CC=C(C=C247)COC248=CC=C(C=C248)COC249=CC=C(C=C249)COC250=CC=C(C=C250)COC251=CC=C(C=C251)COC252=CC=C(C=C252)COC253=CC=C(C=C253)COC254=CC=C(C=C254)COC255=CC=C(C=C255)COC256=CC=C(C=C256)COC257=CC=C(C=C257)COC258=CC=C(C=C258)COC259=CC=C(C=C259)COC260=CC=C(C=C260)COC261=CC=C(C=C261)COC262=CC=C(C=C262)COC263=CC=C(C=C263)COC264=CC=C(C=C264)COC265=CC=C(C=C265)COC266=CC=C(C=C266)COC267=CC=C(C=C267)COC268=CC=C(C=C268)COC269=CC=C(C=C269)COC270=CC=C(C=C270)COC271=CC=C(C=C271)COC272=CC=C(C=C272)COC273=CC=C(C=C273)COC274=CC=C(C=C274)COC275=CC=C(C=C275)COC276=CC=C(C=C276)COC277=CC=C(C=C277)COC278=CC=C(C=C278)COC279=CC=C(C=C279)COC280=CC=C(C=C280)COC281=CC=C(C=C281)COC282=CC=C(C=C282)COC283=CC=C(C=C283)COC284=CC=C(C=C284)COC285=CC=C(C=C285)COC286=CC=C(C=C286)COC287=CC=C(C=C287)COC288=CC=C(C=C288)COC289=CC=C(C=C289)COC290=CC=C(C=C290)COC291=CC=C(C=C291)COC292=CC=C(C=C292)COC293=CC=C(C=C293)COC294=CC=C(C=C294)COC295=CC=C(C=C295)COC296=CC=C(C=C296)COC297=CC=C(C=C297)COC298=CC=C(C=C298)COC299=CC=C(C=C299)COC300=CC=C(C=C300)COC301=CC=C(C=C301)COC302=CC=C(C=C302)COC303=CC=C(C=C303)COC304=CC=C(C=C304)COC305=CC=C(C=C305)COC306=CC=C(C=C306)COC307=CC=C(C=C307)COC308=CC=C

RN	147067-42-3	CAPLUS
CN	Acetic acid, 2,2'-[1,2-ethanediylbis[[5-(carboxymethoxy)-2-hydroxy-4,1-	


phenylene)methylene[4-(phenylmethoxy)-2,1-phenylene]oxy]]bis- (9CI) (CA INDEX NAME)



RN 147067-44-5 CAPLUS

CN Acetic acid, [3-[[5-(carboxymethoxy)-3-[[5-(carboxymethoxy)-3-[[5-(carboxymethoxy)-3-ethyl-2-methoxyphenyl]methyl]-2-methoxyphenyl]methyl]-2-methoxyphenyl]methyl]-4-methoxyphenoxy] - (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B


—CO₂H

RN 147067-45-6 CAPLUS

CN Acetic acid, [3-[[5-(carboxymethoxy)-3-[[5-(carboxymethoxy)-3-[[5-(carboxymethoxy)-3-[[5-(carboxymethoxy)-3-ethyl-2-methoxyphenyl]methyl]-2-methoxyphenyl]methyl]-2-methoxyphenyl]methyl]-2-methoxyphenyl]methyl]-2-methoxyphenyl]methyl]-4-methoxyphenoxy] - (9CI) (CA INDEX NAME)

PAGE 1-A





IT 147067-82-1P 147067-83-2P



RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction of, in preparation of oligomeric hydrocinnamate derivs.

as glycosaminoglycan mimetics)

RN 147067-82-1 CAPLUS


CN Benzoic acid, 3-[[5-(2-amino-2-oxoethoxy)-3-[[5-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-2-methoxy-3-methylphenyl]methyl]-2-methoxyphenyl]methyl]-5-[[5-(2-amino-2-oxoethoxy)-2-[2-(1,1-dimethylethoxy)-2-oxoethoxy]phenyl]methyl]-4-methoxy-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 147067-83-2 CAPLUS

CN Acetic acid, [4-(2-amino-2-oxoethoxy)-2-[[3-[[5-(2-amino-2-oxoethoxy)-3-[[5-(carboxymethoxy)-2-methoxy-3-methylphenyl]methyl]-2-methoxyphenyl]methyl]-5-(carboxymethoxy)-2-methoxyphenyl]methyl]phenoxy]-(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—NH₂

—CO₂H


IT 147067-37-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 147067-37-6 CAPLUS

CN Acetic acid, [4-(2-amino-2-oxoethoxy)-2-[[5-(2-amino-2-oxoethoxy)-3-[[5-(2-amino-2-oxoethoxy)-3-[[5-(carboxymethoxy)-2-methoxy-3-methylphenyl]methyl]-2-methoxyphenyl]methyl]-2-methoxyphenyl]methoxy]phenoxy] - (9CI) (CA INDEX NAME)

PAGE 1-A



—NH₂—CO₂H

IT 147067-95-6


RL: RCT (Reactant); RACT (Reactant or reagent)


(reaction of, in preparation of oligomeric hydrocinnamate derivs. as glycosaminoglycan mimetics)

RN 147067-95-6 CAPLUS

CN Acetic acid, [3-[[5-[[[(1,1-dimethylethoxy)carbonyl]oxy]-3-[[5-[[[(1,1-dimethylethoxy)carbonyl]oxy]-3-[[5-[[[(1,1-dimethylethoxy)carbonyl]oxy]-3-[[5-[[[(1,1-dimethylethoxy)carbonyl]oxy]-3-[[5-[[[(1,1-dimethylethoxy)carbonyl]oxy]-2-methoxyphenyl]methyl]-2-methoxyphenyl]methyl]-2-methoxyphenyl]methyl]-2-methoxyphenyl]methyl]-5-ethyl-4-methoxyphenoxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A





L7 ANSWER 83 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1993:147300 CAPLUS

DN 118:147300

TI Preparation of phenoxyacetic acid derivatives for treatment of organic or functional disorders from ischemia

IN Tatsuoka, Toshio; Suzuki, Kenji

PA Suntory, Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 15 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN. CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 04226937	A2	19920817	JP 1991-130100	19910601
	JP 3016625	B2	20000306		
				JP 1990-141676	A1 19900601

OS MARPAT 118:147300

AB The title compds. (I and II; R1-R3 = C1-5 alkyl or alkoxy; R4 = CO₂H, its ester or amide; R5, R6 = OH, C1-5 alkoxy), inhibiting blood platelet aggregation, cell injury, and brain edema and useful for treating heart ischemia diseases such as angina pectoris, cardiac infarction, and heart failure and brain ischemic diseases such as brain edema and apoplexy sequelae, are prepared Thus, acetylation of 4-(2,5-dimethoxy-3,4,6-trimethylphenyl)methylphenol ((preparation given) with Ac₂O in pyridine in the presence of 4-dimethylaminopyridine and oxidation of the product acetate with (NH₄)₂Ce(NO₃)₆ in aqueous MeCN gave, after deacetylation with NaHCO₃ in aqueous MeOH, 4-(3,5,6-trimethyl-1,4-benzoquinon-2-yl)methylphenol which was alkylated by BrCH₂CO₂CMe₃ in acetone containing K₂CO₃ to give title compound II (X = CH₂CO₂CMe₃). II (X = CH₂CO₂Et) showed IC₅₀ of 3.8 and 4.2 (concentration unit not given) for inhibiting collagen- and arachidonic acid-induced aggregation of rabbit blood platelets. A total of 19 I were prepared


IT **146476-33-7P**

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of, as intermediate for (benzylphenoxy)acetate derivative for treating ischemic brain and heart disease)

RN 146476-33-7 CAPLUS

CN Acetic acid, [3-[(2-hydroxy-3,4-dimethoxy-6-methylphenyl)methyl]phenoxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




IT 146476-01-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, for treatment of ischemic brain and heart disease)

RN 146476-01-9 CAPLUS

CN Acetic acid, [3-[(2,5-dimethoxy-3,4,6-trimethylphenyl)methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



L7 ANSWER 84 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1993:7128 CAPLUS

DN 118:7128

TI Oxygen atom transfer in the reaction between hexakis(dimethyl-tert-butylsiloxy)ditungsten and nitric oxide. A remarkable difference in the reactivity of the tungsten-tungsten triple bond as a function of the attendant ligands: tert-BuO versus tert-BuMe2SiO

AU Chisholm, Malcolm H.; Cook, Cindy M.; Folting, Kirsten; Streib, William E.

CS Dep. Chem., Indiana Univ., Bloomington, IN, 47405, USA

SO Inorganica Chimica Acta (1992), 198-200, 63-77

CODEN: ICHAA3; ISSN: 0020-1693

DT Journal

LA English

OS CASREACT 118:7128

AB The siloxy complex $W_2(OSiMe_2CMe_3)_6$ (I) and NO react in hydrocarbon solvents in the presence of pyridine (py) to give the oxo tungsten compds. $W(O)(OSiMe_2CMe_3)_4(py)$ (II), $W_2(O)_4(OSiMe_2CMe_3)_4(py)_2$ (III) and $W(NO)(OSiMe_2CMe_3)_3(py)_2$ (IV). The relative amts. of the oxo compds. II and III to the nitrosyl complex IV obtained from I depend upon the reaction temperature with low temps. (-72°) favoring the nitrosyl derivative IV. An intermediate in the reaction is formulated as $W_2(\mu-O)(OSiMe_2CMe_3)_6(py)_2$ and is formed along with N_2O after the coupling of two nitrosyl ligands. The N_2O liberated in the reaction is then also active in oxygen atom transfer to yield II and III along with N_2 . Compds. II, III and IV are inert with respect to further reactions with NO and N_2O under the conditions leading to their formation. An alternative synthesis of IV involves the reaction between $W(NO)(OCMe_3)_3(py)$ and CMe_3Me_2SiOH (3 equivalent) in the presence of pyridine. Compds. II, III and IV were characterized by single crystal x-ray crystallog., 1H and ^{13}C NMR spectroscopy, IR spectroscopy and elemental anal. Compound II contains a distorted octahedral geometry about tungsten with trans oxo and pyridine

ligands. Compound III involves an edge-shared bioctahedron with terminal and bridging oxo ligands. Compound IV is pseudo-octahedral with trans nitrosyl and pyridine ligands. A derivative of the intermediate $W_2(\mu-O)(OSiMe_2CMe_3)_6(py)_2$ was characterized by x-ray crystallog. as $W_2(\mu-O)(\mu-OCMe_3)(OSiMe_2CMe_3)_5(py)_2$ (V). Compound V contains bridging oxo and t-butoxide ligands that span a formal tungsten-tungsten double bond. In contrast to the above $Mo_2(OSiMe_2CMe_3)_6$ (made by the addition of CMe_3Me_2SiOH (6 equiv) to $Mo_2(OCMe_3)_6$) and NO (>2 equiv) react in hydrocarbon solns. to give $[Mo(NO)(OSiMe_2CMe_3)_3]_2$, an analog of the previously structurally characterized compound $[Mo(NO)(OCMe_3)_3]_2$ that contains a centrosym. $(ON)(O_2M(\mu-O)2MO_2(NO))$ skeleton with a linear M-N-O moiety and no M-M bond.


IT **119935-62-5P**

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (preparation and mol. structure of)

RN 119935-62-5 CAPLUS

CN 2-Propenoic acid, 3-(5-benzoyl-2-cyanophenyl)-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L7 ANSWER 85 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1992:633774 CAPLUS

DN 117:233774

TI Synthesis and spectral properties of phthalimidines and phthalides

AU Stankevicius, A.; Terent'ev, P. B.; Aniulis, A.

CS Mosk. Gos. Univ., Moscow, 117234, Russia

SO Khimiya Geterotsiklicheskikh Soedinenii (1992), (4), 472-6

CODEN: KGSSAQ; ISSN: 0132-6244

DT Journal

LA Russian

AB Base-catalyzed hydrolysis of cis-2-cyanocinnamic acids I ($R_1 = H$, $R_2 = H$, Br , Me_2NSO_2 ; $R_1 = OH$, Me , $R_2 = H$) gave 64-93% of the corresponding phthalimidines II, but acidic hydrolysis of the same acids gave 72-89% of the corresponding phthalides III.


IT **144402-57-3**

RL: RCT (Reactant); RACT (Reactant or reagent) (acid hydrolysis of)

RN 144402-57-3 CAPLUS

CN Benzoic acid, 4-benzoyl-2-(2-carboxyethenyl)-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 119935-62-5P 144402-64-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and base-catalyzed hydrolysis of)

RN 119935-62-5 CAPLUS

CN 2-Propenoic acid, 3-(5-benzoyl-2-cyanophenyl)-, (Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 144402-64-2 CAPLUS

CN 2-Propenoic acid, 3-(5-benzoyl-2-cyanophenyl)-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L7 ANSWER 86 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1992:407653 CAPLUS

DN 117:7653

TI Preparation of 2'-(6-phenyl-5-hexenyloxy)phenylpropionates and analogs as leukotriene B4 inhibitors

IN Heindl, Josef; Skuballa, Werner; Buchmann, Bernd; Froehlich, Wolfgang; Ekerdt, Roland

PA Schering A.-G., Germany

SO Ger. Offen., 8 pp.

CODEN: GWXXBX

DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4028866	A1	19920312	DE 1990-4028866	19900907
	CA 2091182	AA	19920308	CA 1991-2091182	19910828
				DE 1990-4028866	A 19900907
	WO 9204311	A1	19920319	WO 1991-DE690	19910828
	W: AU, CA, HU, JP, NO, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
				DE 1990-4028866	A 19900907
	AU 9184037	A1	19920330	AU 1991-84037	19910828
				DE 1990-4028866	A 19900907
				WO 1991-DE690	A 19910828
	EP 549621	A1	19930707	EP 1991-915659	19910828
	EP 549621	B1	19950927		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
				DE 1990-4028866	A 19900907
				WO 1991-DE690	W 19910828
	HU 63372	A2	19930830	HU 1993-623	19910828
				DE 1990-4028866	A 19900907
	JP 06504984	T2	19940609	JP 1991-513850	19910828
				DE 1990-4028866	A 19900907
				WO 1991-DE690	W 19910828
AT 128453	E	19951015	AT 1991-915659	19910828	
			DE 1990-4028866	A 19900907	
ES 2078541	T3	19951216	ES 1991-915659	19910828	
			DE 1990-4028866	A 19900907	
NO 9300747	A	19930301	NO 1993-747	19930301	
			DE 1990-4028866	A 19900907	
			WO 1991-DE690	W 19910828	
US 5352701	A	19941004	US 1993-50195	19930505	
			DE 1990-4028866	A 19900907	

OS MARPAT 117:7653

AB Title compds. [I; R1 = OH, alkoxy, ar(alkyl)oxy, NHR4; R4 = H, (cyclo)alkyl, aralkyl; X = O, CH2; Y = alkoxy, RS(O)0-2; R = alkyl; Z = H, COACO2H; A = alkylene, 1,3-phenylenediyl, 2,6- or 3,5-pyridylenediyl] were prepared as leukotriene B4 inhibitors (no data). Thus, 4-MeOC6H4CHO was condensed with PH3P(CH2)4CO2H and the product reduced to give, after bromination, (E)-4-MeOC6H4CH:CH(CH2)4Br which was condensed with 2-HOC6H4CH2CH2CO2Me to give, after saponification, I (R1 = OH, X = CH2, Y = 4-OMe, Z = H).


IT 141773-87-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of leukotriene B4 inhibitors)

RN 141773-87-7 CAPLUS

CN Benzoic acid, 3-[3-(2-ethoxy-2-oxoethoxy)-4-[[6-(4-methoxyphenyl)-5-hexenyl]oxy]benzoyl]-, methyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




IT 141773-88-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as leukotriene B4 inhibitor)

RN 141773-88-8 CAPLUS

CN Benzoic acid, 3-[3-(carboxymethoxy)-4-[[6-(4-methoxyphenyl)-5-hexenyl]oxy]benzoyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L7 ANSWER 87 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1992:255288 CAPLUS

DN 116:255288

TI The tetramerization of 2,4-dimethoxycinnamates. A novel route to calixarenes

AU Botta, Bruno; Iacomacci, Paolo; Di Giovanni, Cristina; Delle Monache, Giuliano; Gacs-Baitz, Eszter; Botta, Maurizio; Tafi, Andrea; Corelli, Federico; Misiti, Domenico

CS Cent. Chim. Recett., Univ. Cattol., Rome, 00168, Italy

SO Journal of Organic Chemistry (1992), 57(12), 3259-61

CODEN: JOCEAH; ISSN: 0022-3263

DT Journal

LA English

OS CASREACT 116:255288

AB (E)-2,4-Dimethoxycinnamic acid Me ester was treated in CHCl₃ with BF₃.Et₂O in a molar ratio 1:1.5 at room temperature. Two products were formed after 15 h in an overall high yield (75%). On the basis of extensive spectral anal., they were assigned the general structure 2,8,14,20-tetrakis-(carbomethoxymethyl)-4,6,10,12,16,18,22,24-octamethoxy[14]metacyclophane, which existed as a flattened-cone conformer I (60%) with the substituents all cis, and a 1,2-alternate conformer II (40%) with the substituents in a cis-trans-cis position relative to C-2. The assigned conformations and configuration were confirmed by mol. modeling studies. Notably, the percentage of II in the reaction mixture decreased with time and the conversion II → I was achieved both by heating II with BF₃ in the ratio 1:1.5 and by increasing this ratio at room temperature. With a ratio 1:1

of BF₃ and a minor reaction time (7 h), the intermediate III was isolated. Finally, the reaction was extended with good yields to the substrates (E)-2,4-(MeO)₂C₆H₃CH:CHCO₂R (R = Et, CHMe₂).


IT 140111-49-5P

RL: FORM (Formation, nonpreparative); PREP (Preparation)
(formation of, as intermediate in tetramerization of dimethoxycinnamate)

RN 140111-49-5 CAPLUS

CN Benzenepropanoic acid, β-(2,4-dimethoxyphenyl)-2,4-dimethoxy-5-(3-methoxy-3-oxo-1-propenyl)-, methyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L7 ANSWER 88 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1992:20960 CAPLUS

DN 116:20960

TI Preparation and formulation of benzylpiperazines and [dihydrodibenz[b,e]oxepinylidene]alkylamines

IN Lever, Oscar William; King, Ann Christie; Harfenist, Morton; Chao, Esther Yu Hsuan

PA Wellcome Foundation Ltd., UK

SO PCT Int. Appl., 69 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9015599	A1	19901227	WO 1990-GB935	19900618
	W: AU, CA, FI, HU, JP, KR, NO, SU				
				GB 1989-14040	A 19890619
				GB 1989-14060	A 19890619
				GB 1989-14061	A 19890619
				GB 1989-14062	A 19890619
	CA 2059127	AA	19901220	CA 1990-2059127	19900618
				GB 1989-14040	A 19890619
				GB 1989-14060	A 19890619
				GB 1989-14061	A 19890619
				GB 1989-14062	A 19890619
	AU 9058281	A1	19910108	AU 1990-58281	19900618
	AU 650421	B2	19940623		

			GB 1989-14040	A	19890619
			GB 1989-14060	A	19890619
			GB 1989-14061	A	19890619
			GB 1989-14062	A	19890619
			WO 1990-GB935	A	19900618
EP 409406	A2	19910123	EP 1990-306612		19900618
EP 409406	A3	19910403			
EP 409406	B1	19930908			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE					
			GB 1989-14040	A	19890619
			GB 1989-14060	A	19890619
			GB 1989-14061	A	19890619
			GB 1989-14062	A	19890619
DD 295088	A5	19911024	DD 1990-341780		19900618
			GB 1989-14040	A	19890619
ZA 9004716	A	19920226	ZA 1990-4716		19900618
			GB 1989-14062	A	19890619
EP 487502	A2	19920527	EP 1992-100224		19900618
EP 487502	A3	19920624			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE					
			GB 1989-14040	A	19890619
			GB 1989-14060	A	19890619
			GB 1989-14061	A	19890619
			GB 1989-14062	A	19890619
HU 59377	A2	19920528	HU 1990-4785		19900618
			GB 1989-14040	A	19890619
			GB 1989-14060	A	19890619
			GB 1989-14061	A	19890619
			GB 1989-14062	A	19890619
US 5124330	A	19920623	US 1990-539836		19900618
			GB 1989-14040	A	19890619
US 5124339	A	19920623	US 1990-539837		19900618
			GB 1989-14062	A	19890619
US 5124338	A	19920623	US 1990-539839		19900618
			GB 1989-14060	A	19890619
JP 04506072	T2	19921022	JP 1990-508659		19900618
			GB 1989-14040	A	19890619
			GB 1989-14060	A	19890619
			GB 1989-14061	A	19890619
			GB 1989-14062	A	19890619
			WO 1990-GB935	W	19900618
AT 94061	E	19930915	AT 1990-306612		19900618
			GB 1989-14040	A	19890619
			GB 1989-14060	A	19890619
			GB 1989-14061	A	19890619
			GB 1989-14062	A	19890619
			EP 1990-306612	A	19900618
US 5300282	A	19940405	US 1990-539838		19900618
			GB 1989-14061	A	19890619
IL 94768	A1	19950831	IL 1990-94768		19900618
			GB 1989-14040	A	19890619
			GB 1989-14060	A	19890619
			GB 1989-14061	A	19890619
			GB 1989-14062	A	19890619
CZ 277925	B6	19930317	CZ 1990-3037		19900619
			GB 1989-14040	A	19890619
			GB 1989-14060	A	19890619
			GB 1989-14061	A	19890619
			GB 1989-14062	A	19890619
NO 9104960	A	19911216	NO 1991-4960		19911216

			GB 1989-14040	A 19890619
			GB 1989-14060	A 19890619
			GB 1989-14061	A 19890619
			GB 1989-14062	A 19890619
			WO 1990-GB935	W 19900618
US 5208238	A	19930504	US 1992-896305	19920610
			US 1990-539837	A3 19900618
US 5346897	A	19940913	US 1992-899710	19920610
			US 1990-539839	A3 19900618
US 5364843	A	19941115	US 1992-895925	19920610
			GB 1989-14040	A 19890619
			US 1990-539836	A3 19900618
US 5395610	A	19950307	US 1993-69809	19930528
			GB 1989-14061	A 19890619
			US 1990-539838	A3 19900618

OS MARPAT 116:20960

AB The title compds. [I; A = Q, Q1, Q2 wherein n = 0-3; R1 = H, halo, C1-4 (substituted) alkyl, alkoxy; R2 = H, halo, C1-4 alkoxy, PhCH2O, etc.; R3, R4 = H, C1-4 alkyl; NR3R4 = heterocyclyl optionally containing addnl. hetero atom; R5, R6 = H; R5R6 = CH2CH2, CH2O, OCH2, NHCH2, CH2NH; X = CH, N; p, q = 1-4], useful as enhancers for cancer chemotherapy and as antihistaminics or antiasthmatics, were prepared BuLi in hexane was added to a suspension of 24 g II in THF at 0° under N, followed by 10 g III, the mixture refluxed 18 h and the product chromatographed on SiO2 to give 1.10 g pure (Z)-IV and 0.11 g (E)-IV.HCl. In vitro cytotoxicity of I as potentiating agents in human KB epidermoid carcinoma cells and in Chinese hamster ovary cells was given. Tablet, capsule, injection, etc., formulations were given.


IT **134446-38-1P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as antihistaminic and antineoplastic enhancer)

RN 134446-38-1 CAPLUS

CN 2-Propenoic acid, 3-[3-[(4-chlorophenyl)(4-methyl-1-piperazinyl)methyl]phenyl]-, ethyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L7 ANSWER 89 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1991:656016 CAPLUS
 DN 115:256016
 TI Preparation of diarylstyrylquinoline diacids as leukotriene antagonists
 IN Young, Robert N.; Gauthier, Jacques Yves; Zamboni, Robert; Belley, Michel
 L.
 PA Merck Frosst Canada, Inc., Cote d'Ivoire
 SO Eur. Pat. Appl., 144 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 399818	A1	19901128	EP 1990-305640	19900523
	EP 399818	B1	19950816		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	US 5104882	A	19920414	US 1989-356478	A 19890524
				US 1990-527236	19900522
				US 1987-125050	B2 19871125
				US 1988-275160	B2 19881122
				US 1989-356478	B2 19890524
	CA 2017376	AA	19901124	CA 1990-2017376	19900523
	CA 2017376	C	20000718		
	NO 9002301	A	19901126	US 1989-356478	A 19890524
				NO 1990-2301	19900523
				US 1989-356478	A 19890524
	AU 9055811	A1	19901213	AU 1990-55811	19900523
				US 1989-356478	A 19890524
	ZA 9003983	A	19910327	ZA 1990-3983	19900523
				US 1989-356478	A 19890524
	JP 03072459	A2	19910327	JP 1990-132754	19900524
	JP 07103107	B4	19951108		
	US 5204358	A	19930420	US 1989-356478	A 19890524
				US 1992-818598	19920109
				US 1987-125050	B2 19871125
				US 1988-275160	B2 19881122
				US 1989-356478	B2 19890524
				US 1990-527236	A3 19900522

PATENT FAMILY INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 318093	A2	19890531	EP 1988-202606	19881121
	EP 318093	A3	19901205		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	CA 1339802	A1	19980407	US 1987-125050	A 19871125
				CA 1988-583726	19881122
				US 1987-125050	A 19871125
	ZA 8808766	A	19890830	ZA 1988-8766	19881123
				US 1987-125050	A 19871125
	AU 8825896	A1	19890601	AU 1988-25896	19881124
				US 1987-125050	A 19871125
	DK 8806552	A	19890804	DK 1988-6552	19881124
				US 1987-125050	A 19871125
	JP 02138259	A2	19900528	JP 1988-296383	19881125
	JP 06086433	B4	19941102		
	US 5104882	A	19920414	US 1987-125050	A 19871125
				US 1990-527236	19900522
				US 1987-125050	B2 19871125
				US 1988-275160	B2 19881122

US 5204358	A	19930420	US 1989-356478	B2 19890524
			US 1992-818598	19920109
			US 1987-125050	B2 19871125
			US 1988-275160	B2 19881122
			US 1989-356478	B2 19890524
			US 1990-527236	A3 19900522

OS MARPAT 115:256016


AB Title compds. I [R1 = 7-Cl, 7-MeO, 6-F3C, 7-F3C, 6-MeSO2, H, 6,7-Cl2; Y = CH:CH, CH2CH2, CH2O, CHMeCH2; A = HO2C(CH2)2S, Me2NCO(CH2)2S, 3-(HO2C)C6H4S, Me3CNHCO(CH2)2S, 4-carboxy-2-pyridyl, [(1-adamantylamino)carbonylethyl]thio, 1-tetrazol-5-ylmethylthio, etc.; B = 2-(HO2C)C6H4CH2CH2, 3-(HO2C)C6H4, 5-carboxy-2-thiophenyl, HO2CCH2CHMe(CH2)2, 6-carboxy-2-pyridyl, 2-(Me3CNHCO)C6H4S, 3-[(1-tetrazol-5-yl)methyl]phenyl, etc.] and their salts, useful as inhibitors of leukotriene biosynthesis, antiasthmatic, antiallergic, antiinflammatory, and cytoprotective agents (no data, assays described), are prepared I may also be used to treat erosive gastritis, inflammatory bowel disease, prevention of SRA-release (no data). To a suspension of [(7-chloroquinolin-2-yl)methyl]triphenylphosphonium bromide in THF was added BuLi, the reaction mixture was stirred at -78° and Me 2-[3-[2-(methoxycarbonyl)ethylthio]-3-(3-formylphenyl)propyl]benzoate [preparation from 3-(BrCH2)C6H4CN given] added, the mixture warmed to room temperature to give I [R1 = 7-Cl; Y = CH:CH; A = HO2C(CH2)2S; B = 2-(HO2C)C6H4CH2CH2] (II) as the di-Me ester, which in THF and MeOH was saponified to give II.2Na salt. A capsule, injectable suspension and tablet formulations comprising I are given. Pharmaceutical composition of I may comprise an addnl. active ingredient such as nonsteroidal antiinflammatory drug, peripheral analgesic, cyclooxygenase inhibitor, etc.

IT 124037-52-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as leukotriene antagonist)

RN 124037-52-1 CAPLUS

CN Benzeneacetamide, 3-[[3-[(7-chloro-2-quinolinyl)methoxy]phenyl][3-(dimethylamino)-3-oxopropyl]thio]methyl]-N-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



L7 ANSWER 90 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1991:449102 CAPLUS

DN 115:49102

TI Preparation of benzophenone compounds and their copolymers

IN Kashiwai, Kazuto; Yoshida, Takashi; Suga, Akira; Ikeda, Yoshiji; Kumagai, Shinichi

PA Ipposha Oil Industries Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 22 pp.

CODEN: JKXXAF

DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 03031235	A2	19910212	JP 1989-166229	19890628
	JP 2835396	B2	19981214		
				JP 1989-166229	19890628

OS MARPAT 115:49102


AB Benzophenone derivs. [I; X = R1CO (wherein R1 = OH, C1-4 alkoxy, NHNH2), R1CO2, (R1CO)2CHO, R1COR2O (wherein R2 = C1-4 alkylene), etc.; Y, Z = H, OH, C1-4 linear or branched alkyl, any group defined for X; R1, R4 = H, C1-4 linear or branched alkyl, etc.; h, l = 1-4; m = 4-1; n = 4-h] and their copolymers having UV-absorbing properties are prepared. A mixture of 2,4-(HO)2C6H3COPh, ClCH2CO2Me, and NaHCO3 in MeCN was refluxed to give 63% ester II, which showed λ_{\max} of 235 and 285 nm. Polyesters and polyamides using I as monomers were also prepared and showed excellent weatherability.

IT 134762-36-0P 134762-37-1P 134762-44-0P
134762-45-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as monomer for UV-absorbing copolymers)


RN 134762-36-0 CAPLUS

CN Acetic acid, (3-benzoyl-4-hydroxyphenoxy)-, methylester (9CI) (CA INDEX NAME)




RN 134762-37-1 CAPLUS

CN Acetic acid, (3-benzoyl-4-hydroxyphenoxy)- (9CI) (CA INDEX NAME)




RN 134762-44-0 CAPLUS

CN Acetic acid, 2,2'-[(4-benzoyl-3-hydroxy-1,2-phenylene)bis(oxy)]bis-, dimethyl ester (9CI) (CA INDEX NAME)



RN 134762-45-1 CAPLUS
 CN Acetic acid, 2,2'-[(4-benzoyl-3-hydroxy-1,2-phenylene)bis(oxy)]bis- (9CI)
 (CA INDEX NAME)



L7 ANSWER 91 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1991:61921 CAPLUS
 DN 114:61921
 TI Preparation of indole derivatives and analogs as 5-lipoxygenase inhibitors
 IN Batt, Douglas Guy
 PA du Pont de Nemours, E. I., and Co., USA
 SO Eur. Pat. Appl., 20 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 377450	A1	19900711	EP 1990-100085	19900103
	EP 377450	B1	19940727		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL				
	US 5093351	A	19920303	US 1989-293522	A 19890105
	CA 2006201	AA	19900705	US 1989-293522	19890105
	CA 2006201	C	19981110	CA 1989-2006201	19891220
				US 1989-293522	A 19890105
	HU 53073	A2	19900928	HU 1989-6825	19891229
				US 1989-293522	A 19890105
	SU 1799379	A3	19930228	SU 1989-4742832	19891229
				US 1989-293522	A 19890105
	ES 2060818	T3	19941201	ES 1990-100085	19900103
				US 1989-293522	A 19890105
	FI 9000041	A	19900706	FI 1990-41	19900104
				US 1989-293522	A 19890105
	NO 9000022	A	19900706	NO 1990-22	19900104
	NO 174345	B	19940110		
	NO 174345	C	19940420		

IL 92971	A1	19930708	US 1989-293522	A	19890105
			IL 1990-92971		19900104
AU 9047694	A1	19900712	US 1989-293522	A	19890105
AU 628121	B2	19920910	AU 1990-47694		19900105
			US 1989-293522	A	19890105
JP 02288856	A2	19901128	JP 1990-143		19900105
			US 1989-293522	A	19890105
ZA 9000093	A	19910925	ZA 1990-93		19900105
			US 1989-293522	A	19890105


OS MARPAT 114:61921

AB The title compds. I [X = O, S, NR1; R1 = H, C1-4 alkyl, PhCH2; R2 = H, COR4; R3 = pyridyl, (substituted) Ph, aromatic heterocyclic ring, etc.; R4 = C1-4 alkyl, alkoxy] were prepared. A mixture of 1-methyl-4-oxo-4,5,6,7-tetrahydroindole, PhCHO, and tert-BuOK in tert-BuOH was refluxed for 18 h to give I (X = NMe; R2 = H; R3 = Ph) (II). II in vitro exhibited IC50 of 0.056 μ M against 5-lipoxygenase.

IT **131628-73-4P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and reaction of, in preparation of lipoxygenase inhibitor)

RN 131628-73-4 CAPLUS

CN 2-Propenoic acid, 2-azido-3-[2-(phenylmethoxy)-3-(phenylmethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



L7 ANSWER 92 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1990:552189 CAPLUS

DN 113:152189

TI Succinimide esters and glycine amides of non-steroidal antiinflammatory drugs

AU Singh, Pritpal; Hingorani, L. L.; Trivedi, G. K.

CS Surrendra Ind. Compd., M/s Walter Bushnell Ltd., Thane, 400 606, India

SO Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1990), 29B(6), 551-5
 CODEN: IJSBDB; ISSN: 0376-4699

DT Journal

LA English


OS CASREACT 113:152189

AB Succinimide esters and glycine amides of nonsteroidal antiinflammatory drugs, e.g., d-naproxen, ibuprofen, ketoprofen, aspirin, diclofenac and indomethacin were synthesized. Thus, indomethacin was treated with N-hydroxysuccinimide in the presence of DCC to give 91% the succinimide ester I. Antiinflammatory and ulcerogenic properties were compared with those of the parent drugs. Against carrageenin-induced paw edema in rats I was more effective than any of the parent acids or other prepared compds. and inhibited 82.5% of the swelling.

IT **129612-72-2P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and ulcerogenic and antiinflammatory activities of)

RN 129612-72-2 CAPLUS

CN Glycine, N-[2-(3-benzoylphenyl)-1-oxopropyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 93 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1990:55629 CAPLUS
 DN 112:55629
 TI Quinoline diacid derivatives useful as leukotriene antagonists, and their pharmaceutical compositions and use in medicaments
 IN Young, Robert N.; Zamboni, Robert; Gauthier, Jacques Y.; Belley, Michel L.
 PA Merck Frosst Canada, Inc., Can.
 SO Eur. Pat. Appl., 68 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 318093	A2	19890531	EP 1988-202606	19881121
	EP 318093	A3	19901205		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
				US 1987-125050	A 19871125
	CA 1339802	A1	19980407	CA 1988-583726	19881122
				US 1987-125050	A 19871125
	ZA 8808766	A	19890830	ZA 1988-8766	19881123
				US 1987-125050	A 19871125
	AU 8825896	A1	19890601	AU 1988-25896	19881124
				US 1987-125050	A 19871125
	DK 8806552	A	19890804	DK 1988-6552	19881124
				US 1987-125050	A 19871125
	JP 02138259	A2	19900528	JP 1988-296383	19881125
	JP 06086433	B4	19941102		
				US 1987-125050	A 19871125
	US 5104882	A	19920414	US 1990-527236	19900522
				US 1987-125050	B2 19871125
				US 1988-275160	B2 19881122
				US 1989-356478	B2 19890524
	US 5204358	A	19930420	US 1992-818598	19920109
				US 1987-125050	B2 19871125
				US 1988-275160	B2 19881122
				US 1989-356478	B2 19890524
				US 1990-527236	A3 19900522


PATENT FAMILY INFORMATION:

FAN 1991:656016

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 399818	A1	19901128	EP 1990-305640	19900523
	EP 399818	B1	19950816		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
				US 1989-356478	A 19890524
	US 5104882	A	19920414	US 1990-527236	19900522
				US 1987-125050	B2 19871125

AN 1989:165601 CAPLUS
 DN 110:165601
 TI Synthesis and antiviral activity of cinnamic acid derivatives
 AU Stankevicius, A.; Stankeviciene, L.; Saprasoniene, M.; Korobchenko, L. V.; Boreko, E. I.; Vladyko, G. V.
 CS NII Fiziol. Patol. Serdechno-Sosudistoi Sist., Kaunas, USSR
 SO Khimiko-Farmatsevticheskii Zhurnal (1988), 22(12), 1451-5
 CODEN: KHFZAN; ISSN: 0023-1134
 DT Journal
 LA Russian
 OS CASREACT 110:165601
 AB Cinnamic acid derivs. (I, R = 5-PhCO, 5-Me2NSO2, 5-Br, 4-OH, 4- or 5-OMe, R1 = OH, OMe or NH2; cis and trans isomers) were prepared by the ring cleavage-rearrangement of the corresponding 1-nitroso-2-naphthols with PhSO2Cl and NaOH to give the substituted cinnamic acids followed by esterification or amidation. E.g., I (R = 5-Me2NSO2, R1 = OMe, cis-isomer; R = H, R1 = OH, trans-isomer; and R = 5-Br, R1 = OH, trans isomer) showed antiviral activity against small pox virus. Structure-activity relations and lipophilicity were determined. Some of the compds. had weak activity against herpes virus.
 IT **119935-62-5P**
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation and antiviral activity of)
 RN 119935-62-5 CAPLUS
 CN 2-Propenoic acid, 3-(5-benzoyl-2-cyanophenyl)-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L7 ANSWER 95 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1989:23438 CAPLUS
 DN 110:23438
 TI Optical resolution, asymmetric synthesis and absolute configuration of m-benzoyl-2-phenoxypropionic acids
 AU Azzolina, O.; Vercesi, D.; Ghislandi, V.
 CS Dip. Chim. Farm., Univ. Pavia, Pavia, Italy
 SO Farmaco, Edizione Scientifica (1988), 43(5), 469-78
 CODEN: FRPSAX; ISSN: 0430-0920
 DT Journal
 LA English
 OS CASREACT 110:23438
 AB Acids I (R1 = H, Cl; R2 = H, Me) were prepared. The etherification of 3-PhCOC6H4OH by (R)-(+)-MeCHBrCO2H and subsequent saponification gave (S)-(-)-I (R1 = R2 = H).
 IT **117819-26-8P 117819-30-4P 117852-24-1P**


117852-26-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(asym. synthesis of)

RN 117819-26-8 CAPLUS

CN Propanoic acid, 2-[3-(4-chlorobenzoyl)-2-methylphenoxy]-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 117819-30-4 CAPLUS

CN Propanoic acid, 2-[3-(4-chlorobenzoyl)-2-methylphenoxy]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 117852-24-1 CAPLUS

CN Propanoic acid, 2-(3-benzoylphenoxy)-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 117852-26-3 CAPLUS

CN Propanoic acid, 2-(3-benzoylphenoxy)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 117819-27-9P 117819-28-0P 117819-31-5P

117852-25-2P 117852-27-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and hydrolysis of)

RN 117819-27-9 CAPLUS


CN Cinchonan-9-ol, (8 α ,9R)-, mono[(R)-2-[3-(4-chlorobenzoyl)-2-methylphenoxy]propanoate] (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 117819-26-8

CMF C17 H15 Cl O4

Absolute stereochemistry.




CM 2

CRN 485-71-2

CMF C19 H22 N2 O

Absolute stereochemistry.




RN 117819-28-0 CAPLUS
CN L-Lysine, mono[(R)-2-[3-(4-chlorobenzoyl)-2-methylphenoxy]propanoate]
(9CI) (CA INDEX NAME)

CM 1

CRN 117819-26-8
CMF C17 H15 Cl O4


Absolute stereochemistry.



CM 2

CRN 56-87-1
CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 117819-31-5 CAPLUS
CN D-Lysine, mono[(S)-2-[3-(4-chlorobenzoyl)-2-methylphenoxy]propanoate]
(9CI) (CA INDEX NAME)

CM 1

CRN 117819-30-4
CMF C17 H15 Cl O4

Absolute stereochemistry.




CM 2

CRN 923-27-3

CMF C6 H14 N2 O2

Absolute stereochemistry.



RN 117852-25-2 CAPLUS


CN Cinchonan-9-ol, (8 α ,9R)-, mono[(R)-2-(3-benzoylphenoxy)propanoate]
(salt) (9CI) (CA INDEX NAME)

CM 1

CRN 117852-24-1

CMF C16 H14 O4

Absolute stereochemistry. Rotation (+).




CM 2

CRN 485-71-2

CMF C19 H22 N2 O

Absolute stereochemistry.




RN 117852-27-4 CAPLUS
 CN Cinchon-9-ol, (8 α ,9R)-, mono[(S)-2-(3-benzoylphenoxy)propanoate]
 (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 117852-26-3

CMF C16 H14 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 485-71-2

CMF C19 H22 N2 O

Absolute stereochemistry.




IT 117819-32-6P 117819-33-7P 117819-34-8P
 117819-35-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and saponification of)

RN 117819-32-6 CAPLUS

CN Propanoic acid, 2-(3-benzoylphenoxy)-, ethyl ester, (S)- (9CI) (CA INDEX
 NAME)


Absolute stereochemistry.



RN 117819-33-7 CAPLUS

CN Propanoic acid, 2-(3-benzoylphenoxy)-, ethyl ester, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 117819-34-8 CAPLUS

CN Propanoic acid, 2-[3-(4-chlorobenzoyl)-2-methylphenoxy]-, ethyl ester, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 117819-35-9 CAPLUS

CN Propanoic acid, 2-[3-(4-chlorobenzoyl)-2-methylphenoxy]-, ethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 74168-02-8 74168-08-4

RL: PROC (Process)
(resolution of)


RN 74168-02-8 CAPLUS

CN Propanoic acid, 2-(3-benzoylphenoxy)- (9CI) (CA INDEX NAME)



RN 74168-08-4 CAPLUS

CN Propanoic acid, 2-[3-(4-chlorobenzoyl)-2-methylphenoxy]- (9CI) (CA INDEX NAME)



L7 ANSWER 96 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1988:437712 CAPLUS

DN 109:37712

TI Substituted 4H-1-benzopyran-4-ones (chromones): synthesis via palladium-catalyzed coupling of their halo derivatives with alkenes

AU Davies, Stephen G.; Mobbs, Bryan E.; Goodwin, Christopher J.

CS Dyson Perrins Lab., Oxford, OX1 3QY, UK

SO Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1987), (12), 2597-604

CODEN: JCPRB4; ISSN: 0300-922X

DT Journal

LA English

OS CASREACT 109:37712

AB Coupling of bromochromenes, e.g. I (R = Br, R1 = H; R = H, R1 = Br), with CH2:CHR2 (R2 = CO2Me, Ph, cyano) in the presence of Pd(PPh3)2Cl2 and Et3N regiospecifically gave 55-76% of the corresponding vinylchromones I (R =

CH:CHR2, R1 = H; R = H, R1 = CH:CHR2) as predominantly the E-isomers. A similar coupling of 3,6-dibromochromone with CH2:CHCO2Me gave 41% divinylchromone II and 8% ring-opened cinnamate III.


IT **115237-41-7P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 115237-41-7 CAPLUS

CN Benzoic acid, 3-[2-hydroxy-5-(3-methoxy-3-oxo-1-propenyl)benzoyl]-, methyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L7 ANSWER 97 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1988:186319 CAPLUS

DN 108:186319

TI Preparation of benzylbenzoquinone derivatives for treatment of cerebral disorders

IN Tatsuoaka, Toshio; Suzuki, Kenji; Sato, Fumio; Miyano, Seiji; Sumoto, Kunihiro

PA Suntory, Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 10 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN. CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 62286949	A2	19871212	JP 1986-131139	19860606
	JP 2506337	B2	19960612		
				JP 1986-131139	19860606

AB Title compds. I [R1, R2, R3 = H, Me, MeO; R4 = H, HOCH2, (esterified or amidated) carboxyl; A = ethylene, vinylene; n = 0, 1] are prepared Refluxing II (R5 = OH) (preparation given) in SOCl2 for 12 h, followed by treatment of the resulting product with Zn at room temperature for 3 h gave 24.5% II (R5 = H), which was treated with picolinic acid and (NH4)2Ce(NO3)6 in MeCN-H2O at room temperature for 30 min to afford 44.0% I (R1 - R3 = H, R4 = CO2Et, A = 3-vinylene) (III). III at ≤12.5 mg/kg i.p. showed antihypoxia activity in mice. A capsule was formulated containing III 50, lactose 59.5, corn starch 40, and SiO2 0.5 mg.


IT **114072-82-1P 114072-83-2P 114072-88-7P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction of, in preparation of antihypoxia agent)


RN 114072-82-1 CAPLUS

CN 2-Propenoic acid, 3-[3-[(2,5-dimethoxyphenyl)hydroxymethyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 114072-83-2 CAPLUS

CN 2-Propenoic acid, 3-[3-[(2,5-dimethoxyphenyl)methyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 114072-88-7 CAPLUS

CN 2-Propenoic acid, 3-[3-[(2,5-dimethoxyphenyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 98 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1986:206920 CAPLUS

DN 104:206920

TI Diphenylmethane compounds

IN Findlay, John W. A.; Coker, Geoffrey G.

PA USA

SO U.S., 8 pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4564685	A	19860114	US 1983-474729	19830310
				US 1983-474729	19830310

AB The title compds. (I; R = H, Br, Cl, alkyl, alkoxy; R1, R2 = H, Cl-4 alkyl; NR1R2 = pyrrolidino, piperidino, morpholino; Z = bond, alkylene, alkenylene), effective antihistaminics in guinea pigs, were prepared Thus, 1.6M BuLi was added to a cooled suspension of 17.6 g benzophenone derivative II in THF at 0° with stirring, 10.16 g phosphonium salt III in THF was added, and the mixture was heated to 55° to give 9.8 g I Me ester

(R = Me, NR1R2 = pyrrolidino, Z = bond) as the Z and E mixture Hydrolysis of the mixed esters in aqueous NaOH-EtOH gave the corresponding individual isomers of I by crystallization


IT 102092-50-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and Wittig reaction of, with pyrrolidinoethylphosphonium bromide)

RN 102092-50-2 CAPLUS

CN 2-Propenoic acid, 3-[3-(4-methoxybenzoyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



IT 87849-32-9P 87849-33-0P 87849-50-1P


87849-51-2P 87849-59-0P 87849-60-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and antihistaminic activity of)

RN 87849-32-9 CAPLUS

CN 2-Propenoic acid, 3-[3-[1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl]phenyl]-, (E,E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 87849-33-0 CAPLUS

CN 2-Propenoic acid, 3-[3-[1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl]phenyl]-, hydrochloride, (E,E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




● HCl

RN 87849-50-1 CAPLUS

CN 2-Propenoic acid, 3-[3-[1-(4-methoxyphenyl)-3-(1-pyrrolidinyl)-1-propenyl]phenyl]-, (E,Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 87849-51-2 CAPLUS


CN 2-Propenoic acid, 3-[3-[1-(4-methoxyphenyl)-3-(1-pyrrolidinyl)-1-propenyl]phenyl]-, (E,E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 87849-59-0 CAPLUS
CN 2-Propenoic acid, 3-[3-[3-(dimethylamino)-1-(4-methylphenyl)-1-propenyl]phenyl]-, (E,E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 87849-60-3 CAPLUS
CN 2-Propenoic acid, 3-[3-[3-(dimethylamino)-1-(4-methylphenyl)-1-propenyl]phenyl]-, (E,Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 102092-52-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrogenation or Wittig reaction of)
RN 102092-52-4 CAPLUS
CN 2-Propenoic acid, 3-[3-(4-methylbenzoyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



IT 87849-31-8P 87849-48-7P 87849-49-8P


87849-57-8P 87849-58-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and hydrolysis of)

RN 87849-31-8 CAPLUS

CN 2-Propenoic acid, 3-[3-[1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl]phenyl]-, methyl ester, (E,E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 87849-48-7 CAPLUS

CN 2-Propenoic acid, 3-[3-[1-(4-methoxyphenyl)-3-(1-pyrrolidinyl)-1-propenyl]phenyl]-, ethyl ester, (E,E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 87849-49-8 CAPLUS

CN 2-Propenoic acid, 3-[3-[1-(4-methoxyphenyl)-3-(1-pyrrolidinyl)-1-propenyl]phenyl]-, ethyl ester, (E,Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 87849-57-8 CAPLUS

CN 2-Propenoic acid, 3-[3-[3-(dimethylamino)-1-(4-methylphenyl)-1-propenyl]phenyl]-, ethyl ester, (E,E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 87849-58-9 CAPLUS

CN 2-Propenoic acid, 3-[3-[3-(dimethylamino)-1-(4-methylphenyl)-1-propenyl]phenyl]-, ethyl ester, (E,Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




L7 ANSWER 99 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1986:180209 CAPLUS
 DN 104:180209
 TI Antiinflammatory N2-[2-(3-benzoylphenyl)propionyl]-L-glutamine
 IN Ozawa, Shinji; Kumonaka, Yasuhiro; Wakabayashi, Toshio
 PA Terumo Corp., Japan
 SO Jpn. Kokai Tokkyo Koho, 3 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 60260514	A2	19851223	JP 1984-117798	19840608
				JP 1984-117798	19840608

AB N2-[2-(3-Benzoylphenyl)propionyl]-L-glutamine (I) is an antiinflammatory agent. I (1.5 mg/kg) administered orally to rats for 20 doses (20 days) was effective in inhibiting exptl. induced edema in the footpad. I was prepared by reaction of 2-(3-benzoylphenyl)propionic acid with L-glutamine.
 IT **81416-76-4P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as inflammation inhibitor)
 RN 81416-76-4 CAPLUS
 CN L-Glutamine, N2-[2-(3-benzoylphenyl)-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 100 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1985:185103 CAPLUS
 DN 102:185103
 TI Benzhydrylpiperazines
 IN Coker, Geoffrey George; Findlay, John William Addison


PA Wellcome Foundation Ltd., UK
 SO Eur. Pat. Appl., 29 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 133323	A1	19850220	EP 1984-109053	19840731
	EP 133323	B1	19880203		
	R: CH, DE, FR, GB, LI				
	JP 60056973	A2	19850402	GB 1983-20701	A 19830801
	JP 04015786	B4	19920319	JP 1984-161452	19840731
	US 4757074	A	19880712	GB 1983-20701	A 19830801
				US 1986-833665	19860224
				GB 1983-20701	A 19830801
				US 1984-635250	A3 19840727


AB Title compds. I [R = CO₂H, CH:CHCO₂H, (CH₂)_nCO₂H, O(CH₂)_nCO₂H; R₁ = alkyl, PhCH₂, alkylbenzyl; R₂ = alkoxy, alkyl, halo; n = 1-4], and esters or amides thereof, were prepared. Thus, 4-BrC₆H₄Cl was treated with BuLi and 3-BrC₆H₄CHO to give 3-BrC₆H₄CHOHC₆H₄Cl-4, which was chlorinated with SOCl₂ and treated with N-methylpiperazine to give I (R = 3-Br, R₁ = Me, R₂ = Cl). The latter compound was treated with CH₂:CHCO₂Me in the presence of Pd(OAc)₂ in a steel bomb at 125° for 24 h to give I [R = (E)-3-CH:CHCO₂Me, R₁ = Me, R₂ = Cl], which was saponified to give the acid (II). In the antihistamine assay with isolated guinea-pig ileum, II had a pA₂ of 6.2 compared with 8.6 for chlorcyclizine.

IT 96223-00-6P 96223-05-1P 96223-06-2P
 96223-07-3P 96223-15-3P 96223-17-5P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and antihistaminic activity of)

RN 96223-00-6 CAPLUS
 CN 2-Propenoic acid, 3-[3-[(4-chlorophenyl)(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 96223-05-1 CAPLUS
 CN Acetic acid, [3-[(4-chlorophenyl)(4-methyl-1-piperazinyl)methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 96223-06-2 CAPLUS

CN Acetic acid, [3-[(4-chlorophenyl) [4-[(3-methylphenyl)methyl]-1-piperazinyl]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 96223-07-3 CAPLUS

CN Acetic acid, [3-[(4-chlorophenyl) [4-[(1,1-dimethylethyl)phenyl]methyl]-1-piperazinyl]methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 96223-15-3 CAPLUS

CN Acetic acid, [3-[(4-chlorophenyl) (4-methyl-1-piperazinyl)methyl]phenoxy]-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 96223-05-1


CMF C20 H23 Cl N2 O3



CM 2


CRN 144-62-7

CMF C2 H2 O4



RN 96223-17-5 CAPLUS

CN Acetic acid, [3-[(4-chlorophenyl)(4-methyl-1-piperazinyl)methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


IT 96223-11-9P 96223-14-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation and saponification of)


RN 96223-11-9 CAPLUS

CN 2-Propenoic acid, 3-[3-[(4-chlorophenyl)(4-methyl-1-piperazinyl)methyl]phenoxy]-, methyl ester, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 96223-14-2 CAPLUS
 CN Acetic acid, [3-[(4-chlorophenyl)(4-methyl-1-piperazinyl)methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




IT **96223-16-4 96223-18-6**
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (saponification of)
 RN 96223-16-4 CAPLUS
 CN Acetic acid, [3-[(4-chlorophenyl)[4-[(3-methylphenyl)methyl]-1-piperazinyl]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 96223-18-6 CAPLUS
 CN Acetic acid, [3-[(4-chlorophenyl)[4-[(1,1-dimethylethyl)phenyl]methyl]-

1-piperazinyl]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



L7 ANSWER 101 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1985:184863 CAPLUS

DN 102:184863

TI Wittig-Horner reaction in a heterogeneous medium. VI. Selectivity of the reaction on bifunctional compounds

AU Villieras, Jean; Rambaud, Monique; Graff, Micheline

CS Lab. Synth. Org. Select., Fac. Sci., Nantes, 44072, Fr.

SO Tetrahedron Letters (1985), 26(1), 53-6

CODEN: TELEAY; ISSN: 0040-4039

DT Journal

LA French

OS CASREACT 102:184863

AB Heterogeneous liquid-liquid (K₂CO₃-H₂O) or solid-liquid (K₂CO₃-PhMe) media of low basicity allow the Wittig-Horner reaction of fragile aldehydes and unprotected hydroxy, nitro and keto aldehydes to take place with excellent yields. The reaction is applied to the synthesis of royal jelly acid [HO(CH₂)₇CH:CHCO₂H] and queen substance of honey bee [MeCO(CH₂)₅CH:CHCO₂H].


IT 96251-93-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, by Wittig reaction)

RN 96251-93-3 CAPLUS

CN 2-Propenoic acid, 3-(3-benzoylphenyl)-, ethyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L7 ANSWER 102 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1984:6345 CAPLUS

DN 100:6345
 TI Aromatic compounds
 IN Coker, Geoffrey George; Findlay, John William Addison
 PA Wellcome Foundation Ltd., UK
 SO Eur. Pat. Appl., 66 pp.
 CODEN: EPXXDW

DT Patent
 LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 85959	A2	19830817	EP 1983-101036	19830203
	EP 85959	A3	19840718		
	EP 85959	B1	19890419		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
				GB 1982-3261	A 19820204
				GB 1982-29705	A 19821018
	US 4501893	A	19850226	US 1983-462872	19830201
				GB 1982-3261	A 19820204
	US 4562258	A	19851231	US 1983-462874	19830201
				GB 1982-3261	A 19820204
	DK 8300436	A	19830805	DK 1983-436	19830203
	DK 164662	B	19920727		
	DK 164662	C	19921214		
				GB 1982-3261	A 19820204
				GB 1982-29705	A 19821018
	FI 8300380	A	19830805	FI 1983-380	19830203
	FI 82450	B	19901130		
	FI 82450	C	19910311		
				GB 1982-3261	A 19820204
				GB 1982-29705	A 19821018
	NO 8300368	A	19830805	NO 1983-368	19830203
	NO 162556	B	19891009		
	NO 162556	C	19900117		
				GB 1982-3261	A 19820204
				GB 1982-29705	A 19821018
	AU 8310982	A1	19830811	AU 1983-10982	19830203
	AU 555083	B2	19860911		
				GB 1982-3261	A 19820204
				GB 1982-29705	A 19821018
	GB 2114565	A1	19830824	GB 1983-2971	19830203
	GB 2114565	B2	19850626		
				GB 1982-3261	A 19820204
				GB 1982-29705	A 19821018
	JP 58164557	A2	19830929	JP 1983-16847	19830203
	JP 01053671	B4	19891115		
				GB 1982-3261	A 19820204
				GB 1982-29705	A 19821018
	HU 27600	O	19831028	HU 1983-377	19830203
	HU 189223	B	19860630		
				GB 1982-3261	A 19820204
				GB 1982-29705	A 19821018
	ES 519491	A1	19840401	ES 1983-519491	19830203
				GB 1982-3261	A 19820204
				GB 1982-29705	A 19821018
	ZA 8300737	A	19840926	ZA 1983-737	19830203
				GB 1982-3261	A 19820204
	CS 235306	B2	19850515	CS 1983-754	19830203
				GB 1982-3261	A 19820204
				GB 1982-29705	A 19821018

PL 140708	B1	19870530	PL 1983-240412	19830203
			GB 1982-3261	A 19820204
			GB 1982-29705	A 19821018
PL 140809	B1	19870530	PL 1983-245841	19830203
			GB 1982-3261	A 19820204
			GB 1982-29705	A 19821018
PL 140810	B1	19870530	PL 1983-245842	19830203
			GB 1982-3261	A 19820204
			GB 1982-29705	A 19821018
PL 140811	B1	19870530	PL 1983-245843	19830203
			GB 1982-3261	A 19820204
			GB 1982-29705	A 19821018
PL 140812	B1	19870530	PL 1983-245844	19830203
			GB 1982-3261	A 19820204
			GB 1982-29705	A 19821018
PL 141639	B1	19870831	PL 1983-245845	19830203
			GB 1982-3261	A 19820204
			GB 1982-29705	A 19821018
EP 249950	A1	19871223	EP 1987-108671	19830203
EP 249950	B1	19910619		
			R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE	
			GB 1982-3261	A 19820204
			GB 1982-29705	A 19821018
			EP 1983-101036	P 19830203
IL 67829	A1	19880630	IL 1983-67829	19830203
			GB 1982-3261	A 19820204
			GB 1982-29705	A 19821018
SU 1436871	A3	19881107	SU 1983-3555527	19830203
			GB 1982-3261	A 19820204
IL 78419	A1	19890131	IL 1983-78419	19830203
			GB 1982-3261	A 19820204
			GB 1982-29705	A 19821018
			IL 1983-67829	A 19830203
AT 42282	E	19890515	AT 1983-101036	19830203
			GB 1982-3261	A 19820204
			GB 1982-29705	A 19821018
			EP 1983-101036	A 19830203
AT 64596	E	19910715	AT 1987-108671	19830203
			GB 1982-3261	A 19820204
			GB 1982-29705	A 19821018
			EP 1987-108671	A 19830203
DD 209446	A5	19840509	DD 1983-247730	19830204
			GB 1982-3261	A 19820204
			GB 1982-29705	A 19821018
CA 1249830	A1	19890207	CA 1983-420912	19830204
			GB 1982-3261	A 19820204
			GB 1982-29705	A 19821018
ES 523414	A1	19841001	ES 1983-523414	19830620
			GB 1982-3261	A 19820204
			GB 1982-29705	A 19821018
ES 523415	A1	19841001	ES 1983-523415	19830620
			GB 1982-3261	A 19820204
			GB 1982-29705	A 19821018
ES 523416	A1	19841001	ES 1983-523416	19830620
			GB 1982-3261	A 19820204
			GB 1982-29705	A 19821018
ES 523417	A1	19841001	ES 1983-523417	19830620
			GB 1982-3261	A 19820204
			GB 1982-29705	A 19821018
ES 523418	A1	19841001	ES 1983-523418	19830620

			GB 1982-3261	A	19820204
			GB 1982-29705	A	19821018
SU 1301312	A3	19870330	SU 1983-3652410		19831017
			GB 1982-3261	A	19820204
SU 1416057	A3	19880807	GB 1982-29705	A	19821018
			SU 1983-3652703		19831017
SU 1447280	A3	19881223	GB 1982-3261	A	19820204
			SU 1983-3652921		19831017
			GB 1983-20699		19830801
			GB 1982-3261		19820204
SU 1516009	A3	19891015	SU 1983-3654489		19831017
			GB 1982-3261	A	19820204
CS 235347	B2	19850515	CS 1984-2018		19840321
			GB 1982-3261	A	19820204
			GB 1982-29705	A	19821018
			CS 1983-754	A3	19830203
CS 235348	B2	19850515	CS 1984-2019		19840321
			GB 1982-3261	A	19820204
			GB 1982-29705	A	19821018
			CS 1983-754	A3	19830203
CS 235349	B2	19850515	CS 1984-2020		19840321
			GB 1982-3261	A	19820204
			GB 1982-29705	A	19821018
			CS 1983-754	A3	19830203
CS 235350	B2	19850515	CS 1984-2021		19840321
			GB 1982-3261	A	19820204
			GB 1982-29705	A	19821018
			CS 1983-754	A3	19830203
US 4650807	A	19870317	US 1985-753791		19850708
			GB 1982-3261	A	19820204
US 4657918	A	19870414	US 1983-462789	A1	19830201
			US 1985-779877		19850925
			GB 1982-3261	A	19820204
JP 63033343	A2	19880213	US 1983-462874	A3	19830201
JP 03048181	B4	19910723	JP 1987-106133		19870428
			GB 1982-3261	A	19820204
			GB 1982-29705	A	19821018
NO 8704330	A	19830805	NO 1987-4330		19871016
NO 172341	B	19930329			
NO 172341	C	19930707			
			GB 1982-3261	A	19820204
			GB 1982-29705	A	19821018
			NO 1983-368	A1	19830203
JP 01079153	A2	19890324	JP 1988-135352		19880601
JP 02051897	B4	19901108			
			GB 1982-3261	A	19820204
			GB 1982-29705	A	19821018
CA 1275102	A2	19901009	CA 1988-575487		19880823
			GB 1982-3261	A	19820204
			GB 1982-29705	A	19821018
			CA 1983-420912	A3	19830204
JP 01301661	A2	19891205	JP 1989-98616		19890418
JP 04000068	B4	19920106			
			GB 1982-3261	A	19820204
			GB 1982-29705	A	19821018

PATENT FAMILY INFORMATION:

FAN 1985:504855

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

PI EP 135087 A1 19850327 EP 1984-109056 19840731
 EP 135087 B1 19880622
 R: CH, DE, FR, GB, LI

SU 1447280 A3 19881223 GB 1983-20699 A 19830801
 SU 1983-3652921 19831017
 GB 1983-20699 19830801
 GB 1982-3261 19820204
 US 4590199 A 19860520 US 1984-635308 19840727
 GB 1983-20699 A 19830801
 JP 60056957 A2 19850402 JP 1984-161450 19840731
 JP 04017190 B4 19920325
 GB 1983-20699 A 19830801

OS CASREACT 100:6345


AB Amines I (X = N, CH; R = CO₂H, carboxyalkyl, carboxyalkenyl; R₁ = H, halogen, OH, cyano, acyloxy, alkoxy, alkyl, haloalkyl; R₂, R₃ = H; R₂R₃ = bond; NR₄R₅ = amino) were prepared (E,E)-II was prepared from 2,6-dibromopyridine, 4-MeC₆H₄CN, EtO₂CH₂P(O)(OEt)₂, and (2-pyrrolidinoethyl)triphenylphosphonium bromide in 5 steps. II has an antihistaminic pA₂ of 8.6.

IT **87849-31-8P 87849-48-7P 87849-49-8P**
87849-52-3P 87849-53-4P 87849-58-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and hydrolysis of)

RN 87849-31-8 CAPLUS

CN 2-Propenoic acid, 3-[3-[1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl]phenyl]-, methyl ester, (E,E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 87849-48-7 CAPLUS

CN 2-Propenoic acid, 3-[3-[1-(4-methoxyphenyl)-3-(1-pyrrolidinyl)-1-propenyl]phenyl]-, ethyl ester, (E,E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 87849-49-8 CAPLUS

CN 2-Propenoic acid, 3-[3-[1-(4-methoxyphenyl)-3-(1-pyrrolidinyl)-1-propenyl]phenyl]-, ethyl ester, (E,Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 87849-52-3 CAPLUS

CN 2-Propenoic acid, 3-[3-[1-(4-chlorophenyl)-3-(1-pyrrolidinyl)-1-propenyl]phenyl]-, ethyl ester, (E,E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 87849-53-4 CAPLUS

CN 2-Propenoic acid, 3-[3-[1-(4-chlorophenyl)-3-(1-pyrrolidinyl)-1-propenyl]phenyl]-, ethyl ester, (E,Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 87849-58-9 CAPLUS

CN 2-Propenoic acid, 3-[3-[3-(dimethylamino)-1-(4-methylphenyl)-1-propenyl]phenyl]-, ethyl ester, (E,Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




IT 87849-47-6P 88142-48-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, with pyrrolidinyethylphosphonium bromide)

RN 87849-47-6 CAPLUS

CN 2-Propenoic acid, 3-[3-(4-methoxybenzoyl)phenyl]-, ethyl ester, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 88142-48-7 CAPLUS

CN 2-Propenoic acid, 3-[3-(4-chlorobenzoyl)phenyl]-, ethyl ester, (E)- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.



IT 87849-32-9P 87849-33-0P 87849-50-1P

87849-51-2P 87849-54-5P 87849-55-6P

87849-56-7P 87849-57-8P 87849-59-0P


87849-60-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 87849-32-9 CAPLUS

CN 2-Propenoic acid, 3-[3-[1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl]phenyl]-, (E,E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 87849-33-0 CAPLUS

CN 2-Propenoic acid, 3-[3-[1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl]phenyl]-, hydrochloride, (E,E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




● HCl

RN 87849-50-1 CAPLUS

CN 2-Propenoic acid, 3-[3-[1-(4-methoxyphenyl)-3-(1-pyrrolidinyl)-1-propenyl]phenyl]-, (E,Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 87849-51-2 CAPLUS

CN 2-Propenoic acid, 3-[3-[1-(4-methoxyphenyl)-3-(1-pyrrolidinyl)-1-propenyl]phenyl]-, (E,E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 87849-54-5 CAPLUS

CN 2-Propenoic acid, 3-[3-[1-(4-chlorophenyl)-3-(1-pyrrolidinyl)-1-propenyl]phenyl]-, (E,Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 87849-55-6 CAPLUS

CN 2-Propenoic acid, 3-[3-[1-(4-chlorophenyl)-3-(1-pyrrolidinyl)-1-propenyl]phenyl]-, (E,E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 87849-56-7 CAPLUS

CN 2-Propenoic acid, 3-[3-(4-methylbenzoyl)phenyl]-, ethyl ester, (E)- (9CI)
(CA INDEX NAME)


Double bond geometry as shown.



RN 87849-57-8 CAPLUS

CN 2-Propenoic acid, 3-[3-[3-(dimethylamino)-1-(4-methylphenyl)-1-propenyl]phenyl]-, ethyl ester, (E,E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 87849-59-0 CAPLUS

CN 2-Propenoic acid, 3-[3-[3-(dimethylamino)-1-(4-methylphenyl)-1-propenyl]phenyl]-, (E,E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 87849-60-3 CAPLUS


CN 2-Propenoic acid, 3-[3-[3-(dimethylamino)-1-(4-methylphenyl)-1-propenyl]phenyl]-, (E,Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




L7 ANSWER 103 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1982:163143 CAPLUS
 DN 96:163143
 TI Studies on the synthesis of new analgesic, antipyretic, and
 antiinflammatory agent using L-glutamine
 AU Cook, Cheo Ho; Lah, Woon Lyong; Cho, Youn Sang; Jew, Sang Sup; Kim, Dae
 Kee
 CS Coll. Pharm., Seoul Natl. Univ., Seoul, S. Korea
 SO Soul Taehakkyo Yakhak Nonmunjip (1980), 5, 67-9
 CODEN: STYNDJ; ISSN: 0250-3336
 DT Journal
 LA English
 AB RR1CHCO-L-Glu-OH [I; R = 6-methoxy-2-naphthyl, p-(Me2CHCH2)C6H4, m-BzC6H4,
 R1 = Me; R = Q, R1 = H] were prepared by acylating L-glutamine with
 RR1CHCOCl by a modified Schotten-Baumann reaction. I are presumably more
 effective antiinflammatory agents than arylalkanoic acids and produce less
 gastrointestinal irritation.
 IT **81416-76-4P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as inflammation inhibitor)
 RN 81416-76-4 CAPLUS
 CN L-Glutamine, N2-[2-(3-benzoylphenyl)-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 104 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1981:480061 CAPLUS
 DN 95:80061
 TI Synthesis of carbon-14-labeled 2-(3-benzoylphenoxy)-2-methylpropionic acid
 (LF.599)
 AU Luu Duc, C.; Charlon, C.; Bourgogne, J. P.; Sornay, R.
 CS Groupe Etud. Rech. Med., UER Sci. Pharm. Biol. Grenoble, Tronche, F-38700,
 Fr.

SO Journal of Labelled Compounds and Radiopharmaceuticals (1981), 18(4), 583-6
 CODEN: JLCRD4; ISSN: 0362-4803
 DT Journal
 LA English
 OS CASREACT 95:80061
 AB 3-PhCOC6H4OCMe2CO2H, a structural analog of the antilipemic drug Procetofen and an effective analgesic, was prepared with a ¹⁴C label in the ketone group by Grignard reaction of m-BrC6H4OMe with Ba¹⁴CO3 followed sequentially by chlorination (SOCl2), Friedel-Crafts reaction with C6H6, hydrolysis of the MeO group (HBr, AcOH), condensation with BrCMe2CO2Me (MeOH, K2CO3), and hydrolysis of the ester (NaOH, MeOH).
 IT **78646-07-8P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and hydrolysis of)
 RN 78646-07-8 CAPLUS
 CN Propanoic acid, 2-(3-benzoyl-carbonyl-¹⁴C-phenoxy)-2-methyl-, methyl ester (9CI) (CA INDEX NAME)



IT **78646-02-3P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 78646-02-3 CAPLUS
 CN Propanoic acid, 2-(3-benzoyl-carbonyl-¹⁴C-phenoxy)-2-methyl- (9CI) (CA INDEX NAME)



L7 ANSWER 105 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1981:127386 CAPLUS
 DN 94:127386
 TI Treatment of algiae
 IN Majoie, Bernard
 PA Societe de Recherches Industrielles (SORI) S. A., Fr.
 SO U.S., 3 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	US 4242358	A	19801230	US 1979-6105	19790124


AB I (X1 and X2 = H, Me, OMe, F, Cl, Br, or Cf; R1 and R2 = H or Me) have antalgic activity and lower levels of hypolipemic, hypocholesteremic and antiinflammatory activity. I, e.g., I (X1 = X2 = H, R1 = R2 = Me) [62809-78-3] showed at least or greater antalgic activity than Glaphenine in decreasing cramping induced by phenylbenzoquinone in mice upon i.p. administration at .apprx.350-800 mg/kg. Descriptions of pharmaceutical formulations were given.

IT 62809-78-3 62809-80-7 62809-86-3
 62809-88-5 62809-97-6 74168-02-8
 74168-05-1 74168-11-9 76960-06-0
 76960-07-1 76960-08-2 76960-09-3
 76960-10-6 76960-11-7 76960-12-8
 76960-13-9 76960-14-0 76960-15-1
 76960-16-2 76960-17-3 76960-18-4
 76960-19-5 76960-20-8 76960-21-9
 76960-22-0 76960-23-1

RL: BIOL (Biological study)
 (analgesic)


RN 62809-78-3 CAPLUS

CN Propanoic acid, 2-(3-benzoylphenoxy)-2-methyl- (9CI) (CA INDEX NAME)




RN 62809-80-7 CAPLUS

CN Propanoic acid, 2-[3-(4-methoxybenzoyl)phenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 62809-86-3 CAPLUS

CN Propanoic acid, 2-methyl-2-[3-[3-(trifluoromethyl)benzoyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 62809-88-5 CAPLUS


CN Propanoic acid, 2-methyl-2-[3-(4-methylbenzoyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 62809-97-6 CAPLUS
 CN Propanoic acid, 2-[3-(3,4-dimethylbenzoyl)phenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 74168-02-8 CAPLUS
 CN Propanoic acid, 2-(3-benzoylphenoxy)- (9CI) (CA INDEX NAME)




RN 74168-05-1 CAPLUS
 CN Propanoic acid, 2-[3-(2,4-dichlorobenzoyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 74168-11-9 CAPLUS
 CN Propanoic acid, 2-[3-(4-methylbenzoyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 76960-06-0 CAPLUS
 CN Propanoic acid, 2-[3-[3-(trifluoromethyl)benzoyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 76960-07-1 CAPLUS
 CN Acetic acid, [3-(2,4-dichlorobenzoyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 76960-08-2 CAPLUS
 CN Propanoic acid, 2-[3-(2,4-dimethylbenzoyl)phenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 76960-09-3 CAPLUS
 CN Propanoic acid, 2-methyl-2-[3-(2-methylbenzoyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 76960-10-6 CAPLUS
 CN Acetic acid, [3-(4-methylbenzoyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 76960-11-7 CAPLUS
 CN Propanoic acid, 2-(3-benzoylphenoxy)-2-methyl-, sodium salt (9CI) (CA INDEX NAME)




● Na

RN 76960-12-8 CAPLUS
 CN Propanoic acid, 2-[3-(4-methoxybenzoyl)phenoxy]-2-methyl-, sodium salt (9CI) (CA INDEX NAME)




● Na

RN 76960-13-9 CAPLUS
 CN Propanoic acid, 2-methyl-2-[3-[3-(trifluoromethyl)benzoyl]phenoxy]-, sodium salt (9CI) (CA INDEX NAME)




● Na

RN 76960-14-0 CAPLUS
 CN Propanoic acid, 2-methyl-2-[3-(4-methylbenzoyl)phenoxy]-, sodium salt (9CI) (CA INDEX NAME)




● Na

RN 76960-15-1 CAPLUS
 CN Propanoic acid, 2-[3-(3,4-dimethylbenzoyl)phenoxy]-2-methyl-, sodium salt (9CI) (CA INDEX NAME)




● Na

RN 76960-16-2 CAPLUS
 CN Propanoic acid, 2-(3-benzoylphenoxy)-, sodium salt (9CI) (CA INDEX NAME)




● Na

RN 76960-17-3 CAPLUS
 CN Propanoic acid, 2-[3-[3-(trifluoromethyl)benzoyl]phenoxy]-, sodium salt (9CI) (CA INDEX NAME)




● Na

RN 76960-18-4 CAPLUS
CN Propanoic acid, 2-[3-(2,4-dichlorobenzoyl)phenoxy]-, sodium salt (9CI)
(CA INDEX NAME)




● Na

RN 76960-19-5 CAPLUS
CN Acetic acid, [3-(2,4-dichlorobenzoyl)phenoxy]-, sodium salt (9CI) (CA
INDEX NAME)




● Na

RN 76960-20-8 CAPLUS
CN Propanoic acid, 2-[3-(2,4-dimethylbenzoyl)phenoxy]-2-methyl-, sodium salt
(9CI) (CA INDEX NAME)




● Na

RN 76960-21-9 CAPLUS
CN Propanoic acid, 2-methyl-2-[3-(2-methylbenzoyl)phenoxy]-, sodium salt
(9CI) (CA INDEX NAME)




● Na

RN 76960-22-0 CAPLUS
 CN Acetic acid, [3-(4-methylbenzoyl)phenoxy]-, sodium salt (9CI) (CA INDEX NAME)



● Na

RN 76960-23-1 CAPLUS
 CN Propanoic acid, 2-[3-(4-methylbenzoyl)phenoxy]-, sodium salt (9CI) (CA INDEX NAME)



● Na

L7 ANSWER 106 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1981:121032 CAPLUS
 DN 94:121032
 TI Analgesic and antiinflammatory properties of m-benzoylphenoxy alkanoic acids
 AU Astoin, Jacques; Lepage, Francis; Fromantin, Jean Pierre; Poisson, Micheline
 CS Cent. Rech. Lab., Paris, 75012, Fr.
 SO European Journal of Medicinal Chemistry (1980), 15(5), 457-62
 CODEN: EJMCA5; ISSN: 0009-4374
 DT Journal
 LA French
 OS CASREACT 94:121032
 AB 3-Hydroxybenzophenones were O-alkylated by α -haloalkanoate esters and the products were saponified to give the title acids I (R = H, Me, Cl,


PhO, Br, F; R1 = H, Cl; R2 = H, Me, Cl; R3 = H, Me; R4 = H, Me; R5 = H, Me; R6 = Me, H), which exhibited analgesic and antiinflammatory activity; the 3-hydroxybenzophenones were prepared by different methods. Thus, 2,3-Me(4-ClC6H4CO)C6H3OH was treated with MeCHBrCO2Et and K2CO3, and the product was saponified to give I (R = Cl, R4 = R6 = Me, R1 = R2 = R3 = R5 = H).

IT 74167-91-2P 74167-96-7P 74168-00-6P
 74168-02-8P 74168-03-9P 74168-04-0P
 74168-05-1P 74168-06-2P 74168-07-3P
 74168-08-4P 74168-09-5P 74168-10-8P
 74168-11-9P 74168-12-0P 74168-13-1P
 74168-14-2P 74168-15-3P 76981-38-9P
 76981-39-0P 76981-40-3P 76981-41-4P
 76981-42-5P 76981-43-6P 76981-44-7P
 76981-45-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation and analgesic and antiinflammatory activity of)


RN 74167-91-2 CAPLUS

CN Propanoic acid, 2-(3-benzoylphenoxy)-, ethyl ester (9CI) (CA INDEX NAME)




RN 74167-96-7 CAPLUS

CN Propanoic acid, 2-[3-(4-chlorobenzoyl)-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 74168-00-6 CAPLUS

CN Propanoic acid, 2-[2-methyl-3-(4-methylbenzoyl)phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 74168-02-8 CAPLUS

CN Propanoic acid, 2-(3-benzoylphenoxy)- (9CI) (CA INDEX NAME)




RN 74168-03-9 CAPLUS
 CN L-Lysine, 2-(3-benzoylphenoxy)propanoate (9CI) (CA INDEX NAME)

CM 1

CRN 74168-02-8

CMF C16 H14 O4




CM 2


CRN 56-87-1

CMF C6 H14 N2 O2


Absolute stereochemistry.




RN 74168-04-0 CAPLUS
 CN Propanoic acid, 2-(3-benzoyl-2-methylphenoxy)- (9CI) (CA INDEX NAME)




RN 74168-05-1 CAPLUS
 CN Propanoic acid, 2-[3-(2,4-dichlorobenzoyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 74168-06-2 CAPLUS
 CN Propanoic acid, 2-[3-(4-bromobenzoyl)phenoxy] - (9CI) (CA INDEX NAME)



RN 74168-07-3 CAPLUS
 CN Propanoic acid, 2-[3-(4-fluorobenzoyl)phenoxy] - (9CI) (CA INDEX NAME)




RN 74168-08-4 CAPLUS
 CN Propanoic acid, 2-[3-(4-chlorobenzoyl)-2-methylphenoxy] - (9CI) (CA INDEX NAME)



RN 74168-09-5 CAPLUS
 CN L-Lysine, 2-[3-(4-chlorobenzoyl)-2-methylphenoxy]propanoate (9CI) (CA INDEX NAME)

CM 1

CRN 74168-08-4
 CMF C17 H15 Cl O4




CM 2

CRN 56-87-1


CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 74168-10-8 CAPLUS

CN Propanoic acid, 2-[5-(4-chlorobenzoyl)-2-methylphenoxy] - (9CI) (CA INDEX NAME)



RN 74168-11-9 CAPLUS

CN Propanoic acid, 2-[3-(4-methylbenzoyl)phenoxy] - (9CI) (CA INDEX NAME)




RN 74168-12-0 CAPLUS

CN L-Lysine, 2-[3-(4-methylbenzoyl)phenoxy]propanoate (9CI) (CA INDEX NAME)

CM 1

CRN 74168-11-9


CMF C17 H16 O4




CM 2

CRN 56-87-1
CMF C6 H14 N2 O2


Absolute stereochemistry.




RN 74168-13-1 CAPLUS
CN Propanoic acid, 2-[3-(2,4-dichlorobenzoyl)-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 74168-14-2 CAPLUS
CN Propanoic acid, 2-[2-methyl-3-(4-methylbenzoyl)phenoxy] - (9CI) (CA INDEX NAME)




RN 74168-15-3 CAPLUS
CN Propanoic acid, 2-[3-(2,4-dimethylbenzoyl)phenoxy] - (9CI) (CA INDEX NAME)




RN 76981-38-9 CAPLUS
CN Propanoic acid, 2-[3-(2,4,6-trimethylbenzoyl)phenoxy] - (9CI) (CA INDEX NAME)




RN 76981-39-0 CAPLUS
CN Propanoic acid, 2-[3-(3,4-dichlorobenzoyl)phenoxy] - (9CI) (CA INDEX NAME)




RN 76981-40-3 CAPLUS
CN Propanoic acid, 2-[3-(4-phenoxybenzoyl)phenoxy] - (9CI) (CA INDEX NAME)




RN 76981-41-4 CAPLUS
CN Propanoic acid, 2-[3-(2,4-dimethylbenzoyl)-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 76981-42-5 CAPLUS
CN Propanoic acid, 2-[3-(3,4-dichlorobenzoyl)-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 76981-43-6 CAPLUS
CN Acetic acid, (3-benzoylphenoxy) - (9CI) (CA INDEX NAME)




RN 76981-44-7 CAPLUS
 CN Acetic acid, [2-methyl-3-(4-methylbenzoyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 76981-45-8 CAPLUS
 CN Acetic acid, [3-(4-chlorobenzoyl)-2-methylphenoxy]- (9CI) (CA INDEX NAME)



IT 74167-92-3P 74167-93-4P 74167-94-5P
 74167-95-6P 74167-97-8P 74167-98-9P
 74167-99-0P 74168-01-7P 76981-49-2P
 76981-51-6P 76981-52-7P 76981-56-1P
 76981-64-1P 76981-68-5P 76981-69-6P
 76981-70-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and saponification of)
 RN 74167-92-3 CAPLUS
 CN Propanoic acid, 2-(3-benzoyl-2-methylphenoxy)-, ethyl ester (9CI) (CA
 INDEX NAME)




RN 74167-93-4 CAPLUS
 CN Propanoic acid, 2-[3-(2,4-dichlorobenzoyl)phenoxy]-, ethyl ester (9CI)
 (CA INDEX NAME)




RN 74167-94-5 CAPLUS

CN Propanoic acid, 2-[3-(4-bromobenzoyl)phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 74167-95-6 CAPLUS

CN Propanoic acid, 2-[3-(4-fluorobenzoyl)phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 74167-97-8 CAPLUS

CN Propanoic acid, 2-[5-(4-chlorobenzoyl)-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 74167-98-9 CAPLUS

CN Propanoic acid, 2-[3-(4-methylbenzoyl)phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 74167-99-0 CAPLUS

CN Propanoic acid, 2-[3-(2,4-dichlorobenzoyl)-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 74168-01-7 CAPLUS

CN Propanoic acid, 2-[3-(2,4-dimethylbenzoyl)phenoxy]-, ethyl ester (9CI)
(CA INDEX NAME)




RN 76981-49-2 CAPLUS

CN Propanoic acid, 2-[3-(2,4,6-trimethylbenzoyl)phenoxy]-, ethyl ester (9CI)
(CA INDEX NAME)




RN 76981-51-6 CAPLUS

CN Propanoic acid, 2-[3-(3,4-dichlorobenzoyl)phenoxy]-, ethyl ester (9CI)
(CA INDEX NAME)




RN 76981-52-7 CAPLUS


CN Propanoic acid, 2-[3-(4-phenoxybenzoyl)phenoxy]-, ethyl ester (9CI) (CA
INDEX NAME)




RN 76981-56-1 CAPLUS
 CN Propanoic acid, 2-[3-(2,4-dimethylbenzoyl)-2-methylphenoxy]-, ethyl ester
 (9CI) (CA INDEX NAME)




RN 76981-64-1 CAPLUS
 CN Propanoic acid, 2-[3-(3,4-dichlorobenzoyl)-2-methylphenoxy]-, ethyl ester
 (9CI) (CA INDEX NAME)




RN 76981-68-5 CAPLUS
 CN Acetic acid, (3-benzoylphenoxy)-, ethyl ester (9CI) (CA INDEX NAME)



RN 76981-69-6 CAPLUS
 CN Acetic acid, [2-methyl-3-(4-methylbenzoyl)phenoxy]-, ethyl ester (9CI)
 (CA INDEX NAME)



RN 76981-70-9 CAPLUS
 CN Acetic acid, [3-(4-chlorobenzoyl)-2-methylphenoxy]-, ethyl ester (9CI)
 (CA INDEX NAME)



L7 ANSWER 107 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1980:446189 CAPLUS

DN 93:46189

TI 2-(m-Benzoylphenoxy)propionic acid and derivatives

IN Fromantin, Jean Pierre Marie Joseph

PA UNICLER S. A., Fr.

SO Brit. UK Pat. Appl., 7 pp.

CODEN: BAXXDU

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 2016460	A	19790926	GB 1979-9597	19790319
	GB 2016460	B2	19820603		
	FR 2420522	A1	19791019	FR 1978-7962	A 19780320
	FR 2420522	B1	19800919	FR 1978-7962	19780320
					A
	US 4277497	A	19810707	US 1979-21311	19790316
				FR 1978-7962	A 19780320
	DE 2910942	A1	19791004	DE 1979-2910942	19790320
	DE 2910942	C2	19840802		
				FR 1978-7962	A 19780320
	JP 54145645	A2	19791114	JP 1979-31848	19790320
				FR 1978-7962	A 19780320

AB Eleven title compds. I (R = H, Me; R1 = H, Me, Cl; R2 = H, F, Br, Me, Cl), useful as analgesics and inflammation inhibitors, were prepared from 3-hydroxybenzophenones by treatment with BrCHMeCO2Et and K2CO3 (Me2CO, reflux, 10 h; average yield 85%) followed by hydrolysis (aqueous-alc. Na2CO3,

12

h, ambient temperature; average yield 95%). I salts and esters were also prepared


The analgesic activities of I were assessed in mice by the Siegmund-Cadmus-Lu method; their antiinflammatory activities were assessed by the carrageenan edema test. LD50 values for I were 500-2000 mg/kg orally. Compns. containing I are described.

IT 74167-91-2P 74167-92-3P 74167-93-4P
74167-94-5P 74167-95-6P 74167-97-8P
74167-98-9P 74167-99-0P 74168-00-6P
74168-01-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 74167-91-2 CAPLUS

CN Propanoic acid, 2-(3-benzoylphenoxy)-, ethyl ester (9CI) (CA INDEX NAME)




RN 74167-92-3 CAPLUS

CN Propanoic acid, 2-(3-benzoyl-2-methylphenoxy)-, ethyl ester (9CI) (CA INDEX NAME)




RN 74167-93-4 CAPLUS

CN Propanoic acid, 2-[3-(2,4-dichlorobenzoyl)phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 74167-94-5 CAPLUS

CN Propanoic acid, 2-[3-(4-bromobenzoyl)phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 74167-95-6 CAPLUS

CN Propanoic acid, 2-[3-(4-fluorobenzoyl)phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 74167-97-8 CAPLUS


CN Propanoic acid, 2-[5-(4-chlorobenzoyl)-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 74167-98-9 CAPLUS
 CN Propanoic acid, 2-[3-(4-methylbenzoyl)phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 74167-99-0 CAPLUS
 CN Propanoic acid, 2-[3-(2,4-dichlorobenzoyl)-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 74168-00-6 CAPLUS
 CN Propanoic acid, 2-[2-methyl-3-(4-methylbenzoyl)phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 74168-01-7 CAPLUS
 CN Propanoic acid, 2-[3-(2,4-dimethylbenzoyl)phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




IT 74167-96-7P 74168-02-8P 74168-03-9P
 74168-04-0P 74168-05-1P 74168-06-2P
 74168-07-3P 74168-08-4P 74168-09-5P
 74168-10-8P 74168-11-9P 74168-12-0P
 74168-13-1P 74168-14-2P 74168-15-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as analgesic and inflammation inhibitor)


RN 74167-96-7 CAPLUS

CN Propanoic acid, 2-[3-(4-chlorobenzoyl)-2-methylphenoxy]-, ethyl ester
 (9CI) (CA INDEX NAME)



RN 74168-02-8 CAPLUS

CN Propanoic acid, 2-(3-benzoylphenoxy)- (9CI) (CA INDEX NAME)




RN 74168-03-9 CAPLUS

CN L-Lysine, 2-(3-benzoylphenoxy)propanoate (9CI) (CA INDEX NAME)

CM 1

CRN 74168-02-8

CMF C16 H14 O4




CM 2


CRN 56-87-1

CMF C6 H14 N2 O2


Absolute stereochemistry.




RN 74168-04-0 CAPLUS
 CN Propanoic acid, 2-(3-benzoyl-2-methylphenoxy) - (9CI) (CA INDEX NAME)




RN 74168-05-1 CAPLUS
 CN Propanoic acid, 2-[3-(2,4-dichlorobenzoyl)phenoxy] - (9CI) (CA INDEX NAME)




RN 74168-06-2 CAPLUS
 CN Propanoic acid, 2-[3-(4-bromobenzoyl)phenoxy] - (9CI) (CA INDEX NAME)



RN 74168-07-3 CAPLUS
 CN Propanoic acid, 2-[3-(4-fluorobenzoyl)phenoxy] - (9CI) (CA INDEX NAME)



RN 74168-08-4 CAPLUS
 CN Propanoic acid, 2-[3-(4-chlorobenzoyl)-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 74168-09-5 CAPLUS

CN L-Lysine, 2-[3-(4-chlorobenzoyl)-2-methylphenoxy]propanoate (9CI) (CA INDEX NAME)

CM 1

CRN 74168-08-4

CMF C17 H15 Cl O4




CM 2

CRN 56-87-1


CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 74168-10-8 CAPLUS

CN Propanoic acid, 2-[5-(4-chlorobenzoyl)-2-methylphenoxy] - (9CI) (CA INDEX NAME)



RN 74168-11-9 CAPLUS

CN Propanoic acid, 2-[3-(4-methylbenzoyl)phenoxy] - (9CI) (CA INDEX NAME)




RN 74168-12-0 CAPLUS

CN L-Lysine, 2-[3-(4-methylbenzoyl)phenoxy]propanoate (9CI) (CA INDEX NAME)

CM 1

CRN 74168-11-9

CMF C17 H16 O4




CM 2

CRN 56-87-1


CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 74168-13-1 CAPLUS

CN Propanoic acid, 2-[3-(2,4-dichlorobenzoyl)-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 74168-14-2 CAPLUS

CN Propanoic acid, 2-[2-methyl-3-(4-methylbenzoyl)phenoxy] - (9CI) (CA INDEX NAME)



RN 74168-15-3 CAPLUS

CN Propanoic acid, 2-[3-(2,4-dimethylbenzoyl)phenoxy]- (9CI) (CA INDEX NAME)



L7 ANSWER 108 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1980:33775 CAPLUS

DN 92:33775

TI Beclobrate and eniclobrate hydrochloride, new diphenylmethane derivatives as agents for lowering cholesterol and triglyceride levels. Part 1: Synthesis and consideration of structure-activity relations

AU Thiele, Kurt; Ahmed, Q.; Jahn, U.; Adrian, R. W.

CS Pharm.-Forsch. Entwickl., Siegfried A.-G., Zofingen, Switz.

SO Arzneimittel-Forschung (1979), 29(5), 711-20

CODEN: ARZNAD; ISSN: 0004-4172

DT Journal

LA German


AB Ninety-eight diphenylmethane derivs. were synthesized and tested for anticholesteremic and hypolipemic effects and toxicity in mice and rats. Beclobrate (I) [55937-99-0] and eniclobrate-HCl (II-HCl) [60662-17-1] were selected for further study because of their low toxicity, strong hypolipemic activity, and relatively low production of hepatomegaly. Some structure-activity relations are discussed.

IT 71549-06-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and lipid-lowering activity of)

RN 71549-06-9 CAPLUS


CN Butanoic acid, 2-[3-[(4-chlorophenyl)methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)



L7 ANSWER 109 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1977:189537 CAPLUS
 DN 86:189537
 TI Phenoxyalkylcarboxylic acid derivatives
 IN Majoie, Bernard
 PA Societe de Recherches Industrielles (SORI), Fr.
 SO Ger. Offen., 56 pp.
 CODEN: GWXXBX
 DT Patent
 LA German
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2637098	A1	19770224	DE 1976-2637098	19760818
				GB 1975-34689	A 19750820
	GB 1563195	A	19800319	GB 1975-34689	19750820
					A A
	FR 2321276	A1	19770318	FR 1976-24545	19760811
	FR 2321276	B1	19820521		
				GB 1975-34689	A 19750820
	US 4146385	A	19790327	US 1976-714504	19760816
				GB 1975-34689	A 19750820
	NL 7609137	A	19770222	NL 1976-9137	19760817
				GB 1975-34689	A 19750820
	ES 450774	A1	19770901	ES 1976-450774	19760817
				GB 1975-34689	A 19750820
	AU 510126	B2	19800612	AU 1976-16911	19760817
				GB 1975-34689	A 19750820
	CA 1081705	A1	19800715	CA 1976-259295	19760817
				GB 1975-34689	A 19750820
	AT 7606124	A	19800415	AT 1976-6124	19760818
				GB 1975-34689	A 19750820
	HU 174980	P	19800428	HU 1976-SO1177	19760818
				GB 1975-34689	A 19750820
	BE 845308	A1	19770221	BE 1976-2055252	19760819
				GB 1975-34689	A 19750820
	SE 7609223	A	19770221	SE 1976-9223	19760819
				GB 1975-34689	A 19750820
	DD 125658	C	19770511	DD 1976-194397	19760819
				GB 1975-34689	A 19750820
	JP 52039637	A2	19770328	JP 1976-100117	19760820
				GB 1975-34689	A 19750820
	US 4287209	A	19810901	US 1979-1011	19790104
				GB 1975-34689	A 19750820
				US 1976-714504	A3 19760816
AB	3-RC6H4OCR1R2COR3 (R = R4CO, R4CHOH, R4CHOAc, R4CHOMe, R4C:CH2, R4CMeOH; R1, R2 = H, Me; R3 = OH, alkoxy, substituted alkoxy, amino, SEt; R4 = Ph, substituted phenyl, Me, Bu, 2-thienyl, 2-furyl, 2-ethyl-3-benzofuryl, 3-pyridyl) (74 compds.) were prepared. Thus, PhCl was treated with 3-O2NC6H4COCl, 4-ClC6H4COC6H4NO2-3 reduced, 4-ClC6H4COC6H4NH2-3 diazotized and hydrolyzed, and 4-ClC6H4COC6H4OH-3 treated with CHCl3 and Me2CO to give 4-ClC6H4COC6H4OCMe2CO2H-3, which at 50 mg/kg orally in rats caused a 36.5% decrease in total blood lipids and a 35% decrease in blood cholesterol.				
IT	62809-66-9P 62809-71-6P 62809-72-7P 62809-74-9P 62809-78-3P RL: SPN (Synthetic preparation); PREP (Preparation) (preparation and anticholesteremic and hypolipemic activity of)				
RN	62809-66-9 CAPLUS				

CN Propanoic acid, 2-[3-(4-chlorobenzoyl)phenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 62809-71-6 CAPLUS

CN Propanoic acid, 2-[3-(4-chlorobenzoyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 62809-72-7 CAPLUS

CN Propanoic acid, 2-[3-(4-bromobenzoyl)phenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 62809-74-9 CAPLUS

CN Propanoic acid, 2-[3-(3-chlorobenzoyl)phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 62809-78-3 CAPLUS

CN Propanoic acid, 2-(3-benzoylphenoxy)-2-methyl- (9CI) (CA INDEX NAME)




IT 62809-84-1P 62809-86-3P 62809-91-0P
62809-92-1P 62809-93-2P 62810-23-5P
62810-25-7P 62810-32-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and anticholesteremic and hypolipemic activity of)


RN 62809-84-1 CAPLUS

CN Propanoic acid, 2-[3-(4-fluorobenzoyl)phenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 62809-86-3 CAPLUS

CN Propanoic acid, 2-methyl-2-[3-[3-(trifluoromethyl)benzoyl]phenoxy]- (9CI)
(CA INDEX NAME)




RN 62809-91-0 CAPLUS

CN Propanoic acid, 2-[3-(3-fluoro-4-methylbenzoyl)phenoxy]-2-methyl- (9CI)
(CA INDEX NAME)




RN 62809-92-1 CAPLUS

CN Propanoic acid, 2-[3-(2-chlorobenzoyl)phenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 62809-93-2 CAPLUS


CN Propanoic acid, 2-methyl-2-[3-[4-(trifluoromethyl)benzoyl]phenoxy] - (9CI)
(CA INDEX NAME)




RN 62810-23-5 CAPLUS
CN Propanoic acid, 2-[3-[(4-chlorophenyl)hydroxymethyl]phenoxy]-2-methyl-
(9CI) (CA INDEX NAME)




RN 62810-25-7 CAPLUS
CN Propanoic acid, 2-[3-[(4-bromophenyl)hydroxymethyl]phenoxy]-2-methyl-
(9CI) (CA INDEX NAME)



RN 62810-32-6 CAPLUS
CN Propanoic acid, 2-[3-[(4-chlorophenyl)methyl]phenoxy]-2-methyl- (9CI) (CA
INDEX NAME)




IT **62810-30-4P 62810-41-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and saponification of)
RN 62810-30-4 CAPLUS
CN Propanoic acid, 2-[3-[(4-chlorophenyl)hydroxymethyl]phenoxy]-2-methyl-,
1-methylethyl ester (9CI) (CA INDEX NAME)



RN 62810-41-7 CAPLUS

CN Propanoic acid, 2-methyl-2-[3-[[4-(trifluoromethyl)phenyl]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




IT 62809-67-0P 62809-68-1P 62809-69-2P
 62809-70-5P 62809-73-8P 62809-75-0P
 62809-77-2P 62809-79-4P 62809-80-7P
 62809-81-8P 62809-85-2P 62809-87-4P
 62809-88-5P 62809-89-6P 62809-94-3P
 62809-95-4P 62809-96-5P 62809-97-6P
 62809-98-7P 62809-99-8P 62810-02-0P
 62810-03-1P 62810-05-3P 62810-07-5P
 62810-08-6P 62810-09-7P 62810-16-6P
 62810-17-7P 62810-21-3P 62810-22-4P
 62810-24-6P 62810-26-8P 62810-27-9P
 62810-28-0P 62810-29-1P 62810-31-5P
 62810-33-7P 62810-34-8P 62810-35-9P
 62810-36-0P 62810-37-1P 62850-36-6P
 62850-37-7P 62850-38-8P 62850-39-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)


RN 62809-67-0 CAPLUS

CN Propanoic acid, 2-[3-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 62809-68-1 CAPLUS


CN Propanoic acid, 2-[3-(4-chlorobenzoyl)phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 62809-69-2 CAPLUS
 CN Propanoic acid, 2-[3-(4-chlorobenzoyl)phenoxy]-2-methyl-, methyl ester
 (9CI) (CA INDEX NAME)




RN 62809-70-5 CAPLUS
 CN Propanoic acid, 2-[3-(4-chlorobenzoyl)phenoxy]-, 1-methylethyl ester (9CI)
 (CA INDEX NAME)



RN 62809-73-8 CAPLUS
 CN Propanoic acid, 2-[3-(4-bromobenzoyl)phenoxy]-2-methyl-, 1-methylethyl
 ester (9CI) (CA INDEX NAME)



RN 62809-75-0 CAPLUS
 CN Propanoic acid, 2-[3-(3-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl
 ester (9CI) (CA INDEX NAME)



RN 62809-77-2 CAPLUS
 CN Propanoic acid, 2-[3-(4-chlorobenzoyl)phenoxy]-2-methyl-,


2-(hexahydro-1H-azepin-1-yl)ethyl ester, ethanedioate (9CI) (CA INDEX NAME)

CM 1


CRN 62809-76-1

CMF C25 H30 Cl N O4

PAGE 1-A




PAGE 2-A



CM 2

CRN 144-62-7


CMF C2 H2 O4



RN 62809-79-4 CAPLUS


CN Propanoic acid, 2-(3-benzoylphenoxy)-2-methyl-, methyl ester (9CI) (CA

INDEX NAME)




RN 62809-80-7 CAPLUS

CN Propanoic acid, 2-[3-(4-methoxybenzoyl)phenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 62809-81-8 CAPLUS

CN Propanoic acid, 2-[3-(4-methoxybenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 62809-85-2 CAPLUS

CN Propanoic acid, 2-[3-(4-fluorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 62809-87-4 CAPLUS


CN Propanoic acid, 2-[3-(4-fluorobenzoyl)phenoxy]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 62809-88-5 CAPLUS
 CN Propanoic acid, 2-methyl-2-[3-(4-methylbenzoyl)phenoxy] - (9CI) (CA INDEX NAME)




RN 62809-89-6 CAPLUS
 CN Propanoic acid, 2-[3-(3-bromobenzoyl)phenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 62809-94-3 CAPLUS
 CN Propanoic acid, 2-[3-(3,4-dichlorobenzoyl)phenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 62809-95-4 CAPLUS
 CN Propanoic acid, 2-[3-(3-bromobenzoyl)phenoxy]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 62809-96-5 CAPLUS
 CN Propanoic acid, 2-[3-(2,4-dichlorobenzoyl)phenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 62809-97-6 CAPLUS
 CN Propanoic acid, 2-[3-(3,4-dimethylbenzoyl)phenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 62809-98-7 CAPLUS
 CN Propanoic acid, 2-[3-(3,4-dimethylbenzoyl)phenoxy]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 62809-99-8 CAPLUS
 CN Acetic acid, [3-(4-fluorobenzoyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 62810-02-0 CAPLUS
 CN Propanoic acid, 2-[3-(4-chlorobenzoyl)phenoxy]-2-methyl-, 4-(dimethylamino)-4-oxobutyl ester (9CI) (CA INDEX NAME)




RN 62810-03-1 CAPLUS
 CN Propanoic acid, 2-[3-(4-fluorobenzoyl)phenoxy]-2-methyl-, octyl ester
 (9CI) (CA INDEX NAME)




RN 62810-05-3 CAPLUS
 CN Propanoic acid, 2-[3-(4-fluorobenzoyl)phenoxy]-2-methyl-, tetradecyl ester
 (9CI) (CA INDEX NAME)



RN 62810-07-5 CAPLUS
 CN Propanoic acid, 2-[3-(4-bromobenzoyl)phenoxy]-2-methyl-, tetradecyl ester
 (9CI) (CA INDEX NAME)




RN 62810-08-6 CAPLUS
 CN Propanoic acid, 2-[3-(4-bromobenzoyl)phenoxy]-2-methyl-, 3-pyridinylmethyl ester, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 62810-09-7 CAPLUS
 CN Propanoic acid, 2-[3-(4-bromobenzoyl)phenoxy]-2-methyl-,
 2-(diethylamino)ethyl ester, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 62810-16-6 CAPLUS
 CN Propanoic acid, 2-[4-chloro-3-(4-chlorobenzoyl)phenoxy]-2-methyl- (9CI)
 (CA INDEX NAME)




RN 62810-17-7 CAPLUS
 CN Propanoic acid, 2-[5-(4-chlorobenzoyl)-2-hydroxyphenoxy]-2-methyl- (9CI)
 (CA INDEX NAME)




RN 62810-21-3 CAPLUS

CN Propanoic acid, 2-methyl-2-[3-[4-(trifluoromethyl)benzoyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 62810-22-4 CAPLUS

CN Propanoic acid, 2-methyl-2-[3-[4-(trifluoromethyl)benzoyl]phenoxy]-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 62810-24-6 CAPLUS

CN Propanoic acid, 2-[3-[(4-chlorophenyl)hydroxymethyl]phenoxy]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 62810-26-8 CAPLUS

CN Propanoic acid, 2-[3-[(4-bromophenyl)hydroxymethyl]phenoxy]-2-methyl-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 62810-27-9 CAPLUS

CN Propanoic acid, 2-[3-[hydroxy(4-methoxyphenyl)methyl]phenoxy]-2-methyl-
(9CI) (CA INDEX NAME)




RN 62810-28-0 CAPLUS

CN Propanoic acid, 2-[3-[hydroxy(4-methoxyphenyl)methyl]phenoxy]-2-methyl-,
1-methylethyl ester (9CI) (CA INDEX NAME)




RN 62810-29-1 CAPLUS

CN Propanoic acid, 2-[3-[(acetyloxy)(4-chlorophenyl)methyl]phenoxy]-2-methyl-,
1-methylethyl ester (9CI) (CA INDEX NAME)




RN 62810-31-5 CAPLUS


CN Propanoic acid, 2-[3-[(4-chlorophenyl)methoxymethyl]phenoxy]-2-methyl-,
(9CI) (CA INDEX NAME)




RN 62810-33-7 CAPLUS
 CN Propanoic acid, 2-[3-[(4-chlorophenyl)methyl]phenoxy]-2-methyl-,
 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 62810-34-8 CAPLUS
 CN Propanoic acid, 2-[3-[(4-fluorophenyl)hydroxymethyl]phenoxy]-2-methyl-,
 methyl ester (9CI) (CA INDEX NAME)




RN 62810-35-9 CAPLUS
 CN Propanoic acid, 2-[3-[(4-fluorophenyl)hydroxymethyl]phenoxy]-2-methyl-,
 (9CI) (CA INDEX NAME)



RN 62810-36-0 CAPLUS
 CN Propanoic acid, 2-[3-[1-(4-fluorophenyl)ethenyl]phenoxy]-2-methyl-, (9CI)
 (CA INDEX NAME)




RN 62810-37-1 CAPLUS
 CN Propanoic acid, 2-[3-[1-(4-fluorophenyl)-1-hydroxyethyl]phenoxy]-2-methyl-,
 ethyl ester (9CI) (CA INDEX NAME)




RN 62850-36-6 CAPLUS

CN Acetic acid, [3-(4-chlorobenzoyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 62850-37-7 CAPLUS

CN Propanoic acid, 2-methyl-2-[3-[4-(trifluoromethyl)benzoyl]phenoxy]-, 3-(dimethylamino)-3-oxopropyl ester (9CI) (CA INDEX NAME)



RN 62850-38-8 CAPLUS

CN Propanoic acid, 2-methyl-2-[3-[4-(trifluoromethyl)benzoyl]phenoxy]-, [5-hydroxy-4-(hydroxymethyl)-6-methyl-3-pyridinyl]methyl ester (9CI) (CA INDEX NAME)




RN 62850-39-9 CAPLUS

CN Propanoic acid, 2-methyl-2-[3-[4-(trifluoromethyl)benzoyl]phenoxy]-, 2-(hexahydro-1H-azepin-1-yl)ethyl ester, hydrochloride (9CI) (CA INDEX NAME)


c1ccccc1C=Cc2ccccc2C(=O)O

L7 ANSWER 111 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1976:405378 CAPLUS
 DN 85:5378
 TI 4-(3-Benzoylphenyl)butyric acids
 PA Roussel-UCLAF, Fr.
 SO Fr. Demande, 36 pp. Addn. to Fr. Demande. 2,150,631.
 CODEN: FRXXBL
 DT Patent
 LA French
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2269330	A2	19751128	FR 1973-7168	19730228
	FR 2269330	B2	19771223		
				FR 1973-7168	A 19730228
AB	Five 4-(3-benzoylphenyl)butyric acids I (R = OMe, H, F, Cl, NMe ₂ ; R ₁ = Me, H, OH; R ₂ = H, Me) and a 2-butenic acid analog II, prepared by different known reactions, showed analgesic and antiinflammatory activity.				
IT	41652-19-1P RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation and analgesic and antiinflammatory activity of)				
RN	41652-19-1 CAPLUS				
CN	2-Butenoic acid, 4-[3-(4-chlorobenzoyl)-2-methylphenyl]- (9CI) (CA INDEX NAME)				



IT **41652-07-7P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and saponification of)
 RN 41652-07-7 CAPLUS
 CN 2-Butenoic acid, 4-(3-benzoylphenyl)-2-methyl-, methyl ester (9CI) (CA INDEX NAME)



IT **41652-06-6P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 41652-06-6 CAPLUS
 CN 2-Butenoic acid, 4-(3-benzoylphenyl)-2-methyl- (9CI) (CA INDEX NAME)



L7 ANSWER 112 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1975:605952 CAPLUS

DN 83:205952

TI 4-(m-Benzoylphenyl)butanoic(or -2-butenic) acids

PA Roussel-UCLAF, Fr.

SO Austrian, 6 pp. Division of Austrian 322,537.


CODEN: AUXXAK

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	AT 324314		19750825	AT 1972-7578	19720904
AB	The benzophenone derivs. I (R = F, Z = CH2CH2; R = Cl, Z = CH:CH) were prepared. Thus, 2,3-Me(H2N)C6H3COC6H4F-4 was converted into the diazonium salt, which reacted with CuCl and H2C:CHCH:CH2 to give II (R1 = Cl). Treatment of this intermediate with KOAc in HOAc gave II (R1 = AcO) which was heated with MeOH-NaOH to give II (R1 = OH). Hydrogenation of this alc., followed by oxidation with CrO3-H2SO4 gave I (R = F, Z = CH2CH2). I were useful as analgesics (no data).				
IT	41652-19-1P				
	RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)				
RN	41652-19-1 CAPLUS				
CN	2-Butenoic acid, 4-[3-(4-chlorobenzoyl)-2-methylphenyl]- (9CI) (CA INDEX NAME)				



L7 ANSWER 113 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1975:98151 CAPLUS

DN 82:98151

TI Introduction of organic groups into ethylenically unsaturated aldehydes or ketones using a Group VIII metal salt

IN Heck, Richard F.

PA Hercules, Inc.

SO U.S., 12 pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
--	------------	------	------	-----------------	------

PI	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3855302	A	19741217	US 1972-250461	19720504	
			US 1965-479665	A3	19650813
			US 1969-883287	A1	19691208
US 3527794	A	19700908	US 1965-479665		19650813
				A	

PATENT FAMILY INFORMATION:

FAN	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
1970:509514					
PI	US 3527794	A	19700908	US 1965-479665	19650813
					A
	US 3783140	A	19740101	US 1971-197542	19711110
				US 1965-479665	A3 19650813
				US 1969-883288	A3 19691208
	US 3855302	A	19741217	US 1972-250461	19720504
				US 1965-479665	A3 19650813
				US 1969-883287	A1 19691208

FAN	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
1973:71699					
PI	US 3700727	A	19721024	US 1969-883288	19691208
					A
	US 3763213	A	19731002	US 1971-197541	19711110
				US 1969-883288	A3 19691208
	US 3783140	A	19740101	US 1971-197542	19711110
				US 1965-479665	A3 19650813
				US 1969-883288	A3 19691208

FAN	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
1973:546135					
PI	US 3763213	A	19731002	US 1971-197541	19711110
				US 1969-883288	A3 19691208
	US 3700727	A	19721024	US 1969-883288	19691208
					A

FAN	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
1974:145810					
PI	US 3783140	A	19740101	US 1971-197542	19711110
				US 1965-479665	A3 19650813
				US 1969-883288	A3 19691208
	US 3527794	A	19700908	US 1965-479665	19650813
					A
	US 3700727	A	19721024	US 1969-883288	19691208
					A


AB Unsatd. compds., e.g., ethylene, styrene, Me acrylate, and Me vinyl ketone, were arylated or alkylated with aryl- or alkyl metal compds., e.g., Ph₂Hg, Ph₄Pb, Me₄Sn, 2-(chloromercuri)-thiophene, m-(chloromercuri)benzoic acid, MeOC₆H₄HgCl, and PhSnCl₃, to give, e.g. styrene, cinnamaldehyde, Me acrylate, 3-(2-thienyl)acrylate, Me crotonate, and Et cinnamate (.apprx.50 compds.). E.g., Me acrylate and PhHgCl gave Me cinnamate.

IT 20883-27-6P 32195-04-3P


RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 20883-27-6 CAPLUS

CN 2-Propenoic acid; 3,3'-(carbonyldi-3,1-phenylene)bis-, dimethyl ester
(9CI) (CA INDEX NAME)



RN 32195-04-3 CAPLUS
 CN 2-Propenoic acid, 3-(3-benzoylphenyl)-, methyl ester (9CI) (CA INDEX NAME)



L7 ANSWER 114 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1974:145810 CAPLUS
 DN 80:145810
 TI Introduction of organic groups into ethylenically unsaturated carboxylic acids using a Group VIII metal salt
 IN Heck, Richard F.
 PA Hercules Inc.
 SO U.S., 9 PP. Division of U.S. 3,700,727 (CA 78; 71699f).
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3783140	A	19740101	US 1971-197542	19711110
				US 1965-479665	A3 19650813
				US 1969-883288	A3 19691208
	US 3527794	A	19700908	US 1965-479665	19650813
					A
	US 3700727	A	19721024	US 1969-883288	19691208
					A

PATENT FAMILY INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3527794	A	19700908	US 1965-479665	19650813
					A
	US 3783140	A	19740101	US 1971-197542	19711110
				US 1965-479665	A3 19650813
				US 1969-883288	A3 19691208
	US 3855302	A	19741217	US 1972-250461	19720504
				US 1965-479665	A3 19650813
				US 1969-883287	A1 19691208

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3700727	A	19721024	US 1969-883288	19691208
					A
	US 3763213	A	19731002	US 1971-197541	19711110
				US 1969-883288	A3 19691208

US 3783140	A	19740101	US 1971-197542	19711110
			US 1965-479665	A3 19650813
			US 1969-883288	A3 19691208

FAN 1973:546135
PATENT NO. KIND DATE APPLICATION NO. DATE

PI	US 3763213	A	19731002	US 1971-197541	19711110
				US 1969-883288	A3 19691208
	US 3700727	A	19721024	US 1969-883288	19691208

FAN 1975:98151
PATENT NO. KIND DATE APPLICATION NO. DATE


PI	US 3855302	A	19741217	US 1972-250461	19720504
				US 1965-479665	A3 19650813
				US 1969-883287	A1 19691208
	US 3527794	A	19700908	US 1965-479665	19650813

AB RCR1:CR2R3 (R, R1, R2 = H, organic substituents; R3 = Ph, substituted phenyl, naphthyl, Me, etc.) were prepared by reaction of RCR1:CHR2 with organometallic compds. of R3H with Hg, Sn, or Pb in the presence of group VIII metal compds. E.g., a mixture of PhHgCl, Me acrylate, and LiPdCl3 in MeCN was stirred 16 hr at 24° to give Me cinnamate. Sixty-four other examples were given.

IT **20883-27-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 20883-27-6 CAPLUS

CN 2-Propenoic acid, 3,3'-(carbonyldi-3,1-phenylene)bis-, dimethyl ester
(9CI) (CA INDEX NAME)



L7 ANSWER 115 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1973:546135 CAPLUS

DN 79:146135

TI Introduction of organic groups into ethylenically unsaturated carboxylic nitriles using a group VIII metal salt

IN Heck, Richard F.

SO U.S., 9 pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 3763213	A	19731002	US 1971-197541	19711110
				US 1969-883288	A3 19691208
	US 3700727	A	19721024	US 1969-883288	19691208

PATENT FAMILY INFORMATION:

FAN 1970:509514

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----

PI	US 3527794	A	19700908	US 1965-479665	19650813
				A	
	US 3783140	A	19740101	US 1971-197542	19711110
				US 1965-479665	A3 19650813
				US 1969-883288	A3 19691208
	US 3855302	A	19741217	US 1972-250461	19720504
				US 1965-479665	A3 19650813
				US 1969-883287	A1 19691208

FAN	1973:71699				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 3700727	A	19721024	US 1969-883288	19691208
				A	
	US 3763213	A	19731002	US 1971-197541	19711110
				US 1969-883288	A3 19691208
	US 3783140	A	19740101	US 1971-197542	19711110
				US 1965-479665	A3 19650813
				US 1969-883288	A3 19691208

FAN	1974:145810				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 3783140	A	19740101	US 1971-197542	19711110
				US 1965-479665	A3 19650813
				US 1969-883288	A3 19691208
	US 3527794	A	19700908	US 1965-479665	19650813
				A	
	US 3700727	A	19721024	US 1969-883288	19691208
				A	


FAN	1975:98151				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 3855302	A	19741217	US 1972-250461	19720504
				US 1965-479665	A3 19650813
				US 1969-883287	A1 19691208
	US 3527794	A	19700908	US 1965-479665	19650813
				A	

AB Organometallic compds. of Group IIB and IVA metals reacted with R₂C:CHR₁ (R = H, Ph, PhCH₂; R₁ = H, CO₂Me, CN, CHO, etc.) in the presence of Group VIII metal salts to give products in which the ethylenic H was replaced by an organic group. Thus, PhHgCl reacted with CH₂:CHCO₂Me in the presence of LiPdCl₃ to give PhCH:CHCO₂Me. About 35 compds. were prepared

IT **20883-27-6P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 20883-27-6 CAPLUS

CN 2-Propenoic acid, 3,3'-(carbonyldi-3,1-phenylene)bis-, dimethyl ester
 (9CI) (CA INDEX NAME)



L7 ANSWER 116 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1973:147596 CAPLUS
 DN 78:147596
 TI Phenylbutyric acids

IN Allais, Andre; Meier, Jean; Dube, Jacques
 PA Roussel-UCLAF
 SO Ger. Offen., 77 pp.
 CODEN: GWXXBX
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	DE 2243444	A1	19730308	DE 1972-2243444	19720904
	DE 2243444	B2	19760909		
	DE 2243444	C3	19770428		
	FR 2150631	A1	19730413	FR 1971-31902	A 19710903
				FR 1971-31902	19710903
	CH 557319	A	19741231	CH 1972-12555	A 19720824
				FR 1971-31902	A 19710903
	CH 557320	A	19741231	CH 1974-7345	19720824
				FR 1971-31902	A 19710903
	ES 406081	A1	19750816	ES 1972-406081	19720824
				FR 1971-31902	A 19710903
	IL 40207	A1	19750831	IL 1972-40207	19720825
				FR 1971-31902	A 19710903
	HU 165605	P	19740928	HU 1972-RO676	19720828
				FR 1971-31902	A 19710903
	US 3931302	A	19760106	US 1972-284575	19720829
				FR 1971-31902	A 19710903
	BE 788316	A1	19730301	BE 1972-121609	19720901
				FR 1971-31902	A 19710903
	NL 7211971	A	19730306	NL 1972-11971	19720901
				FR 1971-31902	A 19710903
	ZA 7206023	A	19731031	ZA 1972-6023	19720901
				FR 1971-31902	A 19710903
	AU 7246243	A1	19740307	AU 1972-46243	19720901
				FR 1971-31902	A 19710903
	SU 533332	D	19761025	SU 1972-1828008	19720901
				FR 1971-31902	A 19710903
	CA 1010881	A1	19770524	CA 1972-150845	19720901
				FR 1971-31902	A 19710903
	SE 397973	B	19771128	SE 1972-11388	19720901
				FR 1971-31902	A 19710903
	DK 140545	B	19791001	DK 1972-4328	19720901
	DK 140545	C	19800303		
	JP 48034148	A2	19730516	FR 1971-31902	A 19710903
	JP 57025533	B4	19820529	JP 1972-87996	19720904
				FR 1971-31902	A 19710903
	DD 99156	C	19730720	DD 1972-165440	19720904
				FR 1971-31902	A 19710903
	GB 1374520	A	19741120	GB 1972-40878	19720904
				FR 1971-31902	A 19710903
	AT 322537	B	19750526	AT 1972-7578	19720904
				FR 1971-31902	A 19710903
	SU 511848	D	19760425	SU 1974-2002769	19740307
				FR 1971-31902	A 19710903
	SU 509214	D	19760330	SU 1974-2002748	19740311
				FR 1971-31902	A 19710903
	SU 515439	D	19760525	SU 1974-2003287	19740311
				FR 1971-31902	A 19710903
	US 3995056	A	19761130	US 1975-624733	19751023

FR 1971-31902

A 19710903

US 1972-284575

A3 19720829


AB (m-Benzoylphenyl)butyric acid derivs. [I, R, R2 = H, Me; R1 = H, OH; R3 = H, Et, HOCH2CH(OH)CH2, 2,3-(isopropyl- idenedioxy)propyl, o-C6H4CO2H; X = H, Me, OMe; X1 = H, Cl, MeO, F] and corresponding 2- and 3-butenic acids, useful as antiinflammatory and analgesic agents in treatment of arthritic and related conditions or ulcers, were prepared by several multistep syntheses, generally starting with (benzoylphenyl)-propionic or -acetic acetic acids. Thus, m-benzoylhydrocinnamic acid was converted to the acid chloride and treated with CH2N2 to give 3-(4-diazo-3-oxobutyl)benzophenone, which with Ag oxide, Na2CO3, and Na thiosulfate gave I (R,R1,R2,R3, X,X1 = H); similarly, (m-benzoylphenyl)acetyl chloride was treated with CH2N2, then HCl to give 3-(3-chloroacetyl)benzophenone, which was successively converted to 3-(3-chloro-2-hydroxypropyl) benzhydrol, 3-(3-cyano-2-hydroxypropyl)benzhydrol, 3-(3-cyano-2-hydroxypropyl)benzophenone, and I (R, R2 = H; R1 = OH; R3 = Et; X, X1 = H). Many starting materials and intermediates were characterized.

IT 41652-06-6P 41652-07-7P 41652-19-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 41652-06-6 CAPLUS

CN 2-Butenoic acid, 4-(3-benzoylphenyl)-2-methyl- (9CI) (CA INDEX NAME)




RN 41652-07-7 CAPLUS

CN 2-Butenoic acid, 4-(3-benzoylphenyl)-2-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 41652-19-1 CAPLUS

CN 2-Butenoic acid, 4-[3-(4-chlorobenzoyl)-2-methylphenyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 117 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1973:71699 CAPLUS
 DN 78:71699
 TI Introduction of organic groups into ethylenically unsaturated compounds
 using a Group VIII metal salt
 IN Heck, Richard F.
 PA Hercules Inc.
 SO U.S., 11 pp. Division of U.S. 3,527,794 (CA 73;109514d).
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3700727	A	19721024	US 1969-883288	19691208
				A	
	US 3763213	A	19731002	US 1971-197541	19711110
				US 1969-883288	A3 19691208
	US 3783140	A	19740101	US 1971-197542	19711110
				US 1965-479665	A3 19650813
				US 1969-883288	A3 19691208

PATENT FAMILY INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3527794	A	19700908	US 1965-479665	19650813
				A	
	US 3783140	A	19740101	US 1971-197542	19711110
				US 1965-479665	A3 19650813
				US 1969-883288	A3 19691208
	US 3855302	A	19741217	US 1972-250461	19720504
				US 1965-479665	A3 19650813
				US 1969-883287	A1 19691208

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3763213	A	19731002	US 1971-197541	19711110
				US 1969-883288	A3 19691208
	US 3700727	A	19721024	US 1969-883288	19691208
				A	

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3783140	A	19740101	US 1971-197542	19711110
				US 1965-479665	A3 19650813
				US 1969-883288	A3 19691208
	US 3527794	A	19700908	US 1965-479665	19650813
				A	
	US 3700727	A	19721024	US 1969-883288	19691208
				A	

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3855302	A	19741217	US 1972-250461	19720504
				US 1965-479665	A3 19650813
				US 1969-883287	A1 19691208
	US 3527794	A	19700908	US 1965-479665	19650813
				A	

AB Organometallic salts (especially those of Pd), prepared from Hg, Pb, and Sn salts,
 on treatment with RR1C:CHR2 gave RR1C:CR2R3 (I). Thus, 5 ml 0.4M Ph2Hg in


MeCN was added to 20 ml 0.1M LiPdCl₃ in MeCN and CH₂:CH₂ at 24° and 45 psig to give after 1 hr 62.5% I (R = R₁ = R₂ = H, R₂ = H, R₃ = Ph). Among .apprx.40 other compds. similarly prepared were the following I (R = R₂ = H; R₁ and R₃ given): MeO₂C, Ph; cyano, 2-ClO₂H₇; Ph, Ph; MeO₂C, 2-thienyl; H, CO₂Et.

IT 20883-27-6P 32195-04-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 20883-27-6 CAPLUS

CN 2-Propenoic acid, 3,3'-(carbonyldi-3,1-phenylene)bis-, dimethyl ester
(9CI) (CA INDEX NAME)



RN 32195-04-3 CAPLUS

CN 2-Propenoic acid, 3-(3-benzoylphenyl)-, methyl ester (9CI) (CA INDEX NAME)



L7 ANSWER 118 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1972:461739 CAPLUS

DN 77:61739

TI 4,4'-Dihydroxydiphenylmethane

AU Prajapati, S. P.; Sethna, Suresh

CS Fac. Sci., M. S. Univ. Baroda, Baroda, India

SO Journal of the Indian Chemical Society (1972), 49(4), 391-6

CODEN: JICSAH; ISSN: 0019-4522

DT Journal

LA English

AB Methylenediphenol (I, R = R₁ = H) reacted with MeCOCH₂CO₂H in 80% H₂SO₄ to give coumarin (II, R = Me, R₁ = H), which was treated with KOH and Me₂SO₄ in Me₂CO to afford I (R = H, R₁ = Cme:-CHCO₂H). I (R = Ac, R₁ = H) was heated with AlCl₃ and decomposed with HCl to give I (R = H, R₁ = COMe) (III), which, after methylation with Me₂SO₄, was oxidized with KMnO₄ to I (R = Me, R₁ = CO₂H). Benzoylation of III with BzCl gave I (R = Bz, R₁ = COMe), which was converted to I (R = H, R₁ = COCH₂COPh) by treatment with KOH in pyridine and then refluxed with HOAc and concentrated H₂SO₄ to give bis(6-flavonyl)-methane. I (R = CH₂CO₂Et, R₁ = COMe), prepared by condensation of III with BrCH₂CO₂Et in Me₂CO containing K₂CO₃, was hydrolyzed to I (R = CH₂CO₂H, R₁ = COMe), which was cyclized by AcONa-Ac₂O to benzofuran (IV, R = H, R₁ = Me). I (R = Me, R₁ = H) reacted with paraformaldehyde in HOAc to give I (R = Me, R₁ = CH₂Cl) (IV), which was refluxed with KCN and NaI to give I (R = Me, R₁ = CH₂CN). I (R = Me, R₁ = CHO), prepared by refluxing IV with hexamine in CHCl₃, was demethylated with AlCl₃ in PhNO₂ to I (R = H, R₁ = CHO), which was cyclized to II (R = H, R₁ = CO₂Et) and IV (R = CO₂Et, R₁ = H) (V) with CH₂(CO₂Et)₂ in piperidine and


BrCH(CO₂Et)₂, resp. IV (R = CO₂H, R₁ = H), obtained by hydrolysis of V in alc. KOH, was refluxed with Cu in quinoline to give IV (R = R₁ = H).

IT **37570-68-6P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 37570-68-6 CAPLUS

CN 2-Butenoic acid, 3,3'-[methylenebis(6-methoxy-3,1-phenylene)]bis- (9CI)
(CA INDEX NAME)



L7 ANSWER 119 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1971:405497 CAPLUS

DN 75:5497

TI Introduction of organic groups into ethylenically unsaturated hydrocarbons using a Group VIII metal salt

IN Heck, Richard F.

PA Hercules Inc.

SO U.S., 9 pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3574777	A	19710413	US 1969-883352	19691208
				US 1969-883352	A 19691208
AB	A variety of examples (65) illustrate the title reaction. Thus, C ₂ H ₄ , LiPdCl ₃ , and Ph ₂ Hg in MeCN at 24°/45 psig gave 62.5 PhCH:CH ₂ .CH ₂ :CHMe in place of C ₂ H ₄ gave 56.4% PhCH:CHMe.				

IT **20883-27-6P 32195-04-3P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 20883-27-6 CAPLUS

CN 2-Propenoic acid, 3,3'-(carbonyldi-3,1-phenylene)bis-, dimethyl ester (9CI) (CA INDEX NAME)



RN 32195-04-3 CAPLUS

CN 2-Propenoic acid, 3-(3-benzoylphenyl)-, methyl ester (9CI) (CA INDEX NAME)



L7 ANSWER 120 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1970:509514 CAPLUS
 DN 73:109514
 TI Carboalkoxylation of olefins
 IN Heck, Richard F.
 PA Hercules Powder Co.
 SO U.S., 10 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3527794	A	19700908	US 1965-479665	19650813
	US 3783140	A	19740101	US 1971-197542	19711110
				US 1965-479665	A3 19650813
				US 1969-883288	A3 19691208
	US 3855302	A	19741217	US 1972-250461	19720504
				US 1965-479665	A3 19650813
				US 1969-883287	A1 19691208

PATENT FAMILY INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3700727	A	19721024	US 1969-883288	19691208
	US 3763213	A	19731002	US 1971-197541	19711110
				US 1969-883288	A3 19691208
	US 3783140	A	19740101	US 1971-197542	19711110
				US 1965-479665	A3 19650813
				US 1969-883288	A3 19691208

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3763213	A	19731002	US 1971-197541	19711110
				US 1969-883288	A3 19691208
	US 3700727	A	19721024	US 1969-883288	19691208
					A

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3783140	A	19740101	US 1971-197542	19711110
				US 1965-479665	A3 19650813
				US 1969-883288	A3 19691208
	US 3527794	A	19700908	US 1965-479665	19650813
					A
	US 3700727	A	19721024	US 1969-883288	19691208
					A

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FAN	1975:98151				

PI	US 3855302	A	19741217	US 1972-250461	19720504
				US 1965-479665	A3 19650813
				US 1969-883287	A1 19691208
	US 3527794	A	19700908	US 1965-479665	19650813

A


AB The title process comprises reaction of an ethylenically unsatd. hydrocarbon with an organometallic compound of a Group VIII metal to form an unstable adduct which on decomposition yields the substituted olefin. Thus C₂H₄ at .apprx.25° was contacted with 0.1M LiPdCl₃ in MeCN and ultimately with more C₂H₄ at 24°/45 psig; the solution treated with 0.4M Ph₂Hg (I) in MeCN and agitated 1 hr at 24° gave 62.5% styrene based on I. A mixture of PhHgCl, M CH₂:CHCO₂Me in MeCN, and 0.1M LiPdCl₃ in MeCN stirred 16 hr at 24° gave 100% PhCH:CHCO₂Me (II). A mixture of carbomethoxymurcuric acetate, styrene, and Li₂PdCl₄ in MeOH was stirred 72 hr at 24° to give 33% II. Other examples (64) are given.

IT 20883-27-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 20883-27-6 CAPLUS

CN 2-Propenoic acid, 3,3'-(carbonyldi-3,1-phenylene)bis-, dimethyl ester
(9CI) (CA INDEX NAME)



L7 ANSWER 121 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1970:55662 CAPLUS

DN 72:55662

TI Reactions of organometallic compounds with ethylenically unsaturated compounds

IN Heck, Richard F.

PA Hercules Inc.

SO Brit., 32 pp.

CODEN: BRXXAA

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 1170825		19691119	GB	19670925

AB C₂H₄ (I) (150 ml) was injected into a glass chamber at 25°, 20 ml LiPdCl₃ (0.1M, in MeCN) added by injection, I increased to 45 psig at 24°, 5 ml Ph₂Hg (II) (0.4M, in MeCN) added, and the mixture agitated 1 hr at 24° to give 0.1M styrene (62.5% based on II). Similarly, C₃H₆ gave a mixture 0.075M trans- and 0.015M cis-PhCH:CHMe (56.4%). A mixture of 0.35 g II, 1.68 g acrolein, and 10 ml LiPdCl₃ (0.1M, in MeCN) stirred 16 hrs at 24° gave 60% PhCH:CHCHO. Also prepared were benzalacetone and PhCH:CHCO₂Me (III) in 100% yield based on Pd. Li₂PdCl₄ (20 ml) (0.1M in MeOH) was added to a mixture of 32 g anhydrous CuCl₂, 19.5 g CH₂:CHCO₂Me (IV), 62 g PhHgCl and 160 ml MeO H at 24-40° to give 57% III (99% purity), b₈ 119-37°, m. 33°. Similarly obtained was 24% MeCPh:CHCO₂Me (V), b₅ 110-35°; NMR indicated Ph and CO₂Me were cis). A mixture of 3.6 g p-ClHgC₆H₄CO₂H, 2.68 g CuCl₂, 0.42 g LiCl, 1 g H₂O, 7 g HOAc, 0.8 g MeCOCH:CH₂, and 1 ml Li₂PdCl₄ (0.1M, in HOAc) was


stirred 16 hr at 24° to give 0.64 g p-HO₂CC₆H₄CHClCOMe, m. 133-3.5° (C₆H₆-hexane). Also obtained were 57% 7-phenyl-2-chloro[2.2.1]bicycloheptane (probably), m. 47.5-48° and (2-chloroethyl)mesitylene, m. 56-6.5°, in 1.9% yield. A mixture of 0.21 g RuCl₃, 0.31 g PhHgCl, and 0.48 g IV in 90 ml MeOH was heated 16 hr at 45° to give 20% III. A mixture of 4.9 g 3,5-bis(acetoxymercuri)salicylaldehyde, 14.3 g IV, and 160 ml Li₂PdCl₄ (0.1M, in MeOH) was stirred 16 hr at 24° to give di -Me salicylaldehyde-3,5-diacrylate, m. 193-5° (absolute alc.). O was passed through 62 g PhHgCl, 19.1 g IV, 20 g NaCl, 20 g CuCl₂, 120 ml MeOH, and 40 ml Li₂PdCl₄ in MeOH. At 15-min intervals 10 ml portions of 3M HCl in MeOH were added until 50 ml had been added, then 2 addnl. portions were added 1 hr apart, and the mixture kept 16 hr at 24° to give 60% product b6 110-13° containing 86% III and 14% PhCH₂CH(MeO)CO₂Me. Over 150 examples are reported.

IT 20883-27-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 20883-27-6 CAPLUS

CN 2-Propenoic acid, 3,3'-(carbonyldi-3,1-phenylene)bis-, dimethyl ester
(9CI) (CA INDEX NAME)



L7 ANSWER 122 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1970:54973 CAPLUS

DN 72:54973

TI Compositions obtained from ethylenically unsaturated organic compounds and Group VII metals

PA Hercules Inc.

SO Fr., 26 pp.

CODEN: FRXXAK

DT Patent

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 1553822		19690117	FR	19671010

AB Organometallic compns. of Group VII metals are treated with organic ethylenically unsatd. compds. to give compns. used in the perfumery industry, in the preparation of polymers, as pharmaceutical intermediates, and in agriculture. Thus, 150 ml C₂H₄ at 25° was injected into 20 ml of a 0.1N solution of LiPdCl₃ in MeCN at 24°/4.197 kg/cm² pressure. A 0.4N solution of Ph₂Hg (5 ml) was added and the mixture was stirred 1 hr to give 62.5% styrene as a 0.1N solution in MeCN. Propylene was similarly treated to give a mixture of trans-propenylbenzene and cis-propenylbenzene and other similar reactions were carried out using, acrolein, methyl vinyl ketone, Me acrylate, Me crotonate, norbornene, acrylonitrile, and mesitylene, with PhHgCl, CuCl₂, Li₂PdCl₄, MeOH, p-ClMgC₆H₄OMe, p-ClHgC₆H₄CO₂H, LiCl, AcOH, CH₂Cl₂, RhCl₃, ClHgC₆H₂Me₃, NaCl, 2-naphthylmercuric chloride, bis-(2-naphthyl)mercury, Hg(OAc)₂, HClO₄, 2,4-bis(acetoxymercuri)mesitylene, p-ClMgC₆H₄NEt₂, Pd(OAc)₂, Et₂NH, Ph-OMe, ClHgC₆H₄NO₂, 2-chloromercurithiophene, and styrene to give the products including cinnamaldehyde, benzalacetone, Me cinnamate m.


33°, b8 119-23°, Me 3-phenyl-2-butenolate, Me 2-methylcinnamate, cis and trans-anethole, 1-(p-carboxyphenyl)-2-chloro-3-butanone m. 133-3.5°, 7-phenyl-2-chlorobicyclo[2.2.1]heptane, m. 47.5-8°, 2-(chloroethyl)mesitylene, m. 56-6.5°, Me 2-methoxy-3-phenylpropionate, 3-(2-naphthyl)-acrylonitrile, Me 3-(2-naphthyl)acrylate, Me p-(diethylamino)-cinnamate, m. 41.8-2.2°, p-methoxycinnamate, m. 89-90°, Me m-nitrocinnamate, m. 123-4°, and Me 3-(2-thienyl)acrylate, m. 40-40.2°.

IT **20883-27-6P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 20883-27-6 CAPLUS

CN 2-Propenoic acid, 3,3'-(carbonyldi-3,1-phenylene)bis-, dimethyl ester
(9CI) (CA INDEX NAME)



L7 ANSWER 123 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1969:3476 CAPLUS

DN 70:3476

TI Acylation, methylation, and carboxyalkylation of olefins by Group VIII metal derivatives

AU Heck, Richard F.

CS Res. Center, Hercules Inc., Wilmington, DE, USA

SO Journal of the American Chemical Society (1968), 90(20), 5518-26

CODEN: JACSAT; ISSN: 0002-7863

DT Journal

LA English

OS CASREACT 70:3476


AB Aryl, methyl, and carboxyalkyl derivatives of Group VIII metal salts, particularly Pd, Rh, and Ru salts, react with olefins to produce aryl-, methyl-, or carboxyalkyl-substituted olefins and reduced metal salt or metal. The reaction may be made catalytic with respect to the metal salt by employing CuCl₂ or CuCl, air, and HCl as reoxidants. The reaction is insensitive to O₂ and water and, therefore, provides an extremely convenient method for the synthesis of a wide variety of olefinic compds.

IT **20883-27-6P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 20883-27-6 CAPLUS

CN 2-Propenoic acid, 3,3'-(carbonyldi-3,1-phenylene)bis-, dimethyl ester
(9CI) (CA INDEX NAME)




L7 ANSWER 124 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1967:66207 CAPLUS

DN 66:66207
 TI Polypropylene containing ethyl 3,5-di-tert-butyl-4-hydroxy- α -cyanocinnamate
 IN Knapp, Gordon G.; Worrel, Calvin J.
 PA Ethyl Corp.
 SO U.S., 6 pp.
 CODEN: USXXAM
 DT Patent
 LA English

FAN. CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3280069		19661018	US	19601221
AB	Stabilizers, preferably of structure I, where R1 is C1-12 alkyl, R2 is a α -branched C3-12 alkyl, and R is C1-12 alkyl or C7-12 aralkyl, are used to reduce the deterioration of plastics upon exposure to uv light. Thus, polypropylene containing 0.25 weight % of I (R = Et, R1 = R2 = tert-Bu) exhibited no phys. change upon exposure to irradiation at 2800-4000 A. compared with the oxidative deterioration exhibited by polypropylene alone. I gave similar results when combined with other vinyl polymers, cellulose derivs., polyester resins, polyethers, and synthetic rubber.				
IT	10537-45-8 RL: USES (Uses) (as light stabilizer for polymers)				
RN	10537-45-8 CAPLUS				
CN	Cinnamic acid, α -acetyl-5-benzyl-2-(dodecyloxy)-3-hexyl-, methyl ester (7CI, 8CI) (CA INDEX NAME)				




L7 ANSWER 125 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1966:490762 CAPLUS
 DN 65:90762
 OREF 65:16997c-d
 TI Research on organotin compounds. I
 AU Cheng, Po-Lin
 SO et al. Hua Kung Hsueh Pao (1965), (3), 169-74
 DT Journal
 LA Chinese
 AB The preparation of 2 groups of compds., Bu₃SnO₂CR and Bu₃SnO₂CAr, where R is H, Me, Et, iso-Pr, n-pentyl, n-nonyl, (CH₂)₁₄Me, CH₂F, CH₂Cl, CCl₃, CH₂OMe, CH₂OEt; and Ar is Ph, 3-PhCH₂C₅H₄CH:CH, 2,x-(O₂N)₂C₆H₃, 2-HOC₆H₄, 2,3,5-HO(O₂N)₂C₆H₂, 2-H₂NC₆H₄, or 3-PhCONHCH₂C₆H₄NHC₆H₄. These compds. were prepared by dehydrating tributyltin oxide with an organic acid, or by the condensation of Bu₃SnCl with an organic Na salt. The reaction proceeded smoothly with yields up to 90%. Some phys. consts. of these compds. were also determined Preliminary biol. screening tests showed that the compds. OT002, OT003, and OT007 exhibited remarkably high fungicidal effects on

Hypochnus sasakii shirai. From Sci. Abstract China, Chemical Chemical Technol. 4(1), 9(1966).

IT 60521-27-9, Cinnamic acid, m-benzyl-
(tributyltin derivative)

RN 60521-27-9 CAPLUS

CN 2-Propenoic acid, 3-[3-(phenylmethyl)phenyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 126 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1966:490761 CAPLUS

DN 65:90761

OREF 65:16997b-c

TI Organic tin-nitrogen compounds

AU Jones, K.; Lappert, M. F.

CS Univ. Chem. Lab., Cambridge, UK

SO Organometallic Chemistry Reviews (1966), 1(1), 67-92

CODEN: OMC RAT; ISSN: 0474-6384

DT Journal


LA English

AB A review of the methods of synthesis of compds. with the C-Sn-N linkage and their reactions. All of the known compds. are listed. 81 references.

IT 7653-29-4, Tin, [(m-benzylcinnamoyl)oxy]tributyl-
(preparation of)

RN 7653-29-4 CAPLUS

CN Tin, [(m-benzylcinnamoyl)oxy]-tributyl- (7CI, 8CI) (CA INDEX NAME)



L7 ANSWER 127 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1966:430145 CAPLUS

DN 65:30145

OREF 65:5614e-h,5615a

TI Stabilization of plastics against ultraviolet light

IN Knapp, Gordon G.; Worrel, Calvin J.

PA Ethyl Corp.

SO 9 pp.

DT Patent


LA Unavailable

FAN. CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3244668		19660405	US	19610123
AB	Plastics can be stabilized against oxidation and deterioration by uv light by incorporation of 0.001-3% by weight of a compound of the general formula I, in which R1 is a C1-12 alkyl group, R2 is a C3-12α branched alkyl group, and Q is CHO or NO2; and also 0.001-3% of a compound of general formula II, in which R3 is a C1-12 alkyl group, R4 is an α-branched				

C3-12 alkyl group, R is H, a C1-12 alkyl radical, or a C7-12 aralkyl group, and Z is H, a C1-12 alkyl group, a C6-12 aryl group, or a C7-12 aralkyl group. For example, a solution of 103 g. 2,6-di-tert-butylphenol in 350 g. isooctane was treated during 12 min. with 63 g. of 50% HNO₃ at 20-30°, the solids filtered off, washed with H₂O, and dried to give 62.4 g. (50%) 4-nitro-2,6-di-tert-butylphenol, m. 145-53°. After recrystn., the m.p. was 155.5-56°. The following phenols were similarly prepared: 4-nitro-2-methyl-6-tert-butyl, 4-nitro-2-(2dodecyl)-6-tert-amyl, and 4-nitro-2,6-diisopropyl. In another example, a solution of 22.3 g. 2,6-di-tert-butyl-p-cresol in 300 g. tert-BuOH was treated with 64 g. Br, during which the temperature increased from 25 to 67°. The mixture was cooled to 20° and filtered to yield 3,5-di-tert-butyl-4-hydroxybenzaldehyde (IV), m. 189°. Other benzaldehydes similarly prepared included 3methyl-5-tert-butyl-4-hydroxy and 3-(3-dodecyl)-5-n-dodecyl-4hydroxy. In general, compds. of formula AC(Z):O with a compound of formula XCHY under basic conditions, as when Et 3,5-di-tert-butyl-α-hydroxycinnamate (V) was prepared by reaction of IV with Et cyanoacetate in dioxane made basic with piperidine. The benefits derived from the use of I and II are shown by comparative accelerated weathering tests (ASTM D 795-57T) of uninhibited polyethylene and polyethylene-containing additives. As an example of the manufacture of a stabilized plastic, 5 weight % 3-(ohydroxybenzylidene)-2,4-pentanedione and 2 weight % 6-tert-butyl-2-methyl-4-nitrophenol were mixed with di-Bu phthalate, cellulose acetate was stirred in a heated vessel, and di-Bu phthalate was sprayed onto the powdered resin. The mixture was blended and poured into a mold cavity, where it was extruded into a sheet. When tested in uv light, the stabilized material did not discolor, craze, warp, or chalk. Polyethylene, polypropylene, phenolic resins, poly(vinyl acetate), polyesters, polystyrene, polymethacrylates, nitrocellulose, polybutyrates, polyacetals, polyethers, nylon, poly(tetrafluoroethylene), melamine resins, urea resins, epoxy resins, and SBR, NBR, and natural rubber were stabilized by use of various I and II in different combinations.

- IT 10537-45-8, Cinnamic acid, α-acetyl-5-benzyl-2-(dodecyloxy)-3-hexyl-, methyl ester
(as stabilizer (ultraviolet-light) for plastics)
- RN 10537-45-8 CAPLUS
- CN Cinnamic acid, α-acetyl-5-benzyl-2-(dodecyloxy)-3-hexyl-, methyl ester (7CI, 8CI) (CA INDEX NAME)



- L7 ANSWER 128 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN
- AN 1955:23707 CAPLUS
- DN 49:23707
- OREF 49:4558f-i,4559a-i,4560a-i,4561a-b
- TI Synthetic choleraetics. II. Phenol derivatives
- AU Burtner, Robert R.; Brown, John M.

CS G. D. Searle & Co., Chicago
 SO Journal of the American Chemical Society (1953), 75, 2334-40
 CODEN: JACSAT; ISSN: 0002-7863
 DT Journal
 LA Unavailable
 OS CASREACT 49:23707
 AB cf. C.A. 45, 7553g. A series of cycloalkyl, aryl, and aralkyl PhOH derivs. bearing the β -carboxypropionyl side chain, as well as some closely related types, was prepared and screened for choleretic activity in the dog; several of the compds. were 2-4 times as active as dehydrocholic acid. p-Cyclohexylphenol (176 g.) in 1200 cc. 10% KOH treated during 30 min. with 190 g. Me₂SO₄ (temperature not controlled), the mixture let stand 15 min., stirred 1 h. at 75°, 56 g. KOH in 100 cc. water added at one time, then 63 g. Me₂SO₄ during 15 min. at 65°, the mixture heated 1 h. at 75°, chilled, and filtered yielded 180.6 g. p-cyclohexylanisole (I), b_{0.4} 100°, m. 57-8°. Cyclopentanone (108 g.) added during 30 min. at 30° to the Grignard reagent from 187 g. p-BrC₆H₄OMe and 24.3 g. Mg, the mixture stirred 2 h. at room temperature, refluxed 3 h., hydrolyzed with NH₄Cl, the Et₂O solns. evaporated, and the carbinol distilled with loss of water yielded 111 g. p-cyclopentenylanisole (II), b_{0.4} 96-8°, m. 91-2°. II (40.7 g.) in 250 cc. hot absolute EtOH cooled to room temperature and hydrogenated 75 min. over 0.3 g. PtO₂ at 50 lb., and the product filtered and distilled yielded 36.6 g. p-cyclopentenylanisole, b_{0.35} 78-9°, n_D₂₄ 1.5273. PhOMe (43.2 g.) and 48 g. cyclohexylacetyl chloride in 400 cc. PhNO₂ treated with 53.6 g. AlCl₃ during 30 min. at 0-5°, the mixture stirred 2 h. at 0°, let stand overnight at room temperature, hydrolyzed, the PhNO₂ steam distilled, the oil extracted with Et₂O, and the extract evaporated yielded 62 g. p-(cyclohexylacetyl)anisole (III), b_{0.1} 135-6°, n_D₂₅ 1.5465. III (62 g.) refluxed 48 h. with 120 g. amalgamated Zn in 75 cc. water, 175 cc. 12M HCl, 100 cc. PhMe, and 10 cc. AcOH (four 25-cc. portions of HCl added at 10-h. intervals.), the PhMe layer distilled, the residue refluxed 1 h. with 30 cc. 50% NaOH and 35 g. Me₂SO₄ in 150 cc. Me₂CO, the solvent removed, water added, the mixture extracted with Et₂O, and the extract distilled yielded 30 g. p-(cyclohexylethyl)anisole, b_{0.8} 128-30°, n_D₂₅ 1.5183. o-Cyclohexylanisole (IV) (72 g.) and 94 g. Zn(CN)₂ in 250 cc. C₆H₆ saturated with HCl (ice bath), 80.4 g. AlCl₃ added during 10 min., the mixture let warm to 40-5°, a slow stream of HCl passed in during 3.5 h. (temperature held at 40-5°), the Zn-alimine complex hydrolyzed, filtered, refluxed 20 min. with 200 cc. 6N HCl, chilled, extracted with C₆H₆, and distilled yielded 61.5 g. 3-cyclohexyl-4-methoxybenzaldehyde (V), b_{0.3} 145-6°, n_D₂₅ 1.5640; phenylhydrazone, m. 125-6°. Similarly was prepared 3-phenyl-4-methoxybenzaldehyde (VA), b_{0.3} 149-50° (semicarbazone, m. 167°), and 3-benzyl-4-methoxybenzaldehyde, b_{0.3} 152-5°, m. 59-60° (semicarbazone, m. 173°). Crude 2-methoxy-5-cyclohexylbenzaldehyde (15% yield), b_{0.6} 140-60°, was converted to the cinnamic acid, m. 147°. IV (155 g.) in 450 cc. PhCl heated on a steam bath while 121.5 g. SO₂Cl₂ was added during 30 min., the mixture heated 15 h., cooled, the solvent removed, and the residue distilled yielded 166 g. 2-cyclohexyl-4-chloroanisole, b_{0.3} 120°, n_D₂₅ 1.5470. Methylation of the corresponding phenols, gave p- and o-(α -phenethyl)anisole in excellent yield. Methoxyaroylalkanoic acids were prepared from the phenolic ether and the required anhydride with AlCl₃ in 40-80% yield. For substituted valeric acids, carbomethoxyvaleryl chloride was used instead of adipic anhydride. AlCl₃ (134 g.) added portion-wise during 30 min. to 95 g. IV and 50 g. succinic anhydride (VI)

in 500 cc. PhNO₂ at 0-5°, the mixture stirred 2 h. at 0-5°, let stand overnight, hydrolyzed, steam distilled, filtered, the acid in 2% NaOH at 60° treated with C and the solution acidified yielded 121 g. β-(3-cyclohexyl-4-methoxybenzoyl)propionic acid (VII), m. 161°. AlCl₃ (33.5 g.) added portion-wise to 47.5 g. IV and 44.6 g. δ-carbomethoxyvaleryl chloride in 250 cc. C₆H₆ at 3-8°, the mixture stirred 4 h. in the ice bath, 18 h. at room temperature, hydrolyzed,

the

C₆H₆ evaporated, the Me ester refluxed 30 min. with 16 g. NaOH in 160 cc. MeOH, the MeOH removed and the Na salt diluted and acidified yielded 38.3 g. δ-(3-cyclohexyl-4-methoxybenzoyl)valeric acid, m. 96°. (2-MeOC₆H₄)₂ (53.8 g.) and 22 g. VI treated with 59 g. AlCl₃ in 220 cc. PhNO₂, the neutral products dissolved in hot dilute NaOH, the solution acidified, the precipitate (71.5 g.) extracted with boiling MeOH, the extract concentrated to

150 cc., diluted with 1 l. water yielded 17 g. β-[3-(o-methoxyphenethyl)-4-methoxybenzoyl]propionic acid (VIII), m. 143°.

The MeOH-insol. product yielded 21 g. 2,2'-dimethoxy-5,5'-bis(β-carboxypropionyl)bibenzyl (VIIIa), m. 250° (decomposition).

Methoxyaroylacrylic acids were prepared from the phenolic ether and maleic anhydride (IX) with AlCl₃. AlCl₃ (134 g.) added portionwise to 92 g.

o-MeOC₆H₄OPh and 49 g. IX in 500 cc. PhNO₂ at 0-3°, the mixture stirred 2 h. at 0°, held overnight at room temperature, hydrolyzed, steam distilled, the crude acid dissolved in 2 l. 3% Na₂CO₃ at room temperature, the solution filtered with celite and acidified yielded 52.5 g.

β-(3-phenyl-4-methoxybenzoyl)acrylic acid (X), m. 161°. X heated in 5% NaOH decomposed to give the Me ketone. Br (26.4 g.) in 60 cc. AcOH added dropwise at 60° during 30 min. to 45.5 g.

β-(3-phenyl-4-hydroxybenzoyl)propionic acid (XI) in 455 cc. AcOH, the mixture heated 45 min., the AcOH removed, and the residue suspended in Skellysolve B and filtered yielded 42.5 g. bromo acid (XII), m.

146° (decomposition) XII and 18.8 g. NaOAc refluxed 30 min. and the hot mixture diluted with 1 l. ice water yielded 18 g. β-(3-phenyl-4-

hydroxybenzoyl)acrylic acid, m. 201° (decomposition). In about 50% of the cases, demethylation with AlCl₃ caused internuclear cleavage, e.g., VII yielded principally β-(p-hydroxybenzoyl)propionic acid, and 5%

β-(3-cyclohexyl-4-hydroxybenzoyl)propionic acid, m. 194°. Consequently the demethylation procedures described below were used.

β-(3-phenyl-4-methoxybenzoyl)propionic acid (XIII) (10 g.), m. 131-2°, in 25 cc. Ac₂O and 60 cc. HI (d. 1.7) refluxed about 20

min. and the solution diluted with 200 cc. ice water yielded 8 g. 4-hydroxy acid (XIV), m. 169-70°. Substituted cinnamic acids were prepared by

the Doebner modification of the Knoevenagel condensation. IV (21.2 g.) in 50 cc. pyridine and 1 cc. piperidine heated 4 h. on the steam bath, the mixture chilled, and diluted with 200 cc. ice-cold 20% H₂SO₄ yielded 20 g.

3-phenyl-4-methoxycinnamic acid (XV), m. 227-8°. XV in 50 vols. of AcOH hydrogenated at 60° under 3 atmospheric with PtO₂ gave in excellent

yield β-(3-phenyl-4-methoxyphenyl)propionic acid, m. 135°.

β-(2-Methoxy-5-cyclohexylbenzoyl)propionic acid (XVI), m. 159-60°, (33 g.) in 1320 cc. water containing 93 g. NaOH treated with

93 g. Br during 30 min. at 10-15°, the mixture stirred 3 h. at 10°, held overnight at room temperature, treated with SO₂, made strongly

alkaline, washed with Et₂O, acidified, the oil extracted with C₆H₆, and the

C₆H₆

evaporated yielded 19 g. crude 2-methoxy-5-cyclohexylbenzoic acid (XVII) (did not crystallize), which with HI gave the 2-hydroxy acid (XVIII), m.

151°. The following procedure is more convenient for the preparation of larger amts. of XVII. Br (160 g.) added to 176 g. p-cyclohexylphenol in 750 cc. hot CS₂, the solution refluxed 1 h. and evaporated in vacuo yielded 255 g. 2-bromo-4-cyclohexylphenol, which gave 246 2-bromo-4-cyclohexylanisole

(XIX), b0.6 128°, m. 53°. XIX (134.5 g.) in 500 cc. Et2O added during 1 h. to the BuLi from 69 g. BuCl and 11.4 g. Li, the mixture refluxed 30 min., poured on Dry Ice, 1 l. 5% NaOH added, the aqueous layer washed with Et2O, acidified, extracted with Et2O, the Et2O evaporated and the residue distilled yielded 64 g. XVII, b0.7 180°, m. 70-1°; XVII (60.8 g.) with HI gave 56 g. XVIII, m. 147-8°. Proof of structures: VII (5 g.), 10 g. NaOH, and 175 cc. Chlorox (5.25% NaOCl in 325 cc. water) heated 30 min. at 60°, refluxed 30 min., cooled, washed with Et2O, treated with SO2, and acidified yielded 1.0 g. 3-cyclohexyl-4-methoxybenzoic acid (XX), m. 194-5°. VA (1.0 g.) and 5 g. Ag2O in 100 cc. 1% NaOH refluxed 1 h., filtered, cooled, washed with Et2O, and acidified yielded XX, m. 195°. XV (4.5 g.), 29 g. KMnO4, and 15 g. KOH in 500 cc. water refluxed 4 h., the product filtered, and the filtrates acidified yielded 1.5 g. 3-phenyl-4-methoxybenzoic acid (XXI), m. 221-2°. XXI with HI gave the 4-hydroxy acid, m. 148°. XIII (5 g.) with KMnO4 yielded XXI, m. 220-1°. XIV (3 g.), 15 g. KOH, and 20 g. KMnO4 refluxed 4 h., the mixture cooled, saturated with SO2, extracted with Et2O, and the extract evaporated yielded 1.1 g. BzOH,

m.

121°; BzNHPh, m. 161-2°. The ester from 1.7 g. XX heated 3 h. with 0.2 g. 5% Pd-C, dissolved in 15 cc. EtOH, filtered, the filtrate refluxed 30 min. with 2 g. NaOH, the EtOH evaporated, and the residue acidified yielded 1.1 g. XXI, m. 220°. β -(2-methoxy-5-benzylbenzoyl)propionic acid (4.5 g.), m. 121°, 30 g. KMnO4, and 500 cc. water refluxed 4 h., the mixture filtered, and the filtrate acidified yielded 1.0 g. 2-hydroxy-5-benzoylbenzoic acid, m. 215°; Me ester, m. 94°. β -[p-(2-Hydroxy-4-chlorobenzyl)benzoyl]propionic acid (3.8 g.), 15 g. KOH, and 25 g. KMnO4 in 300 cc. water refluxed 4 h., the product filtered, the filtrate saturated with SO2, strongly acidified, and boiled 20 min. yielded 1.4 g. terephthalic acid, di-Me ester, m. 140°. I (76 g.) and 45.2 g. ClCH2COCl in 400 cc. (Cl2CH)2 treated portionwise at -5 to 0° with 56.3 g. AlCl3, the mixture stirred overnight while coming to room temperature, hydrolyzed, and the organic layer distilled yielded 39.3 g. 2-chloroacetyl-4-cyclohexylanisole (XXII), m. 112-13°. NaCH(CO2Et)2 (from 1.15 g. Na, 8.7 g. CH2(CO2Et)2, and 30 cc. absolute EtOH) and 13.3 g. XXII refluxed 14 h., 8 g. Na in 80 cc. EtOH added, the mixture refluxed 1 h., the EtOH removed, the residue acidified, extracted with Et2O, the Et2O evaporated, the

oil

heated 1 h. at 180-90°, the product in 80 cc. 5% NaOH washed with Et2O, and acidified yielded 2 g. α -methyl- β -(2-methoxy-5-cyclohexylbenzoyl)propionic acid, m. 149-50°. PhCH(CO2Me)CH2CO2H (7.5 g.) and 7.2 g. SOCl2 heated 4 h. at 50-60°, the excess SOCl2 removed by distillation in vacuo and distillation with C6H6, 4 g. AlCl3 added

in 2

portions at 5° to the crude acid chloride, the mixture treated with 5.7 g. I in 30 cc. C6H6, the mixture stirred 14 h. at room temperature, hydrolyzed, extracted with Et2O, the Et2O evaporated, the Me ester refluxed 1

h.


with 3 g. Na in 30 cc. MeOH, the solution diluted with 300 cc. water, washed with Et2O, boiled briefly, and acidified, yielded 4.5 g. α -phenyl- β -(2-methoxy-5-cyclohexylbenzoyl)propionic acid (XXIII), m. 171-2°. I (38 g.) added dropwise to the BuLi from 6.1 g. Li and 37 g. BuCl in 300 cc. Et2O, the mixture refluxed 20 h., treated with Dry Ice, washed with Et2O in 1 l. 2% NaOH, the alkaline solution

acidified,

extracted with Et2O, and the Et2O evaporated yielded 4.5 g. 2-methoxy-3-cyclohexylbenzoic acid (XXIV), m. 113°. XXIV (4 g.), 30 cc. 47% HI, and 12.5 cc. Ac2O refluxed 30 min., diluted with ice water and filtered yielded 2-hydroxy-3-cyclohexylbenzoic acid, m. 159-60°. Other


substituted β -benzoylpropionic acids and their m.ps. are:
 2-hydroxy-5-cyclohexyl, 159-60°; 2-methoxy-5-(β -cyclohexylethyl), 103°; DMP (demethylation product of preceding compound), 105.5°; 2-hydroxy-5-Ph, 136-7°; 2-hydroxy-5-benzyl, 161°; 2-methoxy-5-cyclopentyl, 147°; DMP, 109°; β -(2-methoxy-5-cyclohexylbenzoyl)acrylic acid, 139°; 2-methoxy-5-(α -phenethyl), 104°; ω -(2-methoxy-5-cyclohexylbenzoyl)valeric acid, 95°; DMP, 98°; XXIII, 174°; DMP, 165-6°; α -methyl-2-methoxy-5-cyclohexyl, 151°; DMP, 126°; 3-phenyl-4-methoxy, 131-2°; 8-benzyl-4-methoxy, 133°; DMP, 185.5°; 3-phenoxy-4-methoxy, 158°; DMP, 143°; VIII, 143°; DMP, 147-8°; DMP of VIIIA, 227°; 3-(α -phenethyl)-4-methoxy, 150°; β -(3-cyclohexyl-4-methoxybenzoyl)acrylic acid, 161°; DMP, 206° (decomposition); β -(3-benzyl-4-methoxybenzoyl)acrylic acid, 156°; ω -(3-cyclohexyl-4-methoxybenzoyl)valeric acid, 96°; DMP, 137°; 2-hydroxy-3-cyclohexyl-5-chloro, 174°; p-(2-methoxy-5-chlorobenzyl), 144-5°; DMP, 200-1°; β -[p-(2-methoxy-5-chlorobenzyl)benzoyl]acrylic acid, 162°; p-(4-hydroxyphenyl), 218-20°; 3-benzyl-4-methoxycinnamic acid, 181°; β -(3-cyclohexyl-4-methoxyphenyl)propionic acid 126-7°.

IT 727709-03-7, Acrylic acid, 3-(3-benzyl-p-anisoyl)-
 (preparation of)
 RN 727709-03-7 CAPLUS
 CN Acrylic acid, 3-(3-benzyl-p-anisoyl)- (5CI) (CA INDEX NAME)



L7 ANSWER 129 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1954:80204 CAPLUS
 DN 48:80204
 OREF 48:14083c-e
 TI Relation between molecular structure and physiological activity of plant-growth regulators. II. Formative activity of phenoxyacetic acids
 AU Weintraub, Robert L.; Brown, James W.; Throne, J. Arthur
 CS Camp Detrick, Frederick, MD
 SO Journal of Agricultural and Food Chemistry (1954), 2, 996-9
 CODEN: JAFCAU; ISSN: 0021-8561
 DT Journal
 LA Unavailable
 AB cf. C.A. 46, 5773g; 47, 6593a. The formative activities of approx. 145 ring-substituted phenoxyacetic acids have been measured by the bean-leaf repression technique. The presence of a halogen atom at position 4 appears to be a requisite for high activity. The order of effectiveness of the halogens is Cl > F > Br > I. Further enhancement of activity may ensue through introduction of an addnl. halogen or Me substituent at position 2.
 IT 76981-43-6, Acetic acid, [m-benzoylphenoxy]-
 (as growth substances)

RN 76981-43-6 CAPLUS
 CN Acetic acid, (3-benzoylphenoxy)- (9CI) (CA INDEX NAME)



L7 ANSWER 130 OF 130 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1952:67197 CAPLUS

DN 46:67197

OREF 46:11244f-i,11245a-c

TI Keto aliphatic acids derived from hydroxy and alkoxy diphenylalkanes

IN Burtner, Robert R.; Arbit, Harry A.

PA G.D. Searle and Co.

DT Patent

LA Unavailable

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2588802		19520311	US	
AB	<p>Compds. of the formula Ph-A-C₆H₃(OR)CO-B-CO₂X where A and B are bivalent aliphatic hydrocarbon radicals, X is H or a cation, R is lower alkyl, and wherein the benzene rings may be further substituted by halogen, OH, lower alkyl or alkoxy, and the Ph ring may be substituted by -CO-B-CO₂X, are prepared by a Friedel-Crafts reaction between Ph-A-C₆H₄OR, or a derivative thereof, with the anhydride, acid halide, or half-ester half-acid halide of a dibasic acid, B(CO₂H)₂. Dealkylation gives the corresponding phenols. AlCl₃ 536 is added during 30 min. to a suspension of 2-PhCH₂C₆H₄OMe (I) 396 and (CH₂CO)₂O (II) 200 in PhNO₂ 2400 parts at 0-5°, and the mixture stirred 2 hrs. at 0° kept 15 hrs., and hydrolyzed, giving β-(3-benzyl-4-methoxybenzoyl)propionic acid (III), m. 133°, when purified through the Na salt and recrystd. from MeOH. III 10 in HI (d. 1.7) 120 and Ac₂O 25 parts refluxed 15 min. and hydrolyzed gives the corresponding 4-HO compound, m. 185.5° (from EtOAc). Similarly are prepared the following compds. (reactants given after name of compound): β-(3-benzyl-4-methoxybenzoyl)acrylic acid (maleic anhydride (IV) and I), yellow needles, m. 156°; β-(2-methoxy-5-benzylbenzoyl)propionic acid (II and p-PhOCH₂C₆H₄OMe), pale yellow, m. 121°, 2-HO compound m. 161°, gives an amethyst color with FeCl₃; β-(2,4-dimethoxy-5-benzylbenzoyl)propionic acid (II and 2,4-(MeO)₂C₆H₃CH₂Ph, b_{0.1} 125-30°, m. 98°, n_D²⁵ 1.5764, prepared from 2,4-(MeO)₂C₆H₄, PhCH₂Cl, and Cu powder at 175-200°), m. 177°; β-[p-(2-methoxy-5-chlorobenzyl)benzoyl]propionic acid (II and 5,2-Cl(MeO)C₆H₃CH₂Ph (V), n_D²⁷ 1.5862), m. 144-5° [2'-HO compound, m. 200-1° (decomposition)]; β-[p-(2-methoxy-5-chlorobenzyl)benzoyl]acrylic acid (IV and V), m. 162° (from MeOH and C₆H₆); β-[3-(o-methoxyphenethyl)-4-methoxybenzoyl]propionic acid (VI), m. 141-2°, and 2,2'-dimethoxy-5,5'-bis(β-carboxypropionyl)bibenzyl (VII), m. 250° (decomposition) (II and [2-MeOC₆H₃CH₂]₂) (VII is separated from VI as a MeOH-insol. fraction) [2,2'-di-HO compound to VI, m. 147-8°]; δ-[3-(p-cymenyl)-4-methoxybenzoyl]valeric acid (adipic anhydride (VIII) and the corresponding anisole); β-[2-methyl-4-methoxy-5-(β-methylphenethyl)benzoyl]propionic acid (II and 4,2-Me(MeO)C₆H₃CH₂CHMePh);</p>				

3-(p-methoxyphenyl)-4-(3'-β-carboxypropionyl-4'-methoxyphenyl)hexane (IX) [II and [p-MeOC₆H₄CH₂Et]₂ (X) (meso form, m. 140-2°)] [p,4'-(HO)₂ compound (XI), m. 85-95°]; IX [II and X (racemic form, m. 52-4°)], XI, m. 55-65°; 2-(4'-methoxyphenyl)-3-(3''-β-carboxypropionyl-4''-methoxyphenyl)butane (II and [4-MeOC₆H₄CHMe]₂) and 4',4''-(HO)₂ compound; 3-(p-methoxyphenyl)-4-(3-δ-carboxyvaleryl-4'-methoxyphenyl)hexane (VIII and X) and p,4'-(HO)₂ compound; 3,3'-dihydroxy-4- and 6-(δ-carboxyvaleryl)bibenzyl (VIII and [m-MeOC₆H₄CH₂]₂); 3-(p-hydroxyphenyl)-5-[4-hydroxy-3-(β-carboxypropionyl)phenyl]-4-ethylheptane (II and [p-HOC₆H₄CH₂Et]₂CH₂Et); 2,2',4,4'-tetramethoxy-5,5'-bis(β-carboxypropionyl)biphenyl (II and [2,4-(MeO)₂C₆H₃]₂), m. 232° (from AcOH); 2,2',4,4'-(MeO)₂(HO)₂ compound, m. 315° (decomposition). These compds. are useful as choleretics and parasitocidal agents.

IT 727709-03-7, Acrylic acid, 3-(3-benzyl-p-anisoyl)-
(preparation of)

RN 727709-03-7 CAPLUS

CN Acrylic acid, 3-(3-benzyl-p-anisoyl)- (5CI) (CA INDEX NAME)



=>